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ABSTRACT 
 
With high affinity and specificity, antibodies are now proven biotherapuetics for a wide range 
of diseases, such as cancer and immunological conditions. However, antibody Fc-domain 
mediated cross reactivity with associated side effects has hindered the development of 
antibody therapy in a number of applications. The development of engineered recombinant 
antibody fragments to address the problems seen with whole monoclonal antibodies (mAbs). 
Their smaller size enables rapid antigen localisation, tissue penetration and higher specificity 
ratios. Whereas, poor pharmacokinetics due to fast blood clearance from the circulation is an 
important obstacle to these small molecules, and modification of antibody fragments is 
required for improved tissue exposure and uptake.  
 
In order to improve protein pharmacokinetics whilst maintaining good tissue/tumour to blood 
ratios and low cross-reactivity, conjugation of antibody fragments with a natural polymer 
polysialic acid (PSA) composed by N-acetylneuraminic acid (Neu5Ac or NANA), has been 
investigated. Compared to polyethylene glycol (PEG) conjugation, which is the predominant 
approach, PSA appears to be a better alternative because it is biodegradable, non-toxic and 
highly hydrophilic. 
 
In this project, an anti-carcinoembryonic antigen scFv (MFE-23), and an anti-HER2 scFv 
(C6.5) were used as model antibody fragments to conjugate with PSA. To overcome the 
limitations of chemical conjugations, this project was focused on the investigation of 
recombinant polysialylation of single chain antibodies. ScFv genes were firstly incorporated 
with a naturally polysialylatable (Ig5 and FN1) domains from human neuronal cell adhesion 
molecule. After transfections into polysialyltransferases-expressing HEK-293 cells, the 
biosynthesized sialic acid was enzymatically added to the N-glycosylated fusion protein Ig5 
domain for elongating the attached PSA chain. Expressed by monoclonal cell secretion, 
polysialylated scFvs were successfully generated and purified. Based on the negative charge 
of PSA, an ion exchange method was developed for separating different polysialylated scFv 
isoforms. The degree of polymerization (DP) was detected by mass spectrometry, which 
showed an average of recombinant DP of up to 20 NANA residues attached to a complex N-
glycan core. Affinity binding tests by ELISA confirmed the antibody KD was significantly 
retained at approximately 5nM after polysialylation, however BIAcore kinetic analysis 
demonstrated influencing change to the KD due to the strong negative charge of PSA. In vitro 
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experiments using both FACS and confocal microscopy suggested that recombinant 
polysialylation has no affect of targeting antigens expressed on the live cell surface. 
Molecular hydrodynamic radius increases of polysialylated scFvs were detected by size 
exclusion chromatography, which led to corresponding pharmacokinetic improvement from in 
vivo mice studies with enhanced serum half-lives.  
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“Don't get set into one form, adapt it and build your own, and let it grow, be like water. 
Empty your mind, be formless, shapeless — like water. Now you put water in a cup, it 
becomes the cup; You put water into a bottle it becomes the bottle; You put it in a teapot it 
becomes the teapot. Now water can flow or it can crash. Be water, my friend.” — Bruce Lee 
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Introduction 
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1.1 Antibodies in Therapy 
1.1.1 Antibody – Immune system’s powerful weapon  
Natural antibodies are immunoglobulin glycoproteins, naturally synthesized and secreted by 
all vertebrate B lymphocytes. They are critical components in the mammalian immune system 
which connects the innate and adaptive responses and are specifically produced against 
antigens that are mostly foreign and/or harmful to the organism. The typical immunoglobulin 
(Ig) isotype, IgG, is a Y-shaped molecule, with a molecular weight of 150 kDa and composed 
of two identical heavy chains and two identical light chains linked by disulphide bridges 
(Porter 1973) (Figure 1.1).  
 
 
Figure 1.1. The domain structure of IgG antibody molecule. As the most classical immunoglobulin, IgG has a 
Y configuration and flexible hinge region (black lines) that allows extensive movement of the Fab arms. Both 
identical light chains and heavy chains are indicated, and each light chain and heavy chain is interlinked by 
disulphide bonds (yellow lines) in order to form one half of a full-size antibody molecule. The two halves are 
further covalently linked by disulphide bonds. One light chain (25 kDa) consists of a C-terminal constant domain, 
CL (blue) and an N-terminal variable domain, VL (green), while each heavy chain preserves four compartments, 
one N-terminal heavy variable domain, VH (red), and three constant domains, CH1, CH2, and CH3 (purple). 
Hypervariable regions are associated with both VH and VL domains, which recognise the antigens and initiate the 
antibody-antigen binding. Each IgG molecule has a pair of Fab arms that maintain the same antigen specificity 
of the hypervariable regions, making the antibody bivalent. The CH2 domain in the Fc region contains 
glycosylated moieties (pink) at Asn297 that contribute to immunological responses, and modulate 
pharmacokinetic properties.  
 
 
In humans there are two types of light chain termed kappa (κ) and lambda (λ), which are 
encoded on chromosome 2 (Malcolm et al. 1982) and on chromosome 22 (de la Chapelle et al. 
1983) respectively. The heavy chain locus is found on chromosome 14 (Cox et al. 1982), with 
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its constant region genes dictating five different antibody isotypes (A, D, E, G and M). Each 
heavy chain and light chain are connected by disulphide bonds, forming two halves of the 
antibody. Proteolytic enzyme digestion with papain cleaves above the hinge region, and 
separates the IgG molecule into two 50 kDa Fab (fragment antigen-binding) fragments 
retaining the antigen recognition ability and a 50 kDa domain that can be readily crystallized 
termed Fc (fragment crystallisable) (Deutsch et al. 1961; Porter 1973).  
 
IgG molecules circulate in the blood as one of the most predominant and important serum 
immuno-surveillant proteins to recognise non-self antigens present on various infectious 
agents or allergens that exogenously entered the body, or endogenous malignant targets such 
as cancer antigens. The Fab fragments of an antibody molecule are principally responsible for 
antibody-antigen binding as its name refers to. On the N-terminus of each Fab fragment, the 
association of the heavy and light chain variable domains leads to the antigen combining 
region, and each of the variable domains hosts three hypervariable sequence regions (Figure 
1.1). Scattered within the frame-work of variable sequence regions at the complimentary 
determining regions (CDRs) which are specifically presented to accomplish the targeting 
purpose of the antibody to its cognate antigen epitopes (Chothia et al. 1992; Chothia et al. 
1998). The Fc domain derived primarily by the antibody heavy chain constant domains (CH2 
and CH3) elicits the effector functions including antibody dependent cellular cytotoxicity 
(ADCC) or complement dependent cytotoxicity (CDC), and innate immune responses. With 
the aid of the antibody Fc portion, effector cells including macrophages, neutrophils and 
natural killer (NK) lymphocytes are recruited, pertinently and culminantly to neutralise and 
eliminate the disease-causing sources (Casadevall et al. 2004). Moreover, immunoglobulins 
also have a natural retention system and catabolic clearance control depends on Fc-domain to 
neonatal Fc-receptor (FcRn, salvage receptor) binding via the reticulo-endothelial system 
(Ghetie and Ward 1997; Anderson et al. 2006). IgG compromises four subclasses, IgG1 to 
IgG4, where human IgG1 and IgG3 have the highest binding efficiencies in harnessing 
effector functions among all antibody classes and subclasses, while IgG2 and IgG4 are 
relatively poor. Base on the excellent antigen recognition, IgG1 molecules have been mostly 
chosen to make therapeutic antibodies (Isaacs 2009). 
 
Arguably, as the most useful weapon in the immune system, antibodies exhibit huge variation 
to potential harmful antigenic entity. B-lymphocytes are the manufacturers of different 
antibodies. They have immunoglobulin surface receptors for the decisive engagement to its 
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selected antigen (Moller 1977). This interaction triggers a cascade process co-stimulated by 
T-cells and other immune components, and develops the B-cell with a clonal expansion and 
maturation, together with the secretion of soluble IgMs, which pentavalently target to a 
specific antigenic epitope. The matured B-cells then step into a process called somatic 
hypermutation, during which they may undergo various recombination events that mostly 
occur in the antigen hypervariable regions, and switch class to produce soluble bivalent IgG 
molecules that are possessed with an enhanced affinity to recognise and bind a specific 
antigen (Harriman et al. 1993; Neuberger and Milstein 1995; Li et al. 2004). 
 
 
1.1.2 History of Antibody Based Therapies 
Antibody-based therapies have experienced their historical rises and falls, abandonment and 
renaissance, and now are gradually entering the era of the illustrious. Discovered in the early 
1890s, Behring and Kitasato found that specific antibodies were capable in being used to fight 
against bacterial toxins. This finding led to a vast development of using passive antibody 
therapy for infectious disease treatment (Casadevall and Scharff 1995; Casadevall et al. 2004).  
The initial approaches of antibody generation were derived from immunized animals or 
human donors; therefore this type of antibody therapy was also called “serum therapy”. 
Notwithstanding the effectiveness of serum therapy in infectious disease treatment, the 
associated side effects were far more severe and considerable. This is due to the large amount 
of other foreign proteins in the animal serum also introduced to the patients during this type of 
antibody administration, which caused immediate hypersensitivity reactions to serum sickness. 
Although,  later on improved purification methods reduced the toxicity of antibody 
preparations, serum therapy still went into a decline, as by the late 1940s, sulphonamide drugs 
and other types of chemotherapies were practised clinically to have superior effects to treat 
microbial causing diseases, and produced in a relatively more economical way and safer in 
administration (Casadevall et al. 2004).  This nearly pressurised antibody-based therapy into 
an abandonment for clinical use, however a number of viral and hard to treat diseases kept 
antibody therapies within a niche field, and consequently provoked a reformational 
renaissance of massive therapeutic antibody applications for an expanded range of disease 
treatments.  
 
Tracking the time line back a hundred years ago (Figure 1.2), during the age of serum therapy, 
German chemist Paul Ehrlich proposed that antibodies could be used as "magic bullets" to 
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selectively deliver toxins to targets in order to eradicate human diseases (Ehrlich 1956).  
Following this concept, the revolutionary switch-over of therapeutic antibody history began 
from original immunized animal based polyclonal antibody production to monoclonal 
antibody (mAb) derived from a single cell line. The domination of monoclonal antibody 
based therapies initiated after the first generation of mAbs produced in 1975 from a 
hybridoma cell line developed by Georges Köhler and César Milstein (Kohler and Milstein 
1975). This hybridoma method consisted of the selection of an immunized B-lymphocyte 
clone that persisted in secreting specific antibodies recognising a unique determinant antigen 
epitope. Several murine-originate mAbs were then developed in the early 1980s against 
various antigens, including the first commercialised anti-CD3 mAb, OKT3 (muromonab) 
from Johnson & Johnson‟s Orthoclone and from others targeting cancer antigens (Bargmann 
et al. 1986; Drebin et al. 1986). However, several limitations of these murine mAbs have also 
been critically reviewed from their clinical trials, such as immunogenicity when injected into 
humans, also known as human anti-mouse antibodies (HAMA) responses, shortened plasma 
circulation half-life, and inefficient effector function recitations due to their rodent constant 
regions (Shawler et al. 1985; Ober et al. 2001). The initial strategy to overcome these 
anaphylactic problems was to construct a chimeric antibody consisting around 1/3 parental 
mouse antibody with all antigen recognition features reserved, joined with human constant 
domains for the remaining 2/3 (Boulianne et al. 1984; Morrison et al. 1984). Chimerisation 
reduced the murine limitation somewhat but the significant improvement of mAb activity for 
clinical use was greatly renovated after the development of humanisation, which was 
processed by grafting the murine complementary-determining regions into a human 
immunoglobulin framework (Riechmann et al. 1988), and this process resumed approximately 
95% human protein to the mAb. Finally, fully human mAbs have been made through 
technologies including phage display or using human immunoglobulin transgenic mice 
(McCafferty et al. 1990; Bruggemann et al. 1991; Green et al. 1994; Fishwild et al. 1996; 
Mendez et al. 1997), both of which utilize human variable regions as repertoires in 
construction. Fully human mAbs are predicted to be dominant for the future antibody drug 
launches, as it has the lowest immune related side effects for reaching the highest therapeutic 
function.  
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         (a) 
 
 
 
         (b) 
 
Figure 1.2. Development of monoclonal antibodies. (a) The early timeline of mAb development for clinical 
applications. (b) Schematic evolution of mAbs from murine (green shading) to fully human (blue shading). Red 
spheres indicate glycosylation in the constant domain. Figure (b) was taken from (Deonarain 2008). 
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1.1.3 Approved mAbs for Disease Treatment 
After more than a century of evolutionary research and development, antibodies have now 
proven to be very powerful and valuable biotherapeutics, with more and more candidates 
going into clinical development for human disease diagnosis and treatment. A spectrum of 
diseases, including cancer, autoimmune and inflammatory disorder (AIID), infection, 
ophthalmic disease and heart disease have been treated clinically with specific and innovative 
antibody drugs. The growing list of antibody therapeutics approved by the US Food and Drug 
Administration (FDA) and by the European Medicine Agency (EMEA) also attracted a great 
deal of attention and investment by the pharmaceutical industries (Wu and Senter 2005; 
Reichert 2008). The global market for antibody therapy has economically succeeded in 2006 
worth approximately US $24 billion (Maggon 2007), and sales are projected to increase by 
14% per year between 2006 and 2012 (Reichert 2008). 
 
Hundreds of antibodies have been clinically tested since the 1980s, and by now, at least 36 of 
them have been approved world wide (Walsh 2006; Deonarain 2008; Reichert 2008). A list of 
approved monoclonal antibodies with details of generic formats, antigen targets, clinic 
applications and approval details are shown in Table 1.1 below.  
 
 
Table 1.1. A to Z of therapeutic monoclonal antibodies approved for disease treatment and diagnostic 
purposes.  
 
Drug name Generic name 
Target and 
format 
Major 
therapeutic 
category 
Year approved 
and 
manufacturer 
Arzerra Ofatumumab 
CD20, Human 
IgG1 
Cancer 
2009, 
Genmab/GSK 
Avastin Bevacizumab 
VEGF, 
Humanized 
IgG1κ 
Cancer  2004, Genentech 
Bexxar 
131
I-Tositumomab 
CD20, Murine  
131
-Iodine 
IgG2aλ 
Cancer  2003, GSK 
Campath Alemtuzumab 
CD52, 
Humanized 
IgG1κ 
Cancer  
2001, Genzyme/ 
Schering 
CEA-scan Arcitumomab 
CEA, Murine 
technetium-99m 
IgG1κ Fab  
Cancer 
(diagnosis) 
1996, 
Immunomedics 
Cimzia Certolizumab pegol 
TNFα, 
Humanized 
PEGylated Fab 
Immunological 2008, UCB 
CroFab 
CrotalidaePolyvalent 
Immune Fab (Ovine)  
Snake venom, 
Ovine IgG Fab 
Poison antidote 
2000,  
Protherics Inc 
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Drug name Generic name 
Target and 
format 
Major 
therapeutic 
category 
Year approved 
and 
manufacturer 
Digibind 
Digoxin-specific 
antibody fragment 
Digoxin, Ovine 
IgG Fab 
Poison antidote 2001, GSK 
DigiFab 
Digoxin Immune 
Fabs (Ovine) 
Digoxin, Ovine 
IgG Fab 
Poison antidote 
2001,    Protherics 
Inc 
Erbitux Cetuximab 
EGFR, 
Chimeric IgG1κ 
Cancer  
2004, 
Imclone/Bristol-
Myers Squib 
Herceptin Trastuzumab 
Her2, 
Humanized 
IgG1κ 
Cancer  1998, Genentech 
HumaSpect Votumumab 
CAA, Human 
technetium99m 
IgG1κ 
Cancer 
(diagnosis) 
1998, Organon 
Teknika 
Humira Adalimumab 
TNFα, Human 
IgG1κ 
Immunological 2002, Abbott 
Indimacis 125 Igovomab 
CA-125, Murine 
111
-Indium mAb 
fragment (Fab2) 
Cancer 
(diagnosis) 
1996, CIS Bio 
LeukoScan Sulesomab 
NCA-90, 
Murine 
technetium-99m 
IgG1κ Fab  
Infection and 
inflammation 
(diagnosis) 
1997, 
Immunomedics 
Lucentis Ranibizumab 
VEGF,  
Humanized 
IgG1κ Fab 
Ophthalmic 
2006, Genentech/ 
Novartis 
Mylotarg 
Gemtuzumab 
ozogamicin 
CD33, 
Humanized 
IgG4κ-
calicheamycin 
Cancer 
2000, Wyeth 
pharmaceuticals 
MyoScint imciromab pentetate 
Myosin, Murine 
111
-Indium 
IgG2aκ Fab 
Heart disease 
(diagnosis) 
1996, Centocor 
OncoScint 
CR/OV 
Satumomab 
pendetide 
TAG-72, 
Murine 
111
-
Indium IgG1κ 
Cancer 
(diagnosis) 
1992, Cytogen  
OrthocloneOKT3 Muromonab 
CD3, Murine 
IgG2α 
Immunological 
1986, Johnson & 
Johnson 
ProstaScint Capromab pentetate 
PSMA, Murine 
111
-Indium 
IgG1κ 
Cancer 
(diagnosis) 
1996, Cytogen 
Raptiva Efalizumab 
CD11a, 
Humanized 
IgG1κ 
Immunological 
2003, Genentech/ 
Merck Serono 
Remicade Infliximab 
TNFα, Chimeric 
IgG1κ 
Immunological 1998, Centonor 
ReoPro 
 
Abciximab 
Glycoprotein 
(GP) IIb/IIIa, 
Chimeric IgG1κ 
Fab 
Hemostasis 1994, Centocor 
Table 1.1-Contioued 
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Drug name Generic name 
Target and 
format 
Major 
therapeutic 
category 
Year approved 
and 
manufacturer 
Rituxan Rituximab 
CD20, Chimeric 
IgG1κ 
Cancer 
1997, Genentech/ 
Biogen/IDEC 
Simponi Golimumab 
TNFα, Human 
IgG1κ 
Immunological 
2009, 
Centocor/Schering-
Plough 
Simulect Basiliximab 
CD25, Chimeric 
IgG1κ 
Immunological 1998, Novartis 
Soliris Eculizumab 
Complement-5, 
Humanized 
IgG2/4κ 
Immunological 
2007, Alexion 
Pharmaceuticals 
Synagis Palivizumab 
RSV, 
Humanized 
IgG1κ 
Infection 
1998, MedImmune/ 
Abbott 
Tecnemab KI - 
HMW-MAA, 
Murine mAb 
fragments 
(Fab/Fab2 mix) 
Cancer 
(diagnosis) 
1996, Sorin 
Tysabri Natalizumab 
α4-integrin, 
Humanized 
IgG4κ 
Immunological 
2004, Biogen 
IDEC/Élan 
Vectibix Panitumumab 
EGFR, Human 
IgG2κ 
Cancer 2006, Amgen 
Verluma 
Nofetumomab 
merpentan 
CAA, Murine 
technetium-99m 
IgG1κ Fab 
Cancer 
(diagnosis) 
1996, Boehringer 
Ingelheim/ 
NeoRx 
Xolair Omalizumab 
IgE, Humanized 
IgG4κ 
Immunological 
2003, Genentech/ 
Novartis 
Zenapax Daclizumab 
CD25, 
Humanized 
IgG4κ 
Immunological 
1997, Hoffmann–
La Roche 
Zevalin Ibritumomab tiuxetan 
CD20, Murine   
90
-Yttrium 
IgG1κ 
Cancer 2002, Biogen IDEC 
 
Monoclonal antibody nomenclature: Generic names for complex drug molecules such as antibodies follow a 
nomenclature system used by the WHO and US adopted names. The name provides information about the 
antibody target and source. For example, a „tu(m)‟ denotes miscellaneous tumours whereas a „pr(o)‟ denotes 
prostate cancer and „go(v)‟ denotes ovarian cancer. This is then followed by „o‟ for murine, „u‟ for human, „xi‟ 
for chimeric or „zu‟ for humanised followed by the suffix „mab‟. There is a variable, specific prefix in front of 
the name (Deonarain 2008). Full details can be found in http://www.amaassn.org/ama/pub/category/2956.html 
(last accessed 18 January 2010). 
 
Abbreviations: 
CA-125: Carbohydrate antigen -125; CAA: Carcinoma-associated antigen; CEA: Carcinoembryonic antigen; 
EGFR: Epidermal growth factor receptor; Her2: Human EGF receptor 2; HMW-MAA: Human high molecular 
weight melanoma-associated antigen; NCA: Nonspecific cross-reacting antigen; PSMA: Prostate specific 
membrane antigen; RSV: Respiratory syncytial virus; TAG: Tumour-associate glycoprotein; TNFα: Tumour 
necrosis factor-alpha; VEGF: Vascular endothelial growth factor.  
 
 
Table 1.1-Contioued 
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Instead of treating infectious diseases, as was the intended initial purpose of antibodies in 
serum therapy, the application and development of modern mAbs are predominately focused 
on another two therapeutic categories – cancer and immunological diseases (Reichert and 
Pavolu 2004). As shown in Table 1.1, nine of the approved antibodies are used for direct 
cancer treatment with an additional 7 products applied for cancer diagnostic purposes. For 
immunological disease treatment, such as autoimmune and inflammatory disorders, ten mAb 
approvals have already been launched successfully. 
 
 
1.1.4 Therapeutic Mechanisms of Approved mAbs 
In contrast to Ehrlich‟s 1908 Noble Prize predictions, the most successful cases of antibody 
therapeutics in most of clinical disease treatment have been when the antibody was directly 
utilized as naked IgG without conjugation (Table 1.1). Based on the structural specificity of 
antibodies, antibody therapy is determined to be one of the subclasses of “targeted therapy”. 
The wide variety of targeted therapy can be classified into direct and indirect approaches 
(Schrama et al. 2006), and a summary of direct approaches are schematically showed in 
Figure 1.3. 
 
 
Figure 1.3. Direct actions of therapeutic antibodies. Cells expressing various antigens (green) can be targeted 
by corresponding mAbs (orange), which then induce effector functions including ADCC (via binding between 
Fc from antibody and Fcγ receptor on the effector cells) and CDC (via C1 component). Signal transductions 
induced cell growth, proliferation and angiogenesis can be inhibited by specific mAbs, whose bindings down-
regulate the signalling proteins, such as vascular endothelial growth factor (VEGF) and other growth factors 
(GFs). Signalling interferences can cause subsequent apoptotic cell death to the targeted cells. Endocytosis of 
internalizing cell surface antigens bound with corresponding mAbs also leads to cell damage and cell death. This 
figure is cited from (Ben-Kasus et al. 2007). 
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Using medications in cancer therapy as a typical example, several approved mAbs with 
numerous clinical trial pipeline candidates are following direct approaches in terms of 
fulfilling their therapeutic purposes. The direct targets contain tumour specific or associated 
proteins, and the direct approaches for therapeutic mAbs executing malignancies (Figure 1.3) 
include alteration of the cancerous cell signalling pathways, which lead to cell death or the 
effectiveness of antibody Fc domain mediated immune functions, such as ADCC and CDC 
(Deonarain 2008; Nimmerjahn and Ravetch 2008).  
 
1.1.4.1 Antibodies Interfering in Cell Signalling Transduction Mechanisms（Fab-
mediated activities） 
It is becoming clear that tumourigenesis involves a myriad of interactions and processes. 
Factors that maintain a tumour-favourable environment have turned out to be an important 
area for target therapies, and consequently, these factors are termed “tumour-associated 
targets”. One of the most important and well studied tumour-associated targets is vascular 
endothelial growth factor (VEGF). It is a heparin-binding homodimeric glycoprotein consists 
of two identical 23 kDa subunits. Several different VEGF gene splicings encode a number of 
VEGF isoforms (Ferrara 1999). Normal embryonic vessel formation and angiogenesis were 
reported as essential functions of VEGFs (Adams and Weiner 2005), which are achieved by 
binding to VEGF tyrosine kinases receptor (VEGFR). Various subsequent signalling cascades 
are induced by the VEGFRs, including the Phosphoinositide 3-kinases (PI3K), the Akt (RAC-
α serine/threonine-protein kinase or protein kinase B) pathways that enhance the cell survival 
capacity, Ras/Raf/MEK/ERK signalling transduction (see legend for Figure 1.4) and mitogen-
activated protein kinase (MAPK) mediates DNA replication and cell proliferations (Roy et al. 
2006; Ho and Kuo 2007). Upregulated oncogenic VEGF and its receptors are frequently over 
produced by tumour cells to propagate tumour growth, tumour-associated angiogenesis and 
metastasis  (Fukumura et al. 1998; Tsuzuki et al. 2000; Dvorak 2002).  
 
Bevacizumab (Avastin
®
)  
Bevacizumab is a recombinant humanized mAb against VEGF modified from its murine 
format mAb A4.6.1 (Kim et al. 1992; Presta et al. 1997) with a very high affinity (kd ~ 0.5nM). 
Bevacizumab binds specifically to all human VEGF-A isoforms and bioactive fragments, but 
no evidence has shown its binding to other VEGF gene family members (Presta et al. 1997; 
Ferrara et al. 2004). As one of the well-characterized representative mAbs, bevacizumab set a 
presidence for the therapeutic success in signalling transduction interference. Preclinical and 
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clinical development showed bevacizumab significantly neutralized VEGF interaction with 
VEGFRs in cancer patients and restrained the subsequent downstream signalling pathways 
assisting tumour growth and vascularising as mentioned above (Dvorak 2002). Pericytes can 
be recruited to the tumour vasculature after VEGF blockage by bevacizumab, which stabilize 
tumour vessel formation, and enhance the delivery of oxygen to the hypoxic zones (Winkler 
et al. 2004). Mediated by angiopoietin-1 and matrix metallproteinnases, tumour angiogenesis 
can be normalized, making a solid tumour which is more sensitive to radio- and chemotherapy 
(Lin and Sessa 2004; Winkler et al. 2004). In combination with cytotoxic chemotherapies, 
bevacizumab has provided prolonged survival to patients with colorectal, lung, and breast 
cancer, especially for the treatment of metastatic cases. It may act as an active angiogenesis 
inhibitor to be singly applied in ovarian and renal cancer therapies (Ferrara et al. 2004; Adams 
and Weiner 2005). In terms of pharmacokinetic properties, bevacizumab has been previously 
described with consistent terminal half-life between 17 to 21 days (Lin et al. 1999), and no 
antibody-related side effects have been reported in clinical trials to date. 
 
Trastuzumab (Herceptin
®
) 
Bevacizumab is an excellent example of an antibody curtailing tumour angiogenesis by 
blocking the soluble signal initiating cytokine binding to its receptor, which induces the 
malfunction of subsequent signal transduction pathways. Another successful humanized mAb, 
trastuzumab demonstrates an alternative approach to interrupt the signalling mechanisms in 
cancer treatment. Trastuzumab targets human epidermal growth factor receptor 2 (HER2; 
erbB2/neu), an 185 kDa glycoprotein that belongs to the ErbB class of epithelial growth factor 
receptor (EGFR) family – a family of transmembrane receptor tyrosine kinases (RTKs). Other 
members such as HER1 (also known as EGFR), HER3 (erb3) and HER4 (erB4) are also 
included in the EGFR family (Adams and Weiner 2005; Spector and Blackwell 2009). The 
family is prominently involved in regulating signal transduction, particularly during 
embryogenesis, which lead to cell growth, survival, differentiation, and migration (Yarden 
2001; Park et al. 2008). Except HER2, most HER proteins are activated on ligand binding, 
which then undergo homo- or heterodimerization among other family monomers. HER2, 
having no known ligand, is constitutively active, and ready to be dimerized in the absence of 
ligand. This makes HER2 a preferred coupling partner with other HER proteins, and these 
heterodimers are potent in signalling initiation (Pinkas-Kramarski et al. 1996; Graus-Porta et 
al. 1997). Phosphorylation of the intracellular tyrosine kinases linked to the receptors after 
their dimerization trigger downstream survival, differentiation and proliferation signalling 
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events (Yarden 2001). Like VEGF-VEGFR induced signalling pathways, PI3K and MAPK 
are closely involved in the intercessions of HER2 induced signal networks (Figure 1.4).  
 
HER2 became an attractive therapeutic target from its over-expression in a variety of human 
adenocarcinomas, including breast, ovary, prostate, lung and gastrointerstinal cancers 
(Slamon et al. 1989). The HER2 gene is located on chromosome 17,  approximately 20%-
25% breast cancers are currently estimated to be related to HER2 gene amplification and 
protein over-expression (Slamon et al. 1987; Owens et al. 2004), and HER2-positive tumours 
are detected in large proportions among breast cancer occurrences annually (Ferlay et al. 
2007), associated with poor prognosis and decreased response to hormonal and 
chemotherapies in clinical treatment (Slamon et al. 1987; Gusterson et al. 1992; Leitzel et al. 
1995). Following the normal signal transduction, cancer over-expressed HER2 actively 
accelerates homodimer formation, which deregulates subsequent signal networks and has a 
vital impact on tumour cell survival, expansion, metastasis and transformation (Wang and 
Greene 2008). 
  
Blockage of HER2 activation has been demonstrated in preclinical models and it was shown 
that inhibition of the survival pathways led to the induction of tumour cell apoptosis (Yakes et 
al. 2002). Trastuzumab was designed with high selectivity and affinity (~5nM) to HER2 
(Carter et al. 1992), and predominantly tested for HER2 over-expressed metastastatic breast 
cancer (Cobleigh et al. 1999; Vogel et al. 2002). Like bevacizumab, trastuzumab is also a 
humanized IgG1 version of its murine precursor, called 4D5, that targets c-erbB2, the 
extracellular domain (ECD) of HER2  (Fendly et al. 1990; Carter et al. 1992). The exact 
antitumour mechanisms exerted by trastuzumab are not fully understood at the moment, but 
several possible approaches have been proposed from different studies (Figure 1.4).  
 
As opposed to bevacizumab (which mainly blocks a tumour associated cytokine interacting 
with its receptor), shown in Figure 1.4 trastuzumab actively targets and down-regulates 
tumour cell surface expressing HER2 receptor to cease HER2-provoked intracellular survival 
and growth signalling messages. Similar to bevacizumab, key signalling pathways, such as 
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Figure 1.4. Tumour-HER2 induced signal transductions and potential therapeutic actions of trastuzumab. 
Both possible extracellular and intracellular mechanisms of trastuzumab are depicted. BAD, proapoptotic protein 
of the Bcl-2 family; JNK, c-Jun N-terminal kinase; MEK, MAPK/extracellular signal-related kinase; MEKK, 
MEK kinase; mTOR, mammalian target of rapamycin; NK, natural-killer cell; PAI-1, plasminogen activator 
inhibitor-1; TGF-α, transforming growth factor α. (Spector and Blackwell 2009). 
 
 
PI3K-Akt and MAPK pathways were disrupted after trastuzumab-HER2 interaction, resulting 
in reduced tumour cell growth and survival rates, and making the cells more vulnerable to 
death in harsh conditions (Nagata et al. 2004). Moreover, trastuzumab recognises HER2 ECD, 
but does not inhibit HER2 dimerization.The HER2 heterodimer often undergoes 
internalization after antibody targeting, followed by ubitiquination and proteolysis (Maier et 
al. 1991; Gilboa et al. 1995; Qian et al. 1997). Internalized trastizumab bound HER2 is 
degraded by lysosomes through clathrin-mediated endocytosis. This process also 
subsequently quenches the HER2 mediated tumour survival signal transductions (Hurwitz et 
al. 1995; Klapper et al. 2000). Signal transduction inhibitions also result in the accumulation 
of cyclin-dependent kinase (CDK) inhibitor p21/WAF1 in the cell nucleus that decreases the 
CDK2 activity, which leads to cell cycle arrest and apoptosis (Xia et al. 2004; Hudis 2007). 
DNA damage can also be induced in cancer cells as an outcome of blocking HER2 mediated 
DNA repair response, as trastuzumab promotes the cell to escape early from DNA-repair 
required cycle arrest (G1 and S) phases especially after combined chemo- and radiotherapies 
(Pietras et al. 1994; Pietras et al. 1999). Inhibition of angiogenesis was thought to be another 
signalling interference feature of trastuzumab. In a similar way seen with bevacizumab 
treatment, downregulation of intratumoral VEGF, and other pro-angiogenic factors by 
trastuzumab were shown from preclinical murine xenograph tumour model combined with 
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chemotherapeutic drug treatment. Tumour blood vessel shrinkage and reduced tumour growth 
were also reported (Izumi et al. 2002). Additionally, HER2 often undergoes proteolytic 
cleavage shedding the ECD into blood circulation, and leaving the truncated membrane-
bound fragment capable of signalling (Fornier et al. 2005). Trastuzumab prevents both basal 
and activated HER2 ectodomain cleavage, which stops further receptor activation for 
signalling transduction (Molina et al. 2001).  
 
Rituximab (Rituxan
®
) 
CD20 is a cell surface anchored receptor protein found on both healthy B-cell and 99% of B-
cell lymphomas and leukaemias (Coiffier 2007). No ligand has been reported for CD20, and 
as yet its biology is poorly understood. However, it has been found that CD20 assembles as a 
tetramer into lipid rafts upon antibody binding and acts as a store-operated calcium channel 
modulator for downstream caspase activation and signalling events (Polyak et al. 1998; 
Bonavida 2007). Rituximab, the first antibody approved by the US FDA, was engineered as a 
chimeric IgG1 that specifically targets CD20, and originally applied for indolent B-cell non-
Hodgkin‟s lymphoma (NHL) treatment (McLaughlin et al. 1998).  
 
Rituximab works on the CD20 signalling pathways to cause cancer cell apoptosis by two 
main routes: acceleration of calcium ion flux rate, and inhibition of intrinsic signalling 
cascade including MAPK proliferative signalling mediated by p38-MAPK/NF-κB and 
extracellular regulated kinase (erk) (Ben-Kasus et al. 2007). Together with other signalling 
inhibition on Akt and other cancerous associated anti-apoptotic survival pathways and caspase 
activations, these signal alterations induced by the cross-linking of rituximab and CD20 can 
also greatly increase cancer cell apoptosis and make tumour cells more sensitive to chemo- 
and radiotherapies (Bonavida 2007).  
 
Certolizumab pegol (Cimzia
®
) 
Not only applied to the whole monoclonal Ig molecule, cell signal transduction impedances 
are expected to be more efficiently exhibited by the smaller derivative of antibodies – 
antibody fragments. In April 2008, certolizumab pegol, a recombinant humanized antibody 
Fab fragment conjugated to a ~40 kDa polyethylene glycol (PEG) for plasma half-life 
enhancement, was approved by the US FDA for the treatment of moderate-to-severe Crohn‟s 
disease (CD) (Melmed et al. 2008). The antibody Fab targets specifically tumour necrosis 
factor α (TNFα), one of the most important pro-inflammatory cytokines involved in chronic 
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inflammatory diseases (Bouma and Strober 2003; Korzenik and Podolsky 2006). More details 
on certolizumab pegol as a powerful anti-inflammatory signal blocker will be discussed in the 
later antibody engineering sections. 
 
As listed in Table 1.1, a number of mAbs have been approved for interfering signalling 
molecules or receptor proteins to achieve their therapeutic applications. Like trastuzumab, 
some mAbs even have several possible disease-fighting mechanisms, such mAbs include 
cetuximab (Erbitux
®
), adalimumab (Humira
®
), ranibizumab (Lucentis
®
), natalizumab 
(Tysabri
®
), panitumumab (Vectibix
®
) and infliximab (Remicade
®
). 
 
 
1.1.4.2 Antibodies Eliciting Host Effector Functions (Fc mediated activities): 
Apart from those targeting functions involved in alteration of cell signalling networks, a more 
significant and effective degree of naked full-length therapeutic mAb is mediated by Fc-based 
immune responses such as CDC, ADCC, and antibody-dependent cell phagocytosis (ADCP). 
This engagement of the host immune system has the potential to augment the efficacy for 
antibody direct therapeutic activities against functional antigens (i.e. signalling) and also has a 
further prospective to turn non-functional antigens into useful targets (Griggs and Zinkewich-
Peotti 2009). In order to react with the antibody Fc domain, a range of Fcγ receptors (FcγRs) 
are expressed by a diverse set of immune cell populations, including B cells, dendritic cells, 
macrophages, mast cells, NK cells, and neutrophils (Desjarlais et al. 2007). Most FcγRs are Ig 
superfamily glycoproteins, and often appear in activatory and inhibitory polymorphisms 
(Nimmerjahn and Ravetch 2008). Activatory (FcγRI, FcγRIIA and FcγRIII) and inhibitory 
(FcγRIIB) Fcγ receptors are co-expressed and regulate the actions of effector cells. B cells 
and NK cells are exceptions, as B cells only express FcγRIIB to inhibit endogenous IgG 
activation, while NK cells only express FcγRIII for independent cell killing after target 
confirmation (Ravetch and Bolland 2001). A serial signal transduction cascade can be 
triggered after the antibody Fc engagement to the activating FcγRs, which leads to the final 
activation of ADCC and ADCP. Immune effector cells under the targeted antibody 
recruitment can then perform a variety of functions, including the release at local cytolytic 
proteins (i.e. granzymes and perforins) and phagocytosis of the target cell. The lysis of the 
target cell facilitates the antigen presentation, which stimulates T cell activation and 
production of various regulatory cytokines (Carter 2001). CDC is triggered through classical 
activation pathway, which is initiated by the binding of complement component C1q to the Fc 
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portion of antigen bound IgG molecule. The targeted antigen expressing cell can be lysed, by 
the consequent formation of membrane attack complex (MAC) of the complement system 
(Iannello and Ahmad 2005; Desjarlais et al. 2007). Variations of active IgG isotypes exist on 
the capacity of immune effector cell recruitment. Based on the FcγR expression profile, 
human IgG1 and IgG3 (and murine IgG2a) are normally present as principal functional 
isotypes with relatively high affinity to activate the immune responses, while extended hinge 
region makes IgG3 less stable, resulting IgG1 is usually more preferred for drug design also 
because of its longer serum half-life (Dijstelbloem et al. 2001; Nimmerjahn and Ravetch 2005; 
Desjarlais et al. 2007). 
 
Containing an IgG Fc structure, both trastuzumab and rituximab also exhibit important anti-
cancer advances through their Fc mediated immune responses (Lazar et al. 2006). Both in 
vitro and in vivo studies suggested that ADCC was induced by trastuzumab and no anti-
tumour response was detected from FcγR deficient mice models (Cooley et al. 1999; Clynes 
et al. 2000; Mimura et al. 2005). Pivotal preclinical and clinical studies also provided 
supportive evidence showing that trastuzumab has a role in engaging cognate FcγR on the 
immune effector cells (predominantly NK cells) as key therapeutic mechanisms (Gennari et al. 
2004; Arnould et al. 2006). There is also strong evidence supporting rituximab in utilizing Fc 
elicited cytotoxic and therapeutic effects. Clinical trials of NHL patients with Fc receptor 
polymorphisms indicated ADCC as an approach of rituximab immunotherapy (Cartron et al. 
2002; Weng and Levy 2003). In addition, combinational use of NK cell promoting cytokines, 
including granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 
(IL-2), was reported to enhance rituximab effect with increase NK cell development and 
immune activity (Olivieri et al. 2005).  
 
CDC was also showed to be activated by trastuzumab in vitro when human serum was tested 
but was not activated when applied to sera from mouse origin (Spiridon et al. 2002). 
Investigations in animals lacking C1q and employing complementary inhibitory proteins 
showed a reduced efficacy of rituximab indicating the mAb has a role in activating 
complement lysis (Golay et al. 2001; Di Gaetano et al. 2003). Other important therapeutic 
mAbs supporting immune effector functions include cetuximab (Erbitux
®
), alemtuzimab 
(Campath
®
), tositumomab (Bexxar
®
) and many others. 
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1.1.4.3 Indirect Antibody Targeting Therapeutic Approaches: 
In contrast to direct therapies, antibody indirect therapies rely on specific target delivering 
different kinds of effector molecules that are fused or conjugated to the antigen recognising 
antibodies. As a result, researchers have selected a variety of ammunition to equip antibodies, 
including drugs, toxins, radionuclides, and recombinant fusion proteins, and there are a whole 
collection of ways for mAb arming listed in Figure 1.5 below. 
 
 
 
 
Figure 1.5. Summary overview of indirect therapeutic actions by antibody. a. Directed antibody targeted 
therapy. b. Antibodies fused with cytokines or ligand proteins that can modulate immune response after the 
antigen targeting. Bispecific single chain variable fragments (scFvs) binding the antigen and provoking the 
immune system are classified in the same category. In addition, antibody–ligand fusion proteins can induce 
apoptosis to targeted cells as well as bystander cells by. c. Direct cytotoxicity can be induced to the antibody 
target through conjugated cytotoxic drug , toxin  or radionucleotides. d. The antibody-directed enzyme 
prodrug therapy (ADEPT) approach specifically aims at delivering antibody-enzyme fusion to the disease target, 
and the enzyme part takes part in converting the subsequently applied prodrug to a chemotherapeutic (Schrama 
et al. 2006).  
 
 
The armed mAbs are speculated to be more powerful therapeutics compared to the naked 
mAbs. Rather than traditional chemo- and radiotherapies, antibody immunoconjugates or 
fusions function by delivering lethal doses of cytotoxicity or radiation to the malignant targets, 
resulting in cell death (Goldenberg and Sharkey 2006; Schrama et al. 2006) while achieving 
diminished systemic toxicity through mAb based targeting strategies. In this regard, one 
antibody conjugated with an extremely cytotoxic compound, and two radiolabelled mAbs 
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have been approved for cancer treatment (also see Table 1.1). In order to optimise the 
conveyance purpose, low immunogenic chimeric or humanized mAbs, even antibody 
fragments with high affinities to antigens were often used for conjugation. Efficient antibody 
internalization into cells after target binding, site-specific modification for uniform 
conjugation with retention of antibody binding, linker technologies to enhance the novel cell 
killing agents, selection of new drugs and radioisotope with better therapeutic potencies, and 
optimizing pharmacokinetics and clearance are the important regulating issues in this field 
(Wu and Senter 2005). 
 
Gemtuzumab ozogamicin (Mylotarg
®
) 
Gemtuzumab ozogamicin is the only clinically approved mAb-drug conjugate. It consists of a 
humanized anti-CD33 IgG4 and the antitumour antibiotic ozogamicin (N-acetyl-γ calicheamin) 
that causes DNA breaks. The two parts are connected by an acid-labile hydrazone linker 
(Bross et al. 2001). Mylotarg has been approved to treat CD33 over-expressing acute myeloid 
leukaemia (AML), and the rapid internalization of CD33 after antibody targeting implied a 
significant breakthrough of gemtuzumab ozogamicin with positive data from previous clinical 
trials (Sievers et al. 1999; Sievers and Linenberger 2001). Other cytotoxic drugs include 
doxorubicin, DM1, monomethyl auristatin E and geldanamycin (Baloglu et al. 2004; Schrama 
et al. 2006), together with toxins such as denileukin diftitox (Frankel et al. 2000), are 
currently under investigations. 
 
131
I-Tositumomab (Bexxar
®
) and 
90
Y-Ibritumomab tiuxetan (Zevalin
®
) 
Acceding to the success of radiotherapies for disease treatment, radio-immunotherapeutic 
antibodies have aimed to improve this.  Successfully applied in haematological cancers (i.e. 
NHL), two anti-CD20 antibodies, 
131
I-Tositumomab and 
90
Y-Ibritumomab tiuxetan (see Table 
1.1) conjugated with two different radioisotopes have to date been approved. Like rituximab, 
both antibodies utilized in the immunoconjugates are good CD20 binders with high 
specificities to the antigen expressing cancer cells (Sharkey and Goldenberg 2005; Davies 
2007). Toxic radionuclides 
131
I and 
90
Y were attached to the antibodies by either direct 
tyrosine residue conjugation or chemical chelation. 
90
Y emits a short path length beta 
emission with short radioactive half life, while 
131
I alternatively gives off both beta and 
gamma radiation with a longer path length and more prolonged half life (Milenic et al. 2004). 
Significant responses of both radiolabelled antibodies were dramatically indicated in treating 
rituximab-refractory NHL (Wu and Senter 2005). Other powerful isotopes such as bismuth-
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213 (
213
Bi) and Astatine-211 (
211
At) producing alpha particles have also been tested for 
conjugation with mAbs for therapeutic applications (Sgouros et al. 1999; Milenic et al. 2004).  
Coupling of gamma-emitting isotopes, such as technetium-99m (
99m
Tc) or Indium-111 (
111
In) 
to full length mAb and antibody fragments have been extensively used for computed 
tomography as a major part of radioimmunoscintigraphy for preclinical and clinical imaging 
aspects (Wu and Senter 2005). According to Table 1.1, eight mAbs have been approved for 
imaging. A number of positron emitters (for example, 
18
F, 
64
Cu, 
68
Ga, 
86
Y or 
124
I) have been 
attached to antibodies for positron emission tomography (PET) for better imaging evaluations 
with higher sensitivity and molecular resolution (Olafsen et al. 2005; Robinson et al. 2005). 
 
Rather than relying on binding to internalized antigen to deliver the lethal insult into the target 
cell, to expand targeting non-internalized ligands, antibody-directed enzyme prodrug therapy 
(ADEPT) was devised. This method enzymatically turns weakly-low toxic prodrug to highly 
toxic agents at the antibody-antigen site (see Figure 1.5), allowing the cytotoxin to freely 
defuse into the targeted cell (Bagshawe 1987; Denny 2004).  
 
As reviewed above, most conjugated antibodies achieve direct killing of the cell by the 
attached toxic or radioactive components. New approaches involving antibody fusion proteins 
and antibody fragment combinations with more than one binding specificities (see Figure 1.5) 
acting by various therapeutic mechanisms are evolving as promisingly new generations of 
indirect antibody targeting therapies. 
 
 
 
1.2 Antibody Engineering – Fragmentation and Recombinant 
Fusion 
 
As described in the section above, the historical milestones of antibodies in therapies have 
revealed a development of protein drugs. From the “serum therapy” which uses polyclonal 
antibodies from different species, to hybridoma cell line produced murine monoclonal 
antibodies; this nascent field has already come through its third generation, the booming stage 
which was fundamentally achieved by the advances of antibody engineering to characterise 
the mAbs with essential human properties (see Figure 1.2b) and expand mAb with broad 
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clinical applicabilities (Weiner 2007). Seeing the great success of generating fully human full-
length mAbs with two already approved for therapies - Adalimumab (Humira) and 
Panitumumab (Vectibix), the phase of mAb development third generation seems to have been 
well established, but unfortunately it has not brought a “mission accomplished”. The 
occurrence of limitations and new problems, especially for the whole IgG format, in clinical 
practise and laboratory investigations require improvements and other perspectives for the 
next generation of this field. 
 
 
1.2.1 Strength and Weaknesses of the Antibody Fc Domain 
Generally speaking, mAbs are still expensive biopharmaceuticals to commercially produce, 
and the primary applications of therapeutic mAbs are introduced in treating extreme and 
refractory diseases. The main attention of antibody engineering has been for years focused on 
improving the antigen binding variable domains with the development of a number of 
techniques to enhance the affinity of antibody clones (Loo et al. 2008). However, effects 
brought out by the distal constant region Fc portion also have significant pharmacological 
impacts. Effective modifications to exaggerate the Fc properties have won noteworthy 
improvements, however undesirable consequences can be very serious, and maybe even 
unavoidable.   
 
1.2.1.1 Therapeutic Efficacies and Side Effects 
As powerful as it has been repeatedly proved in many different therapeutic applications such 
as tumour cell killing and infectious disease treatment (Wallace et al. 1994), antibodies 
engage immune system through Fc fragment mediated ADCC and ADCP after FcγR binding 
and CDC by a series of complement system constitutional blood proteins. The mechanisms of 
the effector system signal activation and consequential immune responses (i.e. T cell 
activation, and cytokine release) were described with approved mAb models in the previous 
section (1.1.4). In order to enhance Fc-stimulated effector functions, a number of engineering 
modifications have been evolved. Pioneering studies on antibody isoforms, variants and 
glyco-forms led to a way of variety of Fc engineerings. For improving ADCC elicitation, 
investigations primarily focused on amino acid sequence and oligosaccharide modifications in 
the Fc domain. Amino acid mutation changes of IgG1 Fc have been reported to modulate 
binding affinity to FcRIIIA (Shields et al. 2001). Recent mutational studies by yeast display 
selected an IgG1 Fc variant having ~ 10-fold increased affinity to FcRIIIA, which led to 
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increased an ADCC capacity (Lazar et al. 2006). Such protein engineering modifications have 
also been carried out on trastuzumab and alemtuzumab for therapeutic ADCC activity 
augmentation (Lazar et al. 2006). The N-linked oligosaccharide in the CH2 domain of Fc 
fragment have an important role in Fc bio-activities, especially ADCC (Wright and Morrison 
1997). The addition of a bisecting N-acetylglucosamine (GlcNAc) to the core mannose 
residue and removal of fucose residue from IgG1 Fc glycosylation structure respectively 
exhibited more than ~10 and ~100-fold respectively higher ADCC activity in various systems 
(Lifely et al. 1995; Shinkawa et al. 2003; Niwa et al. 2005). CDC activity has also been 
engineered by facilitating mAb Fc to C1q binding. Mutations on Fc CH2 domain or hinge 
region, together with generation of mixed IgG1 and IgG3 constant region sequences have all 
shown different degrees of CDC enhancement (Idusogie et al. 2001; Dall'Acqua et al. 2006; 
Natsume et al. 2008). Financially backed by many big pharmaceutical and biotech companies, 
the pharmacological impacts of Fc induced immune effector functions are pivotal in certain 
disease treatment, and Fc-modified antibodies have shown great improvement from clinic 
data (Desjarlais et al. 2007; Strohl 2009). Moreover, this improvement also provides Fc-
fusion proteins with more promising development.  
 
On the other hand, unwanted drug side effects seem never to be avoidable and they are also 
associated with therapeutic mAbs.  These problematic issues are mostly related to whole 
antibody Fc domain-dependent immunotoxicities, which are predominantly caused by 
unnecessary cross-reaction immunogenicity and immunostimulation (Swann et al. 2008).  
 
Immunogenicity 
Based on the preferred parenteral administration routes (e.g. intravenous [IV], subcutaneous 
[SC] or intramuscular [IM]) of delivery antibody products, all approved intact therapeutic 
mAbs to date have shown some degree of immunogenicity, especially due to their murine 
origin (Tang et al. 2004). Examples such as first approved murine mAb, muromonab-OKT3 
have been reported with therapeutic inefficiencies due to the generation of neutralising anti-
globulin or HAMA response (Schroeder et al. 1990). Although influential reductions have 
been made during the antibody generational development by converting its murine origin to 
human type, as both chimeric and humanised antibodies were both designed with human Fc 
domains, human anti-chimeric antibody (HACA) and human anti-human antibody (HAHA) 
responses were still seen in patients (Mirick et al. 2004). Despite any foreign protein 
sequences left in the “designer” intact mAbs, the constant regions of the immunoglobulin 
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have always been the direct targets for the host antiglobulin responses, where Fc fragment 
consists of 50% of total constant regions, typically after repeat systemic administrations 
(Batra et al. 2002). Although the development has already achieved to place human Fc in the 
antibody structure, the basis of elicitment of antibody response to therapeutic mAbs still 
remains as a debate by now; however, it is clear that size reduction will lead to diminishment 
of immunogenic side effects and the choice between eliminating size from either the antigen 
selecting Fab domain (more precisely the CDR regions) or pharmacological immune response 
eliciting Fc domain seems to be obvious but also tough in clinical applications. 
 
N-linked glycosylations at asparagine-297 of CH2 domain of IgG presents another feature of 
antibody Fc domain, which may induce extra potential immunogenic risks. As glycosylation 
is a species- and cell-specific dependant characteristic, the production of these therapeutic 
proteins, even the fully human recombinants are not exactly the same as the natural 
endogenous protein (Hermeling et al. 2004; Descotes and Gouraud 2008). The maintenance of 
human type glycosylation consistency is very critical for mAb production (Jefferis 2005). 
However, different innovative eukaryotic cell expression methods (e.g. yeast, plant, 
mammalian expression system) with promising yield may increase the risk of producing 
heterogeneous glyco-profiles of the antibody (Filpula 2007). The host-specified antibody Fc 
fragment glycosylation portfolio can significantly influence the mechanisms of effector 
function activation. Even with modifications of ADCC improved glycostructure presentations, 
the oligosaccharide alterations of intact mAb Fc domain can lead to increased xenogenic 
potentials causing host hypersensitivity reactions (Jain et al. 2007).  
 
Immunostimulation 
Immunostimulation from Fc fragment normally involves both antigen-specific immune 
responses with canonical therapeutic effects and unnecessary/non-antigen-specific immuno-
toxic effects. Interaction with antigen expressed on tissues other than the intended target can 
cause the antibody Fc part cross-linking with the Fc receptors expressed on the effector cells, 
leading to the same immune responses utilized to fight against malignancies to the healthy 
tissues. These non-specific toxicity occurrences resulting from the unexpected 
pharmacological effects of the mAbs may include infusion reactions (IRs) and massive 
cytokine release (Roskos et al. 2004). 
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Most IR are allergic-type reaction, and mAb induced infusion reactions can be clinically 
characterized as mild flu-like symptoms like fever, chills, rash, nausea and so on; however in 
rare cases it can be fatal such as cardiovascular collapse and respiratory failure (Chung and 
O'Neil 2009). The associated immunological mechanisms behind IR often vary, however 
there is experimental evidence indicating cross-linking of effector cells by FcγRs targeting 
bispecific antibodies which can elicit infusion reactions (Curnow 1997; McCall et al. 2001). 
This consequently designates the possibility of antibody Fc cross-reacting with the effector 
cells with facilitated IRs. Severe reactions seen in patients including elevated lymphocyte 
counts and anaphylactic activation of complement cascades have also been evidenced in acute 
IRs caused by unexpected Fc-Fc receptor cross-linking from various mAbs, especially 
reported in rituximab treatment (Winkler et al. 1999; van der Kolk et al. 2001). The immune 
effector responses gathered by the therapeutic Fc domain to the healthy cells after their 
inevitable non-specific antigen binding were estimated to cause the life-threatening IR 
symptoms. Such symptomatic heart failure severity was observed in patients treated with 
trastuzumab for HER2-overexpression metastatic breast cancer, and relevant adverse effects 
of trastuzumab‟s ADCC and CDC on HER2-expressing cardiomyocytes were subsequently 
elucidated (Cook-Bruns 2001; Roskos et al. 2004).  
 
In addition, it has been clinical confirmed that cytokine release also plays a pivotal role in the 
IR mechanisms. As normally dedicated, cytokines act in a much localized microenvironment 
as autocrine or paracrine factors at the site of an immunological synapse. During antibody 
therapy, as a consequence of direct activation of various immunocompetent cells by the mAb 
Fc region, essentially released cytokines work as an important part in immunotherapies, 
including differentiation and activation of more cytotoxic immunocompetent cells to the 
target area (Waldmann 2003). However, non-specific antigen binding of mAb to healthy 
tissues can lead to imbalance release of pro-inflammatory cytokines, later reported as 
“cytokine storm” (Suntharalingam et al. 2006), causing IR associated symptoms, which is 
clinically termed as the cytokine-release syndrome (Breslin 2007). Symptoms seen in 
monotherapy trials of different approved mAbs, initially from muromonab-OKT3 to other 
recent approvals including rituximab, cetuximab, alemtuzumab, and trastuzmumab, have all 
suggested various levels of cytokine-release associated adverse reactions to patients, which 
are theoretically stimulated by mAb Fc cross-linkings to FcγRs (Kang and Saif 2007; 
Descotes and Gouraud 2008; Wing 2008; Chung and O'Neil 2009). Cytokine release triggered 
by intact mAb administration seems to be unavoidable especially for those antibodies utilizing 
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Fc domains to fulfil their therapeutic duties. Redundant cytokines produced after treatment 
with muromonab-OKT3 were believed to be caused by Fc mediated therapeutic mechanisms, 
such as T cell opsonisation and subsequent lympholysis (Gaston et al. 1991). 
Inadequate/unexpected cytokine release can give significant hazards to allergic and aged 
patients; therefore adequate
 
premeditation, careful patient monitoring, and prompt 
intervention are required when hypersensitivity signs occur. For severe IR cases, the mAb 
therapy needs to be discontinued, which may significantly disturb the treatment progress, 
especially to the patients suffering cancer or immunological diseases (Lenz 2007). 
 
 
1.2.1.2 Pharmacokinetics (PK) and Biodistribution 
The pharmacokinetic and biodistribution mechanisms of protein drugs, in terms of their 
plasma half life, transportation/localisation, as well as absorption, distribution, metabolism 
and excretion (ADME) profiles, are influenced by several factors including their size, shape, 
charge, hydrophilicity, antigen/tissue binding properties, and proteolytic sensitivities (Tang et 
al. 2004). Intact therapeutic mAbs exhibit specialized pharmacokinetic and biodistributional 
characteristics, where properties of the IgG Fc domains play a central role. 
 
Plasma Half Life 
Attesting to the importance and prevalence in the serum and non-mucosal tissue, the immune 
protective role of IgG antibodies is mediated by their extensive blood circulation periods (1 to 
almost 4 weeks depending on the subclasses). Research found the preservation of these long-
lived molecules were closed related to neonatal Fc receptor (FcRn) (Ghetie and Ward 1997; 
Anderson et al. 2006). The major histocompatibility complex (MHC) class I related receptor, 
FcRn was initially recognised as a salvage receptor that transfer the IgGs in intact from the 
mother to offspring (Simister and Rees 1985). Recent studies showed the present of the FcRn 
also has an intricate function of maintaining the homeostasis of IgGs in the circulation (Ghetie 
and Ward 1997). Illustrated in Figure 1.6, with high expression level of FcRn in vascular 
epithelial cells and the reticuloendothelial system (RES), the elevated affinity binding of IgG 
Fc domain with FcRn at acidic pH (<6.5) makes the immunoglobulin internalized into these 
cells and recycled or delivered through transcytosis back to the basolateral side of the cells, 
where the neutral pH dissociate the FcRn binding and releases the IgG back to circulation, 
thus extending its serum half-life (Ghetie and Ward 1997; Dall'Acqua et al. 2002; Kenanova 
et al. 2005). The expression of FcRn has also been detected from a range of cell and tissue 
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types including antigen-presenting cells (APCs), adult guts, kidneys, lungs and blood-brain 
barriers. The precise biophysiological reasons for the existence of FcRn on such tissues are 
not fully understood; however, their interactions with IgG Fc, followed by internalization 
process, are hypothesized as a facilitate mechanism for IgGs cross-membrane transport to 
achieve their antigen targeting motives (Ghetie and Ward 1997; Roopenian and Akilesh 2007). 
 
 
Figure 1.6. Proposed mechanism for IgG retention by FcRn. Described in the text, binding between IgG Fc 
and FcRn receptor is a pH dependent interaction. Cycling of FcRn salvage pathway increases IgG blood 
residence time by avoiding both serum proteolytic proteins and lysosomal catabolism. Figure from (Ghetie and 
Ward 1997). 
 
 
The alteration and manipulation of this pH-dependent IgG Fc-FcRn interaction has been 
investigated in many antibody and Fc-fusion pharmacokineticals for various research and 
therapeutic purposes. Using site-directed mutagenesis, functional amino acids of the Fc region 
involved in the interaction of IgG and FcRn have been mapped (Medesan et al. 1997; Kim et 
al. 1999; Shields et al. 2001), and several researchers have introduced different mutations in 
the Fc region critical to the FcRn binding site of human, mouse and human-mouse chimeric 
IgGs. They have showed significantly prolonged antibody serum half-life with increased 
binding affinity to FcRn at pH 6.0 and inhibited interaction at pH 7.5 in mice (Ghetie and 
Ward 1997; Hornick et al. 2000; Shields et al. 2001), rhesus monkeys (Hinton et al. 2004; 
Hinton et al. 2006), cynomolgus monkeys (Dall'Acqua et al. 2006) and humanized mice 
models (Petkova et al. 2006). Along with increased serum half-life, opportunities for antigen 
binding and major effector functions such as ADCC and CDC can be also improved 
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indicating the modification of increase Fc-FcRn affinity may prove to be an effective way of 
retaining antibody pharmacological purposes.  
 
Conversely, the extended blood residence time caused by the interaction between FcRn and 
antibody Fc can be highly undesirable for situations such as the administration of 
radioisotopes, toxins, and other cytotoxic reagents conjugated with therapeutic mAbs or using 
mAbs for biological imaging purposes. An acute effect is therefore required, as the 
transcytosis mediated by FcRn also uptakes the poison doses conjugated with the mAb into 
the healthy tissues, prolonged exposure of these toxic doses in the circulation can be 
extremely harmful to patients, and revoking the concept of antibody targeted therapies. Long 
exposure time of imaging materials linked with mAbs significantly increase the background 
interference, causing enormous difficulties and inaccuracies and poor contrast for diagnosis 
purposes and biodistribution studies. In addition, potential immunogenic and 
immunostimulatory side effects brought along with the therapeutic mAbs can be consequently 
exaggerated by the increased exposure of the therapeutic IgG molecule enabled by the 
recycling process established between antibody Fc domain and cell surface FcRn receptor. 
Strategies to interfere with FcRn-Fc interaction involve mutations in the IgG Fc structure to 
reduce the level of IgG in the circulation. Kim et al. and Medesan et al. created shorter half-
lived chimeric IgGs (Medesan et al. 1997; Kim et al. 1999), and they were introduced in the 
immunotoxins work later on, in order to minimise the toxin side effects and improve 
therapeutic indices (Pop et al. 2005). In the field of tumour imaging using radiolabeled 
antibody, both enhanced antigen localization rate and improved clearance rate were required. 
To tailor the pharmacokinetics and imaging properties, attenuating the IgG Fc-FcRn 
interaction provides a helpful approach in controlling the antibody serum half-time for 
optimised antigen targeting with reduced imaging background interference and side effects 
(Kenanova et al. 2005; Jaggi et al. 2007).  
 
Extravasation and Biodistribution  
The movement of molecules across tissue membranes is generally governed by active and/or 
passive transport processes. Active transport is mediated by specific receptor or carrier, 
whereas the passive transfer is more likely to happen via simple diffusion. As shown in Figure 
1.7 below, the passive diffusion is generally regulated by factors such as tissue permeability, 
membrane surface area, concentration, and pressure gradients of drug across the membrane 
(Tabrizi et al. 2009).  
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Classified as a large, hydrophilic substance, IgG antibodies transport across the vascular 
endothelial cells very slowly, and diffusion and convection are believed to the primary driven 
force to drag the antibodies from blood fluid to tissue interstitial fluid. The following “into-
tissue” extravasation movement of antibodies through various capillary networks is 
determined by the rates of fluid movement from blood to lymph and the sieving effect of 
paracellular and lymphatic pores in the vascular endothelial beds that allow antibody 
permeability.  
 
 
Figure 1.7. Passive diffusion processes for molecules move between blood and body tissues. In general, 
blood flow limited perfusion (a) and physiological structures (i.e. permeability) (b) of tissue membrane regulate 
the rate of drug distribution in tissues. Pressure gradient mediated molecule convection (c), and concentration 
difference induced diffusion (d) processes are two main mechanisms of transvascular transport that may 
facilitate macromolecules extravasation. Figure taken from (Tabrizi et al. 2009). 
 
 
There are four types of blood capillaries that could facilitate the transport of mAbs, however, 
only the sinusoids having clefts (~100nm) around organs such as liver and spleen can allow 
mAb travel freely. Fenestrated capillaries found in the gastrointerestinal (GI) tract, various 
glands and renal glomeruli with clefts about 30-80nm in diameter can already be restrictive to 
IgG transport, and disallow the macromolecule renal clearance. Consequently, much slower 
diffusion of mAbs is found in structures such as skin, muscle and other connective tissues 
through the continuous capillaries, and nearly no IgG antibodies can be distributed into the 
brain duo to the tight brain capillary endothelial wall, also known as the blood-brain barrier 
(Wang et al. 2008; Tabrizi et al. 2009). Concentrations of unbound IgG are approximately 
tenfold lower than plasma concentrations in many tissues, except those with leaky vasculature 
capillaries (Tabrizi et al. 2009).  
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Shown in Figure 1.8, receptor-mediated and fluid phase endocytosis may be another 
important pathway for antibody to distribute in body tissues (Lobo et al. 2004).  
Internalization of interstitial antibodies bound to membrane antigens, and FcγRs via Fc 
domain may initiate blood–tissue hydrostatic pressure gradient facilitating antibody 
convective transport into tissue fluid.  
 
 
 
Figure 1.8. Antibody distribution. (a) Antibody transport to the tissue interstitium or return to the blood via 
fluid phase endocytosis by FcRn mediated entry into vascular endothelial cells; (b) Sieving effect of paracellular 
pores in the vascular endothelium regulates the entry of antibody into the tissue interstitium via convective 
transport, and the return of antibody to lymph fluid with much quicker rate duo to larger diameter of lymphatic 
vessels. It is reasonable to expect lower antibody concentrations in interstitial fluid relative to blood. However, 
exceptional distribution can be found in organs with leaky capillary structures and high affinity/high capacity 
binding of antibody in tissue; (c) Binding of antibody to cellular antigens. Scheme is cited from (Lobo et al. 
2004). 
 
 
More importantly, fluid phase endocytosis has been suggested for antibody extravasation via 
vascular endothelial cell internalization contributed by FcRns, specially supported by FcRn 
bi-directional (apical and basolateral) manner of transporting IgG (Antohe et al. 2001; Lobo et 
al. 2004). The wide expression of FcRn in different cells may facilitate transport of IgG 
molecules, and it does not mediate the uptake or influx of IgG in the blood to tissue direction 
(Ghetie and Ward 1997; Roskos et al. 2004). As outlined in Figure 1.8, this antibody 
“distribution” phase is also termed as the α-phase when measured by the biexponatial 
clearance model. 
 
Clearly, the excessive large size of intact IgG molecule significantly limits its in vivo 
distribution, which limits quantities delivered to malignant tissues or tumours, and poor 
diffusion to the neoplastic blood vessels around the tumours (Batra et al. 2002). Insufficient 
therapeutic effects, increased side-effects and cytotoxicity, and poor bio-imaging efficiency 
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can all be considered due to poor extravasation and antigen localization via using whole 
length IgG antibodies. Particularly for treating larger tumour mass, irregular vasculature, cell 
density, tissue structure, extracellular matrix (ECM) composition, and most crucially, the 
hypoperfused tumour regions with elevated interstitial fluid pressure could make the diffusion 
of an IgG across half a centimetre in weeks to months (Jain and Baxter 1988; Beckman et al. 
2007). Therefore, in order to deliver mAbs into brain and solid tumour masses, tailoring 
antigen specificity with smaller molecular size of antibody for better tissue penetration is 
highly required in order to achieve improved therapeutic effects of the antibody (Beckman et 
al. 2007; Pardridge 2008). The Fc domain that consists of one third of the total IgG structure 
could possibly be considered as a redundant part, especially when cytotoxic payloads or 
imaging materials are conjugated, while functionally, targeting specific antigens seems to be 
more important and valuable for mAbs in different therapeutic purposes. 
 
Degradation and Clearance 
Therapeutic IgG molecules can be degraded and eliminated from body circulation through a 
number of mechanisms, which are affected by many Fc domain related factors including 
affinity to FcRn receptor, immunogenicity and glycosylation degree of the mAb, 
susceptibility for the mAb to proteolysis, and antigen-mediated eliminations (Mascelli et al. 
2007). Due to the large size of IgG molecule, other than normal urinal excretion via kidney, 
intact mAbs are primarily degraded by plasma proteolytic catabolism, following fluid-phase 
or antigen-mediated endocytosis. 
 
Pointed out previously, binding between IgG Fc to FcRn receptors protect the IgG molecules 
from a variety of proteolytic enzymes and lysosomal catabolic destinies. This reinforcement 
for therapeutic mAb blood stability was observed in clinical trials from short half-life of 
murine originated mAbs to long circulation time of more human-like mAbs, due to different 
interspecies of IgG Fc domain affinities to human FcRn (Roskos et al. 2004). However, 
excessive administration of stable IgG molecules with prolonged serum half-life can be 
aetiological agents in certain types of autoimmune disease treatment. Strategy to modulate in 
vivo antibody levels, developed by Vaccaro et al., uses administration of engineered IgGs 
with high affinity but reduced pH-dependent binding to FcRn. Therefore, these IgGs are not 
readily to be released by FcRn at the cell surface, and the excessive of this accumulation can 
block the FcRn of recycling other serum IgGs. They called this man-made IgG “Abdeg”, and 
it has the function of enhancing IgG degradation. The inability of FcRn-binding caused by 
- 55 - 
Abdegs may be useful in autoimmune disorders or inducing rapid clearance of IgG-toxin or 
IgG-drug complexes (Vaccaro et al. 2005). The concept was also supported by the research of 
Petkova et al. from their humanized mouse models (Petkova et al. 2006).  
 
Based on the phenomenon of the concentration-catabolism effect, FcRn‟s IgG restorement 
can be interfered or abolished by competitive occupation and saturation of FcRn receptor, 
which then facilitates IgG clearance. Overloading with “innocuous” exogenous IgG raises the 
serum concentration above the equilibrium set point and saturates the FcRn. This has been 
one possible way to shorten the half-life of excess IgGs with potential side effects. Losing the 
chance to bind to FcRn, the IgGs have to enter the degradation pathways (Yu and Lennon 
1999). Monoclonal antibody directly against FcRn as well as small molecules or peptide 
inhibitors of the FcRn-Fc interaction could be used as alternative approaches to modulate the 
intact mAb clearance (DeLano et al. 2000; Marino et al. 2000; Liu et al. 2007). 
 
Antigen-mediated antibody elimination is also very important to remove circulating IgGs via 
lysosomal catabolism, and significantly affect the PK of antibodies. Although three classes of 
FcγRs as introduced previously (section 1.1.4.2) are primarily responsible in regulating 
various effector cells functions after binding IgG Fc domains with varying degrees of affinity, 
they are also contributing impact on antibody clearance. In the case of targeting soluble 
antigens, therapeutic IgG molecules establish antigen-antibody complexes (or immuno 
complexes) after antigen binding. Recent findings highlight that FcγRs expressed on 
phagocytic cells capture the immuno complexes through FcγR and IgG Fc interaction, and 
internalize the complexes to lysosome for protein degradation and eventual clearance (Tabrizi 
et al. 2009). Both experimental and theoretical studies have also predicted more rapid 
clearance rate followed by increases in antibody-antigen binding in circulation (Johansson et 
al. 2002; Johansson et al. 2002). The antigen-mediated clearance mechanism is very dose 
dependent, and it considerably shortens the therapeutic mAb half-life when the dose level is 
insufficient to saturate the antigen pool (Roskos et al. 2004). An obvious deduction of 
trastuzumab half-life was reported in patients expressing both low and high serum levels of 
shed HER2 (Baselga et al. 1996). 
 
As mentioned previously, exogenous mAb induced immunogenicity is a product specific 
phenomenon, where IgG Fc domain specifically highlights the immunogenic features. The 
presence of endogenous anti-globulin antibodies may lead to a wide range of PK effects, as 
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the sizes of different immune complexes formed between the endogenous anti-drug antibodies 
and the therapeutic mAbs can lead to various elimination rates through FcγR featured 
phagocytosis, and this impact on the disposition of therapeutic mAb can be complex and hard 
to predict (Wang et al. 2008).  
 
 
1.2.2 Antibody Fragmentations and Recombinant Fusions 
In the context of using antibodies as therapeutic agents the advantages and disadvantages of 
antibody have been compared in the text and summarized in Table 1.2.  
 
Table 1.2. Properties of intact IgG based mAbs modulated by the Fc fragment in clinical development. The 
summary was partially adapted from previous reviews (Baumann 2006; Mascelli et al. 2007). 
 
Property Intact IgG based therapeutic mAbs 
Physicochemical 
large molecular weight (150 kDa); 
Complex and undefined properties (e.g. tertiary structure, extent and type 
of glycosylation); 
High cost of biotechnological production by host cell lines and isolated 
from culture media; 
Broad specifications which may change during development, difficult to 
standardize. 
Toxicological 
Antigen-mediated toxicity; 
Inappropriate Fc receptor (FcγR and FcRn) cross-interactions; 
Cytokine release; 
Exaggerated pharmacodynamic responses and biological toxicity. 
Immunogenicity Usually elicits antigenic responses 
Pharmacokinetic 
Very long half-life of a magnitude of weeks; 
Distribution usually limited to plasma and/or extracellular fluids; 
Poor extravasation for antigen localisation, and heterogeneous 
tissue/tumour penetration; 
Potential over-exposure to normal organs; 
Eliminated primarily by serum/lymphatic proteolytic degradation and 
lysosomal catabolism to endogenous amino acids; 
Slow blood clearance, which may not be linear (eg. receptor mediated 
disposition). 
Usability 
Relatively stable in therapeutic usage; 
Limited therapeutic efficacies in brain and solid tumour treatments, due to 
restricted capillary diffusion and hypoperfusion; 
Limited application in imaging studies. 
 
 
The engineering of antibodies is sometimes required to eliminate the undesirable negative 
effects associated with the Fc fragment. Various fragmentation approaches and different 
innovative structural and recombinant designs have been used to engineer a new generation of 
smaller antibodies without an Fc domain. Additionally, new molecular strategies have aimed 
to create novel antibody products with enhanced affinity, stability, reduced side effects, 
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modulated PK, and therapeutic efficacies. Recombinant technology has also provided a high 
yield and low cost lower cost method of production, allowing for the economically viable 
manufacture of therapeutic agents.  
 
 
1.2.2.1 Design of Antibody Fragments  
Initial attempts to remove the Fc domain and make smaller antibody fragments were based on 
the digestion of full length IgGs by the proteolytic enzymes pepsin or papain, which generates 
Fab2 or Fab fragments, respectively (Figure 1.9). These fragments retain their specific 
antigen-targeting capacities, demonstrate enhanced tissue distribution and antigen localization, 
and have faster homogenous tumour penetration and reduced immunological side effects 
compared with intact IgGs (Batra et al. 2002; Holliger and Hudson 2005; Jain et al. 2007). 
The production of different recombinant antibody fragments has also been facilitated by 
advances in recombinant DNA technology.  
 
The development of genetically engineered antibody fragments was initiated nearly 20 years 
ago through the engineering of a single gene encoding the variable heavy (VH) and light (VL) 
chains connected by a short flexible polypeptide linker (Figure 1.9), resulting in the 
production of a single-chain variable fragment (scFv) with monovalent antigen binding 
capability like that of the parental Fab fragment from which it was derived (Bird et al. 1988; 
Huston et al. 1988; Holliger and Hudson 2005).  Based on the influential invention of the 
scFv, numerous recombinant possibilities have been explored with regards to modifying 
antibody valency, functionality, biodistribution, PK, and therapeutic efficacies (Hudson and 
Souriau 2003). A schematic illustration of versatile recombinant antibody designs that have 
been investigated by now is shown in Figure 1.9 below. 
 
Monovalent Recombinant Antibody Fragments 
In the early 70s, initial reports described studies of antibody variable domains isolated from 
enzymatic digestion which were non-covalently associated and retained all the  antigen 
binding characteristics of the related Fab fragment  (Inbar et al. 1972). These 26 kDa 
molecules termed Fv fragments (Figure 1.9) exhibited improved tissue penetration due to 
their smaller size. However, poor stability at low concentrations and heterogeneity during 
purification significantly limited the expansion of this format (Skerra and Pluckthun 1988; 
Ward et al. 1989). fragment design forward and managed toresolve the problems seen in Fv  
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Figure 1.9. Schematic diagram of different recombinant antibody formats. Structures of three intact 
immunoglobulin molecules predominantly found from camel, shark and human are illustrated. They are named 
as camelid VhH-Ig, shark Ig-NAR and the „classic‟ IgG respectively. The V domains are responsible for target 
binding, where the monomer of camelid V domain is a called VhH, and the shark variable domain monomer is 
known as V-NAR. Both of the monomers (~15 kDa) have monovalent binding capacities and also known as 
nanobodies with various functional purposes. A variety of recombinant antibody fragments are also depicted, 
including single-domain VH, Fab, scFv and their multimeric formats, alongside different scFv fusion derivatives 
as well (sizes given in kilo Daltons are approximate). Figure was taken from (Holliger and Hudson 2005) and 
modified based on the reviews from (Hudson and Souriau 2003; Kontermann 2005; Carter 2006; Deonarain 
2008). 
 
 
fragment production. Both antibody VH and VL domains were commonly tethered by a 15 
amino acid (Gly4Ser)3 linker that provides both flexibility and hydrophilicity to the more 
stabilized monomeric single chain antibody fragment (Bird et al. 1988; Huston et al. 1988; 
Maynard and Georgiou 2000). In order to investigate scFvs further for improving 
functionality, stability and expression levels, issues including domain orientation (VH-linker-
VL versus VL-linker-VH) (Tsumoto et al. 1994; Kim et al. 2008) and the nature (i.e. length and 
composition) of the inter-domain linker were subjects of additional study (Stemmer et al. 
1993; Turner et al. 1997). Aggregation tendency is another characteristic associated with 
scFvs which is primarily influenced by the intrinsic antibody sequence (Arndt et al. 1998). An 
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alternative monovalent format to the scFv is known as a dsFv, which stabilizes both the VH 
and VL domains by inserting a disulfide bond into the Fv framework region, and has been 
found to offer greater stability and less aggregation compared to the scFv (Kreitman et al. 
2001).  
 
With an even smaller size than Fv fragments, high affinity single variable (V)-like domains 
have been discovered from at least two types of organisms – the camelid (camels and llamas) 
and cartilaginous fish (sharks), and named as VhH in camelids and V-NAR in sharks (De 
Genst et al. 2004; Streltsov et al. 2004; Dooley and Flajnik 2005). These single V-like 
domains (~15 kDa) are generally soluble and stably expressed (Figure 1.9). Nanobodies are 
derivatives of theVhH and V-NAR antibodies. Modifications based on their ultra-small sizes 
and unique antigen binding surface structures, sensitive diagnostic and therapeutic nanobodies 
have promised to accomplish superior tissue penetration and targeting cryptic epitopes (i.e. 
enzyme active sites and canyons in viral and infectious diseases) (Cortez-Retamozo et al. 
2004; Stanfield et al. 2004; Stijlemans et al. 2004). Attempts to make nanobodies from human 
IgG single variable domain would be more preferred with reduced immunogenic side effect 
brought along current xenogenic nanobody formula (Colby et al. 2004; Jespers et al. 2004; 
Holliger and Hudson 2005). 
 
In general, monovalent antibody fragments (i.e. Fab, scFv, Fv, dsFv, and nanobodies listed 
above) are easily expressed with good yields and can be manipulated by genetic engineering 
to produce different monovalent fusion formats and various multi-functional and multivalent 
polymeric designs for therapeutic applications (Holliger and Hudson 2005; Jain et al. 2007; 
Weisser and Hall 2009). In terms of bi-functional fusion, a vast range of molecules (see 
section 1.1.4 and Figure 1.5) have been fused to provide important ancillary activities after 
target binding (Hudson and Souriau 2003). Various scFv-based fusion proteins have utilized 
these formats, such as scFv-enzyme fusions for ADEPT in cancer therapies and scFv-cytokine 
fusions for treating immunological diseases (Kousparou et al. 2002; Gafner et al. 2006; 
Kanter et al. 2007; Afshar et al. 2009). In this study, rather than delivering a secondary agent 
to a target, the primary purpose of producing a bifuctional fusion was to use the ancillary 
component to modulate the pharmacokinetic modality of the antibody for therapy. (described 
in more detail in section 1.5). 
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Bivalent and Multivalent Recombinant Antibody Fragments 
A major characteristic of monovalent interactions is the moderate dissociation constant (KD) 
and modest retention time between antibody fragments and their antigen, especially in the 
non-equilibrium environment of body vasculature and tissues (Holliger and Hudson 2005). 
For many applications requiring a slower target off-rate, and longer retention times, the use of 
multivalent antibodies with increased avidity and optimal size that can be beneficial in 
providing both improved binding kinetics and increased serum half-life (Jain et al. 2007; 
Weisser and Hall 2009).   
 
As illustrated in Figure 1.9, Fab, scFv fragments and nanobodies can all be engineered into di-, 
tri, tetrameric formats conjugated primarily by either chemical approaches or genetic linker 
designs. Construction of multimeric scFv‟s can be easily achieved through the reduction of 
scFv linker length to between zero to five amino acid residues. The shortened inter-linker of 
scFv molecule enables the VH of one chain to non-covalently pair with the VL of another, 
and consequently form a dimer molecule (diabody, ~50 kDa) (Holliger et al. 1993). Linkers 
less than 3 amino acids can force scFv‟s to associate into tri-bodies or tetrabodies (Iliades et al. 
1997; Dolezal et al. 2003). A cysteine-modified diabody has also been engineered to improve 
the structural confirmation consolidation of the non-covalent format, and facilitate additional 
chemical modifications (eg. with a radiometal for imaging) (Olafsen et al. 2004). Different 
strategies such as genetically engineering linkers between two or more monomeric fragments 
and using multimerization domains (eg. streptavidins, p53, leucine zippers and verotoxin) 
fused to antibody monomer fragments have been studied to generate various divalent, such as 
tandem single chain variable fragment (taFv) and single chain diabody (scDb) and multivalent 
molecules (Batra et al. 2002; Kontermann 2005; Jain et al. 2007). 
 
Bispecific and Multispecific Recombinant Antibody Fragments 
The combination of two or more different antibody fragments with more than one antigen 
target can have therapeutic applications. The bi- or multispecific antibody fragment can be 
constructed following the same principle used to form bi- or multivalent antibody fragments 
with different monomer elements (see Figure 1.9 for bispecific scFv and diabodies as 
schematic examples) (Todorovska et al. 2001). One of the most important and useful 
characteristics possessed by antibody fragments with dual or multiple specificities is the 
direction of effector functions towards the targeted antigen. With one arm targeting a specific 
antigen and the other arm engaging effector targets, such as T cell CD3, NK cell CD16, and 
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complement C1q. Such multispecific antibody fragments can recruit effector function without 
needing the antibody Fc domain (Holliger and Hudson 2005; Filpula 2007; Weisser and Hall 
2009); therefore overcoming the side effects associated with the Fc domain as mentioned in 
section 1.2.1.1. Equipped with more than one antigen targeting specificities, bi- and 
multispecific antibody can also be very important in the treatment of autoimmune and 
inflammatory diseases (van Spriel et al. 2000). 
 
Minibodies are recombinant antibodies consisting of antigen binding antibody fragments and 
intact or truncated Fc domains (eg. scFv-CH3 dimers in Figure 1.9, and scFv2-Fc). This 
arrangement can be considered as another bifunctional design, where the Fc domain can elicit 
effector functions, however, these formats can only be most useful where the negative effects 
of having the  Fc domain present are not considered detrimental to function (Batra et al. 2002; 
Jain et al. 2007; Weisser and Hall 2009).  
 
 
1.2.2.2 Advantages of therapeutic Antibody Fragments 
When engineering antibodies for therapy, agents must generally exhibit high affinity with 
discriminating specificity, minimal immunogenicity and low cross-reactivity (Ober et al. 
2001); these are the criteria for the successful development of a antibodies for therapy. Good 
expression yields, relatively simple construction, easy manipulation by recombinant 
engineering, has placed monovalent Fab or scFv fragments in the forefront of antibody 
engineering development.  Large natural and synthetic immune repertoires have been used to 
create various molecular library formats for selecting specific high-affinity antibodies 
(Hoogenboom and Chames 2000; Krebs et al. 2001; Hudson and Souriau 2003). The 
established display formats including bacteriophage display (McCafferty et al. 1990), 
ribosome display (Hanes and Pluckthun 1997; He and Taussig 1997), cell surface display 
(Francisco et al. 1993) and transgenic mice (He et al. 2002). More frequently, increased and 
repeated selection cycles have also been used to enhance antibody affinity maturation. As 
required, the selected high-affinity small monovalent antibody fragments can be reassembled 
back to Ig or multivalent or specific variants as described previously. A wide variety of 
expression hosts can be used for  high yield production of monoclonal antibody fragment, 
including prokaryotes (i.e. E. Coli and B.subtilis) and eukaryotes, including yeast, insect, 
plant and mammalian cells (Weisser and Hall 2009). However, the production of smaller and 
unglycosylated antibody fragments can be easier and less costly to produce in microbial 
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expression systems than in conventional mammalian cell culture systems. 
 
The humanization of smaller formats can also reduce immunogenicity to a significant degree. 
Using as an example the anti-TNFα humanized recombinant Fab fragment certolizumab pegol, 
which was approved by the FDA for Crohn‟s disease treatment, it was shown through safety 
and efficacy assessments that it had a lower rate of adverse-events than any other approved 
anti-TNF agent (Nesbitt et al. 2007; Sandborn et al. 2007), and a similar therapeutic efficacy 
to infliximab, a market leader for CD treatment (Melmed et al. 2008; Peyrin-Biroulet et al. 
2008). Low levels of human anti-Cimzia antibodies were detected in patients with various 
concentrations of intravenous infusions, especially lower incidence in patients injected with 
higher doses after a treatment cycle (Choy et al. 2002). Furthermore, data from patients 
suggested Cimzia has no cross-reactivity with other therapeutic agents, and other agents 
induced antidrug antibodies. Thus, combinational use of the Fab fragment, especially use as a 
replacement for patients develop immune response to traditional IgG antibodies (i.e. 
infliximab) can propose further therapeutic impact for CD treatment. 
 
Other FDA approved mAb Fab fragments with direct therapeutic functions are abciximab that 
prevents blood clots in angioplasty treatment, and ranibizumab for wet age-related macular 
degeneration treatment, CroFab
TM
 for snake venom neutralization, and DigiFab
TM
/Digibind
TM
 
as antidote for digitoxin poisoning, alongside one approved in China (metuximab) for cancer 
treatment (Holliger and Hudson 2005; Nelson and Reichert 2009). With a diversity of clinical 
antigen targets, a number of antibody fragment products have already been tested in different 
clinical and preclinical trial stages (Figure 1.10), while a huge pipeline of ongoing fragments 
also attracting a great deal of research and investment attentions. Among these products, 
novel scFv and nanobody based technologies have been added with Fab fragments to lead the 
new development wave of therapeutic mAbs (Nelson and Reichert 2009).  
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Figure 1.10. Statistics of selected therapeutic antibody fragments in clinical and preclinical development. 
Three molecular clusters including Fab and derivatives, scFv and derivatives, and others, such as nanobodies and 
minibodies are respectively indicated with their research profiles. Numbers of ongoing (red) and discontinued 
(blue) fragment candidates from each molecular class are also shown. Clinical trial phases 1, 2, and 3 are 
presented in Arabic numerals on the x-axis for each bar chart; PC, preclinical; App, approved. Figure modified 
from (Nelson and Reichert 2009). 
 
 
The remaining approved mAb fragments (6 in total) are applied in imaging for diagnostic 
usages (see Table 1.1). Most importantly, the sm   aller version of antibody fragments exhibit 
strong points such as enhanced tissue penetration, rapid vascular extravasation and antigen 
localization, which are the key factors to improve solid tumour antibody therapies (Jain and 
Baxter 1988; Holliger and Hudson 2005). Faster blood clearance rate as another major 
characteristic associated with small mAb fragments has been considered as ideal outcome to 
deliver enhanced imaging and radiotherapy applications with low background and high 
contrast and minimized over-exposure hazards to normal tissues (Holliger and Hudson 2005). 
However, this quick clearance rate can be a major concern to the antibody fragments to 
realize their therapeutic activity before being eliminated from the body circulation. 
 
 
1.2.2.3 Pharmacokinetics of Small Antibody Fragments  
One of the most important issues in antibody engineering is developing ones which exhibit 
optimal pharmacokinetics: appropriate dosing leading to optimal bioavailability, uptake, 
distribution and clearance in targeted and non-targeted tissues, leading to optimal 
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pharmacodynamics (Beckman et al. 2007; Constantinou et al. 2010). Due to the small size for 
most monovalent and bivalent antibody fragments (less than 50 kDa), renal metabolism is the 
major pathway for small protein and peptide elimination. Three possible routes are involved 
in kidney elimination, (1) glomerular filtration followed by (2) proximal tubules reabsorption 
and (3) hydrolytic degradation (Tang et al. 2004; Mahmood and Green 2005). The glomerular 
filtration selectivity is regulated by the size, molecular conformation, and charge of the 
protein. In general, protein sizes less than the approximate 70 kDa cut-off point are easily 
sieved out, which is typically small mAb fragments (Akhtar and Al Mana 2004). Studies on 
glomerular charge-selectivity also suggested anionic polymers are less readily to pass through 
the negatively charged basement membrane of the glomerulum than cationic molecules (Deen 
et al. 2001; Tang et al. 2004). As mAb hence have little charge influence, hydrolysis by brush 
border enzymes located on the luminal membrane appears to be more efficient and specific to 
small linear proteins (Carone et al. 1982). Lastly, rapid and feasible extravasation of size-
reduced mAb fragments also facilitates the post-glomerular capillary reabsorptions through 
proximal tubules (Tang et al. 2004).  
 
Despite the many benefits of being engineered into smaller versions, the biggest drawback of 
using small mAb fragments in therapies is its quick body clearance predominately via kidney 
elimination. Outlined in Figure 1.11, molecular size (often represented by proteins molecular 
weights) deductions of different recombinant antibody and fragments, migrated from intact 
IgG molecule (150 kDa) to monovalent scFv (30 kDa) and single V domain (15 kDa) 
antibody fragments, indicate corresponding plasma half-life (particularly drug elimination 
time, t1/2) reductions in general. Comparing to full length IgG molecules, a significantly 
shortened half-life has been shown to size reduced antibody fragments. As most mAb 
fragments are Fc domain free constructs, losing the Fc structure leads to the subsequent loss 
of Fc mediated FcRn salvage recycles, which adds another mechanism for fragments having a 
curtailed blood circulation time, on top of the size-provoked rapid renal clearance (Holliger 
and Hudson 2005; Kontermann 2009; Weisser and Hall 2009). As depicted in Figure 1.11 (b) 
above, small scFvs typifying small antigen binding proteins, have an extremely shortened 
residence time through both blood circulation and targeting tissues (i.e. tumour). Fragments 
with monovalent binding property also result in a poor antigen-expressing tissue retention 
capacity implied by the tumour/blood ratio analysis. Together with the rapid vascular 
extravasation and increased blood clearance rate via kidney elimination, a decreased in vivo 
antigen recognising window, reduced retentive support and decreased drug concentration 
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Figure1.11. The diversity of mAb formats. (a) A cartoon representation of different antibody formats together 
with their respective molecular weights (kDa) and human serum half-life (β phase). The glomerular cut-off (~70 
kDa) line is also indicated. (b) Biodistribution of different Her2 targeting mAb formats in two xenograft models. 
Left graph: tumour (solid lines) and blood levels (dashed lines) plotted against time after injection (h) for anti-
Her2 mAb IgG (blue), diabody C6.5 (black) and scFv C6.5 (red) in severe combined immune deficient (SCID) 
mice bearing solid Her2 expressing tumour. Right graph: Tumour-to-blood ratios of anti-CEA IgG, minibody, 
diabody and scFv in athymic mice with LS174 (CEA expressing) colon carcinoma xenografts plotted versus time 
after infusion (h). Figure adapted from (Holliger and Hudson 2005) and (Olafsen et al. 2004; Kenanova et al. 
2005; Olafsen et al. 2005). 
 
 
and accumulation at the site of action can be seen in small antibody fragments after injection. 
It has been shown by anti-tumour diabodies having bivalent antigen binding capacity but 
failed to show improvement in serum half-life and tumour retention times (Figure 1.11b), due 
to its smaller size than the renal cut-off point. These unwanted pharmacokinetic features can 
be disadvantageous for a range of treatments requiring prolonged blood residence time (eg. 
neutralizing harmful cytokines or toxins) or enhanced target binding and tissue retention or 
accumulation specificities (i.e. antibody directed solid tumour and payloads delivery 
therapies). Without the FcRn salvage pathways mediated by Fc domain interaction, there is an 
increased likehood that antibody fragments will be degradated by serum proteolytic enzymes 
or lysosomal catabolism. This can be considered as another cause leading antibody fragments 
to a reduced serum half-life. Therefore, an ideal biopharmaceutical reagent, specifically for 
administrative longevity needed tumour treatment or neutralization purposes, probably 
requires an intermediate molecular size with consistent (perhaps multivalent) binding 
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specificity, which provides rapid tissue penetration and antigen localization, high target 
retention and relatively good blood clearance rate to avoid over-exposure and immunogenicity 
elicitation (Holliger and Hudson 2005; Carter 2006). 
 
 
 
1.3 Modulating the Pharmacokinetics of Therapeutic Antibodies 
 
As previously described, the therapeutic efficacy of recombinant antibodies is strongly 
dependent on their pharmacokinetic properties, especially the time course within body 
circulation and their particular retention and concentration at the target site (Kontermann 
2009). Specifically subjected to the advent of small antibody fragments and alternative 
binding scaffolds, that are devoid of Fc-regions, strategies to increase the half-life of small 
proteins are becoming increasingly important (Constantinou et al. 2010). Traditionally, in 
order to prevent the rapid elimination via renal filtration and degradation (Tang et al. 2004), 
repeated large doses of these small protein drugs have to be administrated by infusion or 
intravenous bolus injections for high therapeutic efficacy maintenance over a long time period, 
and difficult administrative approaches, such as loco-regional intravitreal injection, has to be 
used to preserve a good antibody concentration at the disease site (Lobo et al. 2004; 
Kontermann 2009). Not only with respect to therapeutic functions, can this pharmacokinetic 
remediation significantly increase the risks of immunogenicity and other side-effects. The 
huge productive expenditure, as well as the cost, convenience and compliance to patient to 
complement this kind of administrative consumption is another reason for the expansion of 
using antibody fragments in therapies (Mahmood and Green 2005; van de Weert et al. 2005; 
Kontermann 2009).  
 
There are two general approaches to extending the longevity and stability of therapeutic 
proteins: chemical methods and recombinant/genetic techniques (Figure 1.12). Chemical 
methods pre-date the recombinant approaches and involve the chemical attachment of 
moieties which alter the physiochemical properties of the protein. Applied to antibodies, this 
includes the attachment of polymers, sugars and protein domains. Recombinant methods 
require the genetic engineering of the target protein or host cell line to produce variants with 
altered structure or function. The structural changes which lead to altered pharmacokinetics 
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include size, hydrodynamic volume, aggregation status and electric charge (pI) and the 
functional changes include various receptor binding abilities (Werle and Bernkop-Schnurch 
2006; Kontermann 2009; Constantinou et al. 2010). 
 
Chemical conjugation methods has been the most investigated method for modulating 
antibody pharmacokinetics so far, where by chemically inert moieties are strategically 
attached (see Figure 1.12 strategies 1-3). The main function of the conjugates is to effectively 
increase the apparent size or hydrodynamic volume of a given small particle, and 
consequently alter its pharmacokinetic properties. In general, the larger the conjugate attached 
the greater the half-life becomes, and this is most significant for proteins below the molecular 
weight cut-off threshold of glomerular filtration (Akhtar and Al Mana 2004; Tang et al. 2004; 
Constantinou et al. 2010).  
 
 
 
 
However, a balance must be achieved for the pharmacokinetic modifications, in case the 
benefits of lower clearance rates are not gained at the expense of significantly poorer tissue 
penetration and/or poor tissue to blood ratios. This is a particularly important consideration if 
antibodies are used as carriers of cytotoxic agents, such as radioisotopes (Davies 2007), where 
high doses leading to extended systemic residency could cause damage to normal tissues. 
Certainly, for antibodies neutralising systemic factors such as VEGF for solid tumour 
Figure 1.12. Schematic diagram 
illustrating the different pharmacokinetic 
enhancing strategies. Both chemical and 
recombinant methods are involved. Strategies 
1–3 work by increasing hydrodynamic 
radius, via conjugating chemicals (i.e. PEG 
or polysialic acid), homo amino acid polymer 
(HAP) fusions and fusion with polysialic acid 
(PSA) carriers; whereas strategies 4–9 utilize 
long serum-living proteins that have binding 
capacities to the neonatal Fc receptor, and 
methods in turns are bispecific albumin 
binding antibody fragment, chemicals, 
peptides or proteins, and direct albumin 
fusion, along with reconstruction with Fc 
portion. Key: blue line connections represent 
recombinant fusions and grey line 
connections represent chemical linkages. 
This figure has been directly taken from 
(Constantinou et al. 2010). 
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treatment (Panares and Garcia 2007) or tissue TNFα for Crohn‟s disease (Tracey et al. 2008), 
a long half life is desirable.  
 
Clearly, “one size fits all” form of conjugation is not practically applicable in manipulating 
small antibody drug pharmacokinetics. However, one general pharmacokinetic improvement 
profile is commonly required to be achieved, which includes extending the longevity of the 
antibody, allowing a more level range of bioavailability with enhanced potency, and directing 
the antibody particular mechanism of action specifically at the target site (Constantinou et al. 
2010).  
 
 
1.3.1 Chemical Conjugation 
1.3.1.1 Random (amine) versus Site-specific (thiol) Coupling 
Chemical conjugation mostly happens by interacting with various reactive groups within the 
primary antibody sequence. Typical reactive groups are lysine, cysteine, histidine, arginine, 
aspartic acid, glutamic acid, serine, threonine and tyrosine, as well as the N-terminal amino 
group and C-terminal carboxylic acid groups of the peptide. Lysine residues are traditionally 
used as active conjugating points as they often have a high surface propensity. However, these 
functional groups are not automatically predisposed as a conjugation point normally. Reactive 
groups may be sterically hindered as they are often embedded within the core tertiary 
structure of the antibody and therefore unavailable for conjugation. Moreover, essential amino 
acids for the antibody‟s function represent undesirable sites for conjugations. Although non-
site specific random conjugation has shown some success (Lee et al. 1999; Chapman 2002), 
the more prevalent and preferred approach is to engineer proteins that eliminate residues 
where conjugation is undesired and re-engineer specific sites where conjugation is desired, 
particularly thiol-containing cysteines (Kaushik and Moots 2005; Junutula et al. 2008; 
Constantinou et al. 2009). Unlike the ubiquitous nature of amine groups, surface-available 
thiol (-SH) group are not frequently expressed on proteins, and this modification and 
manipulation of thiol groups are becoming increasingly favoured for conjugation purposes. 
As a remnant from the whole immunoglobulin structure, a free thiol is often found in antibody 
Fab fragments at the C-terminus of the light chain and it can be easily be introduced in other 
recombinant fragments. Three major benefits can be achieved through such engineering for 
chemical conjugations; firstly conjugations at undesirable sites that can be detrimental to 
protein activity are avoided, secondly a more homogeneous form of conjugates with specific 
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conjugate isoforms are established in order to accomplish more effective pharmaceutical 
usages, and lastly, the number of conjugation reactive sites can be engineered for potential 
pharmacokinetic manipulation. In comparison, random amine coupling is a more feasible and 
direct approach for chemical conjugation, however unprosperous, undesired and protein 
function detrimental results are the most significant hindrance or even stop points for this type 
of conjugations. Summarised in previous studies, amine-directed chemical polysialic acid 
conjugation (see below) was successfully used to modify the PK of an anti-tumour Fab 
(Constantinou et al. 2008), however the same process reduced the antigen recognising 
function of an anti-tumour scFv which was resolved by site-specific coupling modification 
(Constantinou et al. 2009). Similarly, conjugation of larger polymer chains was found to be 
more detrimental on antibody activity after random amine coupling, which has been observed 
from an anti-TAG-72 scFv conjugated with long PEG chains (Lee et al. 1999). This 
demonstrates that antibody bioactivity has a dependence on different residues within the 
complementarity-determining region (CDR) which are difficult to predict in the absence of 
structural information. If known, sensitive conjugation sites can be eliminated by mutagenesis. 
Such approach has been successfully utilized to mutate a non-essential lysine residue in the 
VH CDR3 of the C6.5 scFv into a non-conjugatable alanine residue to prevent unwanted 
chemical conjugation in the anti-HER2 scFv antigen binding site (Adams et al. 2000). 
 
 
1.3.1.2 PEGylation - Hydrophilic Polymer Conjugates 
As illustrated in Figure 1.12, a wide range of polymers and attachment moieties have been 
studied so far for their pharmacokinetic modulatory properties. For polymer conjugates, apart 
from their basic chemistry properties, factors including conjugation number, length and 
structural complexity of the polymer can be varied in order to produce a different 
pharmacokinetic impact. A number of polymers, such as polydextrans (PD), 
polyvinylalcohols (PVA), polystyrene-co-maleic acid, polysialic acid (PSA), polyglycerols, 
polyals, hydroxyethyl starch (HES) and polyethylene glycol (PEG) has been investigated as 
conjugation candidates for therapeuticals pharmacokinetic modification purposes 
(Kontermann 2009; Constantinou et al. 2010). Typically, the residual components of these 
polymer molecules have a high hydrophilic ability allows their interactive attraction to water 
molecules in solution.  Accumulatively, such hydrated polymers appear to have a much 
greater apparent molecular weight and hydrodynamic radius than the polymer alone after the 
attachment of the water molecules. Pharmacological explorations of these hydrophilic 
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polymers conjugated to therapeutic molecules have resulted in masking immunogenicity, 
solubility improvement and pharmacokinetics modulation of native proteins (Figure 1.13).  
 
 
Figure 1.13. Main advantages of PEGylated protein. The figure represents a polymer-protein conjugate. PEG, 
as a water attracting polymer establishes a “watery shield” surround the protein surface and protect the inside 
from degrading agents by steric hindrance. More importantly, the increased hydrodynamic volume of the 
conjugate exceeds the cut-off point of the glomerular filtration, leading to decreased kidney clearance of the 
PEGylated protein. These distinguishable advances demonstrated by PEGylation are also shared by most 
hydrophilic polymers (i.e. polysialic acid). This schematic diagram was taken from (Veronese and Pasut 2005). 
 
 
To date, the physicochemical properties of PEG have been the most extensively studied, 
which serves as the most advanced carrier system technology to date. With a long 
acknowledgeable history as a non-toxic, inert, hydrophilic, uncharged and non-biodegradable 
polymer, PEG has also been approved by the US FDA for therapeutic use (Veronese and 
Pasut 2005). Subjecting to hydrophilicity, each ethylene glycol subunit of PEG can support up 
to three water molecules (Sasahara 1995) indicating PEG can carry water up to its own 
molecule mass, resulting in an great increase of hydrodynamic volume (Harris and Chess 
2003; Fee and Van Alstine 2004). Furthermore, the pharmacokinetic behaviour of the PEG 
chains can be dictated by their lengths and conformations (i.e. linear or branched structure) 
(Yamaoka et al. 1994; Yamaoka et al. 1995; Fee 2007; Gursahani et al. 2009). It has been also 
noticed that the general clearance rate of the protein therapeutics is decreased when the 
polymer-conjugate size increases; however their permeability into potential target sites also 
slows (Cohen et al. 2001; Yang et al. 2003; Gursahani et al. 2009). Additionally, the charge 
associated with the polymer-conjugates can take credits in altering the overall isoelectric point 
of protein being modified, which also influences the pharmacokinetics, and sometimes the 
functioning properties of the conjugated therapeutics. Therefore, a number of factors, such as 
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altering PEG length and/or conjugation ratios, as well as charge, have to be considered to 
modulate according to obtain a desired pharmacokinetic effect. 
 
A number of therapeutic agents benefiting from PEGylation including Adagen™ 
(PEGademase bovine), the treatment of immunocompromised individuals awaiting bone-
marrow transplantation; Oncaspar™ (PEGasparaginase) for the treatment of lymphoblastic 
leukaemia; PEGasys™ (PEGinterferon α-2a; ribavirin) for the treatment of chronic Hepatitis 
C infections; PEGanone™ (ethotoin) for the control of epileptic convulsions, and Macugen™ 
(PEGaptanib sodium) for the treatment macular degeneration have all been approved by FDA 
and showed improved pharmacokinetic outcomes in therapies (Jevsevar et al. 2010). 
Subjected to antibody fragments, the bioactivity and blood clearance rates of an anti-TNFα 
scFv conjugated by maleimide-PEG chains with various molecular weights (5, 20 and 40 kDa 
PEG) at one or both of two available thiol sites have been systematically investigated 
previously. Although some loss of bioactivity was suggested from in vitro binding studies, 
cytotoxicity assays showed similar neutralization IC50 values for all conjugate variants. In 
terms of PK, the half-life of conjugates increased as their PEGylation content increased, and 
up to 100-fold prolongation of circulating half-lives has been demonstrated compared to the 
native scFv (Yang et al. 2003). Other than detrimental effect to the antibody bioactivities, Lee 
et al used different lengths of PEGs ranging from 2 to 20 kDa to conjugate with scFv for PK 
improvement. They found that an increase in polymer length was found to be more effective 
for extending serum half-life than using a corresponding increase in total PEG by using 
smaller polymer lengths at a higher conjugation ratio (Lee et al. 1999). Same conclusions 
were also indicated by non-antibody studies as well (Clark et al. 1996). 
 
Alongside preferential site-specific PEG conjugation approaches, branched PEG chains over 
linear ones has been promotionally generated with promising improvement features for 
circulatory half-lives (Harris and Chess 2003). It is claimed that a branched PEG can act as if 
it were much larger than a corresponding linear PEG of the same molecule weight (Yamasaki 
et al. 1988). As mentioned previously, the first FDA approved PEGylated antibody fragment 
certolizumab pegol is marketed as a branched PEG conjugate (Melmed et al. 2008).  Although 
it has been recently shown that there was no significant difference between the viscosity radii 
of branched and linear PEG-proteins having the same total molecular weight of PEG adducts 
(Fee 2007), branched PEGs are suggested to be better at cloaking the attached protein drugs 
when exposed to proteolytic cleavage. Greater resilience to cleavage than its linear polymer 
- 72 - 
conjugate counterparts was demonstrated, which can be partially considered as an reason to 
explain branched conjugates having a seemingly longer half-life in vivo compared to those 
with linear PEG chains (Monfardini et al. 1995). Since the earliest demonstration in 1977 
(Abuchowski et al. 1977; Abuchowski et al. 1977), PEGylation has expanded into a major 
industrial biotechnology to improve therapeutic protein pharmacokinetics (Harris and Chess 
2003). Antibody fragments are now emerging as favourite protein candidate from this 
modification pipeline, in order to realize better therapeutic efficacies. 
 
PEGylation Chemistries 
With a clear efficacy direction of modulating antibody PK, different chemical conjugational 
approaches are subjected to factors such as conjugate homogeneity and reproducibility. 
Summarised in Table 1.3 below, various methods of activating polymers for conjugation via 
certain functional groups within proteins have evolved over time to minimise problems 
encountered with its predecessors (Roberts et al. 2002). The process of adding PEG polymer 
on to therapeutic proteins, also known as PEGylation, has been through a few generations. 
So-called „first generation‟ PEGylation chemistry, which preferentially react to alpha and 
epsilon amino acids, have used derivatives such as PEG dichlorotriazine, PEG tresylate, PEG 
succinimidyl carbonate, PEG benzotriazole carbonate, PEG p-nitrophenyl carbonate, PEG 
trichlorophenyl carbonate, PEG carbonylimidazole and PEG succinimidyl succinate (Harris 
and Chess 2003; Constantinou et al. 2010). Problematic limitations including unstable 
linkages, PEG impurities, and a lack of selectivity in modification predominately occurred 
when applying these PEG derivatives to low molecular weight moieties. For improvement, 
unifunctional methoxylated PEG (mPEG) has since been generally applied to minimize the 
effect of cross linking between conjugates (Monfardini et al. 1995), while the „second 
generation‟ PEG chemistries that also exploit amine conjugation have been considered of 
taking more credits to reduce the difficulties described above. These include the use of PEG-
aldehydes/hydrate (Table 1.3). Partial selective conjugation is observed preferentially at 
primary amine via a Schiff‟s base, which is subsequently reduced to give a stable secondary 
amine linkage (Kinstler et al. 1996). Conditions of conjugation is also very critical for 
preserving the protein base integrity and PEG-carboxylic acid have been therefore extensively 
used of being more stable and are favoured due to their reactivity at near physiological 
conditions (Zalipsky and Barany 1990). 
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PEG Derivatives Reactivity & Characteristics 
First Generation Agents 
PEG Carbonyl-limidazole  
(Beauchamp et al. 1983; Veronese et al. 1985) 
N-terminal α-amines and lysine ε-amine group acylation 
leading to formation of carbamate linkages.  But reactivity 
to other residues such as histidines and tyrosines may also 
be observed depending on the reaction conditions and the 
pKa effects of neighbouring residues. PEG Benzotriazole 
carbonate and PEG Succinimidyl carbonate are particularly 
noted for forming imidazolecarbonate linkages with 
histidine residues. 
 
It should be noted that the polymer backbone ester of PEG 
succinimidyl carbonate can be readily hydrolyzed leading 
to possible immunogenicity towards the remaining tagged 
conjugate if used in vivo. 
PEG p-nitrophenyl carbonate  
(Veronese et al. 1985) 
PEG Trichlorophenyl carbonate  
(Veronese et al. 1985) 
PEG Benzotriazole carbonate  
(Dolence et al. 1997) 
PEG Succinimidyl carbonate (Zalipsky and Lee 
1992; Miron and Wilchek 1993) 
PEG Succnimidyl succinate  
(Abuchowski et al. 1984) 
PEG Dichlorotriazine (Zalipsky and Lee 1992) 
Reacts with lysine, seine, tyrosine, cysteine and histidine 
residues.   Remaining Chloride may allow cross-linking 
between conjugates. 
PEG Tresylate (Francis et al. 1998) 
May form secondary conjugates with degradable sulfamate 
linkage. 
Second Generation Agents 
PEG Aldehyde: 
1.  Acetalaldehyde; 2.  Propionaldehyde        
(Harris and Herati 1993) 
 
PEG Aldehyde hydrate: 
1.  Acetalaldehyde hydrate 
2.  Propionaldehyde hydrate 
(Kinstler et al. 1996; Bently and Harris 1999) 
 
 
 
Reactive amination, selective for N-terminal α-amines and 
ε-amine groups found on lysine residues via a Schiff base.  
The hydrate form of the PEG aldehyde is more stable and 
therefore the preferred agent to use. 
PEG NHS Esters  
(Zalipsky and Barany 1990) 
Active esters of carboxylic acids are the most favoured 
acylating agents as they allow formation of very stable 
bonds at near physiological conditions. 
Carbohydrate Specific 
PEG Amine  
(Zalipsky and Menon-Rudolph 1997) 
Conjugation to oxidised residues leads to the formation 
amine bonds; however reactivity with other protein amine 
groups can lead to the formation of cross-linked aggregates. 
PEG Hydrazine  
(Gaertner and Offord 1996; Youn et al. 2005) 
Oxidation of carbohydrate residues or N-terminal serine or 
threonine residues allows conjugation by this chemistry.  
The resulting hydrazone bond (shown above) can be 
stabilized by reduction to form a more stable amine bond. 
Thiol Specific 
PEG Maleimide (Goodson and Katre 1990; 
Constantinou et al. 2009) 
Maleimide can react under physiological conditions but is 
not stable under aqueous conditions. 
PEG Vinyl sulfone  
(Morpurgo et al. 1996) 
May also react with lysine residues              
PEG Iodoacetamide (Kogan 1992) 
Reaction must be perfomed under dark conditions to limit 
the generation of free iodine that may react with other 
residues 
PEG o-pyridyl didulfide  
(Woghiren et al. 1993) 
Forms stable disulfide bonds except under reducing 
conditions. 
 
Table 1.3. Development of PEGylation chemistries and modification strategies. A variety of chemistries 
have been used to covalently modify antibodies with specific characteristics. Although primarily used for protein 
PEGylation, other agents can be attached. This table is taken from (Constantinou et al. 2010). 
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Increasingly, conjugations through surface thiol groups which offer greater coupling 
selectivity than that of lysine residues have become more desirable. Furthermore, free 
cysteine groups rarely play a role in biological activity unless they form structurally related 
disulphide bonds; in which case these do not partake in the conjugation process.  Hence, no 
loss of biological is normally expected. As free thiols rarely appear on the surface of proteins, 
recombinantly engineered cysteine residues can be created to facilitate site-specific 
conjugations with the expression of thiol groups (Goodson and Katre 1990; Natarajan et al. 
2005; Constantinou et al. 2009). 
 
Also indicated in Table 1.3, PEG derivatives forming stable thioether linkages such as PEG-
maleimide, PEG-vinylsulphone and PEG-iodoacetamide have all been investigated for site-
specific conjugations (Goodson and Katre 1990; Morpurgo et al. 1996). Achieving stable 
disulfide linkages by PEG derivative like orthopyridyl disulphifide-PEG have shown similar 
site specific conjugational advances, however such linkages are fragile and unstable in 
reducing environments (Woghiren et al. 1993).  Most recently, certolizumab pegol became the 
first approved antibody fragment using thiol specific PEG chemistry with enhanced serum 
half life and successful therapeutic effects. The use of slow-release or hydrolysable 
PEGylation (i.e. PEG-intron
®
) has also been investigated, and such innovations can be 
exceptionally useful to restore the protein bioactivities potentially lost upon previous 
conjugation (Roberts et al. 2002). 
 
Limitations in the use of PEG 
PEG is generally regarded as a non-biodegradable polymer, and longer PEG chains especially 
used for protein PEGylation, are not subjected to metabolism and feasible elimination 
mechanisms. Depending on their molecular mass, renal filtration is less relevant for PEGs 
above 20 kDa, and alternative pathways such as liver uptake or faecal excretion become more 
predominant for higher molecular weight PEGs (Caliceti and Veronese 2003; Veronese and 
Pasut 2005). The concerns of PEG accumulation with high dosages and high molecular 
weight PEG conjugates for life-long therapies are hard predicted at the early stage, and the 
accumulations in liver may increase the risk of toxicity and severe side effects to patients 
(Bukowski et al. 2002; Caliceti and Veronese 2003; Jevsevar et al. 2010). Additional 
toxicology studies also demonstrated that very high dose treatment of PEG-proteins 
conjugates could induce renal tubular vacuolization and this symptom was not observed by 
using non-PEGylated protein (Bendele et al. 1998). PEGylation normally reduces the 
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immunogenicity of therapeutic proteins, transforming non-self proteins into a tolerogen 
(Sehon 1991). However, formation of anti-PEG antibodies has been detected in  
some patients during phase I trial of PEGylated urate oxidase (Ganson et al. 2006) and other 
PEGylated proteins and drug delivery systems (Armstrong et al. 2007; Ishida et al. 2007). The 
antigenicity induced by PEG has been primarily speculated on the chemical structure of its 
derivatives that facilitate drug conjugation purposes, and more exaggerated immunogenic 
responses are anticipated after repeated administration and slow elimination due to the non-
biodegradation nature of PEG (Gregoriadis et al. 2005; Jevsevar et al. 2010). Serum 
complement activation has also been reported after high levels usage of PEG as an 
intravenous therapeutic agent leading to unwanted inflammation and immunotoxicity to 
patients (Hamad et al. 2008). 
 
Like all synthetic polymeric products, PEG‟s polydispersive feature results in a composition 
of various polymers with different number of monomeric residues, and yield a Gaussian 
(normal) distribution of molecular weights to the drug conjugates (Veronese and Pasut 2005). 
Especially when conjugating with small protein drug (i.e. antibody fragments), the PEGylated 
proteins or peptides might have polydispersive biological characteristics that mainly represent 
in body-residence time, clearance rate and safety issues (eg. toxicity and immunogenicity). 
Although improved synthetic and purification procedures have been developed to formulate 
PEGs with less polydispersive and better PK-enhancing characteristics (i.e. branched PEG), a 
high cost is usually induced, which elicits another big problem for manufacturing with high 
demands. 
 
 
1.3.1.3 Polysialylation – The Natural Way  
Of course, the same types of chemistries described above are not unique to PEG conjugates, 
and the same the advantages and disadvantages can be applied to any other hydrophilic 
polymers activated with the same chemistry.  For example polysialic acid (PSA) conjugation 
has been investigated using amine and thiol chemistries with similar observations made. PSA 
applied in various existing therapeutic usages, is a naturally-occurring biopolymer (α-2,8 or α-
2,9 linked sialic acid/N-acetyl neuraminic acid) found as colominic acid (in bacteria) or PSA 
(in mammalian cells) (Janas and Janas 2004). Details of the PSA chain and the sialic acid 
monomers will be described alongside PSA biosynthesis in section 1.4.3. Furthermore, 
polysialic acids have a high degree of chemical versatility, which enables a wide variety of 
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drugs and other molecules to be covalently linked to PSA, with preservation of much of the 
drug‟s activity (Gregoriadis et al. 2005). Gregoriades and colleagues firstly proposed that 
PSA comprises the biophysical properties similar to PEG such that its hydrophilicity could be 
used to modulate the half-life of proteins (Gregoriadis et al. 1993). Initially demonstrated in 
1993 with fluoroscein and in 1996 with catalase (Gregoriadis et al. 1993; Fernandes and 
Gregoriadis 1996), Colominic acids derived from N. meningitidis and Escherichia. Coli K1 
capsular polysaccharides were covalently conjugated to achieve extended serum half-lives 
with preserved protein functions. Also suggested from the immunogenicity aspect of 
chemically polysialylated asparaginase, polysialylation reduced the antigenicity of 
asparaginase and as a result prolongs its circulation in the blood even in the presence of anti-
asparaginase antibodies (Fernandes and Gregoriadis 2001). Other polysialylated proteins 
including insulin (Jain et al. 2003), interferon α-2b, β-Galactosidase, Aprotinin, EPO 
(Gregoriadis et al. 2005) have been investigated in vitro and in vivo with increased solubility 
and stability, reduced immunogenicity, preserved function, and improved pharmacokinetics. 
Extending this application to antibody fragment, in the first instance amine-based reductive 
amination using a PSA-aldehyde, conjugation to H17E2 Fab, an antibody against the 
oncofoetal tumour antigen, placental alkaline phosphatase, was shown to produce conjugates 
that retain activity.  Several coupling ratios were investigated, and all demonstrated increased 
blood residency in vivo compared to the parental Fab and approaching that of the whole 
immunoglobulin. Interestingly, the longest or highest PSA substitution ratio was not the most 
effective (Constantinou et al. 2008). However, the same reductive amination chemistry was 
applied to MFE-23, a single-chain Fv directed against another oncofoetal antigen, 
carcinoembryonic antigen. This resulted in immuno-conjugates of reduced blood clearance 
and high bioavailability, but poor immuno-reactivity. This was resolved using the site-specific 
method with a thiol-directed maleimide activated PSA (Constantinou et al. 2009). In addition, 
as described previously, anionic molecules are more reluctant to be cleared through 
glomerular filtration. PSA, a highly negatively charged molecule must therefore be 
desialyated by neuraminidase-like enzymes before cleared via either kidney or through the 
asialoglycoprotein receptors during hepatic elimination of large molecules (Stockert 1995; 
Deen et al. 2001). The additional desialylation routes consequently imply a delayed clearance 
process of PSA-conjugated molecules. 
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1.3.1.4 HESylation 
Similar to chemical polysialylation, another organic polymer called hydroxyethyl starch 
(HES), a modified, branched amylopectin (e.g. derived from waxy maize starch), composing 
of D-glucose units linked by α1,4-glycosidic bonds and α1,6-bonds for the branched points, 
was chemically conjugated (or HESylated) to several proteins (i.e. erythropoietin and G-CSF) 
with improved bioactivity and pharmacokinetic properties (Besheer et al. 2007; Kontermann 
2009). Various HES derivatives can be prepared with preferable properties serving a flexible 
approach to modulate PKs. Although HESylation has not been applied or described for 
antibody fragment PK, its polysaccharide composition and biocompatibility make it an 
attractive alternative material to existing technologies (Kontermann 2009). 
 
 
1.3.1.5 Conjugating with Modulating Proteins and Peptides 
Another appropriate antibody fragment PK-modulating strategy categorized in chemical 
conjugation involves chemically coupling the mAb fragments with other proteins that have a 
long serum half-life. Similar to immunoglobulin‟s 21 days and also sharing the similar 
salvage recycling strategy by interacting with the neonatal Fc-receptor, albumin (19-day 
serum half-life) is commonly considered as an ideal pharmacokinetic modulating protein 
partner (Anderson et al. 2006). Albumin is a 67 kDa heart-shaped monomeric molecule and is 
found to be the most abundant protein in the blood serum (around 45mg/ml in humans). It 
also has a low pI and consequently a net negative charge in the blood which hampers kidney 
filtration due to the anionic kidney basal membrane (Anderson et al. 2006). Using albumin for 
drug conjugation recovers many of the advantages of the antibody Fc domain such as 
prolonging small molecule blood circulation time, and outweighs the cross-reaction and side 
effects from Fc-mediated annoyances. The most notable example is the work of Smith et al 
(2001) who evaluated three different albumin-binding strategies. Chemical conjugation of rat 
serum albumin (RSA) with an anti-TNFα Fab2 retained immunoreactivity but increased its 
bioavailability 17 to 200-fold (Smith et al. 2001). The same group also chemically cross-
linked an endogenous RSA specific Fab to anti-TNFα Fab2, and produced an 8-fold increase 
in bioavailability (Smith et al. 2001). On top of these successful pioneering studies of 
chemical conjugation, Smith et al investigated recombinant fusion approaches that genetic 
conjugate appropriate protein with antibody fragment, and indeed, most of modulating 
proteins and peptides entitled conjugation approaches have been focussed on recombinant 
fusions (see section 1.3.2 below). 
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1.3.1.6 Conjugates with Modulating Small Molecules  
Inheriting the similar feature of the bispecific anti-RSA-anti-TNF Fab2 motif described above 
(Smith et al. 2001), small organic molecules that bind tightly to serum albumin have been 
identified and applied to increase small protein drug blood-residence time. Among most 
applications, a „portable‟ small albumin-binding molecule called „Albu tag‟ from a DNA-
encoded combinatorial chemical library. This small chemical molecule, a 4-(p-
iodophenyl)butyric acid derivative, interacts with serum albumin and extends the half life of 
imaging agents (Dumelin et al. 2008) and antibodies (Trussel et al. 2009). The portability of 
the „Albu tag‟ retains the tag with a high affinity to albumin upon attachment and overcomes 
the problems such as loss of albumin binding upon chemical conjugation which have often 
seen in other similar attempts.  
 
 
1.3.2 Recombinant Approaches 
Unlike chemical modulations with decades of research experience, genetically engineering 
therapeutic proteins with refined PK characteristics is still at its infant stage. However, 
because of the versatility of recombinant technology and the vast selections of useful fusion 
materials (i.e. long-lived serum proteins and glycosylation domains), the recombinant 
approaches for antibody fragment PK modulation may open many new areas that are more 
applicable, feasible, effective, and economical. 
 
1.3.2.1 Antibody Fragment Engineering 
The proliferation of antibody fragments (Holliger and Hudson 2005), and alternative binding 
frameworks (Ewert et al. 2004) have led to many recombinant approaches to pharmacokinetic 
engineering. The selection and characterisation of scFvs, diabodies, nanobodies, DARPins 
and anticalins is normally followed by the re-engineering into bigger molecules such as 
immunoglobulins, small immune proteins (SIPs) (Borsi et al. 2002) or artificially 
multimerised proteins (Hanes and Pluckthun 1997). Evidence include ones described in 
section 1.2.2.1 and Figure 1.9, using different peptide linkers to develop divalent and 
multivalent scFv molecules with two or more scFvs monomers (Goel et al. 2000; Goel et al. 
2000); the introduction of multimerization domains, including streptavidin, p53 and leucine 
zippers, which have been used for making a variety of antibody fragment fusions (Schultz et 
al. 2000; Willuda et al. 2001; Suntharalingam et al. 2006). A self assembling molecule known 
as the B-subunit of E. Coli verotoxin (VTB) was also engineered to create a pentamerized 
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VHH, and a bispecific decavalent molecules by fusing an antibody pentamer of one specificity 
to the N-terminus and a different one to the C-terminus of VTB (Zhang et al. 2004; Stone et al. 
2007). The association of multiple antibody fragments multiplies the size of one single 
monomer which enables a longer blood half-life due to the increased size, and further more 
improves the binding affinity in the same magnitude.  
 
Larger proteins have a longer blood half-life as of course, immunoglobulins which have a 
natural retention and clearance mechanism through Fc-domain:neonatal Fc-receptor binding 
via the reticulo-endothelial system (Ghetie and Ward 1997; Anderson et al. 2006). There are 
many strategies for increasing or decreasing the affinity between immunoglobulin Fc and 
FcRn to increase or decrease blood serum half-life which have been well described in a 
number of key papers (Roopenian and Akilesh 2007; Presta 2008; Andersen and Sandlie 2009; 
Ward and Ober 2009). As a result of these modifications, smaller version of whole IgG was 
made with antibody fragments such as scFv directly fusing to the Fc region resulted in a 
smaller sized dimeric protein (Colcher et al. 1998; Holliger and Hudson 2005). Much more 
compact antibody forms such as SIPs or minibodies lead a more favoured type of fusion trend 
by restoring antibody fragments with modified parts of the Fc domains. Not only minimizing 
the side-effects brought out by the entire Fc domain, these approaches also effectively 
improve the protein serum half-life control. An anti-Her2 compact antibody (Erbicin) 
currently being evaluated in preclinical studies for cancer treatment is an excellent example of 
Fc portion reunion approach (De Lorenzo et al. 2002; De Lorenzo et al. 2004). 
 
 
1.3.2.2 Albumin Fusion Strategies 
Firstly introduced by direct chemical conjugation (section 1.3.1.4), albumin, particularly 
human serum albumin (HSA) which has a long half life feature in the blood circulation was 
considered to be one of the favourable macromolecules for therapeutic efficacy improvement 
of short-lived proteins (Chuang et al. 2002; Muller et al. 2007), and the genetic engineering 
strategies showed an easy way to produce fusion proteins having HSA in the structure. 
Successful fusion models include hormones e.g. insulin (Duttaroy et al. 2005), human growth 
hormone (Osborn et al. 2002), and cytokines e.g. interferon-α (Osborn et al. 2002), interferon-
β(Sung et al. 2003), and IL-2 (Melder et al. 2005). Antibody-albumin fusions have been 
studied as a way to both slow down and accelerate blood clearance (Figure 1.12). ScFv-HSA 
fusions using a variety of linker peptides increased the blood residence times approximately 
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12-fold (Smith et al. 2001). These fusions expressed well in Pichia pastoris pointing to a way 
for low-cost expression. A radiolabeled anti-CEA scFv-HSA fusion protein („immunobulin‟), 
expressed in mammalian NS0 cells was designed by Yazaki et al. for tumour biodistribution 
and imaging studies. This scFv-HSA fusion showed a dramatic increase in tumour uptake, 
persistent high tumour:blood ratios, and limited normal tissue uptake in comparison with the 
scFv alone (Yazaki et al. 2008). After 72 hr, 27% injected dose/gram was reached with a 
tumour:blood ratio of almost 19:1. This is significantly better than that seen with whole 
immunoglobulins. A series of anti CD3 (T-cell)/anti-CEA (tumour cell) retargeting bispecfic 
antibodies were also fused to HSA in order to prolong their half-life for immunotherapy 
applications (Muller et al. 2007). These rather complex molecules were successfully 
expressed in HEK293 cells. Mammalian cells have been shown by the Kontermann lab and 
others including ourselves (unpublished) to express bispecific scFvs with yields from E. coli 
being very poor (Wright and Deonarain 2007). These constructs, bispecific scFv-, single-
chain diabody- and tandem scFv-HSA fusion proteins (scFv2-HSA, scDb-HSA, and taFv-
HSA) were all stable and had increased in vivo bioavailability, as shown by a 6-8-fold 
increase in the blood exposure time. In vivo therapeutic benefit of such increased residence 
time is yet to be shown. Conversely, „HSAbodies‟ are highly glycosylated scFv-albumin 
fusion proteins which have accelerated blood clearance making them appropriate for 2-step 
drug delivery systems (Huhalov and Chester 2004). 
 
 
1.3.2.3 Albumin Binding Strategies 
Rather than utilising the long residence time of albumin directly, there have been many 
recombinant approaches that “piggy-back” on albumin, in a similar way to the albu-tag 
described above. Using peptide phage display, Dennis et al. identified a specific core 
sequence (DICLPRWGCLW) which bound to albumin with high affinity (Junutula et al. 
2008). They generated a peptide called SA21 that non-covalently bound to albumin with 1:1 
stoichiometry at a site distinct from known small molecule binding sites (Figure 1.12). 
Recombinantly fusing the peptide to an anti-tissue factor Fab (D3H44) significantly reduced 
the Fab in vivo clearance, and achieved 25-43% of the albumin half-life in mice and rabbits 
(Junutula et al. 2008). For tumour targeting, they incorporated the albumin-binding peptide to 
the Herceptin-derived Fab (Fab4D5), and showed a significant improvement in tumour 
deposition and retention, high tumour to blood ratios compared with Fab alone. This 
Genentech technology is known as AB.Fab, which has the advantage of cheap production in E. 
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coli. The authors also suggested that association with albumin leads to an altered route of 
clearance and metabolism (Junutula et al. 2008). A possible refinement of this technology is 
the ability to modulate the pharmacokinetics of AB.Fabs by altering the affinity of the peptide, 
which was demonstrated using peptide with KDs of 4nM to 2.5mM (Nguyen et al. 2006). 
 
Recently, another group applied the same albumin binding strategy to a bivalent anti-
epidermal growth factor receptor (EGFR) nanobody. They also illustrated improved tumour 
uptake (as high as cetuximab), and a reduced blood clearance rate (Tijink et al. 2008). An 
alternative albumin-binding approach is to fuse a homologous albumin-binding domain 
(ABD3-46 amino acids/6 kDa) from streptococcal protein G with a recombinant antibody. 
ABD3, has a broad albumin species specificity, and interacts with HSA with KD of 
approximately 4nM (Johansson et al. 2002; Linhult et al. 2002). Stork et al. applied this 
strategy to a bispecific single-chain diabody (scDb anti-CEA/anti-CD3) developed for 
retargeting of cytotoxic T cells to carcinoembryonic antigen (CEA) expressing tumour cells. 
They successfully showed all three parts of the chimeric protein were functional with 5- to 6-
fold increase of prolonged circulation time. The drawback seemed to be a decreased immuno-
stimulatory activity compared to the diabody alone (scDb) (Muller et al. 2007). In a similar 
approach a radiaolabelled anti-HER2 dimeric Affibody molecule (14 kDa) was also tested 
with ABD fusion for improved therapeutic efficacy. Good cellular retention, and reduced 
renal uptake in comparison with the non-fused dimer molecule were observed (Tolmachev et 
al. 2007).  
 
 
1.3.2.4 Recombinant Amino Acid Polymer 
As described above, the use of inert, hydrophilic polymers represents the major strategy for 
pharmacokinetic engineering. Certain amino acid polymers bear this property and can also be 
advantageously attached to protein by genetic fusion. Schlapschy et al. investigated a glycine-
rich homo-amino-acid polymer (HAP) that had a large hydrodynamic They used anti-HER2 
Fab 4D5 as a model system and fused 100 and 200 residues of a repetitive sequence (Gly4Ser) 
to its light chain. By using size exclusion chromatography, they showed that the 200 residue 
„HAPylated‟ Fab acquired a hydrodynamic volume more than double that of the Fab alone, 
and a moderate rise in half-life, but lower than the enhancement made by the ABD fusion (see 
above). Compared with more hydrophilic polymers such a PEG or PSA, the coiled structure 
of HAPs may hinder its development. However, this moderate effect could be beneficial to 
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specialized applications, such as in vivo imaging (Schlapschy et al. 2007). Other sequences 
and more extended and hydrophilic polymer chains are currently under investigation. Poly-
(Pro-Ala-Ser) fusions have been developed as alternatives (PASylation) which acquire a more 
hydrophilic characteristic and much enhanced hydrodynamic radius, leading to better 
pharmacokinetic enhancement (A. Skerra, unpublished). 
 
Recently, genetic fusion of an unstructured hydrophilic recombinant polypeptide (~864 amino 
acids), called XTEN, to peptide or protein provided an extraordinary plasma half-life 
extension. Such modified exenatide with an original half-life of 2.4 hours showed a projected 
time of 139 hours, and a tuneable manner of the polypeptide was also suggested by the 
authors for different PK requirements in practice (Schellenberger et al. 2009). Supported by 
data of other XTEN fusion proteins, it is very promising to see this method being used for 
improving antibody fragment pharmacokinetics. 
 
 
1.3.2.5 Recombinantly Modified Glycosylation  
As described, glycosylation has been show to influence Fc-mediated effector functions of 
whole IgG molecule (Wright and Morrison 1997), and it also has an effective contribution on 
the plasma half-life modulation (Kontermann 2009). A few studies have performed 
investigations of carbohydrate compositions on pharmacokinetics of recombinant antibody 
molecules. One study genetically engineered two or three tandem or overlapping N-
glycosylation sites at an extension part of a scFv molecule C-terminal, and used yeast system 
to produce a mannose-rich glycosylated scFv. Faster plasma elimination was revealed after 
intravenous injection into mice, and the clearance was explained by the uptake of phagocytic 
cells with high surface expression of mannose receptors (Wang et al. 1998). Two-fold lower 
affinity compared to the parental scFv molecule was also reported by the authors, which 
further demonstrates that post-translational modification can affect antigen binding of small 
antibody fragments seen previously with the chemical conjugation approaches do. The 
introduction of new N-glycans has been found to increase the hydrodynamic radius and thus 
the blood-residence time of the recombinant proteins. Investigations of a bispecific single-
chain diabody molecule with additional 3 to 9 N-glycosylation sites recombinantly introduced 
to the linker and C-terminal extension regions indicated increased hydrodynamic radius of the 
scDb and an approximate 3-fold increase of area under the blood concentration-time curve 
(AUC) from 0-24 hours (Stork et al. 2008).  
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Similar PK enhancing results were also suggested from other hyperglycosylated protein such 
as the synthetic form of EPO (darbepoetin alfa) (Egrie and Browne 2001), follicle stimulation 
hormone (FSH) (Weenen et al. 2004) with additional N-glycosylation site recombinantly 
engineered, and a moderate increase in plasma half-lives has been commonly agreed with this 
type of glycol-modification (Kontermann 2009). Terminal sialic acid residues appearing 
frequently in most protein glycosylation compositions can be considered as a very important 
component contributing in the recombinant glycosylation method for increasing therapeutic 
protein serum half-life (Byrne et al. 2007), and additional of sialic acid content resulted a 
moderate increase of blood residence period suggested by research on sialylation modified 
erythropoietin (Egrie and Browne 2001) and asparaginase (Fernandes and Gregoriadis 2001). 
 
 
1.3.2.6 Recombinant Polysialylation 
Currently, which will be more precisely described in this thesis, a new recombinant 
glycosylation method has been investigated and expected to achieve a more intensive increase 
for antibody fragment plasma half-life improvement through an extreme glycosylation feature 
– polysialylation (Constantinou 2005). Successfully introduced by chemical conjugation for 
PK improvement, PSA, a long chain carbohydrate, and a good organic substitute for PEG, has 
been found in mammals on heavily polysialylated (to 200 sialic acid residues with a unique 
α2-8 linkage) neural cell adhesion molecule (NCAM) (Georgopoulou and Breen 1999). With 
a door opened by HAPylation approach, the idea of using other recombinant approaches to 
obtain hydrophilic biopolymers for pharmacokinetic benefits was also examined in this PhD 
project. We managed to tailor the polysialylatable NCAM domains with the chemical 
properties of PSA to the antibody fragment, and developed recombinantly polysialylatable 
scFv fusion protein that could have particular improvements over chemical modification 
techniques for PK enhancement (following chapters of this thesis).  
 
 
1.3.3 Summary of PK Modulating Approaches for Antibody Fragment  
A wide range benefits were promised by improving the longevity of therapeutic proteins. 
From clinical to commercial aspects, benefits including better dosing regimens and delivery 
profiles, improved therapeutic efficacy and side effect control, as well as extended product 
lifecycles are distinctive. Particularly required by the emergence of antibody fragments and 
alternative binding frameworks, half-life improving technologies are promised to reveal the 
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paramount capabilities and the small size advantages in a range of disease-fighting 
applications. Described in the aforementioned texts, many available PK-modulating 
approaches have already been established or currently investigated for antibody fragments, 
and their overall features are compared in Table 1.4 below. 
 
Table 1.4 Advantages and disadvantages of various pharmacokinetic enhancing strategies. 
 
Approach 
Name 
Modulation 
Type 
Advantage Concerns 
PEGylation Chemical  
Hydrophilic water attraction 
Improved protein solubility/stability 
Industry-established method for 
extending half-life 
Non-biodegradable 
Toxic accumulation 
Immunogenic 
Protein inactivation 
Downstream processing 
Costs and yields 
Homogeneity control 
Polysialylation 
Chemical  
Hydrophilic water attraction 
Improved protein solubility/stability 
Biodegradable 
Potentially non-immunogenic 
Promising clinical data 
Protein inactivation 
Downstream processing 
Costs and yields 
Homogeneity control 
Recombinant 
Hydrophilic water attraction 
Improved protein solubility/stability 
Biodegradable 
Potentially non-immunogenic 
Easier production 
Less downstream processing 
Homogeneity control 
Less advanced technology 
Albumin 
conjugation 
or 
binding 
Chemical  
Potentially non-immunogenic 
Biodegradable 
Impressive pre-clinical data 
Protein inactivation 
Downstream processing 
Costs and yields 
Homogeneity control 
Less advanced technology 
Recombinant 
Hydrophilic water attraction 
Improved protein solubility/stability 
Biodegradable 
Potentially non-immunogenic 
Easier production 
Less downstream processing 
Less advanced technology 
 
Unstructured 
Polypeptide 
Recombinant 
Hydrophilic water attraction 
Improved protein solubility/stability 
Biodegradable 
Potentially non-immunogenic 
Easier production 
Less downstream processing. 
Low hydrophilicity  
Long protein polymers 
Glycosylation 
sites 
Recombinant 
Hydrophilic water attraction 
Improved protein solubility/stability 
Biodegradable 
Potentially non-immunogenic 
Easier production 
Low hydrophilicity  
Low PK affect 
 
 
- 85 - 
1.4 NCAM and Mammalian Polysialic Acid  
This current PhD project focused on a recombinant method of adding polysialic acid on 
special recipient protein domains from neural cell adhesion molecule. As an unusual and 
extreme glycosylation feature, having terminal polysialic acid structure in a glycoprotein 
carbohydrate composition is merely naturally occurred in few proteins. NCAM is one of such 
protein that performs important neuronal and other cell functions which can be strictly 
regulated by its polysialic acid. Furthermore, the understanding of the enzymes that 
specifically catalyse the polysialylation, and the unique biosynthesis pathways of sialic acid, 
hence PSA that have been intensively studied during previous researches, are extremely 
useful for conducting research in recombinantly polysialylating antibody fragments, and the 
further manipulation of this technology for modulating the polymerization degrees. Special 
enzymes involved glycan recycling pathways indicate the organic bio-degradable property of 
PSA as a better polymeric alternative for drug conjugation. 
 
 
1.4.1 Neural Cell Adhesion Molecule  
Initially described as a brain-specific synaptosomal membrane glycoprotein (Jorgensen and 
Bock 1974), NCAM, the first identified neural cell adhesion molecule in the mammalian 
system, was characterised as a unique member of the immunoglobulin superfamily (Thiery et 
al. 1977). The extracellular domain of NCAM consists of five N-terminal immunoglobulin-
like (Ig-like) domains and two fibronectin Type-III (FNIII) domains (Figure 1.13). Depending 
on the attachment to the cell membrane and the length of transmembrane domain (TMD), 
often occur as cell type-specific alternatively spliced variants, three major isoforms of NCAM; 
NCAM-180, NCAM-140, and NCAM-120 (named according to NCAM molecular weight in 
kDa) (Figure 1.13) were found predominantly in glial and neuronal cells (Cunningham et al. 
1987). As a cell adhesion molecule (CAM), implications of different NCAM expression in all 
stages of neurodevelopment have been suggested from intensive previous studies. Containing 
a longer cytoplasmic domain, NCAM-180, predominately expressed in neurons late in 
development, and enriched at sites of cell contact and postsynaptic densities of mature 
neurons (Persohn et al. 1989). NCAM-140, having a distinguishable shorter transmembrane 
domain than NCAM-180, is expressed by both neurons and glia, and localized to migratory 
growth cones and axon shafts of developing neurons and mediates neurite outgrowth 
responses. Both isoforms having TMD connected to the intracellular cytoskeleton for signal 
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transduction. NCAM-120 which attaches the cell membrane with a glycophosphatidyl-inositol 
(GPI) anchor with no intracellular residue is predominantly found on glial cells (Maness and 
Schachner 2007). NCAM has been linked to a number of human brain disorders including 
schizophrenia, bipolar disorder and Alzheimer‟s diseases. Learning and memory deficits 
alongside behavioural abnormalities have also been shown from NCAM-deficient mice (Stork 
et al. 1997; Santuccione et al. 2005; Maness and Schachner 2007) 
 
 
Figure 1.14. Schematic structure of NCAM. All three NCAM isoforms are generated from a single gene by 
alternative splicing. The extracellular portion of all three isoforms consists of five Ig-like domains (Ig1-5) and 
two FNIII repeats (FN1 and FN2). GPI anchor and transmembrane domains are illustrated corresponding to each 
NCAM isoform. The cytoplasmic domains of NCAM-140 and NCAM-180 differ in length due to alternative 
splicing. NCAMs are important PSA carriers. Six N-glycosylation sites and two possible polysialylation are 
schematically indicated upon specific NCAM domains (Kleene and Schachner 2004). 
 
 
Many studies have been suggested that the extracellular Ig-like domains were involved in 
NCAM-mediated homophilic adhesion (Soroka et al. 2010). The subsequent three-
dimensional structure of NCAM Ig modules also localized the homophilic binding through a 
crystal structure of Ig1-2-3 dimer which was consequently suggested as primary domain 
orientated binding and predicted the homophilic adhesion structures of Ig4 and 5 domains 
(Kasper et al. 2000; Soroka et al. 2003; Atkins et al. 2004). The homophilic dimerization of 
NCAM (or trans-interaction) on the same cell surface has important signal transduction and 
neural development (i.e. neuroblast migration, neurite outgrowth, axon path-finding, and 
fasciculation) properties. NCAM trans-interaction activates the fibroblast growth factor (FGF) 
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receptor and a number of different signal transduction pathways guided by regulatory 
molecules such as non-receptor tyrosine kinase p59
fyn
, focal adhesion kinase (FAK), 
phospholiase C (PLC), protein kinase C (PKC) and Ras-MARK, which have significances in 
altering neural cell proliferation and differentiation (Kolkova et al. 2000; Prag et al. 2002; 
Maness and Schachner 2007). Such NCAM dimerization also induces signalling responses via 
calcium influx enhancement through G protein-dependent channels (Ronn et al. 2002).  
 
NCAM homophilic interaction has been proposed in the process of cell-cell adhesion (Kasper 
et al. 2000). More importantly, heterophilic coupling (or cis-interaction) between NCAM and 
other surface molecules provides co-signalling in specific cell types, and such adhesive ligand 
induced cell communication and neurotransmission stimulate specific neural cell migration, 
axonal growth and other neural developmental activities (Berezin et al. 2000; Rougon and 
Hobert 2003; Maness and Schachner 2007). These heterophilic ligands of NCAM comprise 
heparan sulphate and chondroitin sulphate protoglycans (Cole and Burg 1989), L1-CAM 
(Kristiansen et al. 1999), FGF receptor (Kos and Chin 2002), Prion Protein (PrP) 
(Santuccione et al. 2005), and a subunit of glial-derived neurotrophic factor (GDNF) receptor 
(Paratcha et al. 2003). 
 
The two extracellular FNIII domains have also been reported with a function in receptor 
activation and NCAM-mediated neurite growth, signalling and learning (Anderson et al. 2005; 
Kiselyov et al. 2005). Alternative splicing and insertion of sequences between the two FNIII 
domains may modulate the NCAM mediated cell interaction (Doherty et al. 2000; Johnson et 
al. 2004). Probably the most significant property of FN1 domain is that it contains the 
docking site for polysialyltransferases (PolySTs) which catalytically elongate the terminal 
polysialic acid structure of specific N-glycosylation sites on the neighbouring NCAM Ig5 
domain (Muhlenhoff et al. 1996; Mendiratta et al. 2005). 
 
 
1.4.2 NCAM Polysialylation 
NCAM has been claimed as a pivotal regulator of synaptogenesis and synaptic plasticity 
(Dityatev 2006; Gascon et al. 2007; Muller et al. 2008). Together with other NCAM functions,  
a great influence from its extracellular carbohydrate content containing negatively charged 
oligosaccharide chains composed up to 90 sialic acid residues in a unique α2, 8-linked 
polysialic acid chain was confirmed by previous research (Rutishauser 1998; Georgopoulou 
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and Breen 1999; Galuska et al. 2008). Due to the polyanionic and high water possession 
capacities, PSA forms large watery shells that enlarge the space between interactive ligands or 
neighbouring cells and creating steric hindrance, making NCAM less-adhesive and facilitating 
the cell migration, axon growth and synaptic reorganization during brain development 
(Rutishauser 1998; Johnson et al. 2005; Muhlenhoff et al. 2009; Soroka et al. 2010). Evidence 
from both homophilic and heterophilic NCAM interactions showed that PSA worked as a de- 
or anti-adhesive component of NCAM and decreased both NCAM cis- and trans-interactions 
in vitro (Cunningham et al. 1983; Sadoul et al. 1983; Storms and Rutishauser 1998). Studies 
using prokaryotic originated endoneuraminidase (Endo-N) that specifically cleaves off PSA 
from NCAM, also suggested the NCAM adhesive feature restoration after PSA removal 
(Hallenbeck et al. 1987; Rutishauser and Landmesser 1996). 
 
Based on the necessary requirement of vertebrate brain development, the expression of PSA-
NCAM is strictly temporally and spatial regulated. Early, in day 8 of embryonic brain 
development (E8), NCAM start to appear and one day after (E9) PSA consequently emerges 
with corresponding PolySTs transcripts detected at E8.5 (Probstmeier et al. 1994; Kurosawa 
et al. 1997; Ong et al. 1998; Oltmann-Norden et al. 2008). Thereafter, NCAM expression 
increasingly reaches a maximum in the perinatal and early postnatal phase. Alongside the 
NCAM progression, from E11 onwards, the PolyST levels are exceedingly amplified over the 
entire embryonic development, and the upregulation of PolyST gene expression is almost 
identical to parallel the NCAM transcript incline steep (Ong et al. 1998; Oltmann-Norden et al. 
2008). This phenomenon proves a highly efficient enzymatic polysialylation of almost all 
NCAM during the late embryonic brain development. Beginning from the fifth day of the 
postnatal stage (P5) to P11, prominent decrease of PolyST levels was shown, and on the PSA 
product side, a 70% reduction was reflected by the down-regulation of the enzymes during 
early postnatal development (Oltmann-Norden et al. 2008). Coinciding to the completion of 
brain developmental morphogenesis, the conversion to PSA-free NCAM dominates the neural 
cells surface with adhesive cellular interaction properties (Edelman and Chuong 1982; 
Rothbard et al. 1982). All three major NCAM isoforms consistent with structural elements 
can serve as PSA acceptors and heavily polysialylated in the early brain development and 
persist expressed in specific areas of the brain such as the hippocampus, the suprachiasmatic 
nucleus, and olfactory bulb precursors (Franceschini et al. 2001; Colley 2008). In addition, 
NCAM was also identified on the NK cell surface with another name known as CD56. Often 
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expressed as a polysialylated form, the impact of PSA-CD56 has not yet been fully 
understand regarding to NK cell activity (Moebius et al. 2007). 
Polysialylation is an protein-specific glycosylation event (Colley 2008). As indicated in 
Figure 1.15, NCAM polysialylation occurs specifically at the fifth and sixth N-glycosylation 
sites on the Ig5 domain (Nelson et al. 1995; Kleene and Schachner 2004). More precisely, 
asparagines 430 and 459 were identified with suggestions of two separate PSA chains 
attached on the Ig5 domain of NCAM (Nelson et al. 1995; Liedtke et al. 2001). As mentioned 
above, the polysialyltransferases bind to the first FNIII (FN1) domain to enzymatically 
catalyse the PSA elongation on NCAM (Close et al. 2003).  
 
Typically, sialylation and polysialylation normally occurs as a terminal structure in most 
glycoproteins. In most cases, N-glycans contain the core portion consists of three mannose 
and two N-acetylglucosamine residues, and the outer chain portion (Figure 1.15). N-glycans 
are classified into three different groups: high mannose, complex and hybrid (Angata et al. 
2000; Geyer and Geyer 2006). The diversity of N-glycans is mainly caused by tremendous 
variations in the side chains. Particularly highlighted by the terminal sialic acid residue 
numbers, sialylation (1 or 2 sialic acids), oligosialylation (between 2 to 7 sialic acid residues), 
and polysialylation (more than 7 sialic acid residues) are the three common sialic acid 
featured mammalian glycosylation variations (Janas and Janas 2004). 
 
Minimal NCAM Structure Required for Polysialylation 
PolySTs substrate specification feature has been described over several studies previously, 
and NCAM, the most studied polysialoglycopotein was suggested as the best polysialylation 
substrate so far under in vitro conditions. Therefore special protein features within NCAM 
must be recognized by PolySTs to serve as efficient polysialylation glycan substrate (Kojima 
et al. 1997; Angata et al. 2000). Early NCAM truncation studies demonstrated Ig4-Ig5-FN1 
fused to the TMD was polysialylated by endogenous PolySTs, and speculation that all three 
NCAM domains simultaneously recognised by PolySTs was consequently proposed (Nelson 
et al. 1995). Based on a series of NCAM domain deletion mutants, Close et al identified the 
minimal domains that are essential for PolyST to carry out polysialylation (Close et al. 2003). 
Agreeing with the findings from Fujimoto et al (Fujimoto et al. 2001), they suggested that the 
Ig4 domain was not necessary for polysialylation, while Ig5 and FN1 domains together offer 
the basic substrate for PolyST catalysis (Figure 1.18), and either Ig5 or FN1 single domain 
was not enough for polysialylation (Close et al. 2003). Additional findings from soluble  
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Figure 1.15. Glycosylation profile of polysialylated NCAM. (a) Scheme of PSA-NCAM. The N-glycans 
located at the fifth and sixth N-glycosylation sites are modified by one or more PSA chains composed of 
uniquely α2, 8-linked sialic acid residues. Large hydrodynamic radius recruited by PSA is illustrated as pink 
shaded sphere. This watery shell separates NCAM with other binding ligands and increases the synaptic 
plasticity during brain development. The chemical formula of α2, 8-linked PSA has also been depicted 
(Muhlenhoff et al. 2009). (b) Possible structures of mammalian polysialylated N-glycosylations. Possible di- and 
triantennary N-glycan core structures attached to the two N-glycosylation sites within NCAM Ig5 domain are 
presented with terminal multiple α2, 8-linked sialic acids. The PSA chain was found as an extension from one 
antenna initiated from a terminal sialic acid α2, 3 or α2-6-linked to a galactose (the NeuNAcα(2-3) or α(2-6)Gal 
linkages). These two disaccharide linkages were proposed as polysialylation epitopes for PolySTs initiating the 
sialic acid polymerization. Fucoses and bisecting N-acetylglucosamine were found occasionally in some PSA-
carrying N-glycans. Different monosaccharide are annotated and depicted in unique colour spheres (Kleene and 
Schachner 2004).  
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NCAM protein truncates suggested that membrane association was not necessary for 
polysialylation, even the Ig5-FN1 mutants, however membrane association could enhance 
polysialylation level in some cases (Close et al. 2003). 
 
Common findings from all previous polysialylating NCAM domain studies noted that the 
FN1 domain plays an important role in positioning the Golgi membrane-associated PolySTs 
for NCAM recognition, and specific PolyST docking-sites exist for polysialylation of the N-
glycans on the adjacent Ig5 domain (Fujimoto et al. 2001; Close et al. 2003; Angata et al. 
2004; Colley 2008). Previous studies from structural modelling, domain deletion and 
alternative replacement as well as amino acid mutagenesis comfirmed the critical aspects of 
NCAM FN1 for NCAM polysialylation, and a single mutated FN1 domain carrying 
engineered O-glycosylation sites have been suggested to initiate O-glycan based 
polysialylations (Mendiratta et al. 2005; Mendiratta et al. 2006).  
 
Other Polysialylated Mammalian Proteins 
In mammals, PSA is normally presented as a homopolymeric α2, 8-linked Neu5Ac capping 
terminal α2, 3- or α2, 6-linked sialic acid (Figure 1,15b) on the N-linked and O-linked glycans 
of a small group of proteins (Colley 2008). Other than NCAM, proteins specifically modified 
by PSA include α-subunit of the voltage dependent sodium channel (Zuber et al. 1992), CD36 
as a form of the scavenger receptor found in milk (Yabe et al. 2003), neuropilin-2 found on 
dendritic cells (Curreli et al. 2007) and an autopolysialylation feature from the two PolySTs 
(Close and Colley 1998). The limited number of polysialylated proteins found in mammals 
also implies the protein specificity feature of polysialylation process. 
 
Polysialic acid was also found in a huge population of different human tumour cells (Troy 
1995). The α2, 8-polysialylated NCAM with chain length around 55 sialic acid residues was 
firstly reported from neuroblastomas (Livingston et al. 1988; Hildebrandt et al. 1998), and 
nephroblastomas (Wilms‟ tumour) (Roth et al. 1988), and subsequently revealed in a variety 
of many other types, alongside α2, 9-polysialic acid found in ovarian teratocarcinoma (Troy 
1995). Corresponding to the physiochemical properties of PSA, polysialylation in tumour 
cells could enhance the metastatic and mobile potential, which promote the detachment and 
blood vessel penetration of the cancer cells (Soroka et al. 2010). 
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1.4.3 Mammalian Polysialic Acid 
PSA has been identified on the surface of a variety of cells from microbes to vertebrates, and 
is covalently attached to membrane glycoconjugates (glycoproteins or glycolipids) (Troy 
1992; Troy 1995). Regarding this PhD project, the biosynthesis pathway of α2,8-linked PSA 
specifically attached to mammalian glycoprotein will be overviewed. This covers the sialic 
acid monomers that form the PSA chain, mammalian PSA metabolism, and the biosynthesis 
of the basic N-glycan cores that are found in NCAM Ig5 domain to initiate the terminal 
polysialylation. 
 
1.4.3.1 Sialic Acid Monomers 
Based on a cyclic-carbon structure with a carboxylic acid group at the C1 position (Figure 
1.17a), sialic acid comprises a family of about 40 derivatives due to the number of locations 
available for structural modification as well as core variation. Because of the carboxylic acid 
group, sialic acids have an inherent negative charge. The most common sialic acids are 5-N-
acetylneuraminic acid (Neu5Ac, NeuNAc or NANA), 5-N-glycolylneuraminic acid (Neu5Gc), 
and N-acetyl-9-O-acetylneuraminic acid (Neu5,9Ac2) (Traving and Schauer 1998; Schauer 
2004). Substitutions may be made at carbons C4, C7, C8, and C9 and the amine located at C5, 
and multiple substitutions contribute to the variety of possible structures.
 
 
 
In rarer cases, selected sialic acid monomers can interlink each other and form linear 
carbohydrate chemical structure of PSA chains. These chains have been found to consist of 
Neu5Gc, Neu5Ac, or 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (or 2-keto-3-
deoxynononic acid, KDN) -KDN is a 5-deamino-, 5-hydroxyneuraminic acid (Troy 1992; 
Traving and Schauer 1998). Therefore only three natural building-units of the sialic acid 
family form PSA chains, which Neu5Gc is only predominantly found in fish egg 
polysialylglycoproteins (Troy 1992), leaving Neu5Ac and KDN the main component in 
mammalian PSA compositions (Figure 1.17b) with defined intersialyl linkages shown as in 
Figure 1.17c. (Muhlenhoff et al. 1998; Janas and Janas 2004). 
 
 
1.4.3.2 Mammalian Biosynthesis of Sialic Acid and Polysialic Acid 
In the aforementioned text, bacterially produced sialic acid polymer (colominic acid) has been 
chemically conjugated for small protein drug PK modulation. Internal linkages between sialic 
acid monomers in bacterial produced PSA chains are joined through α2,8- or α2,9-ketosidic 
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Figure 1.16. Sialic acid. (a) Neuraminic acid, the core structure of all sialic acids. The nine-carbon backbone 
common to all known sialic acids is shown, in the α-configuration. The following variations can occur at the 
carbon positions indicated by R1, R2, and R3. Annotations of R1-3 and molecule index are also depicted (Varki 
and Schauer 2009). (b) Two common “primary” sialic acids that form polysialic acid chains in mammals: 
Neu5Ac, 5-N-acetylneuraminic acid, and KDN, 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid or 2-keto-3-
deoxynononic acid. Neu5Ac is more common than KDN in most vertebrate cell types, and these are derivatives 
from the neuraminic acid core structure shown in (a) (Varki and Schauer 2009). (c) The most frequent intersialyl 
linkages found in mammalian PSA chains, which α2,8-ketosidic linkage between Neu5Ac is the homopolymeric 
unit forms polysialic acid chains in human NCAM (Janas and Janas 2004). 
 
 
linkage, and the α2,8-linked PSA is identical to the one that found in mammalian 
polysialylproteins, especially NCAM PSA as mentioned above (Traving and Schauer 1998; 
Janas and Janas 2004). Successful innovation of a chemical polysialylation drug delivery 
system using α2,8-linked bacterial colominic acid with low immunogenicity (Gregoriadis et al. 
1993; Fernandes and Gregoriadis 2001; Gregoriadis et al. 2005) led to a more promising 
prospective of introducing human PSA via a recombinant approach (introduced by this PhD 
project). 
 
(a) 
(b) 
(c) 
α2,8-ketosidic linkage 
between Neu5Ac 
α2,9-ketosidic linkage 
between Neu5Ac 
α2,8-ketosidic linkage 
between KDN 
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As a important component within certain bacterial capsule, colominic acid, having a degree of 
polymerization (DP) up to 200 sialic acid residues, employs a unique biosynthesis process 
involving the KPS gene cluster to synthesize PSA chains and transport them to the outer 
membrane for the regulation of distinct polysaccharide capsular expression (Bliss and Silver 
1996; Swartley et al. 1996; Muhlenhoff et al. 1998). However, mammalian cells utilize a very 
different biosynthesis pathway of producing sialic acid and polysialic acid that attach to 
protein substrates. The mammalian sialic acid metabolic system is summarized in Figure 1.18 
below. 
 
Like all mammalian glycosylation, many complex parameters are involved in the biosynthesis 
of sialic acid. Initiated by the influx of de novo or salvage N-Acetyl glucosamine or 
glycolysed fructose-6-phosphate through the hexosamine pathway, which converts GlcNAc-
6P to the nucleotide sugar, UDP-GlcNAc under a series of enzymatic reactions (Figure 1.17A) 
(Hanover 2001). Relatively minor proportion of cytosolic UDP-GlcNAc is converted to 
ManNAc by epimerization of the hydroxyl-group in position 2 and cleavage of UDP by the 
UDP-N-acetylglucosamine 2-epimerase, a part of bifunctional GNE (Stasche et al. 1997). 
ManNAc, the specific sugar precursor for the biosynthesis of mammalian Neu5Ac is 
responsible for increasing the intracellular sialic acid pool (Pels Rijcken et al. 1995). 
Following the sialic acid biosynthetic pathway (Figure 1.17B), almost all ManNAc are 
metabolized to Neu5Ac in the cytosol, and the process is initiated by the phosphorylation of 
ManNAc catalysed by ManNAc kinase, the other part of GNE. After reaction with pyruvate 
and de-phosphorylation, the synthesized primary sialic acid is either modified to other sialic 
acid derivatives for other purposes or transported into the nucleus and converted to CMP-
sialic acid, the substrate to form sialylated glycans (Bork et al. 2009; Du et al. 2009). This 
sugar metabolite can give an allosteric feedback inhibition to GNE (Figure 1.17B), which 
keeps a tight control of ManNAc and consequent by sialic acid production (Keppler et al. 
1999). CMP-Neu5Ac is then transported into the Golgi apparatus via CMP-Neu5Ac 
transporters (CMPNT) (Eckhardt et al. 1996), where synthesis of sialylated glycans begins 
(Figure 1.17C) involving sialyltransferases. This constitutes a class of glycosyltransferases 
that are capable of catalysing the transfer of sialic acid from CMP-NeuAc to distinct glycan 
acceptor structures. These enzymes are highly specific for the linkage that is formed (α2-3, 
α2-6, α2-8), as well as for the primary structure and the spatial conformation of the acceptor 
(Nemansky and van den Eijnden 1993). Based on the nature of different sialyltransferases and 
acceptor specificities, they then catalyse CMP-NeuAc in the sialylation of oligosaccharide 
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Figure 1.17. Overview of mammalian sialic acid and polysialic acid biosynthesis and recycling. Four major 
routes are involved in the sialic acid metabolic system including: (A) The hexosamine pathway that converts 
GlcNAc-6P into UDP-GlcNAc, which is then catalysed to ManNAc by GNE; (B) The sialic acid biosynthetic 
pathway that converts ManNAc, the metabolic precursor into Neu5Ac in the cytosol, which then enters the 
nucleus for the synthesis of CMP-Neu5Ac (in most nonhuman species, a proportion of CMP-Neu5Ac is 
converted to CMP-Neu5Gc); (C) Sialoglycoconjugate production, during which the nucleotide sialic acids are 
transported into the lumen of the Golgi apparatus where several types of sialyltransferases are assembled to 
produce α2,3-, α2,6-, or α2,8-linked sialoglycoproteins or gangliosides. The polysialyltransferases are among 
these enzymes and specifically elongate the α2,8-linked PSA chain (i.e. polysialylated NCAM). Colour 
indications delicate specific sialyltransferases and corresponding glycol-linkage products. (D) The glycan 
recycling process that enables sialo- or polysialosides degradation by neuraminidases, thereby regenerating 
sialic acid monomers that can be re-used by a cell. Abbreviations – GlcNAc: N-Acetyl-D-glucosamine; 
ManNAc: N-Acetyl-D-mannosamine; UDP: uridine diphosphate; CMP: cytidine monophosphate; GNPNAT1: 
glucosamine-phosphate N-acetyltransferase 1; PGM3: phosphoacetylglucosamine mutase; UAP: UDP-N-
acteylglucosamine pyrophosphorylase 1; GNE: glucosamine (UDP-N-acetyl)-2-epimerase/Nacetylmannosamine 
kinase; NANS: N-Acetylneuraminic acid synthase; NANP: N-Acetylneuraminic acid phosphatise; CMAS: 
cytidine monophospho-N-acetylneuraminic acid synthetase; CMPNT: CMP-Neu5Ac transporter; ST3GAL: ST3 
β-galactoside α2,3-sialyltransferase; ST6GAL: ST6 β-galactosamide α2,6-sialyltranferase; ST6GALNAC: ST6 
(α-N-acetyl-neuraminyl-2,3-β-galactosyl-1,3)-N-acetylgalactosaminideα2,6-sialyltransferase; ST8SIA: ST8 α-N-
acetylneuraminide α2,8-sialyltransferase; NEU: neuraminidase. Figure taken from (Du et al. 2009). 
STX 
PST 
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chains of glycoproteins. Polysialyltransferases are distinctive members of sialyltransferases, 
involved in polysialylation to form long chain polymers in certain proteins (i.e. NCAM). 
Lastly, shown Figure 1.17D, bio-degradation of sialylated or polysialylated glycoconjugates 
is processed under the hydrolysis by several mammalian neuraminidases, and the liberated 
sialic acid can be salvaged and recycled by the cells (Du et al. 2009). In addition, a recent 
study indicated that free N-Acetylneuraminic acid is able to scavenge free radicals such as 
hydrogen peroxide and lipid hydroperoxide, and other sialic acids may also have antioxidative 
potentials (Iijima et al. 2009) 
 
Neuraminidases 
Despite the wide distribution in nature from virus to vertebrates, such as human, it has been 
identified that neuraminidases (or exo-α -sialidases) are localized in the cytoplasm, plasma 
membrane and lysosomes intracellularly, and cells expressing neuraminidases can be found 
broadly in a variety of tissues, including the pancreas, skeletal, muscle, kidney, placenta, heart, 
lung, liver and the brain (to a less extent) (Achyuthan and Achyuthan 2001; Monti et al. 2002). 
Belonging to the family of exoglycosidases that catalyze the hydrolytic cleavage of non-
reducing sialic acid residues linked to mono- or oligosaccharide chains of glycoconjugates 
preferentially, human neuraminidases have high catalytic efficiencies cleaving off the 
terminal α2,3 and α2,6-linked sialic acids. They are also capable of hydrolysing α2-8-linked 
neuraminic acid residues with a relatively lower efficiencies (Achyuthan and Achyuthan 2001; 
Monti et al. 2002). Shown in Figure 1.17D, human neuraminidases 1 to 4 are the most 
important ones responsible for sialic acid recycling and have been studies in detail at the 
molecular level. The existence of active neuraminidases implies that PSA is a bio-
degradatable substance, and points to the clearance process of the sugar polymer. Dedicated to 
the removal from the terminal sialic acids, the exo-α –sialidases hydrolysis of PSA chains 
(especially ones with many neuraminic acid residues) with α2,8-linked sialic acid linkages 
will be a time-consuming process, leading to PSA being a sustainable material for conjugation 
purposes. 
 
 
1.4.3.3 Natural Receptors of Sialic Acid 
Within vertebrate species, sialic acid-containing glycans are mainly recognised by two 
families of lectin receptors: the Selectin family and Siglec (Ig-like lectins) family. Selectins, a 
well-known calcium-dependent CAMs, are single-chain transmembrane glycoproteins that 
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have a high affinity for sugar moieties and therefore are considered to be a C-type lectin  
(Varki 2007). Selectin sub-groups including L-selectin on leukocytes, P-selectins on the 
surface of activated platelets and E-selectins on the surface of activated endothelial cells are 
found to target specific sialic acids involved oligosaccharides (i.e. Sialylated Lewis X 
antigen), and such interactions facilitate cellular activities such as lymphocytes and 
endothelial cells at the sites of inflammation (Rosen and Bertozzi 1994; Weninger et al. 2000; 
Pavlovic et al. 2002; Varki 2007). 
 
Siglecs are I-type transmembrane proteins, with Ig-like extracellular domains, a signal 
transduction transmembrane region and a cytoplasmic domain (Angata 2006). They are 
known as the largest vertebrate lectins for sialic acid-containing glycan recognition (Varki 
and Angata 2006). Also known as the sialoadhesion family, Siglecs show high selective 
recognition of sialic acids. Famous family members including sialoadhesin (Sn)/Siglec-1, 
CD22/Siglec-2, CD33/Siglec-3, myelin-associated glycoprotein (MAG)/Siglec-4a, and 
Schwann cell myelin protein (SMP)/Siglec-4b (Angata 2006), are predominately expressed on 
the cells having immunity function, such as B-cells, natural killer cells, monocytes, 
macrophages, neutrophils, and eosinophils. Although the exact mechanism of the coupling 
with sialic acid has not been fully understood yet,  the signal transduction via these Siglec 
receptors has been shown to regulate immune cell activation (Crocker and Varki 2001; 
Crocker and Varki 2001; Varki and Angata 2006). In addition, the binding of sialylated 
glycans by the Siglec receptor reduces the likehood of external viral attachment via 
hemagglutinin-sialic acid binding (Varki and Varki 2007).  
 
With a basic recognizing structure, the Sia-Gal-HexNAc sugar sequence, features including 
the type of sialic acid, its linkage to galactose and the general carbohydrate composition have 
been specified to a high degree by a range of Siglec receptors. Preferentially, polysialylation 
eptopes, Neu5Ac α2-3-linked and Neu5Ac α2-6-linked Galβ1-4GlcNAc are specifically 
bound by Sn/Siglec-1 and CD22/Siglec-2 respectively. Regarding recognition of α2,8-linked 
sialic acid, two human Siglecs has been reported with Siglec-7 having a weak affinity for 
disialic acid (Yamaji et al. 2002), and Siglec-11 having a rapid-diminishing binding style to 
α2-8-linked oligosialylic acid (around 2 to 6 neuraminic acid residues) (Angata et al. 2002). 
Apart from this sialic acid binding, there has not yet been any natural receptor reported for 
polysialic acid recognition, thus making PSA an ideal polymer for drug conjugation with no 
obvious receptor or ligand interactions. Furthermore, a study on bacteria α2,8-linked 
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homopolymerized PSA suggested that PSA alone, as a complex or a conjugate, is poorly 
immunogenic in vivo (Devi et al. 1991). 
 
 
1.4.4 Polysialyltransferases 
Assisted by a series of glycotransferases including essential sialyltransferases (listed in Figure 
1.17C) for the construction glycan cores and polysialylation epitopes, the biosynthesis of 
α2,8-linked PSA chains is catalysed by two polysialyltransferases, ST8SiaII (STX) and 
ST8SiaIV (PST), two closely-related polysialyltransferases that belong to the sialyltransferase 
gene family. They share two conserved
 
amino acid sequences - sialylmotif L and S (Angata et 
al. 1998). Structural dissection of the natural PolySTs demonstrated the enzymes have a short 
cytoplasmic segment but a large intralumenal domain consisting of a stem region and catalytic 
domain. The homologous sialylmotif L is involved in the engagement with the active sugar 
substrate, CMP-NeuNAc, while the sialylmotif S participates in the binding to both the sugar 
metabolite and the glycan acceptors (Figure 1.18) (Datta and Paulson 1995; Datta et al. 1998; 
Angata et al. 2004). STX is the principal enzyme that is expressed in the embryo, whereas 
PST is more prominent in the postnatal brain (Sandi 2004). Both enzymes are capable of 
working independently or cooperatively to induce NCAM polysialylation, and they have been 
frequently found to be expressed in the same tissue during normal development (Nakayama 
and Fukuda 1996; Angata et al. 1997; Angata et al. 2002). However, the differences in their 
biological functions, expressing regulation, and individual contribution remain to be 
unravelled (Seidenfaden et al. 2000). They terminate the polysialylation process when the DP 
reaches a certain size and the repulsion force from the new PSA inhibits the enzymes to 
interact with the polysialylated glycans (Angata et al. 2002). 
 
Although PST and STX are highly homologous to each other with 59% identical amino acids 
sequences, they are very different to the PSA synthases found in bacteria (Troy 1992). 
Substrate specificities of mammalian PolySTs particularly contribute to their unique 
enzymatic activities. As mentioned above in NCAM polysialylation (also illustrated in Figure 
1.18), the two PolySTs have a well-characterised docking-site on the NCAM FN1 domain and 
by sharing the same N-glycans at the fifth and sixth N-glycosylation sites on the adjacent Ig5 
domain, they are generating the same product and consistently synthesize polysialic acid by 
adding the first α2,8-linked sialic acid to α2,3 or α2,6-linked sialic acid, followed by the 
multiple
 addition of α2,8-linked sialic acid residues (Angata et al. 1998; Angata et al. 2002; 
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Angata and Fukuda 2003). Autopolysialylation was also found in both polysialyltransferases, 
which is not required for, but does enhance, NCAM polysialylation (Close et al. 2000). 
 
 
Figure 1.18. Schematic representation of polysialyltransferase (ST8SiaII or ST8SiaIV) in the action of 
polysialylating NCAM. The fourth and fifth Ig-like domains (Ig4 and Ig5) and two FNIII repeats (FN1 and FN2) 
of NCAM are shown on the left. ST8SiaII and ST8SiaIV share structural homologous. The structure of the 
PolyST (right) is dominated by a large intralumenal segment held by two disulfide-bond bridges. Both sialymotif 
L and S outline the catalytic domains of the enzyme, where the L motif is specifically responsible for conveying 
CMP-NeuNAc to the S motif, which catalyses the addition of the active sugar monomer to specialized glycan, 
and the elongation of the PSA chain. The specific recognitions of Ig5 and FN1 domains by the PolyST are also 
depicted, which the PolyST docks on the FN1 domain and begins synthesize α2,8-linked sialic acid to the N-
glycans attached to the Ig5 domain. Denotations: , ,  indicate sialic acid, CMP-NeuNAc and CMP 
respectively. N-glycosylation sites in NCAM are shown as . © and thin lines in between denote cysteine and 
the disulfide bridges. Figure is taken from (Angata et al. 2004). 
 
 
Other four α2,8-sialyltransferases have been identified and cloned so far, among which 
ST8SiaI and ST8SiaV are involved in ganglioside synthesis (Kono et al. 1996) and ST8SiaIII 
adds α2,8-linked sialic acid residues to the same terminal α2,3-linked sialic acid epitope 
utilized by PST and STX (Sato et al. 2000). However, all these α2,8-sialyltransferases can 
only transfer mono- or oligo-α2,8-linked sialic acid to the end structure of the glycan (Angata 
and Fukuda 2003). 
 
 
 
Intralumen Space 
  Golgi Membrane 
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1.5 Concept and Initial Study of Recombinant Polysialylation for 
Improving Antibody Fragment Pharmacokinetics 
 
1.5.1 Concept of Recombinant Polysialylation 
Following the concept of chemical conjugation of naturally-occurring polysialic acid (Section 
1.3.1.3), an alternative polysialylation approach through recombinant fusion of minimal 
polysialylatable domains from NCAM was initiated to provide a chemistry-free 
polysialylation method for modulating protein pharmacokinetics (Constantinou 2005). 
Described in Section 1.4.2, NCAM polysialylation (DP extend up to ~90 α2, 8-linked sialic 
acid residues) has been mainly found during mammalian neonatal nerve system development 
and this phenomenon is strictly regulated by the expression level of specific 
polysialyltransferases (STX and PST) (Abuchowski et al. 1984; Ong et al. 1998; Rutishauser 
1998; Oltmann-Norden et al. 2008). More defined PolyST specificity studies determined 
minimal NCAM structure (Ig5-FN1 domain) for polysialylation to take place, where (showed 
in Figure 1.18) FN1 domain offers the docking site for the enzymes to elongate the α2, 8-
linked PSA chains from two sialylated N-glycans sites located of the Ig5 domain (Close et al. 
2003; Angata et al. 2004).  
 
With the demand of increased blood circulation half-life, antibody fragment scFvs have been 
used as exceptional models in a range of PK modulation studies outlined in an update review 
(Constantinou et al. 2010). The recent study by Dr. Constantinou who chemically conjugated 
PSA to MFE23, an anti-carcinoembryonic antigen (CEA) scFv suggested that random amine 
coupling had detrimental effect to the scFv-CEA binding in vitro, whilst the scFv modified 
with a glycine-cysteine C-terminal peptide enabling site-specific thiol coupling avoided the 
interruption with the scFv binding site, and increased its in vivo half-life (Constantinou et al. 
2009).  Based on these findings, the concept of the recombinant polysialylation approach was 
maturated by genetically constructing a  fusion protein consisting MFE23 scFv and the 
polysialylatable NCAM Ig5-FN1 domains on the C-terminal (Figure 1.19) (Constantinou 
2005). Mammalian cell lines carrying out PSA biosynthesis pathway are also needed to 
express the fusion cDNAs with intracellular polysialylation and perhaps extracellular 
secretion.  
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Figure 1.19. Concept of scFv recombinant polysialylation.  The scFv-fusion protein is schematically showed 
in a polysialylated format, which theoretically follows the NCAM polysialyation features. The hydrodynamic 
volume improvement of the polysialylated scFv-fusion protein in comparison with the scFv was demonstrated 
schematically via PSA mediated water molecule associations.  
 
 
No single chain-Fv polysialylation has been studied for PK enhancement until recent 
chemical conjugation of PSA to MFE23 scFv which targets CEA as a popular tumour marker 
(Constantinou et al. 2009). Like CD20 (described in Section 1.1.4.1 rituximab), CEA is also a 
cell surface expressed, slow-internalizing receptor protein (internalization half-time ranging 
from 10-16 hours) (Schmidt et al. 2008), which enabled an initial investigation on how PSA 
effects scFv antibody targeting on cell surface antigens, in addition to polysialylation 
mediated PK modulation. To compare with the PSA chemical polysialylation, same scFv-
antigen binding model was chosen to understand the effectiveness of recombinantly 
polysialylated scFv-fusion protein. 
 
 
1.5.2 Carcinoembryonic Antigen (CEA)  
CEA belongs to the immunoglobulin superfamily, with two sub-groups differentiate to each 
other based on the C-terminal transmembrane (TM) domain (Olsen et al. 1994). For the 
purpose of this thesis, only the sub-group that contains a hydrophobic TM followed by a 
cytoplasmic domain will be introduced. As a highly N-glycosylated cell surface located 
protein (up to 50% carbohydrate composition of CEA‟s total molecular weight) (Yamashita et 
al. 1987; Yamashita et al. 1989), CEA consists of an Ig variable homology domain (IgV-like) 
and six domains homologous to the Ig C2 constant region (IgC2-like)  (Paxton et al. 1987; 
Williams and Barclay 1988; Olsen et al. 1994).  As an onco-fetal antigen that normally found 
during fetal life and very low level in adults, a specific adult tissue expression profile of CEA, 
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including a number of epithelial and goblet cell types found in colon, stomach, tongue, 
oesophagus, sweat glands, cervix and prostate has been revealed by previous tissue 
distribution studies (Nap et al. 1988; Nap et al. 1992; Prall et al. 1996). It has also been 
suggested that CEA was only found at the apical surface (glycocalyx/micovillus region) of 
polarized cells (Toner et al. 1971). The exact function of CEA has not been fully understood 
so far, however the x-ray crystallography and neutron scattering of the CEA structure 
proposed potential dimerization and protein-protein adhesion interactions (Hammarstrom et al. 
1989; Boehm et al. 1996). Further in vitro studies showed that CEA and CEA related proteins 
can undergo home- or heterophilic adhesive binding process determining CEA is capable of 
acting as a cell adhesion molecule (Benchimol et al. 1989; Oikawa et al. 1992; Zhou et al. 
1993). Additionally, CEA has been proposed for a role in the innate immunity, including 
interaction between fimbriated bacteria with the heavily glycosylated carbohydrate 
compositions of CEA (Leusch et al. 1990; Sauter et al. 1993), and the recognition of CEA N-
domain by Opa proteins in Neisseria gonorrhoeae and Neisseria meningitides (Virji et al. 
1996; Bos et al. 1997). These evidences suggested that micro-organisms can be trapped by 
CEA enriched apical glycocalyx and prevented from invading to the epithelial cells.   
 
Overexpression of CEA has been found in a wide variety of epithelial malignancies, 
especially for colorectal tumors (Minton et al. 1985; Zimmermann et al. 1988; Sheahan et al. 
1990; Kim et al. 1992). In comparison with the healthy individuals, the expression of CEA is 
restricted on the apical surface of mature columnar cells, and its emergence in the blood is 
less than 2μg/l; whilst in colorectal cancer patients, CEA is expressed all over the whole un-
polarized malignant cell surface and frequently shed into the blood. The increased blood and 
tumour level in correlation with the tumour size increment made CEA an exceptional antigen 
marker for therapeutic approaches (Minton et al. 1985; Wanebo et al. 1989). In addition, the 
continuous increase of CEA level has often reported as an indication of tumour recurrence or 
distant metastasis for patients after colorectal cancer surgery (Evans et al. 1978; Minton and 
Martin 1978) 
 
 
1.5.3 MFE23 scFv 
Based on different degrees of specificity, a number of CEA specific IgGs were produced in 
the 1980s (Hammarstrom et al. 1989), and many of which were used for clinical tumour 
imaging purposes (Ledermann et al. 1991; Pedley et al. 1993). Introduced in Section 1.2.1, 
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limitations of full length IgGs, including immunogenicity and Fc domain cross-reactive side 
effects alongside restricted tumour penetration leading to poor tumour/blood ratios 
significantly reduced the speciality of anti-CEA IgGs for targeted therapies. Antibody 
fragments with removed the risk of human immunogenicity and cross reactivity to normal 
tissues were consequently engineered, such as a recombinant Fab of monoclonal A5B7 
antibody, an original anti-CEA IgG (Chester et al. 1994).  
 
MFE23, a high affinity and specificity single chain Fv antibody raised against CEA was the 
first anti-tumour scFv selected by phage display technology (Chester et al. 1994). Other 
becoming much smaller in size, the most distinctive advantage of MFE23 scFv was that it 
displayed a 10-fold greater affinity for CEA than the A5B7 Fab (Chester et al. 1994; Chester 
et al. 1994), and this significantly enhanced the scFv tumour penetration and antigen 
localization potentials, which may gave credits to improved tumour/blood ratios demonstrated 
by mice transplanted with human tumour xenograpfts (Casey et al. 1995; Verhaar et al. 1995). 
Initially radio-labelled with I
123
 for imaging purposes in the clinic (Begent et al. 1996; Mayer 
et al. 2000), MFE23 scFv  represented the first generation of scFv used in patients. Since then, 
MFE23 scFv has been largely used for targeted therapy and showed great clinical potential for 
ADEPT after fusing with a number of enzymes with therapeutic purposes (Bhatia et al. 2000; 
Kousparou et al. 2002; Francis et al. 2004; Sharma et al. 2005). Successes from in vivo 
tumour delivery of a recombinant MFE23 scFv::TNFα fusion protein also demonstrated its 
capacity for targeted therapies (Cooke et al. 2002). Moreover, the previous established 
recombinant MFE23 scFv enzyme or cytokine fusion proteins also suggested the capability of 
MFE23 scFv in forming fusion proteins with sustained antigen binding affinity. However, like 
all the other antibody fragments, MFE23 scFv being a small protein molecule, has a very 
short plasma half life which significantly limits its therapeutic applications. Predominately 
lost from glomerular filtration, MFE23 scFv‟s rapid blood clearance also resulted a high 
kidney accumulation, which appears to be a common drawback when applying scFv with high 
doses for therapeutic use (Huston et al. 1993; Milenic et al. 2004). 
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1.6 Project Aims 
 
The aim of this project is to accomplish the recombinant fusion approach for antibody 
fragment (i.e. scFv) polysialylation, and develop sustainable production and purification 
systems for the polysialylated scFv-fusion protein. Consequent protein characteristic 
investigations will include verifications of correct fusion protein expression, retention of 
scFv-antigen binding affinity as well as the structural studies of associated PSA. As a novel 
and alternative pharmacokinetic modulating method, evaluations of the fusion protein 
hydrodynamic volume and in vivo blood clearance profile will also be conducted in this 
research. The progression of the research will include: 
 
(1) Understanding the requirements for polysialylating scFv-fusion protein, and create 
mammalian cell host producing polysialylated scFv-fusion protein after fusion protein 
DNA transfection; 
(2) Monoclonal selection of mammalian cell lines most capable for producing polysialylated 
scFv-fusion protein; 
(3) Establishing sustainable laboratory-scaled fusion protein production and purification 
system; 
(4) Characterizing the scFv-fusion protein, as well as its in vitro antigen-binding profile in 
comparison with mammalian cell expressed scFv; 
(5) Showing the degree of polymerization of recombinantly elongated PSA and other 
glycosylation features associated with the scFv-fusion protein; 
(6) Showing the changes in hydrodynamic volume of scFv-fusion protein in comparison with 
the scFv, and the bioactivity improvement from in vivo PK studies; 
(7) Establish another scFv-fusion protein indicating with another specialized antigen binding 
profile (i.e. internalization).   
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CHAPTER 2 
 
Materials and Methods 
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2.1 Materials 
 
Solutions needed to be degassed were bubbled by nitrogen gas for sufficient time. Filter 
sterilization through 0.2µm PES vacuum filtration devices (250ml and 500ml, Helana 
Biosciences; 1L VWR) was applied as required. Small amount solutions were syringed 
through 0.2µm or 0.45µm PES sterile syringe filters (VWR) for required sterilization.  
 
All general chemicals and reagents (not specified) were purchased from Sigma-Aldrich, 
Merck KGaA, and VMR. All reusable glassware and plastics were detergent washed prior to 
use and autoclaved where necessary for sterile and molecular work. 
 
2.1.1 General Solutions and Buffers 
 
Water: distilled water (dH2O) was obtained from Purite Select systems and sterilized by 
autoclaving if necessary. Nuclease Free water (Promega) was applied for molecular biology 
experiments.  Tissue culturing specified water was used in making solutions for tissue culture 
applications. 
 
Phosphate buffered saline (PBS): a concentrated (10x) stocked was prepared containing 80g 
NaCl, 2g KCl, 2.4g KH2PO4 and 14.4g Na2HPO4 per litre of dH2O, pH 7.5. The 1x PBS was 
diluted from the 10x stock with distilled water. The 1x PBS-Tween was made from 1x PBS 
with additional 0.01% Tween 20. 
 
Tris buffered saline (TBS): a 10x concentrated stock was prepared with 58.44g NaCl, 
23.64g Tris-HCl and 6.06g Tris-Base per litre of dH2O, pH 7.5. The 1x TBS and 1x TBS-
Tween (TTBS) was produced the same way as described in making PBS buffers. 
 
Others specific buffers and solutions will be explained explicitly with associated 
methodologies in the following content. Without further description, all solution was made in 
dH2O. 
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2.1.2 Agarose Gel Electrophoresis 
 
Tris-acetate EDTA buffer (TAE): the 50x stock solution was commercially purchased from 
VWR. The 1xTAE buffer contains 242g Tris-Base, 37.2g Na2EDTA.2H2O and 57.1ml glacial 
acetic acid per litre of dH2O, and was used as the agarose gel electrophoresis running buffer. 
 
Agarose gel: 1% Agarose (Bioline) in 1x TAE buffer. Ethidium bromide (10mg/ml stock) 
with a final concentration 0.5µg/ml was added into the microwave-heating dissolved gel for 
DNA visualisation.  
 
Others: 
Crystal 5x DNA Loading Buffer Blue (Bioline) 
HyperLadder I
TM
 (Bioline) – detection range from 200bp – 10,000bp 
HyperLadder IV
TM
 (Bioline) – detection range from 100bp – 1000bp 
 
 
2.1.3 Polyacrylamide Gel Electrophoresis (PAGE) 
 
PAGE running buffer: 3.03g Tris-Base, 14.4g glycine, 1g sodium dodecyl sulphate (SDS) 
made up to 1L with dH2O. 
 
Laemmli (SDS-sample) buffer (6x): 375mM Tris-HCl (pH 6.8), 9% SDS, 50% glycerol, 9% 
(fully reducing) or 5% (semi-reducing) β-mercaptoethanol, and 0.03% Bromophenol blue 
made up with dH2O. 
 
Resolving gel: for effective protein display and separation, resolving gels were prepared in 
different polyacrylamide concentrations depends on the size of protein samples. 
 
Table 2.1. Components of making 10ml SDS-polyacrylamide gel with four different concentration. 
ProtoGel
®
 (National diagnostics): 30g acrylamide and 0.8g methylene bis-acrylamide per 100ml solution; APS: 
ammonium persulphate; TEMED: N,N,N‟,N‟-Tetramethylethylenediamine. 
 
Gel 
Tris-HCl 
(pH8.8) 
ProtoGel
®
 10% SDS dH2O 10% APS TEMED 
7% 2.5ml 2.33ml 100µl 4.99ml 80µl 5µl 
8% 2.5ml 2.67ml 100µl 4.65ml 80µl 5µl 
10% 2.5ml 3.33ml 100µl 3.99ml 80µl 5µl 
12% 2.5ml 4ml 100µl 3.32ml 80µl 5µl 
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Stacking gel: 3ml dH2O, 0.5ml 1M Tris-HCl (pH6.8), 0.5ml ProtoGel
®
, 40µl 10% SDS, 40µl 
10% APS, 4µl TEMED. 
 
Semi-dry PAGE transfer buffer: 5.8g Tris-Base, 3g glycine, 0.4g SDS, 200ml methanol 
made up to 1L dH2O. 
 
PAG fix buffer: 45% methanol and 10% acetic acid in dH2O. 
 
 
2.1.4 Bacterial Strains and Culture 
 
Stains: 
The XL1-Blue (Stratagene) E. coli (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZΔM15 Tn10 (Tetr)]) tetracycline resistant were used in DNA cloning by mini- 
and midi-prep.  
 
The HB2151 (GE Healthcare) E. coli (nal r thi-1 ara ∆(lac-proAB) [F' proAB + lacI q 
lacZ∆M15]) were used for the expression of soluble scFv.  
 
Culture Media: 
2TY broth: 16g bacto tryptone, 10g bacto yeast, 5g NaCl made up to 1L with dH2O. 
2TY Agar: 15g bacto agar mixed with 1L 2TY broth (above). 
 
 
2.1.5 Plasmids  
 
pcDNA™4/TO/myc-His A, B, and C (Invitrogen) (Appendix 1) were the main vectors 
utilized in this research for both recombinant fusion construction in molecular level and in 
vitro cell transfection. Modified pcDNA™4/TO/myc-His A vectors incorporated with NCAM 
extracellular expression leader sequence from mammalian cell line as well as NCAM 
polysialylatable domains (Ig5 and FN1) or FN1 domain only (Figure 2.1a) were created  by 
Dr. Antony Constantinou in our lab previously (Constantinou, A. PhD thesis, 2005). He has 
also constituted and donated all four recombinant DNA constructs in pcDNA™4/TO/myc-His 
(FL-NCAM, MFE23-Ig5-FN1, MFE23-FN1, and LS-MFE23) (Figure 2.1b) for the 
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investigation of recombinant polysialylation of MFE23 scFv (Constantinou, A. PhD thesis, 
2005). The MFE23 scFv sequence is outlined in Appendix 6 and the NCAM leader sequence 
as well as the Ig5 and FN1 domain sequences are showed in Appendix 8. Full length 
NCAM140 sequence was originally obtained from pIg vector (Appendix 2) provided by Dr. 
Jane Saffell (Imperial College London). 
 
 
 
 
 
Figure 2.1. The DNA constructs for recombinant polysialylation of scFvs. (a) Intermediate constructs 
containing NCAM extracellular expression leader sequence with Ig5-FN1 domains or only FN1 domain in 
pcDNA™4/TO/myc-His A vector. The gap sequences between PciI and NotI are cleavable for incorporation 
with scFv sequences. (b) Four DNA constructs used in the study for MFE23 scFv recombinant polysialylation. 
LS-MFE23 sequence is contained in pcDNA™4/TO/myc-His C vector, while others are in pcDNA™4/TO/myc-
His A vector. Figure taken and modified from (Constantinou 2005). 
 
 
pUC119 vector (Appendix 4) containing C6.5 scFv sequence (Appendix 7) was a kind gift 
from Professor James Marks (University of California, San Francisco), and was used in the 
study of recombinant polysialylation of C6.5. 
 
PST and STX sequences were inserted in the pcDNA3.1 V5/His B vector (Invitrogen) 
(Appendix 3), and provided by Professor Karen Colley (University of Illinois, USA). 
(a) 
MFE23 scFv 
 
FL-NCAM 
 
 
MFE23-Ig5-FN1 
 
MFE23-FN1 
 
LS-MFE23 
(b) 
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pEGFP-C1 plasmid vector (Appendix 5) containing engineered green fluorescent protein 
(GFP) was purchased from Clontech. 
 
 
2.1.6 Molecular Biology Enzymes and PCR Primers 
 
Restriction endonucleases: all restriction enzymes and associated reaction buffers were 
purchased from Fermentas and New England Biolabs. 
 
DNA Polymerases:  
TAQ: purchased from Fermentas 
PFU-Turbo: purchased from Stratagene 
Both polymerase enzymes were supplied with respective buffers and nucleotide mixtures. 
 
DNA ligase: T4 DNA ligase and reaction buffer (New England Biolabs). 
 
Oligoneucleotide PCR Primers: all primers were designed in-house and ordered from 
Thermo Fisher Scientific (supplied as 100 pmol/µl stock concentration). 
 
Table 2.2. Primers used in construction of recombinant polysialylatable C6.5 scFv. The sequences include 
NcoI and NotI (red), and C6.5 scFv backbones (blue). 
 
Primer Name Direction Primer Sequence (5’ to 3’) 
C6.5 NcoI Forward 
CCT ATT TCC ATG GTG CAG CTG TTG CAG TCT 
GGG 
C6.5 NotI Reverse 
CTT TAC CTT TGC GGC CGC ACC TAG GAC GGT 
CAG CTT 
LS N-terminal Forward ACT AAG GAT CTC ATC TGG 
 
 
 
2.1.7 Mammalian Cell Lines and Culture  
 
Mammalian cell lines: 
Various cell lines were cultured for expression or genetically engineering purposes. Cell types, 
origins and resources were listed in Table 2.3. 
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Table 2.3. Mammalian cell lines utilized during this project and their origin. 
Cell line Origin Gifted or Purchased from 
NB2a Murine neuroblastoma cancer cell 
Professor Yuri Ushkaryov 
(Imperial College London) 
CHO Chinese hamster ovary cell Cancer Research UK (CR-UK) 
COS-1 
African green monkey kidney cell. 
SV40 transformed 
CR-UK 
3T3 
Primary mouse embryonic fibroblast 
cell 
Dr. David Mann 
(Imperial College London) 
HeLa Human cervical cancer cell Dr. David Mann 
HEK-293 Human embryonic kidney cell Dr. David Mann 
LS174T Human colonic adenocarcinoma cell CR-UK 
LoVo Human colon-carcinoma cell 
Professor Kerry Chester 
(University College London) 
KB Human epidermal carcinoma cell CR-UK 
SKOV-3 Human ovarian cancer cell CR-UK 
SKBr-3 Human breast carcinoma cell CR-UK 
 
 
Culture media: 
Standard tissue culturing medium (TCM): Dulbecco‟s modified Eagle‟s medium (DMEM) 
(PAA Laboratories) with 10% heat-inactivated fetal bovine serum (FBS) and 2mM L-
glutamine (from 200mM stock, Invitrogen) plus 1% of penicillin-streptomycin (from 5000 
units/ml penicillin + 5000µg/ml streptomycin stock, Invitrogen).  
To harvest the cells for recombinant protein secretion from stably selected cell lines, 
FreeStyle™ CHO Expression Medium or FreeStyle™ 293 Expression Medium (both from 
Invitrogen) were used with extra 4mM L-glutamine.  
 
Dulbecco’s PBS (1x): Cell culture specialised, without Ca & Mg ions was purchased from 
PAA Laboratories. 
 
Zeocin solution: Zeocin powder was purchased from Malford, and made into 100mg/ml 
solution with tissue culture specialised water, and 0.2µm PES filter sterilized.  
 
Cell lysis buffer: 10mM Tris-HCl, 10mM NaH2PO4, 130mM NaCl and 1% TritonX-100 in 
dH2O, at pH7.5. Each EDTA-free protease inhibitor cocktail tablet (Roche) was added in 
every 100ml of the lysis buffer. 
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Immunoprecipitation buffer: 50mM Tris-HCl, 150mM NaCl, 5mM EDTA, 0.5% NP-40, 
0.1% SDS, and EDTA-free protease inhibitor, pH7.5. 
 
Cell freezing buffer: 1% dimethyl sulfoxide (DMSO) in FBS. 
 
Tissue culture flasks (150, 75cm
2
), plates (3 and 10 cm
2
), and multi-well plates (96-, 24-, and 
6-well) were purchase with brand name BD Falcon
TM
, Nunc
TM
 or Corning. 
 
 
2.1.8 Protein Purification Buffers 
 
Imidazole elution buffer: 200mM imidazole dissolved in 1xPBS or 1xTBS, pH 7.4, and 
filter sterilized. 
 
Anion exchange running buffer:  100mM Tris-HCl in dH2O, pH7.4. Degassed and sterilized 
through 0.2µm PES filter. 
 
Anion exchange high salt buffer: 100mM Tris-HCl, and 1M NaCl in dH2O, pH7.4. 
Degassed and sterilized through 0.2µm PES filter. The high salt buffer was also used to make 
other NaCl concentration buffers for differential protein elution condition. 
  
 
2.1.9 Antibodies, Antigens and Affinity Proteins 
 
Antigens:  
N-A1: CEA domains with interaction with MFE23, expressed from Pichia pastoris. Purified 
native N-A1 has a molecular weight ranging from 38 to 188 kDa, due to glycosylative post-
modification, and was prepared in-house (Sainz-Pastor et al. 2006) and provided by Professor 
Kerry Chester, University College London. 
 
hErbB2/Fc: Chimeric Her2 antigen fused with human IgG Fc domain. Provided by R&D 
system. Recommended 100µg/ml stock was prepared in sterile 1x PBS, and stored in -20ºC. 
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Commercial Antibodies: Details of commercial antibodies used in the project for various 
purposes were listed in Table 2.4. 
 
Table 2.4. Commercial antibodies and their descriptions. HRP – horseradish peroxidase. FITC- fluorescein 
isothiocyanate. AP- alkaline phosphatase. 
 
Antibody Description and Use 
Anti-His HRP (Sigma) 
 
 
Anti-NCAM or CD56 
(Abcam) 
 
 
 
Anti-PSA 
(BD Pharmingen) 
 
 
 
Anti-c-Myc (CR-UK) 
 
 
 
Anti-V5 (AbD serotec) 
 
 
Anti-Mouse IgG-HRP (Fc 
specific) (Sigma) 
 
Anti-Rat IgM-HRP 
(Pierce) 
 
Anti-His (C-term)-FITC 
(Invitrogen) 
 
Anti-Mouse IgG-FITC (Fc 
specific) (Sigma) 
 
Anti-Rat IgM-FITC 
(Abcam) 
 
Anti-Galactose-α(1,3) 
Galactose (Millipore) 
 
Anti-human IgG-HRP 
(Fc specific) (Sigma) 
 
Anti-Digoxigenin-AP 
(Roche) 
 
Alexa Fluor
®
 488 goat anti-
mouse IgG (Invitrogen) 
 
 
Alexa Fluor
® 
594 goat anti-rat 
IgM (μ chain) (Invitrogen) 
 
Mouse monoclonal IgG recognizes poly-histidine conjugated to 
HRP. Dilution 1:4000. 
 
Mouse monoclonal (123C3) IgG1 to NCAM/CD56 recognises 
NCAM epitope between exons 11-13 (first fibronectin type-III, 
FN1). Dilution 1:1000 (for Western blot and ELISA), and 1:500 
(for live cell experiments). Reactivity: Human and rat. 
 
Rat monoclonal (12F8) IgM recognizes the polysialic acid on 
NCAM, with sialic acid residue number > 7. Dilution 1:1000 (for 
Western blot and ELISA), and 1:200 (for live cell experiments). 
Reactivity: all species. 
 
Mouse monoclonal IgG1 recognizes c-Myc tag. Dilution 1:1000 
(for Western blot and ELISA), and 1:500 (for live cell 
experiments) 
 
Mouse IgG2a against V5 tag. Dilution 1:1000 (for Western blot 
and ELISA), and 1:500 (for live cell experiments) 
 
Goat whole IgG recognising the Fc portion of mouse IgG. 
Polyclonal conjugated to HRP. Dilution 1:10,000. 
 
Goat whole IgG polyclonal specific for recognising the μ-Chain 
of rat IgM. Dilution 1: 10,000. 
 
Mouse monoclonal IgG recognizes poly-histidine conjugate to 
FITC. Dilution 1:500 
 
Dilution 1:200.  
 
 
Dilution 1:1000. 
 
 
Baboon polyclonal antibody against porcine Gal-α(1,3) galβ1-
4GlcNAc-BSA. Dilution 1:200. 
 
Goat monoclonal IgG binds to human IgG only. Conjugated with 
HRP. Dilution: 1: 60,000. 
 
Polyclonal sheep anti-Digoxigenin Fab fragments, conjugated 
with alkaline phosphates. Dilution: 1: 1000. 
 
Purified whole goat antibody recognizing mouse IgG and 
conjugated to the bright and photostable Alexa Fluor 488 dye. 
Dilution 1:2000.  
 
Dilution 1:2000. 
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Lectins: Apart from isolectin GS-IB4 (biotinylated) was purchased from Invitrogen, all the 
other lectins were pre-labelled with digoxigenin and obtained within DIG glycan 
differentiation kit from Roche (Table 2.5).  
 
Table 2.5. Indications of sugar linkages through positive reaction with specific lectins, and corresponding 
glycoprotein controls. 
 
Lectins Sugar linkage indication 
Glycoprotein 
controls 
SNA 
(Sambucus nigra agglutinin) 
 
 
 
MAA 
(Maackia amurensis agglutinin) 
 
 
DSA 
(Datura stramonium agglutinin) 
 
 
PNA 
(Peanut agglutinin) 
 
 
GS-I B4 (Griffonia simplicifolia) 
Indicates sialic acid, terminally 
linked (2–6) to galactose or N-
acetylgalactosamine. 
 
 
Indicates sialic acid terminally 
linked (2–3) to galactose. 
 
 
Indicates galactose-β(1–4)-N-
acetylglucosamine. 
 
 
Indicates galactose-β(1–3)-N-
acetylgalac-tosamine. 
 
 
Indicates Galactose-α(1-3)-
Galactose. 
Transferrin 
 
 
 
 
Fetuin 
 
 
 
Fetuin 
 
 
 
Asialo-fetuin 
 
 
 
Transferrin 
(Bovine) 
 
Buffers required for DIG glycan differentiation kit: 
Buffer 1: 1mM MgCl2, 1mM MnCl2, 1mM CaCl2, in 1xTBS, pH 7.5. 
Buffer 2: 0.1M Tris-HCl, 0.05M MgCl2, 0.1M NaCl in dH2O, pH 9.5. 
DIG blocking buffer: supplied with the kit. 
 
 
Others: 
MFE23 scFv: produced in E. coli, and provided by Professor Kerry Chester, University 
College London. 
 
Avidin, streptavidin, protein A, and protein G were supplied by Sigma-Aldrich, and 
dissolved in dH2O with recommended stock concentration. Stored in -20ºC for long term use. 
 
Marvel
®
 milk power (Premier Products): dried skimmed milk powder (99.5%). Diluted 
within 1xPBS or 1xTBS for blocking nitrocellulose membrane used in Western blots. 
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BM-Blue POD (Roche): 3, 3‟-5‟, 5-Tetramethylbenzidine (TMB) ready to use soluble 
peroxidise substrate solution. 
 
ECL Kit (GE Healthcare): enhanced chemiluminescence detection kits. 
 
Coomassie Protein assay reagent (Thermo Fisher Scientific): ready-to-use Coomassie blue 
G-250 based reagent. Mostly used for Bradford protein assay. 
 
EZ-Run protein gel staining solution (Fisher Scientific): ready-to-use Coomassie blue G-
250 based reagent for mini-gel staining. 
 
EZ-Link Sulfo-NHS-LC-LC-Biotin (Pierce, Thermo Scientific): Biotinylation reagent. 
 
 
2.1.10 Glycosidases  
Different glycosidases removing specific glycol-linkages were used in this project for basic 
glycol-structure illustration of interested glycoproteins. Details of each glycosidase are listed 
in Table 2.6, and their specific disaccharide linkage recognitions are illustrated in Figure 2.2. 
 
Table 2.6. Different glycosidases and their specific functions. All required reaction buffers were supplied with 
the enzymes when purchasing. 
 
Glycosidase Source Unit/µl Functional specificity 
Endo-Neuraminidase 
(Endo-N) (Abcys) 
Phage K1 0.7 
Recognises α2-8 linked sialyl residues, 
and requires minimum 5 sialyl residues 
for activity. 
Acetyl-neuraminyl 
hydrolase (Exo-N) 
(New England Biolabs) 
 
Clostridium 
perfringens 
50 
Also known as sialidase, mainly 
catalyzes the hydrolysis of α2-3, α2-6 
linked N-acetyl-neuraminic acid 
residues from glycoproteins and 
oligosaccharides. It also hydrolysis the 
α2-8 linked, but very less efficient. 
N-Glycosidase F 
(PNGase F) 
(New England Biolabs) 
 
Flavobacterium 
meningosepticum 
500 
An amidase that cleaves between the 
innermost GlcNAc and asparagine 
residues of high mannose, hybrid, and 
complex oligosaccharides from N-linked 
glycoproteins. 
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Figure 2.2. Schematic illustration of glycosidase enzymatic specificities.  (a) A typical complex N-glycan 
structure model showing the breaking sites of each glycosidase. (b) Glycosidase specificities indicated from an 
O-glycan. Asn: asparagine; Ser: serine. 
 
 
2.1.11. Murine Models 
Female healthy BALB/c nude mice (6 – 8 weeks old) were used for the purpose of all in vivo 
work (Home Office Project Licence: 70/6982 under Dr. Deonarain, Imperial College London). 
Mice were quarantined for 6 weeks in Central Biomedical Service (CBS) unit of Imperial 
College London before any experiment and maintained in individually vented cages with 
sterile bedding and supplied with autoclaved food and water by fully trained animal 
technicians from CBS Unit. 
 
 
 
 
 
α2/3 
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α2/6 
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2.2 Methodologies 
 
2.2.1 Bacteria Culture 
 
2.2.1.1 Preparation of Chemically Competent Escherichia coli 
Both competent E. coli strains XL-1 Blue and HB2151 were prepared according to the 
following protocol. E.coli single colonies grown on 2TY-agar plate (containing 15µg/ml 
tetracycline for the XL-1 Blue strain) were inoculated into a 5ml 2TY broth and cultured 
overnight at 37ºC shaking (280rpm) in an orbital shaking incubator.  This culture was then 
sub-cultured (1:100) into 100ml of fresh 2TY broth (containing 15µg/ml tetracycline for the 
XL-Blue strain). The culture was grown at 37ºC with shaking (250rpm) until the culture 
optical density at 600nm (OD600) reached between 0.6 and 0.8. The culture was chilled on ice 
for 30 minutes, and split in 50ml volumes into two centrifuge tubes. Subsequent centrifuge 
was carried out at 3000rpm for 10 minutes at 4ºC. Each pellet was responded in 50ml pre-
cooled 100mM CaCl2 (0.2µm filter sterilized) and left on ice for another 30 minutes. The 
bacteria solution were span down once again at 3000rpm for 10 minutes at 4ºC and each 
pellet was dissolved in 1.5ml of 100mM CaCl2 with 15% glycerol (0.2µm filter sterilized). 
The competent bacterial cells were aliquoted in 50µl volumes, snap-frozen by liquid nitrogen 
and stored at -80ºC. 
 
 
2.2.1.2 Transformation of Chemically Competent E.coli 
The bacteria transformation was carried out by heat shock method. An aliquot of competent E. 
Coli was mixed with 1µg of plasmid DNA with gentle agitation with the pipette, and 
incubated on ice for 30 minutes. Heat-shock of the bacteria was applied in 42ºC water bath for 
60 seconds, followed by incubation on ice for at least 2 minutes. The 37ºC pre-warmed SOC 
medium (1ml) was added for recovering the bacteria, which was then incubated at 37ºC 
shaking incubator (280rpm) for an hour. Depends on the size of the agar plates, transformed 
bacteria culture (between 25µl to100µl) was plated onto the agar plates with 1% glucose 
and100µg/ml of carbenicillin (analogous antibiotics like ampicillin, but more stable) , as most 
of the vectors used in this project containing ampicillin resistant gene. For pEGFP-C1 vector, 
100µg/ml kanamycin is used instead of carbenicillin for plasmid selection. Additional 
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15µg/ml tetracycline was added for XL-1 Blue strain only. The plates were incubated in 37ºC 
for 12 to16 hours for the colonies to form. 
 
 
2.2.2 Molecular Biology Techniques 
 
2.2.2.1 Isolation and Purification of DNA  
DNA required to be isolated in this project were mainly from bacterial plasmid, PCR mixtures 
and agarose gels. QIAquick
TM 
Spin range of DNA isolation and purification kits 
manufactured by QIAGEN were used for this purpose. This establish technology utilises a 
spin column containing a silica based membrane which selectively binds DNA molecules in 
the presence of high concentration of chaotropic salts and lower pH conditions (pH 5.0 
optimum). Contaminants pass through the column, and following ethanol-based washing steps. 
DNA is eluted in nuclease free water or a Tris based buffer, pH 7.4. The protocol for isolating 
DNA varies depending on the type and source of acquired DNA. Detailed information and 
protocol can be obtained from appropriate manufacturer handbooks. 
 
Plasmid DNA 
QIAGEN Mini and Midiprep kits were used to produce and purify bacteria plasmid DNA 
from transformed E.coli XL-Blue strain. Cultures of 10ml (for Miniprep) or 200ml (for 
Mideprep) were grown in 2TY broth with 100µg/ml of carbenicillin or kanamycin, 1% 
glucose at 37ºC for 12-16 hours and 15µg/ml tetracycline. The bacteria were pelleted by 
centrifugation at 4000rpm for 10 minutes at room temperature. The pellets were lysed and 
DNA were purified throughout the manufacturer protocols and using the buffers and reagents 
supplied in the kits. Purified DNA was stored at -20ºC for long term usage. 
 
DNA Fragment Isolation by Gel Extraction  
In this project, DNA fragments were generated mostly from PCR and enzymatic digestions. A 
high standard purity was required in applications such as ligation to the DNA fragments. 
Isolation of the fragment can be done through agarose gel, and consequent clean-up method 
using QIAquick Gel Extraction Kit. Samples containing interested DNA fragments underwent 
electrophoresis in a 1% agarose gel with ethidium bromide staining. The DNA fragment of 
interest was visualised under low intensity UV light using a UV transilluminator, and 
separated from the gel by excision with a scalpel blade. Briefly, the extracted gel slice was 
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weighted and dissolved in buffer QG which contains guanidine thiocyanate. The DNA was 
then isolated and cleaned by 100% isopropanol through a silica-based spin column, according 
to the manufacturer protocol. Following the wash step with buffer PE, the DNA was eluted in 
30µl of nuclease free water, and stored in -20ºC. 
 
 
2.2.2.2 Agarose Gel Electrophoresis 
DNA samples were typically visualized and analysed by agarose gel electrophoresis. For the 
gel size of the electrophoresis system (Anachem/Scotlab) used requires 30ml of agarose gel 
solution (1%) together with ethidium bromide (0.5µg/ml final concentration). DNA samples 
were prepared by mixing with 5 x DNA loading buffer in a ratio of 1:4. The voltage applied 
as 100V for electrophoresis. Results were detected by BioDoc-It
TM
 UV Transilluminator 
(Jencons-PLS) or FujiFilm LAS-3000 CCD imaging system (UV setting) after gel running. 
Gel images were formatted and edited using CorelDRAW Graphic Suite X3 software. 
 
 
2.2.2.3 DNA Concentration Determination  
Plasmid DNA was quantified using a Thermo Scientific NanoDrop
TM
 1000 
Spectrophotometer. The device allowed accurate determination of concentration and purity 
using only 2.5µl of neat sample. The sample absorption at 260nm and 280nm was measured, 
and the 260nm value was converted to DNA concentration based on the calibration that 1.0 
OD reading equates to plasmid DNA concentration of 50µg/ml. The 260nm/280nm ratio was 
used as a measurement for sample purity determination, and standard pure sample should 
have this value higher than 1.6.  
 
For concentration determination of PCR products, laser scanning densitometry was employed 
by using FujiFilm LAS-3000 instrument. The density degree of ethidium bromide stained 
sample bands were compared with the molecular weight marker Hyperladder I or IV, which 
has standard indications between DNA concentration and density degree. 
 
 
2.2.2.4 Polymerase Chain Reaction (PCR)  
PCR was used to amplify specific DNA fragment for this research. The exact details for 
individual experiments are outlined in the relevant results chapters. Briefly for this project, 
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PCR was involved in amplifying inserts for ligation, and conducting colony PCR to check 
insert sizes post-ligation before sending to sequence. Generally TAQ polymerase (of Thermus 
aquaticus) was applied mainly in all PCRs, and the reactions were taken place by using 
Mastercycler
®
 gradient (Eppendorf). 
 
Table 2.7. Common PCR reaction constituents and cycling conditions. For 25µl final reaction volume. 
 
Reaction Constituents Standard PCR 
Primer 1 (10 pmol/µl) 2.5µl 
Primer 2 (10 pmol/µl) 2.5µl 
10x Buffer* 2.5µl 
MgCl2 (25mM) 2.5µl 
dNTP Mix (25mM) 2.5µl 
TAQ DNA polymerase (5U/µl) 0.25µl 
Template (culture or 50ng/µl) Trace culture or 0.5µl 
Nuclease-free water 10.5µl 
 
* 10x Buffer: 750mM Tris-HCl (pH 8.8), 200mM (NH4)2SO4 and 0.1% (v/v) Tween-20. 
 
 
General PCR cycling condition: 
Step 0 Hot lid (100ºC) 
Step 1 Initial denaturation at 96ºC for 5 minutes 
Step 2 Denaturation at 94ºC for 1 minute 
Step 3 Annealing for 1 minute at a determined temperature for both primers or a 
serial of temperature gradient (if the annealing temperature is unknown 
initially) 
Step 4 Extension for 1 minute at 72ºC 
Step 5 Repeat of Step 2-4 for 30 cycles 
Step 6 Final extension for 10 minutes 
Step 7 Hold at 4ºC until use 
 
 
Colony PCR (cPCR)  
Rather than using DNA template, trace amount of bacterial cells selected from single colonies 
were used to donate their chromosome as PCR template after initial 100ºC boiling step. Same 
PCR cycling conditions were applied to the cPCR. 
 
 
2.2.2.5 Enzymatic Restriction Digestion 
Typical restriction enzymes digestions were set up according to the suppliers‟ protocols, and 
used mostly for DNA double digestions. In order to achieve maximum digestion all reaction 
incubations were carried out for overnight. A typical reaction would contain 10 units of each 
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enzyme used, genomic DNA (up to 5µg), reaction buffer and any other supplements such as 
bovine serum albumin (BSA), and the reaction conditions is shown in Table 2.7 below. 
Nuclease-free water was used to dilute the reaction buffer and enzyme associated glycerol 
concentration.  
 
Table 2.8. Conditions for restriction enzyme DNA double digestions.  
Enzymes Enzyme 
Ratios 
Reaction 
Temperature (ºC) 
Buffer 
PciI (or PstI)* and NotI* 1:1 37 Buffer O* 
NcoI* and NotI* 4:1 37 Buffer O* 
HindIII* and NotI* 1:4 37 Buffer R* 
EcoRV
†
 and XbaI
†
 2:1 37 Buffer 2
† 
+ BSA 
*: Purchased from Fermentas  
†
: Purchased from New England Biolabs.  
 
Buffer Composition: 
10x Buffer O:  
50mM Tris-HCl, 10mM MgCl2, 100mM NaCl, and 0.1mg/ml BSA, pH 7.5. 
 
10x Buffer R:  
10mM Tris-HCl, 10mM MgCl2, 100mM KCl, and 0.1mg/ml BSA, pH 8.5. 
 
1x Buffer 2: 
50mM NaCl, 10mM Tris-HCl, 10mM MgCl2, 1mM Dithiothreitol, pH 7.9. 
 
 
2.2.2.6 DNA Ligation 
Following double digestion with relevant restriction endonuclease enzymes, both vector and 
insert were purified by gel extraction and quantified by laser scanning densitometry. Two 
insert to vector molar ratios, 1:1 and 3:1 were applied for ligation. In practice, normally 100ng 
of vector was used, and following the molar ratios, appropriate insert amount can be worked 
out. T4 DNA ligase (0.1units) was added for catalysing the ligation process with associated 
T4 DNA ligase reaction buffer (for 1x buffer: 50mM Tris-HCl, 10mM MgCl2, 1mM ATP, 
and 10mM dithiothreitol, pH7.5) The reaction was then made up to 20µl by nuclease-free 
water, and incubated at 16ºC overnight in the PCR thermo-cycler.  
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2.2.2.7 DNA Sequencing   
Various DNA sequencing services were used during this PhD research. Initially, the service 
was done by Dr Wonda Stow at the Advanced Biotechnology Centre, Imperial College 
London, using ABI377 Automated DNA Sequencers following in-house standard protocols. 
External DNA sequencing was taken place in Cogenics 
(http://www.cogenics.com/sequencing/service/primerwalking.cfm), and the sequencing 
protocol is available from the website as well. The DNA sequencing results were viewed and 
analysed by ChromasPro 1.41 (Technelysium Pty Ltd). Alignment and comparison of DNA 
sequences were achieved through National Center for Biotechnology Information (NCBI) 
website specialised BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
 
 
2.2.3 Tissue Culture Techniques 
 
2.2.3.1 Cell Growth and Maintenance 
All cell lines were grown in standard DMEM tissue culture medium (TCM) with 10% FBS, 
plus 2mM L-glutamine and 1% of penicillin-streptomycin (see section 2.1.7), and sustained in 
a humidified incubator at 37ºC and constantly supplying 5% CO2. All cell lines listed in Table 
2.3 were adherent and sub-cultured when they reached to 70%-80% confluent (culturing days 
varies to different cell type). To sub-culture the cells, the old culturing media was removed 
and the cells were washed once with 1xPBS. Trpsin/EDTA (1x) from Invitrogen was added to 
cover the culturing surface (approximately 1ml/75cm
2
), and left for 5 minutes or more at 37ºC 
in the cell culture incubator until cells were dislodged from the surface. The cells were then 
diluted in TCM and split in an appropriate ratio depending on the cell growth speed and usage 
of other experimental purpose. The more dilute, the less cell numbers will be split out in each 
aliquot for seeding. 
 
 
2.2.3.2 Cell Lysis 
To lyse the cells grown in 60mm culture dishes, 1ml ice cold cell lysis buffer was added and 
incubated on ice for 30 minutes, with repeated pipetting every 5 minute. Soluble material was 
separated from the cell debris by centrifugation at 13,000rpm for 10 minutes. The soluble 
material was decanted and stored in -20ºC until ready for analysis. 
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2.2.3.3 Tissue and Cell Homogenation 
Embryonic (E11.5) mouse brain (dissected and gifted by Dr. Anita Hall, Imperial College 
London) was frozen at -80ºC initially. After thawing, 1ml of ice-cold immunoprecipitation 
buffer was added to each brain. Homogenation of the brain was carried out by syringing the 
brain through a needle (26-gauge) 7 times, followed by top speed centrifugation for 5 minutes. 
The supernatant was then collected, aliquoted, and frozen stored before use. 
 
 
2.2.3.4 Cell Storage Techniques 
Cells reached 80% confluent in a 75cm
2
 tissue culture flask were normally enough to be put 
into a 2ml Cryo
TM
Tube vial (Nunc
TM
) as one stock. Generally, the cells was washed once with 
1x PBS, trpsinized, and collected by TCM in 10ml total volume. After centrifuging at 
1500rpm for 5 minutes, TCM was aspirated and the cell pellet  was resuspended in cell 
freezing buffer (1ml for one vial), before transferring into the vial. The vials were 
immediately moved in -80ºC and can be store there for a short time period (normally no more 
than 6 months) and later transferred to liquid nitrogen tank for long term storage.  
 
 
2.2.3.5 Cell Counting 
Relatively accurate cell numbers were required occasionally depending on the experiment. To 
do this, cells were firstly washed with 1x PBS and trypsinized as described in section 2.2.3.1. 
Dislodged cells were then collected in an appropriate volume of TCM, and 50µl of the cell 
suspension was removed to mix with 50µl of 0.4% trypan blue solution (1:1 ratio). 
Approximately 15µl of the mixture was added through the edge into the counting area of 
Neubauer heamocytometer affixed with a clean cover-slip. Viable cells appeared white under 
microscope while the dead cells were dyed into blue.  The number of viable cells (N) in the 
middle big square of the grooved/counting area on the heamocytometer was counted, and the 
concentration of the cell suspension collected in TCM equals to N x 10
4
 (viable cells/ml). 
 
 
2.2.3.6 Cell Culture Transfection  
Cell transfection protocols involved in this research were based on cationic lipids. The lipids 
mix with plasmid DNA to produce liposomes, which fuse with the cell membrane and deposit 
the cargo inside. This brings the minimum damage to live cells. A few existing transfection 
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reagents utilizing this protocol were selected at the beginning of the research, and an 
optimization test was carried out in order to find the best reagent and condition to induce the 
highest transfection efficiency. The reagents tested were Fugene
®
 6, Fugene
®
 HD (both from 
Roche), and Lipofectamine
TM
 2000 (Invitrogen). The methods of using each transfection 
reagent and corresponding condition settings will be described in the results section.  
 
After this optimization process, Fugene
®
 HD was chosen and used with optimized condition 
for cell transfection throughout the PhD research. The transfection protocol was modified 
from Fugene
®
 HD handbook. Normally, Cells (~ 3 x 10
6
) were plated on 10cm tissue-culture 
dishes (achieving ~80% confluent for an overnight incubation) prior to transfection. On the 
following day, all media, reagents, and plasmid DNA solutions were pre-warmed in room 
temperature before use. For a single transfection on a 10cm cell culturing surface area, 10µg 
of plasmid DNA was required to cooperate with 40µl of Fugene
®
 HD according to the 
optimized DNA (w) to transfection reagent (v) ratio for best transfection efficiency, and both 
the plasmid DNA and Fugene
®
 HD were mixed with serum free DMEM in a total volume of 
500µl. The transfection complex was then vortex mixed, and incubated at room temperature 
for 15 minutes. Cells ready for transfection were washed with 1x PBS once, and replaced with 
4.5ml serum free DMEM in the 10cm tissue-culture dishes, together with all the transfection 
complex. Incubation of the cells was taken place in the 37ºC cell culture incubator overnight. 
A double transfection can be achieved by sampling mixing both plasmid DNA (10µg each) 
and 80µl of Fugene
®
 HD with serum free DMEM in a total volume of 500µl to form the 
transfection complex. 
 
 
2.2.3.7 Selection of Stable Cell Line 
For stable cell selection, cells after transfection were gently wash once with 1x PBS, then 
trypsinized and collected with TCM for a total volume of 5ml. Five different cell dilution 
plates were set up by loading 0.1, 0.25, 0.5, 1, and 2ml dilutions of the collected cell 
suspension respectively into 5 different 10cm tissue culture dishes and supplemented with 
TCM to 6ml in total. Zeocin (100mg/ml stock) or G418 sulphate solution (50mg/ml, PAA) 
was used for selecting plasmid DNAs containing zeocin or neomycin resistant genes, and they 
were added into each plate to make a final concentration of 1mg/ml. A transfection-free plate 
was also applied the same way to observe antibiotic killing. Cell culturing medium was 
changed every 5 days with serum medium containing 1mg/ml zeocin. Normally after two 
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rounds of 1mg/ml antibiotic incubation, large amount of dead cells was observed, and the 
zeocin concentration was reduced to 0.5mg/ml. However, this selection phenomenon varies to 
different cell types. Another few days, untransfected cells were all killed according to the 
negative control plate, and survived transfected cells formed into monoclonal cell colonies, 
which were beginning to be visualized without microscopes. The antibiotic level was dropped 
down to 0.25mg/ml for minimum selection pressure to maintain the stable cell line. 
 
Polyclonal Selection 
After antibiotic elimination of un-transfected cells, the survived transfectants from the same 
DNA transfection were trypsinised and pooled together. Such collections were also made for 
colonies left over after monoclonal selections. Sub-culturing these cells in the same way 
described in section 2.2.3.1 in TCM with 0.25mg/ml corresponding mammalian selection 
antibiotics, and stocked in liquid nitrogen for long term use. 
 
Monoclonal Selection 
The initial antibiotic treatment after transfection trigged apoptosis to cells without 
incorporation of induced resistance expressing DNA. Visualized individual monoclonal cell 
colonies were then selected from the cell dilution plates. The plates were gently washed with 
1x PBS first. Selected colonies on the plate were picked by trypsin soaked 5mm autoclave 
sterilized paper discs (cut from 3MM Whatman paper by hole punches), and transferred into a 
24-well plate (surface area of each well = 1.9 cm
2
) pre-loaded with 100µl trypsin in each well. 
TCM (900µl) was then applied to each well with gentle suspension in order to shear off the 
cells sticking to the paper discs, and finally the plate was incubated in normal cell culture 
condition. The paper discs were removed after cells were stably growing on the plate surface. 
Sub-culturing of the cells from each well of the 24-well plate was carried out the same way 
described in section 2.2.3.1 in 1ml TCM with 0.25mg/ml corresponding mammalian selection 
antibiotics, in order to control the cells in a similar growth rate for expression selection 
purpose. Selected monoclones were increasingly cultured step-by-step from transferring into 
6-well plates to 75cm
2
 culture flasks. 
 
 
2.2.3.8 Transient Protein Expression after Cell Transfection 
After cell transfection (see section 2.2.3.5), the cells were cultured immediately in 10ml TCM 
without any antibiotic selection followed by removal of the transfection complex. The 
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medium was collected after 3 or 4 days normal cell incubation, and centrifuged at 2000rpm 
for 5 minutes to remove the cells involved in the medium before further applications. 
 
 
2.2.3.9 Protein Expression from Stable Cell Lines 
Selected stable cell lines were increasingly cultured in TCM with normal cell culturing 
condition until they reached ~80% confluence. For cells with polysialylatable functionality, 
additional 1mM valproic acid (VPA) was added in TCM to enhance polysialyltransferases 
activities. Cells were then washed twice with 1x PBS, and replaced with FreeStyle™ CHO 
Expression Medium (for stable NB2a cell lines) or FreeStyle™ 293 Expression Medium (for 
stable HEK293 cell lines), supplemented with 4mM L-glutamine. With incubation in 37ºC 
cell culture incubator, supernatant was collected after 4 days, and the cells was repeatedly 
cultured in the same serum-free medium for another 1 or 2 rounds depending on the healthy 
status of the cells. All collected medium were pooled together, and dialysed through 
Spectra/Por
®
 Dialysis Membrane (MWCO: 12-14,000; vol/length: 18ml/cm) (Fisher 
Scientific) against 1 x PBS before purification. 
 
 
2.2.4 Protein Expression and Purification 
 
2.2.4.1 Selection of Stable Cell Lines with Optimal Protein Expression 
Medium of each selected stable cell lines cultured in 24-well plates was collected when the 
cells have grown approximately above 70% confluent (normally after 4 days culturing), and 
centrifuged at 2000rpm for 5 minutes to remove the cell debris. Two main selection methods 
were used throughout the project: (1) Dot-blot; and (2) ELISA. Both methods were applied 
for checking interested proteins expression from other expression formats and scales. 
 
Dot-Blot 
Bio-Dot
®
 microfiltration apparatus (Bio-Rad) was used for detecting protein expression level 
of each monoclone. It is quick and feasible, and only tells the expression level from a single 
protein characteristic through each immunodetection. By following the manufactory protocol 
of the dot-blot apparatus, 500µl of cell supernatant was loaded on top of pre-wetted nitro-
cellulose membrane embedded in dot-blot apparatus outlined by a 96-well plate format lid. 
Samples were transferred in the membrane by vacuum through the apparatus. The membrane 
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was then blocked in 5% milk in 1x TBS for 40 minutes. Primary antibody was applied onto 
the membrane consequently. Additional secondary antibody conjugated with HRP was added 
when none HRP-conjugate primary antibody was used, with three times of vigorous 1x TTBS 
wash step in between. After another 3 washes in TTBS and then 3 times in TBS, the blot was 
developed by ECL
TM
 (GE Healthcare), and the image was taken by Fujifilm LAS-3000.  
 
Enzyme-Linked Immunosorbent Assay (ELISA) for Selection 
For selecting proteins having two important characteristics from an un-purified buffer 
containing contaminants carrying one or the other characteristics, dot-blot is not accessible in 
such application, but an ELISA principle derived method was designed for the dual-selection. 
Specifically for the selection purpose, two characteristics from the fusion protein needed to be 
determined simultaneously were scFv antigen binding epitope, and polysialic acid. To carry 
out the method, scFv antigens were firstly immobilized on the surface of 96-well plates 
overnight at 4ºC. For selection of monoclones with the best yield of polysialylated MFE23-
Ig5-FN1, 100µl of N-A1 (1µg/ml) was directly coated in each well, while for the 
polysialylated C6.5-Ig5-FN1 selection, 100ng of hErbB2/Fc was immobilized in each well 
with Fc domain interacted with pre-coated protein A (1µg per well). Followed by twice 
washing twice with 1x PBS, the antigen coated plates were blocked with 3% milk in 1x PBS 
(300µl per well), and left at 37ºC for 2 hours. After washing the plates 3 times with 1x PBS, 
250µl of collected medium from the stable cell lines were loaded into each well, and a 
duplicate of each sample was applied. The following steps were continued by standard ELISA 
protocol described in later context (see section 2.2.5.6), and the final read-out was measured 
at 450nm wavelength from 96-well plate reader Spectramax 340pc (Molecular Devices). 
 
 
2.2.4.2 Immobilised Metal Affinity Chromatography (IMAC)  
Most proteins generated from both bacteria and mammalian expression systems within this 
project were tagged with a hexa-histidine (His6) epitope which coordinates strongly with 
certain transition metals such as cobalt. Cobalt metal affinity resin (TALON
TM
, Clontech) was 
used to purify the proteins. For every litre of protein expressing bacterial culture, 2ml of 
TALON
TM
 resin slurry was added to either the bug lysate or concentrated, dialysed 
supernatant. For mammalian expression system, 2ml TALON
 TM
 slurry was used for 500ml 
dialysed cell culture medium. Typically the resin was incubated with the bacterial lysate, 
supernatant or cell culture medium overnight at 4ºC with gentle rolling, and then applied to a 
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10ml gravity flow column containing a scinter for collection of the resin. The flow-through 
was collected, and re-purified if the purification step is not efficient enough. Subsequent 
washing steps were conducted with 1x PBS or 1x TBS, and 4 column volumes of wash buffer 
were normally used. Protein was eluted in 1ml fractions of ice-cold 200mM imidazole buffer 
(pH 7.4). During IMAC purification, elution total protein content was quantitatively traced 
with Coomassie protein assay reagent using 100µl of the reagent and 10µl of sample. 
Fractions were pooled and dialysed exhaustively into the buffers that were required for 
consequent experiments or storage.   
 
 
2.2.4.3 Immunoprecipitation 
TALON
TM
 anti-6xHis cobalt resin and anti-Myc antibody coated sepharose resin (gift from 
Dr. John Silva) were used. Both types of anti-protein tag resin beads were supplied as slurries, 
and incubated with the unpurified medium solution (approximately 100µl in 12ml medium) 
overnight at 4ºC. The medium was then run through a column containing a scinter for 
collection of the resin, and the resins were washed twice with 1xPBS followed by collection 
in 1x PBS as well. Centrifugation to the resin collection was carried out at 4000rpm for 5 
minutes, and the supernatant was carefully removed before applying the resin for further 
experiment. Typically, the resin was diluted by 1x Laemmli (SDS-sample) buffer (Sigma-
Aldrich) and directly used for SDS-PAGE. Other immunoprecipitations were achieved by 
firstly incubating the unpurified medium with specific precipitant recognizing monoclonal 
antibodies, followed by incubation with protein A or G immobilized on the sepharose resins. 
Further steps were processed as standard immunoprecipitation protocol described above. 
 
 
2.2.4.4 Ion Exchange Chromatography 
Further purification of separating proteins with different degrees of polymerization (DP) after 
IMAC purification was achieved by utilizing anion exchange chromatography based on the 
negative charge nature of sialic acid. An AcroSep
TM
 Chromatography Column (1ml bed 
volume) with strong anion exchanger Q Ceramic HyperD
®
 F (Pall Life Sciences) was used 
and optimised for separating proteins with different polysialylation degree. The column is 
suitable for connecting with both automated and pumped chromatography systems. In terms 
of automatically programmed purification, the anion exchange column was connected with 
the BIO-RAD BioLogic DuoFlow fast protein liquid chromatography (FPLC) with gradient 
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valve was served as the automatic system paired up with BioLogic QuadTec UV-Vis Detector 
for simultaneous wavelengths monitoring. Recommended by the column handbook, Tris 
buffer (100mM) with neural pH was selected as basic running and mixing buffer. The anion 
exchanger was firstly activated by washing with 5ml (equally to 5 column volumes) of 
loading buffer and 5ml of high salt elution buffer, and equilibrated with 5-10ml of loading 
buffer. Prior to loading the sample into the FPLC, samples were buffer-exchanged to the 
running buffer by exhaustive dialysis, and injected into the column with a speed of 
1ml/minute based on the pre-designed wizard system. Protein samples were dialysed against 
the ion exchange running buffer and filter sterilized prior to be injected into the column. A 
few optimisation steps were processed and a final optimal programme was determined as 
routine protocol for automated anion exchange chromatography to classify fusion proteins 
with 3 major types of glycosylation or polysialylation feature. Basically, the FPLC instantly 
mixes the 1M high salt elution buffer with running buffer to prepare buffer conditions for 
featured elutions. The salt in the solution competes for binding to the immobilized matrix and 
releases the protein from its bound state at a given concentration. Proteins separate due to the 
amount of salt needed to compete varies with the external charge of the protein. Extra 
washing volumes were applied for better purity of the glycoproteins. During each elution 
steps, proteins were stripped off and collected with 20ml of corresponding elution buffer and 
finalised by 1M NaCl high salt elution buffer. Table 2.9 below outlines the optimised process 
of anion exchange chromatography 
 
Table 2.9. Optimised anion exchange chromatography for sia/polysialylated protein purification. The 
glycoprotein was classified into 3 glyco-forms throughout the purification steps. Buffer A: running buffer; 
Buffer B: 1M NaCl high salt elution buffer. 
 
Steps Buffers 
Buffer Content 
(%) 
NaCl 
concentration 
(mM) 
Volume 
(ml) 
Flow Rate 
(ml/min) 
Isocratic flow Buffer A 100 0 10 2 
Injection* Buffer A 100 0 10 1 
Isocratic flow* Buffer A 100 0 10 2 
Isocratic flow 
Buffer A 95 
50 10 2 
Buffer B 5 
Isocratic flow 
Buffer A 90 
100 20 2 
Buffer B 10 
Isocratic flow 
(Wash 1) 
Buffer A 90 
100 200 2 
Buffer B 10 
Isocratic flow 
Buffer A 80 
200 20 2 
Buffer B 20 
Isocratic flow 
(wash 2) 
Buffer A 80 
200 300 1 
Buffer B 20 
Isocratic flow Buffer B 100 1000 20 2 
* Both injection and the following isocratic flow steps can be multiplied to increase the sample loading into the 
anion exchange column. The column has an ion exchange capacity > 85mg/ml.  
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The chromatographic results were illustrated by BioLogic DuoFlow system (BIO-RAD), and 
indicated NaCl concentration dependent protein elutions were collected and pooled together. 
Consequent dialysis steps removed the associated high salt content. To be noted, proteins 
eluted from 1M salt solution were confirmed to be polysialylated (see results section) and 
dialyzed against 1x TBS instead of 1x PBS for improved preservation of PSA. 
 
 
2.2.5 Protein Characterisation  
 
2.2.5.1 Protein Concentration Determination 
The concentration of protein was determined using either (1) the BCA
TM
 Protein Assay Kit 
(Pierce, Thermo Scientific) or (2) NanoDrop
TM
 1000 Spectrophotometer by measuring protein 
absorbance at 280nm. 
 
(1) Most commonly, the total protein concentration in samples was measured by the BCA 
assay. This method consists of Cu
2+
 to Cu
+
 by protein in an alkaline medium (biuret reaction) 
and subsequent colorimetric detection of Cu
+
 with a reagent containing bicinchoninic acid. 
Protein standards of BSA at 0, 31.25, 62.5, 125, 250, 500, 1000, and 2000µg/ml were 
prepared, and were dissolved in the same buffer as the tested sample proteins. Using a 96-well 
microtitre plate, 25µl of each sample was transferred to each well, and analysed in triplicate, 
together with the BSA standards. The BCA working reagent was a clear green solution 
prepared by mixing 50 parts of BCA reagent A (sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartarate in 0.1 sodium hydroxide) with 1 part of reagent B 
(4% cupric sulphate). To each well, 200µl of BCA working reagent was added (1:8 sample to 
WR ratio) and mixed thoroughly for 30 seconds. The plate was allowed to stand for 30 
minutes at 37ºC with a purple colour change. After cooling down to room temperature, the 
colorimetric detection was then taken place, and the absorbance of the samples was measured 
at 562nm by the 96-well plate reader Spectramax 340pc. A calibration curve using the protein 
standards was constructed and the concentration of the unknown samples was determined by 
extrapolation. The method was often used for protein samples without fully genetic 
information, and provided a detection range between 20 – 2000µg/ml. 
  
(2) The protocol for NanoDrop
TM
 1000 Spectrophotometer was mentioned in section 2.2.2.3 
for DNA concentration determination. For protein (working range: 0.1 to 100mg/ml), the 
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standard protein concentration detection at 280nm option was chosen, and a triplicate reading 
was tested for each sample. Following the Beer-Lambert law (A = ε ·C·l), where A is 
absorbance (no units), ε is the molar absorption (extinction) coefficient (in L mol−1 cm−1), C is 
the molar concentration (in M, i.e. mol L
−1
) and l is the path length of the cuvette (in cm; 
almost always 1 cm), the equations below illustrate conversion between the absorbance and 
protein concentration.  
 
    Read-out of A280                      
  Extinction coefficient 
 
 
Concentration (M) * Molecular Weight (Da) * 1000 = Concentration (µg/ml) 
 
Both the protocols were very accurate for protein concentration detection, however the 
NanoDrop
TM
 provides a quicker way but requires known extinction coefficient and calculated 
molecular weight of the protein sample, which can be obtained from the protein amino acid 
sequence by using ProtParam on the ExPASy Server (http://www.expasy.ch/tools/ 
protparam.html) (Wilkins et al. 1999). 
 
 
2.2.5.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Coomassie Staining 
SDS-PAGE was executed using the BIO-RAD Mini-PROTEAN
®
 3 gel system in accordance 
with the manufacturers‟ instructions. The gel components have been mentioned in section 
2.1.3, and all gels used for this project were reducing gels. Typically, samples were mixed 
with laemmli loading buffer (6x) in a 2:1 ratio, and boiled for 5 minutes. The polysialylated 
samples were mixed with semi-reducing loading buffer, and heated at 65ºC for 10 minutes. 
Samples were then span down and chilled on ice before electrophoresis. The SDS-PAGE was 
normally running under a constant current at 20mA per gel, and the operation time was 
determined by the migration level of sample associated loading dye and standard pre-stained 
protein molecular weight ladders (Fermentas). For Coomassie staining, gels were carefully 
moved out from the glass plate cassettes, and soaked in PAG fix buffer for more than 2 hours 
at room temperature on a gentle rocking platform after electrophoresis. Followed by 3 times 
dH2O wash, the gels were then stained by EZ-Run protein gel staining solution 
(approximately 20ml per gel), and left rocking until clear protein bands appeared. Remove the 
= Concentration (M) 
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staining solution and wash the gel another three times with dH2O before taking an image from 
FujiFilm LAS-3000 laser scanning densitometer (White light EPI setting). 
 
 
2.2.5.3 Western Blotting 
Polyacrylamide gels (above) were transblotted onto Amersham
TM 
Hybond
TM
-ECL 
nitrocellulose membrane (GE Healthcare) using a BIO-RAD Trans-Blot SD semi-dry 
transblotter. The gel was laid over pre-wet nitrocellulose and sandwiched between two think 
slices of Whatman filter paper. All of these components were pre-soaked in transfer buffer for 
5-10 minutes. The transfer was conducted at 15 volts for approximately 40-60 minutes, and 
subsequently the nitrocellulose membrane was blocked with 5% Marvel milk powder in 1x 
PBS (mPBS) for one hour. Antibody detection stages were for 1 hour per layer using dilutions 
recommended by the antibody manufacturers (see Table 2.4). All antibodies were diluted in 
3% mPBS, and the blots were washed vigorously 3 times by 1x PBS-Tween between each 
antibody detection stage. Extra 3 times of 1x PBS wash were performed at the very last round 
of antibody-HRP incubation. Detection of chemiluminescent signal was done using the 
luminance based HRP substrate and imaged using the FujiFilm LAS-3000 densitometer with 
the chemiluminescence detection setting. The pre-stained protein marker image of the same 
blot was taken at white light (DIA) setting, and fused back to the western blot image by 
CorelDRAW Graphics Suite X4 software. 
 
 
2.2.5.4 Glycosidase Treatment 
Typically, excessive amount of each glycosidases listed in Table 2.6 was used to catalyse the 
hydrolysis of the oligosaccharides from the interested proteins (less than 10µg) during an 
overnight incubation at 37ºC. For Endo-Neuraminidase, 2 Units of the enzyme were added 
directly into the protein samples maintained in PBS buffer. Acetyl-neuraminyl hydrolase or 
sialidase (Exo-N) (25 Units) catalysed with 1x G1 Reaction Buffer (50mM sodium citrate, pH 
6.0) in a total reaction volume of 10 µl. Before PNGase F hydrolysis, proteins were denatured 
with 1x Glycoprotein Denaturing Buffer in a total volume of 10µl at 100°C for 10 minutes. 
Together with the additional addition of 1% NP-40 and 1x G7 Reaction Buffer 
(50mM sodium phosphate, pH 7.5), 20 Units of PNGase F are added to form another 10µl 
total reaction volume (20µl in total) and the reaction mix is incubated overnight at 37°C. 
 
- 133 - 
 
2.2.5.5 Digoxigenin (DIG) Glycan Differentiation  
The DIG Glycan Differentiation Kit (Roche) that employs lectins to detect sugar linkages was 
used to give a general identification of certain oligosaccharide linkages. Lectins (listed in 
Table 2.5) extracted from different plant species and labelled with DIG, were found to bind to 
specific glycosidic linkages. The specificity of lectin affinities enables positive identification 
of the presence of certain oligosaccharides. Proteins with or without glycosidase treatments 
were tested. Samples were loaded on SDS-PAGE, and electrically transferred to nitrocellulose 
membrane as described in section 2.2.5.3. Following the manufacturer‟s protocol, the 
nitrocellulose membranes were immersed in 1x blocking solution supplied with the kit for at 
least 30 minutes. After 3 times washing with 1x TBS buffer, the blots were incubated with 
lectins labelled with digoxifenin (10µl of SNA and DSA; 50µl of MAA; 100µl of PNA to 
10ml Buffer 1) for 1 hour. Similar to Western blot, the secondary antibody, anti-digoxigenin-
AP (dissolved in 1x TBS) was induced consequently, and incubated for another hour. With 3 
times TBS washing, blots were stained by immersing without shaking in the staining solution 
(200µl NBT/BCIP solution supplied by the kit dissolved in 10ml Buffer 2), until grey to 
almost black bands developed. Staining reaction was quenched by rinsing with distilled water 
several times. The filters were dried on paper towels and photographed by the FujiFilm LAS-
3000 densitometer with white light (DIA) setting. 
 
 
2.2.5.6 Antigen Biotinylation 
The EZ-Link
®
 Sulfo-NHS-LC-LC-Biotin reagent (sulfosuccinimidyl-6-[biotinamido]-6-
hexanamidohexanoate) is an N-Hydroxysuccinimide ester of biotin which reacts with primary 
amino groups available in lysine residues. According to the manufacturer‟s protocol, a 20:1, 
reagent to protein coupling ratio should be used for an actual 4 or 5 biotin molecule to 
incorporate with 1 molecule of target protein. However, exceeded amount of biotin 
incorporation can mask the antigen binding site, and fatally damage the antibody recognition. 
A 5:1 reagent to protein couple ratio was also prepared to the target protein (for an actual 1:1 
biotin to protein binding) to minimize the hazard of biotin blockage to the antigen binding site. 
Briefly, 10mM biotinylation reagent solution was firs prepared freshly in dH2O. To 
biotinylate 1ml of 1mg/ml N-A1 (~26kDa MW) with 20:1 biotinylation ratio, the amount of 
10mM biotinylation reagent solution was calculated from the following equations:  
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1ml N-A1 * 1mg N-A1/1ml N-A1 * 1mmol N-A1/26,000mg N-A1 * 20mmol Biotin/1mmol 
N-A1 = 0.000769 mmol Biotin 
0.000769mmol Biotin * 1,000,000µl/L * 1L/10mmol = 76.9µl Biotin reagent solution 
 
Following the same equations, the amount of 10mM biotinylation reagent solution required 
for 5:1 ratio was 19.23µl. The biotinylated reagent solution was mixed with 1ml N-A1 stored 
in 1x PBS, and the reaction was incubated on ice overnight or within 1 hour at room 
temperature. The free biotins were removed through a PD-10 desalting column (GE 
Healthcare). Before using the PD-10 column, the column was pre-conditioned by 25ml of the 
appropriate buffer that aimed to exchange to. Protein sample was prepared to 2.5ml in volume 
and added directly into the column, which was eluted by 3ml appropriate exchanging buffer. 
 
 
2.2.5.7 ELISA for Affinity Binding Measurement 
Enzyme-Linked Immunosorbent Assay was mentioned in the above paragraphs for 
monoclonal mammalian cell selection (see section 2.2.4.1). Both N-A1 and hErbB2/Fc 
antigens were coated in the same way for the affinity binding measurement. For biotinylated 
antigen, 100µl per well of 20µg/ml avidin (in 1x PBS) was pre-coated, followed by one hour 
incubation with 100µl biotinylated antigen (10µg/ml) in each well after two washes with 1x 
PBS. The antigen plate was then blocked with 300µl/well of 3% mPBS for 2 hours at 37ºC 
consequently followed by another two washes with 1x PBS. Unlike the ELISA for selection 
procedures, a serial concentration dilution of samples (especially scFvs or scFv fusion 
proteins) was prepared by 3% mPBS with a typical range between 5000nM to 0.05nM. Each 
dilution was tested in a triplicate, and 100µl of each was added for each well followed by 1 
hour incubation. Unless stated otherwise, all subsequent wash steps consisted of three washes 
with 1x PBS-Tween and three times with 1x PBS. Like Western Blotting, antibody detection 
stages were then processed (100µl per well) with manufacturers‟ recommended dilution (in 
3% mPBS) until incubation with HRP conjugated antibodies. BM Blue POD soluble substrate 
(100µl per well) was used for colour development under dark condition, and quenched by 1M 
HCl (100µl per well) until distinctive blue colour change appeared. Absorbance at 450nm was 
taken afterwards by Spectramax 340pc, the 96-well plate reader. The data points in ELISA 
dissociation equilibrium constant (KD) determinations were fitted, using Sigmaplot
®
 10 
software, to a standard 3-parameter sigmoid curve with maximum, minimum, hill-slope, 
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standard errors and EC50 (KD) which corresponds to the concentration of antibody yielding 
50% of the saturating signal. 
 
 
2.2.5.8 Surface Plasmon Resonance Binding Analysis: BIAcore
TM 
Real time binding analysis of MFE23 to its antigen targeting site N-A1 was performed by 
surface plasmon resonance (SPR) on a BIAcore 3000 instrument. The running buffer used 
was 100mM Tris buffer pH7.4 containing 300mM NaCl, 0.005% P20 surfactant and 0.005% 
sodium azide. This buffer was thoroughly degassed and sterilized through a 0.2µm PES 
vacuum filtration unit. All experiments were carried out using two flow-cells of each 
BIAcore
TM
 chip using one for test (with immobilized ligand) and the other as reference.  
 
Ligand Immobilisation 
The new BIAcore® streptavidin (SA) sensor chips were allowed to adapt room temperature 
for 30 minutes before use. After docking and priming the chip with the running buffer, the 
flow cells were then conditioned with three 1-minute pulses of 50mM NaOH + 1M NaCl at a 
flow rate of 30µl/min. Biotinylated N-A1 (1:5, NA-1: biotin ratio) was diluted with the 
running buffer to 2µg/ml, and injected onto the designated “test” flow-cell only from the SA 
chip with initially short 5µl pulse at 20µl/min until approximately 700 to 900 resonance units 
(RU) the immobilized antigen signals were reached. 
 
Kinetic Experiments: 
A serial dilution containing a concentration range of 185nM to 0.4nM of each type of MFE23 
recombinant fusion protein sample was prepared using the running buffer. A kinetic wizard 
was set up using a flow rate of 20µg/min, implementing a 2 minute association phase, 10 
minute dissociation phase and a regeneration phase of 1minute at a flow rate of 30µg/min 
with 10mM HCl (Sainz-Pastor et al. 2006), followed by a 15 minutes stabilization period 
before the next cycle. All concentration were run in duplicate, preceded with 1 buffer cycle 
before and after of each sample cycle, in order to provide double references. The sample 
solutions were run following the order from the most concentrated (185nM) to the least 
concentrated (0.4nM). Same amount of blank running buffer solution was injected into the 
instrument and run under the same wizard programme for subtraction from the sample run to 
minimize the noise signals. 
 
Evaluation of Kinetic Experimental Data 
The scFv and scFv fusion protein kinetic binding experiments were evaluated by the 
BIAevalution software (version 4.1).  Values from the kinetic binding experiments were 
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firstly displayed as the subtractions between the test (with immobilized ligand) and reference 
flow-cells. Next, the response curves were plotted as the subtraction of the responding blank 
buffer run, and the injection and regeneration spikes were removed as well as the pre-injection 
areas from the curves. Then, the curves were “Y-transformed” all together by averaging the 
injection starting area to the zero baseline level. The simultaneous kon/koff approach was used 
to all experiments to fit the data into a suitable kinetic model in order to measure the rate 
constants. Injection start and stop points were set and the association and dissociation phases 
were outlined. Prior to initiate the kinetic fit, the reflection index (RI) values were set to zero 
as constant to avoid software inappropriate default setting, and the maximum resonance 
values (Rmax) were selected as locally fittings. The 1:1 (langmuir) binding model was then 
conducted with visual inspection of fit lines overlaid to the plotted curves and the assessment 
of statistically analysed rate constant values. 
 
 
2.2.5.9 Fluorescence Activated Cell Sorting (FACS) 
FACS provides a powerful method for sorting a heterogeneous mixture of cells based upon 
the specific light scattering and fluorescent characteristics carried by each cell. It was served 
for two major purposes in this project, which are cell surface binding detection and 
intracellular protein detection. 
 
FACS for Cell Surface Antigen Binding Detection 
This detection was focused on antibody and modified antibody derivatives in their antigen 
binding features to live antigen expressing cells. Antibodies tagged with FITC amplify the 
fluorescent signal and indicate the binding activities to the live cell antigen. Typically, 
adherent antigen expressing cells were cultured for 3 days and dissociated from the culture 
flasks by accutase (PAA), a much gentle proteolytic and collagenolytic enzymes for 
preservation of cell surface antigen. Cells (4 x 10
5
) were transferred to autoclaved Eppendorf 
tubes, and centrifuged for 30 seconds at 10,000rpm. Cell pellets were resuspended by 10µg 
antibody samples in a volume of 50µl, and incubated at 4ºC for 1 hour. Re-pelletize the cells 
followed by washing twice with 500µl of FACS buffer (2% FBS and 1mM EDTA in 1x PBS). 
The pellet was mixed with 100µl of serial immunodetection antibodies until incubation with 
FITC conjugated antibodies. All antibodies used were diluted with manufacturers‟ instruction 
in FACS buffer for 1 hour incubation interval. Incubation with FITC conjugated antibody was 
carried out in dark. Repeated centrifugation and FACS buffer washing were carried out twice 
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after each antibody incubation time. Finally, cells were resuspended in 500µl of FACS buffer 
and transferred to round bottom FACS tubes kept at 4ºC with foil covered before analysed by 
dual laser 4 colour Becton Dickinson FACS Calibur analyser linked with Cellquest software 
(FITC setting). 
 
FACS for Endogenous Protein Detection  
This method was used to confirm PolyST transfected cells expressing functional endogenous 
polysialytransferases. Followed by the same protocol for detecting cell surface antigen 
binding, pelletized cells were resuspended in 100µl of 2% formaldehyde (16% methanol-free 
stock, Thermo Scientific) diluted in 1x PBS. The cells were fixed in this buffer for 10 minutes 
at room temperature and washed and re-pelletized by 500µl of FACS buffer. The pellet was 
then resuspended and detected by serial antibodies (100µl each round) until incubation with 
FITC conjugated antibodies. All antibodies used were diluted with manufacturers‟ 
recommendation in FACS buffer for 1 hour incubation interval. Cells were lastly washed in 
500µl of FACS buffer and transferred to round bottom FACS tubes kept at 4ºC in dark. The 
analyses were carried out by Becton Dickinson FACSCalibur analyser and Cellquest software 
as described above. 
 
 
2.2.5.10 Confocal Laser Scanning Microscopy 
Confocal laser scanning microscopy (CLSM) was used for obtaining high-resolution optical 
images with selected depth. It has featured ability, also known as optical sectioning to acquire 
in-focus images from selected depths. Point-by-point images can be acquired and 
reconstructed with a computer, allowing three-dimensional reconstructions of topologically-
complex objects. For this project, CLSM was used for tracking live cell surface antigen 
binding and internalization process, especially comparing these processes between normal 
scFv and the scFv fusion after internalization. Cells were cultured on 13mm cover slips for 
specimen preparation on the glass slides. Basically, individual well of a 24-well plate was 
placed with a piece of 13mm cover slip. The cover slip was disinfected with 0.5ml 70% 
ethanol per well for 1 minute. Followed by washing with 1ml tissue-culture specialized water 
(TC H2O), 0.5ml 0.05mg/ml poly-D-lysine (diluted with TC H2O) was applied per well, and 
the incubation at 37ºC was carried out for 2 hours or at room temperature (sterile condition) 
overnight. Two 1ml TC H2O washing steps were processed after poly-D-lysine attachment 
achieved after the incubation. Typically, 20,000 cells were coated onto each cover slip, and 
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incubated for 2 to 3 days for antigen expression with approximately 50% confluence. Prior to 
antibody binding, cells were washed twice by TCM, and 300µl of antibody constructs 
(5µg/ml) diluted by TCM were added onto each cover slip. One hour antibody-antigen 
binding incubation was allowed prior to the further incubation conditions. Two temperature 
conditions (4ºC and 37ºC) paired up with two incubation period options (5 minutes and 1.5 
hours) were set up specifically for surface antigen binding and internalization detections. 
After the live cell binding and extra conditioning incubation processes, the cells were gently 
washed once with TCM, followed by 1x PBS, and fixed by 250µl of 4% paraformaldehyde 
(in 1x PBS) for each cover slip on ice for 10 minutes, followed by 5 minutes permeabilization 
treatment by 250µl of 0.1% Triton X-100 on ice. Secondary antibodies, such as anti-Myc, 
anti-6xHis, anti-FN1 or anti-PSA antibodies (see Table 2.4 for dilution factors) were prepared 
in TCM, and applied to the cells (250µl/cover slip) for 1 hour incubation. Tertiary 
immunofluorescent antibodies against the secondary were consequently introduced to the 
cells after three times TCM washes. Finally, the tertiary antibodies were removed and the 
cells were washed three times with TCM and twice with 1x PBS, followed by an additional 
fixing step by 4% paraformaldehyde. For cells applied with anti-PSA as secondary antibodies, 
no fixing steps were used to avoid chemical oxidation of PSA. The cover slip was mounted 
(cell-face down) on the specimen slide with one drop of aqueous mounting gel (Sigma) in 
between. The slides were stocked in dark at 4ºC. 
 
Images of prepared specimen were taken by CLSM 510 on the Axioplan 2 microscope stand 
(Carl Zeiss) through control software LSM 510. For both fluorescent dyes, Alexa Fluor
®
 488 
and 594 were exited at wavelength 488nm with emission filter setting between 505 to 550nm. 
Images of planes at various depths (z-stack) with 1µm increments were taken throughout the 
cells. LSM Image Brower was used as the software for image analysis. 
 
 
2.2.5.11 Gel Filtration and Size Exclusion Chromatography (SEC) 
SEC was used for the identification of protein apparent hydrodynamic volume. HiLoad
TM
 
Superdex 200 prep grade column (MW selectivity ranging from 10 to 600 kDa) filled with gel 
filtration media composing dextran covalently bound to highly cross-linked porous agarose 
beads (GE Healthcare) was used for filtrating molecules according to their apparent sizes. The 
BIO-RAD BioLogic DuoFlow fast protein liquid chromatography (FPLC) serving as the 
automatic system was connected with the gel filtration column, which was paired up with the 
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BioLogic QuadTec UV-Vis Detector for simultaneous wavelengths monitoring. Protein 
samples were dialysed to the column running buffer (1xPBS with 0.005% sodium azide, 
degassed and filter sterilized), and concentrated to a high concentration (>0.5mg/ml). Samples 
(0.5ml) were separately injected into the system with buffer flow-rate at 1ml/minute, and 
160ml of running buffer was applied for the gel filtration programme. 
 
Table 2.10. Standard molecular weight markers used for size determination. Approximate MW values are 
displayed in kDa. Information from (http://www.sigmaaldrich.com/life-science/proteomics/protein-
chromatography/mw-markers.html) 
 
 
 
MW standards (Sigma) listed in Table 2.10 were used for gel filtration column calibration 
prior to applying the protein samples. One ml of each MW marker (1mg/ml) were injected 
into the column and running at standard 1ml/minute flow-rate.  
 
 
2.2.6 Mass Spectrometry (MS) for Polysialylated Glycoprotein Structure 
Determination 
 
Initial MS studies (Chapter 3) were carried out by M-Scan Ltd (Wokingham, UK). The MS 
analysis for the polysialylated fusion protein (Chapter 4 and 5) was performed in the 
Glycobiology Centre, Imperial College London with the MS technical support from Dr Kevin 
Canis, and investigatory consultations from Dr Stuart Haslem and Professor Anne Dell. 
 
2.2.6.1 Reduction and Carboxymethylation 
Approximately 100µg glycoprotein samples were lyophilised, and re-dissolved in 300µl of 
2mg/ml dithiothreitol (DTT) in degassed 0.6 M Tris buffer (pH 8.5). Reduction was carried 
out by incubation for 60 minutes at 37°C. The carboxymethylation was then achieved by 
addition of 300µl of 60mg/ml iodoacetic acid in degassed 0.6M Tris buffer (pH 8.5) and 
incubation for one hour at room temperature. The reaction was stopped by dialysing samples 
- 140 - 
against a 50mM ammonium hydrogen carbonate buffer (pH 7.4) for 36 hours at 4°C, and 
samples were lyophilised afterwards.  
 
 
2.2.6.2 Trypsin Digestion 
Reduced-carboxymethylated and lyophilised samples were digested using 300µl of a 
100µg/ml L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPKC) treated bovine 
pancreas trypsin in 50mM ammonium hydrogen carbonate buffer (pH 8.4). Samples were 
incubated for 14 hours at 37°C and reaction was terminated by addition of 2 drops of glacial 
acetic acid. Digested samples were then immediately purified by passing through a Sep-Pak
®
 
C18 cartridge. The reverse-phase Sep-Pak
®
 C18 cartridge (Waters corporation) was attached to 
a glass syringe and conditioned successively with methanol (5ml), 5% (v:v) acetic acid (5ml), 
propan-1-ol (5ml), and 5% (v:v) acetic acid (3 times with 5ml each time). Samples were 
directly loaded onto the cartridge and washed by 20ml of 5% (v:v) acetic acid (elution of 
hydrophilic contaminants). Peptides and glycopeptides were then eluted sequentially with 3ml 
of each 20%, 40% and 100% (v:v) propan-1-ol in 5% (v:v) acetic acid. The volume of each 
fraction was reduced on a Savant Speed-Vac and samples were lyophilised 
 
 
2.2.6.3 PNGase F Digestion (N-glycan Release) 
Release of the N-glycans was achieved by using the PNGase F (Roche) from Flaviobacterium 
meningosepticum. Lyophilised 20% and 40% propan-1-ol fractions resulting from the Sep-
Pak
® 
C18 purification were mixed and dissolved in 200µl of 50mM ammonium hydrogen 
carbonate buffer (pH 8.4). Samples were digested by addition of 5 Units of PNGase F and 
incubation for 36 hours at 37°C. Released N-glycans were separated from digested samples 
using a Sep-pak
®
 C18. A reverse-phase Sep-pak
®
 C18 cartridge was attached to a glass syringe 
and conditioned as before. The samples were directly loaded onto the cartridge. N-glycans 
were eluted by 5ml of 5% (v:v) acetic acid, and peptides and glycopeptides were then eluted 
sequentially with 3ml of each 20%, 40% and 100% (v:v) propan-1-ol in 5% (v:v) acetic acid. 
The volume of each fraction was reduced on a Savant Speed-Vac and samples were 
lyophilised. 
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2.2.6.4 Reductive Elimination (O-glycan Release) 
The lyophilised 20% propan-1-ol fractions resulting from the post-PNGase F digestion were 
dissolved in 400µl of 55mg/ml potassium borohydride (KBH4) in a 0.1M potassium 
hydroxide (KOH) solution and incubated for 24 hour at 45°C. The reaction was stopped by 
addition of 5 drops of glacial acetic acid. An ion-exchange column (2ml bed volume) with 
Dowex
®
 50W-X8 H cation exchanger resin (DOW) was assembled and washed with 15ml of 
5% (v:v) acetic acid. Sample was loaded and eluted with 2.5ml of 5% (v:v) acetic acid. 
Samples were collected and dried on a Savant Speed-Vac. Excess borates resulting from the 
reductive elimination were removed by a co-evaporation with 4 times 500µl of a 10% (v:v) 
acetic acid in methanol solution and samples were finally dried under a steam of nitrogen. 
 
 
2.2.6.5 Polysialylic Acid Digestion by Endo-N 
Purified and dried native oligosaccharide samples (from section 2.2.6.4) were dissolved in a 
50mM ammonium acetate pH 5.5 buffer. Enzyme (25mUnit) was added, and samples were 
incubated for 18 hours at 37°C. Another aliquot of the enzyme was added afterwards for 
completion PSA digestion. Samples were again incubated for 18 hours at 37°C, and finally 
freeze-dried. 
 
 
2.2.6.6 Polysialylic Acid Lactonization on MALDI Plate 
Purified native oligosaccharides (from section 2.2.6.4) were spotted onto a MALDI TOF-MS 
target and allowed to dry. The dried samples were dissolved in 1µl of a 0.1% ortho-
phosphoric acid, incubated for 30 minutes at room temperature and dried under vacuum prior 
to MS analyses. 
 
 
2.2.6.7 Oligosaccharide Cores Permethylation 
Permethylation was carried out on purified and lyophilised glycans. Five pellets of sodium 
hydroxide (NaOH) were placed in a glass mortar and crushed in presence of 3ml of dry 
DMSO. The resulting slurry (1ml) was added to the lyophilised samples and 0.5ml of methyl 
iodide (ICH3) was added. The mixture was vigorously mixed on an automatic shaker for 15 
minutes at room temperature. The reaction was stopped by dropwise addition of water, while 
constantly shaking the tube. Permethylated samples were extracted in 1ml of chloroform and 
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washed several times with 3ml of dH2O. Chloroform was finally evaporated under a stream of 
nitrogen, prior to the C18 purification of derivatised glycans. A reverse-phase C18 cartridge was 
attached to a glass syringe and conditioned successively with methanol (5ml), dH2O (5ml), 
acetonitrile (5ml), and dH2O (3 times of 5ml). The samples were dissolved in 1:1 (v:v) 
methanol:water and loaded onto the cartridge. Samples were washed with 5ml of dH2O, and 
then eluted stepwise with 3ml of each 15%, 35%, 50% and 75% (v:v) aqueous acetonitrile 
solution. Organic solvent from each fraction was removed on a Savant Speed-Vac and 
samples were lyophilised prior to MS analyses 
  
 
2.2.6.8 Matrix Assisted Laser Desorption Ionisation / Time of Flight (MALDI-TOF) MS 
Analyses 
Lactonized samples were dissolved in 1µl of the ATT matrix (20mg/ml 6-aza-2-thiothymine 
in 50:50 (v:v) acetonitrile/50mM ammonium citrate) and allowed to dry under vacuum. 
MALDI-MS analysis was performed using a Voyager DE-STR™ (Applied Biosystems) mass 
spectrometer in the linear negative mode with delayed extraction. The 4700 calibration 
standard, calmix, was used as the external calibrant for the MS mode. Data were acquired 
using Voyager 5 Instrument Control Software, and were processed using Data Explorer MS 
processing software.  
 
Permethylated samples were dissolved in 10µl of 1:1 (v:v) methanol:water. One µl was mixed 
with 1µl of the DHB matrix (10mg/ml of 2,5-dihydroxybenzoic acid in 50:50 (v:v) 
methanol:water) and was spotted onto a MALDI plate and allowed to dry under vacuum. 
MALDI-MS analysis was performed using the same mass spectrometer in the reflectron 
positive mode with delayed extraction. The 4700 calibration standard, calmix, was used again 
as the external calibrant for the MS mode. Data were acquired by Voyager 5 Instrument 
Control Software, and processed by Data Explorer MS processing software as described 
above. 
 
 
2.2.6.9 Matrix Assisted Laser Desorption Ionisation (MALDI) MS/MS  
Permethylated samples were dissolved in 10µl of 1:1 (v:v) methanol:water. Samples (1µl) 
were mixed with 1µl of the DHB matrix and was spotted onto a sample plate and dried under 
vacuum. MS/MS data were acquired using a 4800 MALDI TOF/TOF™ (Applied Biosytems) 
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mass spectrometer. The collision energy was set to 1 kV and air was used as collision gas. 
The instrument was calibrated using [Glu
1
]-fibrinopeptide G human (Sigma-Aldrich) as 
external calibrant for the MS/MS mode and the 4700 calibration standard, calmix, was used as 
the external calibrant for the MS mode. Data were acquired using 4000 Series Explorer 
Instrument Control Software and were processed using Data Explorer MS processing 
software. 
 
 
2.2.7 In vivo Studies of Radio-labelled Fusion Proteins 
 
All mouse maintenance, injections and culling were performed by fully trained staff at the 
CBS unit of Imperial College London.  
 
2.2.7.1 Preparation of Radio-labelled Samples  
Protein samples were dialysed extensively into 1x PBS buffer prior to iodination to remove 
any glycerol or preservatives, and concentrated to 100μg/ml. Pierce® Pre-Coated Iodination 
Tubes (Thermo Scientific) were used to iodinate the protein samples. The tubes were pre-wet 
with 1 ml Tris iodination buffer (25 mM Tris-HCl, pH 7.5, 0.4 M NaCl) and decanted. 
Another 100μl of the Tris buffer was added directly to the bottom of the tube, followed by 
mixing with 10μl (1.0 mCi) Na125I (Amersham). The buffer was allowed to stand for 6 
minutes at room temperature with swirling every 30 seconds for iodide activation. 
Consequently, the buffer was transferred to the protein solution (1ml). For “over-oxidation” 
iodination, the protein solution (1ml) was added directly to the activated iodide tube for 
iodination. The reaction was incubated at room temperature for 9 minutes with swirling every 
30 seconds. To end the reaction, 50μl of scavenging buffer (10mg/ml tyrosine in 1x PBS) was 
added and mixed for 5 minutes at room temperature. In order to remove the free radio-
labelling materials and tyrosine residuals, the radio-labelled protein samples were buffer-
exchanged to 1x PBS through pre-conditioned PD-10 columns (see section 2.2.5.6), and 3ml 
elutions of each radio-labelled protein sample were collected. All samples (with final 
concentration around 33μg/ml individually) were sterilized through 0.2µm PES syringe filters 
before injecting to the mice.  
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2.2.7.2 Sample Injections and Mouse Maintenance 
Up to 300μl (~10μg) of each radio-labelled fusion protein were injected intravenously into the 
mouse tail vein. Due to radioactive nature of the samples, the experiment mice were caged 
and maintained behind purpose made lead-shielding during the time course after sample 
injection.  
 
 
2.2.7.3 In vivo Blood Clearance Studies 
Group of 4 tagged mice was carried out for each protein sample test. At the appropriate time 
points (0.5, 1, 2, 4, and 6 hours) after injection, a cut was made from the mouse tail tip, and 
approximately 20μl blood samples were taken from each mouse by using microhematocrit 
capillary tubes (VWR). Blood cruor inside the capillary tube was stored in the sample tube. At 
24 hours, all mice were culled under terminal anaesthesia and blood was immediately 
collected by cardiac puncture and transferred to sample tubes. 
 
For the purpose of studying in vivo blood clearance pharmacokinetics data values were fitted 
to curves that conform to the two-compartmental intravenous model of clearance, which takes 
into account the biexponential clearance phases; distribution phase and elimination phase, of 
single intravenous doses. This is described by the exponential decay, double, 4-parameter 
equation: y = ae
-bx
 + ce
-dx
; where the distribution phase clearance rate (t1/2α) can be 
determined by (ln2)/b, and the elimination clearance rate (t1/2β) can be determined by (ln2)/d. 
 
 
2.2.7.4 In vivo Biodistribution Analysis 
Group of 6 tagged mice was carried out for each protein sample test. Within each group, three 
mice were culled under terminal anaesthesia at 6 hours after sample injection, and the other 3 
were culled under the same way at 24 hours after injection. Immediately after culling, blood 
was collected by cardiac puncture and transferred to a sample tube. The mouse was then 
dissected and kidney, liver, spleen, intestines, lung and heart were collected for 
biodistribution analysis.  
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2.2.7.5 Radiation Activity Measurement 
The gamma radiation activities of each tissue sample collection were measured by Wallac-
1470 gamma counter with settings for 
125
I isotope. For the PK studies, increased measuring 
time limit was set (1200 seconds) with maximal count limit of 200000; whilst the 
biodistribution analysis was measured with time limit of 60 seconds. The radiation values 
(counts per minute, cpm) were recorded and converted as a percentage of the initial injected 
dose per gram of tissue (% ID/Gram). The weights of each collected tissue samples were 
calculated after the deduction of the pre-weighted corresponding empty containers (i.e. 
sample tube and/or capillary tube).  
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CHAPTER 3 
 
Initial Attempts to Develop a Recombinantly 
Polysialylated Antibody in Neuroblastoma 
(NB2a) Cells 
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3.1 Introduction 
 
With the understanding that polysialylation is a potentially superior drug delivery technique, 
this project focused on producing polysialylated scFvs using a recombinant method 
conjugating PSA chains through a natural orientation, rather than chemical polysialylation. As 
described in section 1.5, the concept of a recombinant polysialylation system was derived 
from naturally occurring NCAM polysialylation, and a fusion construct containing the scFv 
together with the minimal polysialylatable NCAM domains (Ig5 and FN1) was generated 
(Constantinou 2005).  
 
As described in sections 1.4.1 and 1.4.2, NCAM in mammals is predominantly expressed in 
brain glial and neuronal cells. Normally polysialylated NCAM disappears during brain 
development; but certain types of neuroblastoma cells can consistently express PSA-NCAM, 
in order to enhance cancer cell mobility and metastasis (Soroka et al. 2010). Human 
neuroblastoma CHP-134 cells were the first cell line reported to produce NCAM with PSA 
moieties with 55 or more sialyl residues (Livingston et al. 1988). During several later studies, 
human SK-N-SH and IMR-32 neuroblastoma cells, rat PC-12 pheochromocytoma, and mouse 
neuro-2A (NB2a) neuroblastoma cells were confirmed as PSA-NCAM positive cell lines 
(Hildebrandt et al. 1998; Gallagher et al. 2000; Poongodi et al. 2002; Beecken et al. 2005). 
The expression of polysialyltransferases (i.e. PST and STX) were also correspondingly 
reported within these neuroblastoma cell lines, which closely correlated to the degree of 
polysialylation and the cancer differentiation (Stoykova and Glick 1995; Seidenfaden and 
Hildebrandt 2001; Poongodi et al. 2002). Based on this evidence, these neuroblastoma cell 
lines were examined as they express essential enzymes for polysialylating endogenous 
NCAM and therefore can be considered candidate mammalian cell hosts for producing 
polysialylated versions of the scFv and NCAM polysialylatable domains fusion protein. The 
mouse NB2a neuroblastoma cell line (kind gift of Professor Yuri Ushkaryov, Imperial 
College London), one of the previously confirmed endogenous PSA-NCAM positive cell 
lines, was selected as the cell host for initial attempts to express and produce recombinantly 
polysialylated scFv fusion protein in this section of the project. 
 
Constantinou, A. et al. initiated the genetic fusion work to construct recombinantly 
polysialylatable MFE23 scFv, in comparison with the chemical conjugation of PSA to the 
same scFv (Constantinou 2005; Constantinou et al. 2009). DNA constructs including MFE23-
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Ig5-FN1, MFE23-FN1, FL-NCAM, and LS-MFE23, were inherited from this previous study 
(Constantinou 2005).  As shown in Figure 2.1(b), a mammalian cell leader sequence (LS) – 
MLQTKDLIWTLFFLGTAVSLQVD, previously used for extracellular expression of NCAM 
protein, was added at the +1 position for all four constructs. This leader sequence is the signal 
peptide and was artificially created as a synthetic construct for the purpose of human NCAM 
expression and post-modification, but latterly was used as a powerful directory peptide for 
generating other human or humanised recombinant proteins and peptides following the 
mammalian cell secretion pathway through the Golgi apparatus to the cell surface, and 
eventually extracellular matrix (Wiemann et al. 2001). The full length (FL) NCAM gene was 
originally supplied as a recombinant fusion with an Fc ligand constructed in the pIg vector 
(kind gift of Dr. Jane Saffell, Imperial College London) (Appendix 2). The NCAM originated 
from the NCAM-140 isoform, and covered all five Ig-like domains and two fibronectin type-
III domains. Truncation of the NCAM sequence to obtain the fragments encompassing the 
minimal NCAM polysialylation domains (Close et al. 2003) was achieved through DNA 
mutagenesis, digestion and ligation, which has been described in detail previously 
(Constantinou 2005). pcDNA4
TM
/TO/myc-His (Appendix 1) was used as the vector system 
for the genetic incorporation of all the fusion elements, and expression of recombinant 
proteins in the mammalian cell hosts. This vector was chosen based on the following (1) It 
provides a strong expression promoter, also known as human cytomegalovirus (CMV) 
immediate-early  promoter, which allows high-level protein production in a wide range of 
mammalian cells; (2) Double C-terminal peptide epitopes encoding both Myc and 
polyhistidine (His6) metal-binding tags are favourable for purification and detection of 
expressed protein; (3) Most importantly, the vector contains ampicillin and zeocin resistance 
genes for both bacterial and mammalian cell selections.  Selection of highly expressing stable 
mammalian cells was one the main issues involved in this project, in order to provide enough 
research material for structural characterisation, and in vitro and in vivo investigations. The 
Zeocin
TM
 resistance gene enables selection of mammalian cells stably expressing the protein 
of interest incorporated within the pcDNA4
TM
/TO/myc-His vector after transfection (Mulsant 
et al. 1988).  
 
The antibody fragment, MFE23 scFv was investigated as the scFv portion of the fusion 
protein in the recombinantly polysialylated construct. It has been characterised by its 
carcinoembryonic antigen targeting specificity and affinity, good extravasation and tumour 
penetration and localization, and rapid blood clearance rate as a drawback (Casey et al. 1995; 
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Verhaar et al. 1995; Chester et al. 2000; Mayer et al. 2000). Chemically conjugating PSA to 
MFE23 in order to increase the pharmacokinetics of the single chain antibody was previously 
studied (Constantinou et al. 2009), which offered a direct contrast to the recombinant fusion 
approach. Furthermore, the scFv has also been repeatedly reported in many recombinant 
fusion formats for other investigations, such as antibody-directed enzyme prodrug therapy 
(ADPET) (Michael et al. 1996; Chester et al. 2000; Kousparou et al. 2002; Francis et al. 2004; 
Mayer et al. 2004), gene therapy (Whittington et al. 1998; Chowdhury et al. 2004), and other 
targeted therapies (Cooke et al. 2002). With all this previous fusion engineering experience, 
MFE23 scFv was selected as the first model to be genetically fused with the polysialylatable 
domains from NCAM. 
 
 
 
3.2 Aims and Objectives 
 
The aim of this section is to continue the previous research methodology (Constantinou 2005) 
in order to develop a recombinant polysialylation system for antibody fusion proteins as an 
alternative approach to chemical polysialylation, using NB2a as a naturally polysialylating 
cell line to fulfill this purpose. 
 
The objectives are: 
■ Optimizing reagents and conditions for mammalian cell line transfection.  
■ Selection of stable NB2a cell lines expressing the MFE23 fusion proteins (i.e. the 
polysialylated format and other fusion controls).   
■ To further characterize the fusion proteins to confirm true recombinant polysialylation. 
■ To characterize the glycan nature of the MFE23-Ig5-FN1 to see if it can potentially be 
polysialylated. 
■ To examine the antigen-binding potential of the recombinant scFv fusion protein in 
comparison with the scFv alone. 
 
 
 
- 150 - 
 
 
3.3 Results 
 
3.3.1 Preparation and Examination of MFE23 scFv fusion Plasmid DNAs 
The plasmid DNA constructs including LS-MFE23, MFE23-FN1, MFE23-Ig5-FN1 and FL-
NCAM were inherited from previous research (Constantinou 2005) and prepared as described 
in section 2.1.5. These were verified by DNA double digestion before DNA was introduced 
into the mammalian cell hosts for protein production (Figure 3.1).  
 
 
 
                                                                       
                                                        
                                                     
 
 
 
 
 
Figure 3.1. Schematic diagrams showing genetic information of FL-NCAM and all MFE23 fusion 
constructs fused in pcDNA4a vector. Localizations of both Hind III and XhoI restriction sites are addressed, 
and detailed fusion insert conformations are also illustrated corresponding to each fusion construct. The base pair 
(bp) numbers of each insert are calculated from the referred DNA sequences. 
 
 
pcDNA4 mammalian protein expression vector 
pCMV 
 Myc 6xHis 
 Ampicillin      Zeocin 
Fusion Insert LS TATA 
LS Fusion Insert 
LS Ig-5 Ig-4 Ig-3 Ig-2 Ig-1 FN-1 FN-2 
LS MFE23 Ig-5 FN-1 
LS MFE23 FN-1 
LS MFE23 
Hind III   Xho I 
MFE23-Ig5-FN1 (1503bp) 
MFE23-FN1 (1239bp)   
MFE23 (828bp) 
FL-NCAM (2076bp) 
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Corresponding restriction endonucleases were used in the double digestion for each construct. 
As illustrated in Figure 3.2, the double-digested DNA fragments showed the expected sizes 
for each fusion insert matching their DNA sequence calculations (indicated in Figure 3.1). 
 
 
 
 
3.3.2 Optimizing Reagents and Conditions for NB2a Cell Transfection 
Among all the transfection methods, using liposomes as a carrier to deliver DNA is 
considered to be one of the mildest and efficient methods to treat cells. Many liposome-
mediated transfection products are commercially available nowadays. Here, to identify the 
optimal transfection conditions, the three most popular and highly rated liposomal 
transfection reagents - Fugene
® 
6, Fugene
®
 HD (Roche), and Lipofectamine™ 2000, were 
purchased and compared for the expression level of green fluorescent protein (GFP) after 
pEGFP-C1 DNA vector transfection. 
 
In addition to the transfection procedure described in section 2.2.3.6, specific optimization 
protocols were tested for each transfection reagent. For Fugene
® 
6, the recommended reagent 
(μl) to DNA (μg) ratios – 3:1, 3:2 and 6:1 were prepared, whilst for Fugene® HD, a serial of 
ratios were prepared including 3:2, 4:2, 5:2, 6:2, 7:2, and 8:2 (as the protocol recommended). 
Fresh medium was added after overnight transfection complex incubation for all three 
transfection reagents. After transfection and two days recovery, the cells were lysed and the 
GFP fluorescent intensity from each lysate was consequently analysed. The same number 
(2x10
5
) of NB2a cells that have been previously transfected with the same DNA vector (gift 
from Dr. John Silva, Imperial College London) with identified transfection efficiency (8.5%) were 
treated and analysed in the same way for its fluorescent reading.  
 
Figure 3.2.  XhoI/HindIII double 
digestions of DNA vectors containing 
MFE23 fusion constructs. fragments  ~2 
kbp, ~1.5 kbp, ~1.2 kbp and ~0.9 kbp 
referred to the insert sizes from FL-
NCAM, scFv-Ig5-FN1, scFv-FN1 and LS-
scFv (respectively from lane 2, 3, 4, and 5). 
Lane 6 was loaded with empty pcDNA4a 
vector alone. Hyperladder I was used as 
base pair markers in lane 1. 
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In comparison, remarkable results were obtained with GFP extracted from NB2a cells 
transfected with Fugene
®
 HD transfection reagent (Figure 3.3).  Particularly, more than 90% 
transfection efficiency was obtained (reagent to DNA ratios at 7:2 and 8:2). Low cytotoxicity 
of Fugene
®
 HD was also observed after long-term transfection incubation (overnight). Hence, 
Fugene
®
 HD was selected as the optimal transfection reagent for transfecting DNA constructs 
into the NB2a cell line under the reagent to DNA ratio of 8:2.  
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Figure 3.3. Transfection efficiency determination. Comparisons include Fugene
®
 6 with three different reagent 
to DNA ratios – 6:1, 3:1 and 3:2; Fugene® HD with six recommended transfection mix ratios, and 
Lipofectamin
TM
 2000 transfection system, together with positive control with known transfection efficiency as 
8.5%. 
 
 
3.3.3 Selection of Stable Monoclonal NB2a Cell Line Expressing MFE23 
Fusion Proteins 
With the optimised transfection conditions, pcDNA4 vectors containing the genes for the 
fusion proteins were transfected into the NB2a cells respectively. Stable cell lines were 
selected by zeocin resistance as described in section 2.2.3.7. Selection of isolated cell colonies 
were cultured in 24-well plates and the culture media from surviving healthy and growing 
monoclonal cell lines were collected and used for dot-blot, a screening tool for initial 
detection of the expression level of the induced fusion proteins. Monoclonal cell lines stably 
secreting relatively high levels of His6-tagged protein were further selected.  
 
    Fugene® 6    Fugene® HD 
Lipofectamin
TM
 
2000 
    Control 
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Dot-blot results indicated the monoclones which had the best protein expression, as shown by 
the intensity of the anti- His6 dot blot signals. With distinct visual intensity differences of the 
dots shown in Figure 3.4 for each MFE23 fusion constructs, clone 3 of LS-MFE23, clone 6 of 
MFE23-FN1, and clone 3 of MFE23-Ig5-FN1 were considered to be the monoclones that had 
the highest fusion protein expression levels. Monoclonal media collection and dot-blot tests 
were processed again under the same conditions, and the same result was obtained. For cells 
transfected with the FL-NCAM construct DNA, no positive signal was obtained in the dot-
blot. Further FL-NCAM monoclones were also tested, and none produced a positive result 
(results not shown). Comparatively, monoclone 1 (shown on Figure 3.4) of FL-NCAM was 
chosen to be the highest expressor among all FL-NCAM monoclone tested in the dot blot. All 
4 monoclones, one each for the four constructs with the highest fusion protein expression 
levels were then selected to be cultured in a larger scale, in order to produce more protein for 
further intricate protein characteristic determination studies. From the dot-blot, other 
monoclonal cell lines including monoclone 3 and 7 for LS-MFE23, monoclone 2 for MFE23-
FN1, and monoclone 1 for MFE23-Ig5-FN1 were also selected and cultured as backup lines. 
 
 
Figure 3.4. Anti-His6 dot-blot results for selecting monoclones for each fusion construct with best protein 
expression levels. In total, six FL-NCAM, ten LS-MFE23, six MFE23-FN1, and eight MFE23-Ig5-FN1 
monoclones were screened by dot-blot. Three negative controls, which were TCM (a), PBS (b) and untransfected 
NB2a cell culturing medium (c) were used for background reading. Approximately 10μg of a control His6-tagged 
tetanus toxin protein was employed as a positive control.  
 
 
Additionally, all of the selected monoclones from the four recombinant fusion constructs were 
dot-blot screened in the same manner with immuno-detection of anti-PSA (12F8) antibodies. 
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However no positive signal was obtained from any monoclonal supernatant sample (results 
not shown). 
 
3.3.4 Characterisation of the MFE23 Fusion Protein Constructs Purified 
from Selected NB2a Monoclones 
The selected NB2a monoclones with best expression levels for all four fusion constructs were 
cultured in 75cm
2
 flasks under normal tissue culture conditions with serum supplemented 
TCM (section 2.2.3.1). In order to eliminate serum albumin contamination (which will hinder 
protein purification quality), the serum-free medium, FreeStyle™ CHO Expression Medium 
was applied to the cells once they reached approximately 80% confluence. Two rounds of the 
culture medium were collected following the procedure described in section 2.2.3.9. A third 
round of serum-free incubation of the cells was tested as well, and massive cell death was 
observed, and this media was not used in case it contaminated the fusion proteins. 
 
PBS Dialysed serum-free media was used to purify His6-tag fusion protein immobilised by 
metal (TALON
TM
) affinity chromatography (section 2.2.4.2). Purified samples of each 
construct were loaded onto SDS-PAGE with Coomassie staining in order to visualize the 
purity, integrity, and molecular weight of the produced protein. Western-blotting followed by 
immuno-detection was also utilised to identify the recombinant proteins. Results of 
Coomassie stained and Western Blotted purified MFE23 fusion proteins are shown in Figure 
3.5. All three MFE23 fusion proteins (LS-MFE, MFE23-FN1, and MFE23-Ig5-FN1) were 
successfully purified (Figure 3.5a). Each of the MFE23 recombinants also showed the correct 
molecular weight based on their amino acid compositions (Table 3.1). Bands shown in the 
sample flow-through and wash flow-through were considered as major contaminants (i.e. 
serum or growth factor related proteins), which were significantly eliminated after the IMAC 
purification. Unfortunately, the FL-NCAM was not purified from His6 affinity column, as 
measured by Bradford assay of protein elution fractions during the purification process 
(results not shown). The cause of the problem was considered to be His6-tag detachment or 
mis-folding, and this predication was further confirmed by the Western blot results. 
 
Both anti-His6 and anti-FN1 immuno-detection are shown in Figure 3.5b and c. All three 
MFE23 fusion proteins were detected by anti-His6 antibody with the correct MW, but no band 
was seen with FL-NCAM, which may indicate a malfunctioning or missing His6-tag. 
Concentrated supernatant from FL-NCAM monoclones was subsequently subjected to an 
anti-FN1 Western blot immuno-detection, and a positive result was obtained together with  
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Figure 3.5. Recombinant fusion proteins purified from selected stable NB2a monoclonal cell lines. (a) 
Coomassie staining of His6 tag affinity column purified MFE23-Ig5-FN1, LS-MFE23 and MFE23-FN1 
recombinant constructs. Red arrows indicate the purified fusion proteins shown in lane 4 and 5. Lane 2 and 3 
represents sample flow-through and first wash flow-through from the affinity column in purification steps. (b) 
Anti-His6 and (c) Anti-FN1 Western blot analysis. Lane 2, 3, 4, and 5 were loaded with FL-NCAM 
(concentrated but unpurified), MFE23-Ig5-FN1, MFE23-FN1, and LS-MFE23 in both Western blots. The 
recombinant Hc fragment of tetanus neurotoxin (TT-Hc) (Scott et al. 2008) and NCAM-Fc (gift from Dr. Jane 
Saffell) proteins were used respectively as positive controls for both anti-His6 and anti-FN1 immuno-detections, 
and shown in lane 6 of each blot. Untransfected NB2a cell supernatant was prepared as negative control in lane 7. 
 
 
MFE23-Ig5-FN1 and MFE23-FN1 constructs, which also encode a FN1 domain. LS-MFE23 
had no FN1 domain DNA in its fusion construct, and was not detected by anti-FN1 antibody 
as expected. A Myc tag-specific immuno-affinity column was also used to purify FL-NCAM, 
but also failed (Results not shown). The anti-FN1 Western blot confirmed the expression of 
FL-NCAM from the cell medium. However, from all the evidence, it is more likely that the 
expressed FL-NCAM protein did not maintain functioning C-terminal peptide tags. However, 
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results from SDS-PAGE and Western blot showed that the selected monoclones from dot-blot 
were expressing intact MFE23 fusion proteins with correct molecular weights. Anti-PSA 
Western blot detection was also carried on all recombinant fusion proteins including 
concentrated unpurified FL-NCAM monoclonal supernatant. Unfortunately, nothing was 
detected by Western blot. 
 
Another important finding was that the apparent molecule weight values of all three 
recombinant proteins (LS-MFE23, MFE23-FN1, and MFE23-Ig5-FN1) indicated by the 
protein gels and immuno-detections are appeared to be bigger than the computed calculated 
MW values (Table 3.1) according to the proteins corresponding DNA sequences. 
 
Table 3.1. Calculated amino acid molecular weight and extinction coefficient of all three MFE23 fusion 
proteins by ExPASy ProtParam programme. 
 
MFE23 Fusion Proteins 
Molecular Weight 
(Da) 
Extinction Coefficient 
(M
-1
 cm
-1
) at 280nm in water 
LS-MFE23 29251 53860 
MFE23-FN1 43706 76320 
MFE32-Ig5-FN1 53615 97750 
 
 
 
 
More precisely, the apparent MW increases of both LS-MFE23 and MFE23-FN1 were within 
~6 kDa, while a significant MW increase (~20 kDa) was demonstrated by MFE23-Ig5-FN1 
fusion protein, and this indirectly indicated that additional post-translational modification was 
involved especially when a polysialylatable protein domain was carried alongside. 
 
Following the same method as above, large scale production of MFE23-Ig5-FN1, MFE23-
FN1, and LS-MFE23 was carried out in multiple 125cm
2
 culture flasks. The purity and 
integrity of the fusion proteins were checked again (shown in Figure 3.6). All three large-
scale purifications produced recombinant proteins with the correct molecular weights, 
according to their calculated MW outlined in Table 3.1. Both Coomassie staining and Western 
blot also proved the purity and integrity of the proteins. Therefore, the serum-free production 
system is very likely to be an adequate routine system for obtaining fusion proteins expressed 
in mammalian cells, despite some degree of degradation appearing in the MFE23-Ig5-FN1 
fusion protein, as three bands are observed for the protein in Figure 3.7 with one major band 
indicating the glycosylated fusion protein (~70 kDa), and two minor bands with reduced 
MWs.  
Amino acid MW was derived from corresponding protein gene sequences. All MWs include both Myc 
and His6 tags molecular weights. 
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       (a)                                                          (b) 
 
Figure 3.6. Purity and integrity detection of MFE23-Ig5-FN1, MFE23-FN1, and LS-MFE23 recombinant 
fusion proteins produced in large scale. (a) Coomassie staining and (b) anti-His6 tag Western blot. All three 
recombinant proteins were produced from the corresponding NB2a stable monoclones.  
 
 
 
3.3.5 Affinity Binding Assay – ELISA 
In vitro antigen binding profiles were subsequently investigated for further characterisation of 
recombinant MFE23 fusion proteins selected from stable monoclonal NB2a cell lines. The 
ELISA tests were carried out to determine the KD value of all three MFE23-recombinant 
fusions: LS-MFE23, MFE23-FN1 and MFE-23-Ig5-FN1, in order to show that the fusion 
proteins produced from the stable mammalian cell lines have retained antigen binding affinity 
compared to the bacteria-expressed MFE23 scFv and the fusion domains together with the 
potential polysialylatable post-modifications have no significant effect on the binding affinity 
compared to the original scFv. As described in section 2.2.5.7, an ELISA method was used 
with N-A1, the recombinant binding domains of CEA as the actual antigen target in the assays 
(Figure 3.7).  
 
Previously, in vitro studies confirmed that the KD of scFv MFE23 against N-A1 is 
approximately 4.5nM (Sainz-Pastor et al. 2006). As shown in Figure 3.7, results from the 
antigen binding test revealed a similar KD value of MFE23 scFv expressed by both E. Coli 
bacterial and NB2a mammalian cell expression systems, which is almost the same as the 
published KD value. More importantly, NB2a cell expressed MFE23-Ig5-FN1 fusion protein 
also showed a consistent KD value, indicating the recombinant fusion had no effect on antigen 
binding.  
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Figure 3.7. In vitro antigen binding determination by ELISA to all MFE23 recombinant fusion proteins. 
Myc-tag that commonly encoded by all fusion proteins was immuno-targeted for ELISA assay. Antigen 
orientated LS-MFE23. MFE23-FN1 and MFE-Ig5-FN1 expressed by selected NB2a stable cell lines and 
bacterial expressed MFE23 scFv have been detected for their antigen binding affinities. The dissociation 
constant (KD) values are also indicated corresponding to each recombinant protein. A triplicate of each 
concentration point was prepared for each protein sample.  
 
 
3.3.6 Glycosidase Treatment of MFE23-Ig5-FN1 Fusion Protein Expressed 
from Stable NB2a Cell Line 
Due to the lack of anti-PSA immuno-detection of the MFE23-Ig5-FN1, further glycoprotein 
investigation was carried out involving different glycosidases. Glycosidases have unique 
specificities recognising and removing different oligosaccharide structures. The defined 
functions and targets of various glycosidases are mentioned previously in the Material and 
Method section (see Table 2.6 and Figure 2.2). MFE23-Ig5-FN1 was the fusion protein that 
was hypothesised to be polysialylated during the post-translational modification of 
mammalian glyco-protein expression process; therefore the glycosidase treatment was 
focused on this protein (Figure 3.8). Many positive controls were also utilized in order to 
define the specific activities of each glycosidase. 
 
Glycosylation increases the molecular weight of a protein simply through the addition of 
multiple monosaccharides. Glycosidases can hydrolyse specific oligosaccharides. This glyco-
structure removal directly induces a MW loss, which can be easily revealed by SDS-PAGE. 
As shown in Figure 3.8(a) above, Coomassie staining suggested no band shift after either 
Endo- 
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Figure 3.8. Glycosidase treatment analysis. (a) SDS-PAGE analysis (Coomassie staining) of MFE23-Ig5-FN1 
fusion constructs before and after different glycosidase treatments. Coomassie staining of both (b) Exo-N 
treatment for transferrin, and (c) fetuin with Exo-neuraminidase and PNGase F treatments. (d) Anti-PSA/NCAM 
(12F8) Western blotting of homogenized embryonic mouse brain (HEMB) with/without Endo/Exo-N treatments, 
together with intact MFE23-Ig5-FN1 fusion protein. Transferrin, fetuin, and HEMB were used as positive 
controls carrying the corresponding glycosylation features to test the activities of Exo-Neuraminidase, PNGase F, 
and Endo-Neuraminidase. 
 
 
Neuraminidase or O-Glycosidase treatments, indicating no corresponding sugar linkages (α2-
8 linked sialyl residues and GalNAc-Ser/Thr) were present in the MFE23-Ig5-FN1 fusion 
construct. In other words, it is likely that the fusion was not polysialylated. Exo-N 
(NeuNAcα2-3/6Gal specific) treatment indicated a molecular weight shift of approximately 5 
kDa as compared to the intact fusion protein, and a ~10 kDa difference was also detected 
when all N-linked glycans were removed by PNGase F. The activity tests of the glycosidases 
were confirmed simultaneously. Blood proteins, transferrin and fetuin are well acknowledged 
to be heavily sialylated, and specifically, transferrin has been reported to have NeuNAcα(2-
6)Gal terminal sialylation (Finne and Krusius 1979), while NeuNAcα(2-3)Gal linkages 
appeared more often in fetuin (Nilsson et al. 1979; Edge and Spiro 1987). This made these 
blood proteins ideal positive controls for monitoring Exo-N catalytic activity (Figure 3.8). 
Fetuin is also an N-glycan rich protein, so its band shift after PNGase F treatment confirmed 
MFE23-Ig5-FN1 
Transferrin Fetuin HEMB 
(a) 
(b) (c) (d) 
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the enzyme function (Figure 3.8c). Homogenated embryonic mouse brain (HEMB) containing 
polysialylated NCAM was used as positive control for the anti-PSA Western blot (Figure 
3.8d). This also confirmed the intriguing activity of Endo-N, in terms of PSA hydrolysis, and 
the specific polysialic acid recognition of the anti-PSA (12F8) antibody. A smear between 
250 kDa and above was revealed with the immuno-detection of HEMB, suggesting variable 
polysialylation level of the NCAM (the extracellular domain of non-glycosylated NCAM is 
only ~80 kDa) in the fetal mouse brain. The same smear was also detected in Exo-N treated 
HEMB, indicating the inefficiency of Exo-N to cleave the protruding PSA chains that also 
inhibited the glycosidase ability to reach its preferred cleavage sites: Neu5Acα(2-6)Gal or 
Neu5Acα(2-3)Gal, inside the N-glycan structures. Again, no anti-PSA detection was detected 
with the intact MFE23-Ig5-FN1 fusion protein produced by NB2a cells. 
 
 
3.3.7 Oligosaccharide Differentiation by Digoxigenin Linked Lectins 
Lectins have specific abilities to recognise unique glyco-structures. The lectin binding 
exposes the specific sugar linkage existence within glycoproteins. The specificities of each 
lectin are shown in Table 2.5. After failing to detect PSA by Western blot, the MFE23-Ig5-
FN1 fusion construct was then examined in various lectin binding tests, in order to reveal the 
presence of essential oligosaccharides that are responsible for sialylation, and discover the 
epitopes required for further sialic acid elongation – polysialylation. 
 
Bands shown in Figure 3.9 indicated linkages including Neu5Acα(2-6)Gal, Neu5Acα(2-3)Gal, 
and Galβ(1-4)GlcNAc were present in carbohydrate compositions of MFE23-Ig5-FN1 fusion 
protein made from NB2a cells. Galβ(1-3)GlcNAc linkage was not detected by PNA detection, 
suggesting such linkage may not be involved in the fusion protein surface carbohydrate 
presentation. After the glycosidase treatments, no band shift was found with the fusion protein 
after Endo-N treatment (Figure 3.9, SNA and MAA detection) comparing with the non-
glycosidase treated form. This implied that no Endo-N hydrolysis occurred with the MFE23-
Ig5-FN1 fusion protein, which indicated no PSA was attached to on the fusion protein. After 
Exo-N treatment, no band was detected in the SNA lectin binding test, but bands were seen 
with both MAA and DSA detection, and the band in the MAA detection appeared to be 
weaker in intensity.  Both bands found in MAA and DSA after Exo-N treatment also showed 
minor migration differences compared to the non-treated ones. No bands were seen in any 
lectin detection after PNGase F treatment that removes the N-linked glycans.  
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Figure 3.9. Lectin detections of sugar linkages from MFE23-Ig5-FN1, MFE23-FN1, and LS-MFE23 stably 
expressed from NB2a monoclones. Four different lectins SNA, MAA, DSA, and PNA were used to detect 
Neu5Acα(2-6)Gal, Neu5Acα(2-3)Gal, Galβ(1-4)GlcNAc, and Galβ(1-3)GlcNAc respectively. Glycosidase 
treatments were also applied for the oligosaccharide removal. 
 
 
Neither MFE23-FN1 nor LS-MFE23 had any of the four glyco-linkages being detected by 
any lectins (Figure 3.9). All the positive control glycoproteins showed positive results after 
binding with the corresponding lectins, but no bands were seen after glycan removal by 
glycosidases, proving the validity of the DIG glycan differentiation tests, and good catalytic 
abilities of all glycosidases involved. Evidence of MFE23-Ig5-FN1 protein degradation was 
SNA detection MAA detection   
DSA detection                                          
SNA detection 
PNA detection                                          
SNA detection 
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also revealed by lectin detection similar to that seen in the protein immuno-staining (Figure 
3.6b). 
 
 
3.3.8 Structural Analysis of the Carbohydrate Presentation on NB2a 
Expressed MFE23-Ig5-FN1 
The aim of this part of the work was to provide as much information as possible concerning 
the potential N-glycans on the MFE23-Ig5-FN1 peptide backbone using a combination of 
protein and carbohydrate chemistry plus mass spectrometry. The structural analysis services 
were provided by M-Scan Ltd (Wokingham, UK) and approximately 500µg of purified 
NB2a-expressed MFE23-Ig5-FN1 dissolved in 1 x PBS (see section 3.2.4 for purification 
procedure) was used for the analysis. 
 
N-linked oligosaccharide population screening by MALDI-MS 
The samples were reduced and carboxymethylated. A small amount of precipitation was 
observed in the reaction products. The supernatant was removed and purified using a 
Microcon spin cartridge. Trypsin digestion was then performed. The lyophilised products 
were digested using PNGase F and then purified using a C18 Sep-Pak. The 5% aq. acetic acid 
(N-linked oligosaccharide containing) fraction was permethylated and DE-MALDI-TOF mass 
spectra were obtained using a portion of the derivatised oligosaccharides in a high mass range 
for molecular ions. MALDI-TOF mass spectrometry was performed using a Voyager-DE 
STR Biospectrometry Research Station laser-desorption mass spectrometer using Delayed 
Extraction (DE) technology.Table 3.2 lists the predominant molecular ions present in the 
MALDI spectra (Appendix 12). 
 
N-linked oligosaccharide population screening by ES-MS 
Following MALDI-MS analysis, a fraction of the permethylated N-glycans were analysed by 
Electrospray-Mass Spectrometry (ES-MS). ES-MS was performed using a quadrupole-
orthogonal acceleration time of flight (Q-TOF) instrument using Argon as the collision gas. 
Glu-Fibrinopeptide fragment ions in MS/MS mode were used to calibrate the instrument. 
Dried permethylated glycans were redissolved in methanol:0.1% TFA (80:20) before 
analysis.Table 3.3 lists the predominant fragment ions present in the electrospray spectrum 
(Appendix 13). 
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Table 3.2. Masses observed in the MALDI spectra of permethylated N-glycans derived from MFE-Ig5-
FN1. Possible carbohydrate structures according to the corresponding masses were also assigned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3. Low mass fragment ions observed in the Electrospray spectrum of permethylated N-glycans 
derived from MFE-Ig5-FN1. The data obtained show fragment ions which are consistent with antennal 
structures expected to be present in the complex glycans detected by MALDI-MS. 
 
Signals observed 
(m/z) 
Possible Assignment 
260.1 (minor) HexNAc
+
 A-type fragment ion 
344.2 
HexNAc
+
 A-type fragment ion                          
(-methanol) 
376.2 (minor) NeuAc
+
 A-type fragment ion 
432.2 (minor) 
HexHexNAc
+
 A-type fragment ion                   
(-methanol) 
464.2 HexHexNAc
+
 A-type fragment ion 
477.2 Hex2 +Na
+
 (contaminant) 
793.4 
NeuAcHexHexNAc
+
 A-type fragment ion        
(-methanol) 
825.4 NeuAcHexHexNAc
+
 A-type fragment ion 
1186.5 (weak) NeuAc2HexHexNAc
+
 A-type fragment ion 
1293.6 Hex6 +Na
+
 (contaminant) 
 
Signals observed 
(m/z, peak top masses) 
Possible Assignment 
1089.7 Hex5 +Na
+
 (contaminant) 
1293.9 Hex6 +Na
+
 (contaminant) 
1362.7 Hex3HexNAc3 A-type fragment ion 
1416.9 Hex3HexNAc3 +Na
+
 
1526.1 Hex5HexNAc2 A-type fragment ion 
1580.3 Hex5HexNAc2 +Na
+
 
1730.3 Hex6HexNAc2
+
 A-type fragment ion 
1784.5 Hex6HexNAc2 +Na
+
 
2111.8 Not assigned 
2432.4 NeuAcHex5HexNAc4 +Na
+
 
2881.6 NeuAcHex6HexNAc5 +Na
+
 
2922.7 Not assigned 
3127.0 Not assigned 
3243.1 NeuAc2Hex6HexNAc5 +Na
+
 
3604.3 NeuAc3Hex6HexNAc5 +Na
+
 
3692.2 NeuAc2Hex7HexNAc6 +Na
+
 
4053.8 NeuAc3Hex7HexNAc6 +Na
+
 
4415.1 NeuAc4Hex7HexNAc6 +Na
+
 
4777.0 NeuAc5Hex7HexNAc6 +Na
+
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The structural analysis data conclusively confirm the presence of high mannose and complex 
N-glycan structures on the glycoprotein. The major structures present are high mannose 
representing early structures in N-glycan biosynthesis. Complex structures were detected with 
masses consistent with bi-, tri- and tetra-antennary structures with varying levels of sialylation. 
Evidence of polysialylated structures was found but these were detected at minor levels on the 
tetra-antennary glycans. A weak signal (1186.5m/z) consistent with an antennal fragment ion 
containing two sialic acid residues was observed in the electrospray mass spectrum. 
 
 
 
3.4 Discussion 
 
By predominantly following the protocols and indications from a previous study 
(Constantinou 2005), the recombinant polysialylation of MFE-23 scFv research initiated by 
Dr. A. Constantinou was further investigated and characterised as the first part of this PhD 
project. All the DNA constructs including polysialylatable MFE-23 scFv and other control 
constructs MFE23-FN1, LS-MFE-23, and FL-NCAM were inherited from previous research 
(Constantinou 2005) and successfully reproduced as confirmed by DNA double digestion 
(Figure 3.2). The original project design was to transfect the polysialylatable fusion construct 
into a neuroblastoma-2a (NB2a) cell line, a well known PSA-NCAM positive cell line, that 
makes its own polysialylated NCAM, and use this cell line to secrete polysialylated fusion 
proteins. If the NB2a cells express the essential enzymes to polysialylate their own NCAM 
protein, theoretically the fusion protein containing NCAM polysialylatable domains should be 
glycosylated and polysialylated through the cell Golgi apparatus by the responsible enzymes. 
 
Transfection optimization tests using a GFP containing pEGFP-C1 plasmid vector were 
processed initially to optimize the transfection conditions, including plasmid DNA uptake and 
cell viability after transfection, to determine the optimal conditions for following stable cell 
line selections. Moreover, the NB2a cell line is not a standard expressing cell-line and as a 
type of neuronal cell line, is often difficult to transfect, so it was important to verify the 
transfection efficiency prior to the experiments with the MFE23 fusion constructs. Based on 
the high transfection efficiency (Figure 3.3), as well as gentle and low post-transfection 
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toxicity, Fugene
®
 HD was selected as the transfection reagent with an 8:2, reagent (µl) to 
DNA (µg) ratio and overnight transfection incubation time for optimal transfection efficiency. 
These conditions were consequently applied to MFE23 fusion construct transfection and 
stable cell selection. 
 
As shown in Figure 3.5, stable monoclonal cell lines were successfully selected from LS-
MFE23, MFE23-FN1, and MFE23-Ig5-FN1 plasmid DNA transfectants, and fusion proteins 
were characterised with the correct information based on the MW and fusion domains. 
Furthermore, fusion proteins were produced in serum-free medium in order to diminish the 
FBS contamination in serum supplemented culture. With relatively good expression yield 
(~700µg/ml), the stable cell line can be used to constantly produce protein under increased 
production scale within 8 days (every four-day incubation interval) in serum-free medium. A 
72 kDa protein band was predominantly observed for the MFE23-Ig5-FN1 fusion protein 
(Figure 3.5 and 3.6), and two additional smaller bands (~60 and 54 kDa) of the fusion protein 
were also observed (Figure 3.6), which were potentially caused by incomplete post-
translational modifications or protein degradation. To overcome this problem, more rigourous 
cell culturing conditions may need to be applied, such as a suitable serum-free culture 
medium specialized for the NB2a cell line, applying sub-culturing protocols for cells cultured 
in serum-free conditions, elimination of detrimental cell products (e.g. lactic acid and 
glutamine), and many other aspects in routine and scaled-up mammalian cell-culturing 
conditions. Further investigations on essential enzymes and factors influencing the fusion 
protein glycosylation should also be considered for reducing the expression level of poorly 
glycosylated fusion species. 
 
In this intial attempt at making recombinantly polysialylated antibody fragment, no PSA 
could be detected in all recombinant fusion proteins, neither the proteins that theorecticall 
could be polysialylated, nor the negative control constructs. It seemed that polysialylation was 
not occuring, or only occured at an undetectably low level in the fusion constructs (MFE-Ig5-
FN1 and FL-NCAM) that were designated to be polysialylated, as neither fusion proteins was 
detected by any anti-PSA antibodies. Supportive data at the monoclonal selection stage also 
showed no reaction in dot-blots by anti-PSA antibody, which might already indicate negative 
polysialylation outcome would be seen in the protein characterization stage as some of the 
same samples on the dot-blot was strongly detected by anti-His6 immunoblot (Figure 3.5), 
primarily showing the presence of the fusion proteins.  Moreover, the increase in molecular 
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weight of MFE23-Ig5-FN1 produced by NB2a cell system was discussed in the context, 
however this MW augment was not dramatic when compared to the previous NCAM 
polysialylation studies investigated by other groups (Georgopoulou and Breen 1999; 
Franceschini et al. 2001; Close et al. 2003; Angata et al. 2004), as they have suggested around 
50 kDa – 100 kDa increases in MW through protein polysialylation. 
 
By comparing the apparent MWs (Figure 3.6a) and calculated MWs (Table 3.1) of MFE-23-
Ig5-FN1, MFE-23-FN1, and LS-MFE-23 the later two were found to be more or less the same 
as their calculated MW according to their amino-acid sequences (~45 kDa and 33 kDa). The 
polysialylatable fusion was found to have a higher molecular weight (~70 kDa) compared to 
the calculated weight (~54 kDa). The most plausable reason was due to glycosylation of the 
protein, and sialylation may be also involved according to the innate property of NCAM Ig5-
FN1 domain. However, it was not clear whether the 16 kDa MW increment is specifically due 
to the multiple sialic acid repeats (not long enough for anti-PSA detection), or other more 
complicated glycosylated structures. Further studies on fusion protein associated 
glycosylation features were initiated to clarify the glycosylation status of the fusion proteins 
(i.e. lectin binding, glycosidase treatment, and mass spectrometry investigations).   
 
FL-NCAM that contains the entire extracellular domains (Ig1 to 5 domains and fibronectin 1 
& 2 domains) of NCAM was constructed as a positive control to show polysialylation. 
Unfortunately, this FL-NCAM protein could not be purified from anti-His6 and anti-Myc 
affinity purifications, but it could be detected by anti-NCAM antibody from concentrated cell 
supernatant prior to the purification (Figure 3.5c). This might imply that the C-terminal 
peptide tags of the FL-NCAM were cleaved during protein expression by proteases or were 
mis-folded leading to malfunction of protein tag specific affinity bindings. Also, as pointed 
out by previous studies (Constantinou 2005), the protein tag malfunction could also be a 
potential problem encountered in the dot-blots for selecting FL-NCAM monoclones (Figure 
3.4). However, the anti-NCAM (FN1 specific) Western blot applied on concentrated cell 
culture supernatant from FL-NCAM revealed a positive result with a band having reasonably 
higher MW (~120 kDa) than predicted (~100 kDa) according to its primary sequence. The 
successful FN1 domain detection indicated expression of FL-NCAM from the chosen 
monoclonal cell line, and the increase of molecular weight was highly likely to be caused by 
glycosylation of FL-NCAM protein produced by NB2a cells. However, due to the problems 
- 167 - 
in purifying and identifying the mammalian expressed FL-NCAM fusion protein, it was very 
difficult to obtain this protein to serve as a positive control to show successful polysialylation.  
 
The low yield and difficulties in generating purified FL-NCAM protein, and the failure of 
having it to show polysialylation as a positive control in this initial research, led to the key 
requirement for positive materials to illustrate anti-PSA immuno-detection in order to confirm 
our finding of having no polysialylated recombinant fusion protein from the present NB2a 
system. Mouse embryonic brain that contains naturally occurred polysialylated NCAM has 
been repeated reported previously (Eckhardt et al. 2000; Weinhold et al. 2005; Angata et al. 
2007). The homogenized mouse embryonic brain (HMEB) was consequently tested as a 
positive control for anti-PSA (12F8) immunoblot. As seen in a short smear-like pattern in 
Figure 3.8(d), the HMEB successfully demonstrated the efficacy of using IgM antibody 
specifically targeted to NCAM associated polysialic acid. The smear-like immunoblot result 
is a common indication of protein polysialylated to differing degrees resulting in a dispersed 
molecular weight depiction. Compared with the positive result of PSA detection on HMEB, it 
was more certain that the NB2a cell was not producing polysialylated MFE23 fusion proteins. 
 
The following glycosidase treatments, and lectin directed glycan differentiation experiments 
were applied to understand the basic sugar components involved in the glycosylated MFE23-
Ig5-FN1 fusion protein produced from transfected NB2a stable cell line. Clearly shown in 
Figure 3.8a, both sialidase and PNGase F produced a band shift towards lower molecular 
weight, and the distances of band migration were proportionally corresponding to the sugar 
residues being removed by each glycosidase (Figure 2.2 shows the orientation of glycosidase 
treatment to N-glycan). This evidence indicates the existence of NeuNAcα(2-3), and/or α(2-
6)-Gal, and linkage between the innermost GlcNAc and asparagine residues from N-linked 
glycoproteins.  
 
Plant lectins have been widely used for the detection, isolation, and characterization of 
glycoconjugates using their characteristic carbohydrate binding properties (Shibuya et al. 
1987). The DIG glycan differentiation experiment mediated by specific lectin bindings 
(Figure 3.9) suggested the existence of the polysialylation epitopes, NeuNAcα(2-3), and α(2-
6)-Gal, alongside the potential subterminal Galβ1-4GlcNAc linkage on the N-glycan structure 
from the MFE23-Ig5-FN1 fusion protein. Although the precise structural composition of these 
linkages can not be determined by the lectin binding assays, the presence of these 
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disaccharides provides strong evidence for a typical N-linked glycan core with terminal 
polysialylation epitopes based on the current understanding of mammalian glycosylation 
patterns (Oltmann-Norden et al. 2008). No disaccharide linkages were revealed by any lectin 
binding assay with either MFE-FN1 or LS-MFE. This finding indicated the glycosylation is 
probably taking place entirely on the Ig5 domain, which corresponds to the concept that Ig5 is 
the main polysialylation site of NCAM.  
 
From both band shift and glycan differentiation tests, Endo-N, an enzyme catalysing PSA 
hydrolysis, did not have any effect on fusion proteins produced in the NB2a MFE23-Ig5-FN1 
stable cell line. This was probably due to insufficient α2-8 linked sialic acids being present in 
the glycoprotein, as Endo-N requires a minimum of 5 sialyl residues to be active (Hallenbeck 
et al. 1987). Anti-PSA immuno-detection on homogenate embryonic mouse brain before and 
after Endo-N treatment confirmed Endo-N activity on highly polysialylated proteins (Figure 
3.9d). This result provided further evidence that no polysialylation occurred on the MFE23-
Ig5-FN1 fusion protein. 
 
All the data presented (anti-PSA/NCAM immuno-detection, band shift after glycosidase 
treatments, and mass spectrometry) strongly suggests that the fusion protein expressed in the 
NB2a MFE23-Ig5-FN1 stable cell line is sialylated (possibly di-sialylated), but not 
polysialylated. However, the determination of N-linked glycosylation with estimated 
polysialylation epitopes presence on the Ig5 domain of the MFE23-Ig5-FN1 fusion protein 
suggested promising evidence for the elongation of the terminal sialic acid into PSA. 
 
So, why are NB2a cells unable to produce polysialylated fusion protein, even though they are 
fully equipped to mediate endogenous NCAM polysialylation? The problem could be the 
NB2a cell batch itself. The cell line is a cancer cell line, and genetically unstable. Although 
polysialylated NCAM was found to re-express in some metastatic cancers including 
neuroblastoma (Livingston et al. 1988), under laboratory conditions, after excessive passage 
numbers and modifications (i.e. transfection), the cells could acquire mutations, which may 
cause downregulation or deletion of polysialyltransferases genes. Also, the PolyST genes or 
the actual enzyme may become inactivated. Negative detection in anti-PSA immunoblots 
using lysed and homogenized NB2a cells (results not shown) may support this assumption, as 
no essential PolySTs were available in the transfected NB2a cells to polysialylate endogenous 
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protein. As mentioned previously, in the adult and late brain development stage, PolySTs 
become absent within the neuronal cells (Edelman and Chuong 1982; Rothbard et al. 1982). 
As a key function, studies investigating the affinity binding of the fusion protein are another 
significant part of the project. It is clear that without maintaining the antibody-antigen binding 
affinity and specificity, there will be no point performing PK manipulations. In the case of 
this project, the scFv molecule was recombinantly fused with additional protein domains that 
were also glycosylated. Polymeric chain structures were also desired to be recombinantly 
conjugated to the fusion as well. Therefore, it is very important to determine whether the 
antigen binding affinity was perturbed after all these structural modifications. ELISA results 
of all MFE23 recombinant fusion proteins expressed by NB2a cells (Figure 3.7) illustrated 
unchanged in vitro antigen binding affinity as compared with the original bacterial produced 
MFE23 scFv, which indicated the fusion protein retains normal targeting ability. Moreover, as 
we have confirmed that the MFE23-Ig5-FN1 fusion protein was only sialylated, it would be 
interesting to know the KD of the polysialylated fusion version.  
 
In conclusion, during this initial part of the proposed project, we confirmed that the NB2a 
cells utilised were not capable of producing any polysialylated protein. However, we do show 
recombinant MFE23 fusion proteins can be expressed in mammalian cells and high-quality 
purification of the fusion proteins can be obtained. FL-NCAM was not purified due to C-
terminal tag problems. Homogenized embryonic mouse brain was proved to be an alternative 
positive control for PSA-specific immuno-detection. In vitro antigen binding experiments also 
validated the preservation of antigen affinity of mammalian expressed MFE23 fusion proteins. 
However, concerns still remain that changes in the KD value for antigen binding could be seen 
with polysialylated MFE23-Ig5-FN1. Lastly, results from anti-PSA immunoblot, lectin 
binding, glycosidase treatment, and mass spectrometry suggested that the MFE23 fusion 
protein carrying theoretically polysialylatable NCAM domains can only be modified with 
sialylated N-glycosylation by NB2a cells. However, the glycan core structure containing 
terminal polysialylation epitopes provided promising indications that the fusion protein is 
available for polysialylation. According to the PSA biosynthesis process, it was consequently 
deduced that polysialyltransferases are likely to be the stumbling block in accomplishing 
MFE23 fusion protein polysialylation in the mammalian expression system. Investigations 
focused on introducing PolySTs to the mammalian cell lines for recombinant fusion protein 
polysialylation are described in the following ch 
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CHAPTER 4 
 
Generation of Recombinantly Polysialylated 
MFE23 scFv Fusion Protein from NB2a 
Expression System 
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4.1 Introduction 
 
The initial attempt at making recombinantly polysialylated MFE23 scFv fusion protein from 
mammalian neuroblastoma cell line - NB2a alone was not successfully achieved, and the 
problems reported in Chapter 3 pointed to problems in the intracellular biosynthesis of 
polysialic acid on the specific protein substrate, such as NCAM Ig5-FN1 domain (section 
1.4.2 and section 1.4.3). With the successful detection of essential polysialylation epitopes - 
NeuNAcα(2-3 or 6)Gal disaccharide composed in the N-glycan core structure associated with 
the MFE23-Ig5-FN1 fusion protein, the missing factor to accomplish the elongation of α2-8 
linked sialic acid alongside the existing polysialylation epitopes during the entire mammalian 
PSA biosynthesis pathway was considered to be the lack of essential polysialyltransferases. 
As illustrated in Figure 1.17, PolySTs recognise a specific protein epitope, and specifically 
transfer CMP-Neu5Ac to form α2-8 linked PSA as N-terminal in the Golgi apparatus. 
 
Natural PolySTs specifically polysialylating NCAM during brain development are known as 
ST8SiaII (STX) and ST8SiaIV (PST), which have been studied genetically and successfully 
cloned. In order to introduce these two PolySTs into mammalian cells to compensate for 
missing factors required for mammalian PSA biosynthesis, full length human PST and STX 
cDNAs (including the Golgi transmembrane domain) were kindly provided by Professor 
Karen Colley (University of Illinois, USA), whose group has been investigating the two 
enzymes catalysing NCAM polysialylation (Close and Colley 1998; Close et al. 2003; 
Mendiratta et al. 2005; Mendiratta et al. 2006; Colley 2008). The PolyST genes (for PST and 
STX DNA sequences see Appendix 9 and 10) were inserted into the mammalian expression 
vector pcDNA3.1 V5/His B vector using EcoRV and XbaI restriction sites (Close et al. 2003), 
and the two translated PolySTs have a similar MW of approximately 56 kDa (Close et al. 
2000; Foley et al. 2009). V5 and His6-tags were encoded as the C-terminal peptides fused 
with the PolySTs. The vector also contains ampicillin and neomycin antibiotic-resistant genes 
for bacterial and mammalian selection respectively (Appendix 3).  
 
Several different cell lines have been experimentally transfected with the PolyST cDNAs in 
previous studies of mammalian protein polysialylation research. Endogenous NCAM and 
PolyST negative cell lines including COS-1 (Kudo et al. 1998; Close et al. 2000), CHO 
(Close and Colley 1998), 3T3 (Franceschini et al. 2001) and HeLa (Mahal et al. 2001) have 
been co-transfected with PolyST and NCAM to produce polysialylated NCAM. In particular, 
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the PST and STX cDNAs provided by Professor Colley were previously co-transfected into 
COS-1 cells with truncated NCAM domains revealing the minimal structural domains (Ig5-
FN1) for NCAM polysialylation (Close et al. 2003). In addition, tumour function involving 
PSA has also been studied with a number of neuroblastoma cell lines after transfection of the 
PolySTs (Mahal et al. 2001; Seidenfaden et al. 2003). Positive polysialylation has been shown 
by all of these previous investigations after introducing PolyST DNAs into the cells, which 
supported our theory that PolySTs are the key factors required to achieve recombinant 
polysialylation in mammalian expression systems. As shown in Chapter 3, the NB2a MFE23-
Ig5-FN1 monoclonal cell line stably expressing sialylated fusion protein with a good yield 
was considered an ideal model for investigating the systematic polysialylation of the fusion 
protein after the introduction of the PolyST genes. 
 
In order to accurately analyse the glyco-profile of recombinant proteins, mass spectrometry 
(MS) is currently the most sensitive and accepted tool for analysing and characterizing large 
biomolecules of varying complexity (Lennon and Glish 1997). Already utilized in Chapter 3, 
the matrix assisted laser desorption/ionization (MALDI) technique was chosen as the main 
analytical tool to measure PSA and other associated glycosylation structures on the 
recombinant fusion protein. With the addition of time-of-flight (TOF) MS instrument, 
MALDI TOF-MS operates on the principle that when a temporally and spatially well defined 
group of ions of differing mass/charge (m/z) ratios are subjected to the same applied electric 
field and allowed to drift in a region of constant electric field, they will traverse this region in 
a time which depends upon their m/z ratios (Lennon 1997). In order to improve the mass 
resolution in MALDI TOF-MS, a single-stage or a dual-stage reflectron has been utilized 
(illustrated in Figure 4.1).  
 
In terms of the reflectron mode of MS, the reflectron, located at the end of the flight tube, is 
used to compensate for the difference in flight times of the same m/z ions of slightly different 
kinetic energies by means of an ion reflector (Figure 4.1), and eventually focuses the ion 
packets in space and time at the detector. Based on the concept of reflectron mass spectrum, 
better resolved isotopic multiplets can generate greatly enhanced mass resolution which also 
increases the mass accuracy when determining the ion's mass (Lennon 1997).  
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Figure 4.1. Basic components of a linear (upper) and reflecting (lower) TOF mass spectrometer. Figure 
taken from (Lennon 1997). 
 
 
 
4.2 Aims and Objectives 
 
The aim of this chapter‟s work is to express Golgi targeted full length, human PST and STX 
cDNAs in conjunction with the MFE23-Ig5-FN1 construct (containing the polysialylatable 
NCAM motif) in mammalian cell hosts that have been shown to produce polysialylation 
outcomes in previous studies. Successful recombinant polysialylation was anticipated, which 
would lead to characterization and consequential optimization and establishment of a 
manufacturing system to produce the polysialylated fusion protein. Preliminarily, the 
carbohydrate composition of the fusion proteins and their antigen binding affinities will also 
be investigated in this part of the study. 
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The objectives are: 
■ Introduce the polysialyltransferases into mammalian cells for recombinant MFE23-Ig5-FN1 
fusion protein polysialylation, and verify the catalytic capacity of the PolySTs in mammalian 
cells. 
■ Make stable transfections of a previously selected NB2a MFE23-Ig5-FN1 stable cell line 
with PolyST plasmid DNAs and select polyclonal cell lines for production of polysialylated 
MFE23-Ig5-FN1 fusion protein. 
■ Characterize and purify recombinantly polysialylated MFE23-Ig5-FN1 fusion protein from 
genetically-modified NB2a cells. 
■ Determine the carbohydrate composition and degree of polymerization from the expected 
polysialylated MFE23-Ig5-FN1 fusion protein. 
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4.3 Results 
 
4.3.1 Molecular Cloning of Recombinant Human Polysialyltransferases  
Both STX and PST cDNA vectors were produced in E. Coli XL-1 blue with ampicillin 
selection and purified with a DNA Midi-prep kit (QIAGEN). DNA double digestion at both 
EcoRV and XbaI restriction sites was carried out to verify the presence of the two 
polysialyltransferase genes. 
 
 
 
Figure 4.2. DNA double digestion of PST and STX gene containing pcDNA3.1-V5 vectors. Restriction 
enzymes were used for cutting both EcoRV and XbaI restriction sites, between which the PolyST genes were 
originally inserted into. “-” mark indicates plasmid DNA with without digestion; “+” denotes that DNA double 
digestion. Hyper Ladder I (labelled as M) was used on the both side of the agarose gel for base-pair size 
indication. 
 
 
As clearly depicted in the agarose gel presented in Figure 4.2, double digestion of propagated 
DNA produced bands at 1077 and 1128 bp which correspond to the expected sizes of PST and 
STX respectively (Close et al. 2003) and a band at 5.6 kbp corresponding to the “empty” 
pcDNA3.1-V5 vector. This result verified the propagated PST and STX plasmid DNAs before 
transfection into mammalian cells. The undigested PolyST plasmid DNAs were running 
slightly further than the double digestion linearized plasmid DNA, due to the supercoiled 
compactness of bacterial plasmid DNA.  
 
 
4.3.2 Transient Transfections of Polysialyltransferases 
4.3.2.1 With the Appearance of MFE23-Ig5-FN1 
Transient co-transfection of the two PolySTs was carried out on NB2a cells that stably 
expressing MFE23-Ig5-FN1 fusion protein, which were initially selected (Chapter 3). In 
 bp 
- 176 - 
addition, PST, STX and MFE23-Ig5-FN1 plasmid DNAs were transiently triple-transfected 
into 3T3 and HeLa cell lines, which are known as NCAM-negative cell lines, and have been 
previously used as host cells for truncated or mutated NCAM transfection for polysialylation 
research (Nakayama and Fukuda 1996; Angata et al. 2000; Franceschini et al. 2001). Using 
NCAM-negative cell lines avoids the unnecessary problem of polysialylation and 
contamination from endogenous NCAM proteins.  
 
Sixty-mm cell-culture dishes were coated with 10
6
 cells from each cell line and were 
incubated overnight with 5ml of tissue culture medium (TCM). Using the optimized 
transfection protocol described in section 3.3.2, both 3T3 and HeLa cells were triple-
transfected with 5µg each of PST, STX and MFE23-Ig5-FN1 plasmid DNAs, while the NB2a 
MFE23-Ig5-FN1 stable cell line was only co-transfected with 5µg of PST or STX. After 
overnight incubation with the transfection complex, cells were further cultured for 3 days 
(5ml TCM) before the collection of cell supernatants. Both anti-NCAM (FN1-specific) and 
anti-PSA antibody were subsequently used for immunoblotting after separating the collected 
cell-culture samples on reducing SDS-PAGE. In order to avoid physiochemical breakage of 
the PSA chain during protein sample denaturation, reduced heating temperature and semi-
reducing laemmli sample loading buffer were carefully applied (section 2.1.3 and 2.2.5.2).  
 
Compared to non-transfected cells, results from anti-PSA immunoblotting demonstrated the 
existence of PSA secreted into the cell culture medium after MFE23-Ig5-FN1 co-transfection 
with PST and STX plasmid DNAs in NB2a cells, as well as 3T3 and HeLa cells triple-
transfection with the two PolyST and polysialylatable MFE23-Ig5-FN1 plasmid DNAs 
(Figure 4.3). 
 
As shown in Figure 4.3, smears revealed by anti-PSA immuno-detection ranging 
approximately between 100 kDa to over 250 kDa (indicated by HEMB as anti-PSA positive 
control) depicted a possible polydispersive degree of polymerization caused by PSA, which 
were only seen in samples where PolySTs were introduced. The anti-NCAM (FN1 specific) 
antibody only detected single protein band from both NB2a MFE23-Ig5-FN1 cell secretions 
with or without PolyST co-transfection, and the bands were showed to have the same 
molecular weight which (~70 kDa) means both bands were more likely to be the sialylated 
MFE23-Ig5-FN1 as a constant product secreted by the stable NB2a cell line (Chapter 3). 
Neither 3T3 nor HeLa cells triple-transfected samples showed any detection by anti-FN1  
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Figure 4.3. Immunoblots of cell supernatant collected after transient co- or triple-transfections with 
polysialyltransferases (PST and STX). Anti-NCAM (FN1 specific), and anti-PSA immunoblotting were used 
after separating the samples (35μl each) through SDS-PAGE (8% acrylamide). The MFE23-FN1 construct 
produced previously from NB2a MFE23-FN1 stable cell line (Chapter 3) was used as positive control for 
NCAM FN1 domain detection. Homogenate embryonic mouse brain (HEMB) was used as positive control for 
PSA detection. “+” denotes cells underwent co- (for NB2a MFE23-Ig5-FN1 cells) and triple- (for 3T3 and HeLa) 
transient transfections; “-” marks cells have no additional plasmid DNA transfections. 
 
 
antibody from cell medium collections, which raises the question – whether the 
polysialylation signals detected with anti-PSA immunoblot were induced by fusion protein 
specific polysialylation? 
 
We suspected the results of anti-FN1 detection in Figure 4.3 was caused by the PSA chains 
masking the FN1 domain of the fusion protein, which consequently hindered the anti-FN1 
antibody binding to its target. To test this, glycosidase treatments by Endo-N (removing PSA) 
and PNGase F (removing N-glycan) were applied to the triple-transfected HeLa sample used 
in Figure 4.3.  
 
As shown in Figure 4.4, both glycosidases removed the polysialic acid content that was seen 
in the non-glycosidase-treated cell medium from triple-transfected (TT) HeLa cells. Endo-N 
efficiently hydrolysed the α2,8-linked sialic acid residues leaving no detection at all for anti-
PSA immunoblotting, while PNGase F cleaves the last GlaNAc connecting the whole N-
glycan to the peptide and left a faint smeary signal by anti-PSA detection, suggesting 
insufficient PNGase F treatment to the polysialylated species, which was possibly hindered by 
the PSA masking. Samples were also processed for anti-FN1 immunoblotting, but the bands 
detected were weak (seeFigure 4.4). However, the blurry results of anti-FN1 immunoblotting 
did show a trend of de-polysialylation band shift after the two glycosidase treatments. 
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Figure 4.4. Anti-PSA and anti-FN1 immunoblots of glycosidase treated culture medium collected from 
transient triple-transfected HeLa cells. Glysosidases (Endo-N and PNGase F) were used to remove PSA and 
N-glycan respectively. TT: triple-transfection of the two PolySTs and MFE23-Ig5-FN1 DNAs.   
 
 
 
At the same time, two common mammalian expression cell lines, COS-1 and CHO cells were 
also tested by transient triple-transfection with the two PolyST and MFE23-Ig5-FN1 plasmid 
DNAs, following the protocols described above for 3T3 and HeLa cells, in order to confirm 
the reliability of the PolyST for fusion protein polysialylation. The soluble cell products from 
the culture medium were collected 3-days post-transfection, and detected by anti-FN1 and 
anti-PSA Western blot after separation via reducing SDS-PAGE (Figure 4.5). 
 
 
 
Figure 4.5. Immunoblots of cell supernatant collected from transiently triple-transfected COS-1 and CHO 
cells. Both anti-FN1 and anti-PSA immunoblots were processed to COS-1 and CHO samples with (+) or without 
(-) transient triple-transfections with the two PolyST and MFE23-Ig5-FN1 DNAs. Samples (35μl each) were 
separated through 8% SDS-PAGE. Red arrows indicate two protein bands visualized after anti-NCAM (FN1 
specific) immuno-detection.  
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Corresponding to the findings shown in Figure 4.3, positive polysialylation was also obtained 
from COS-1 and CHO cells after introduction of the PolySTs and MFE23-Ig5-FN1 genes into 
the cells (Figure 4.5). Both COS-1 and CHO smear ranges (~100 to >250 kDa) were identical 
to the anti-PSA findings from the previous three cell lines, and more promisingly the anti-
FN1 detection revealed a major band at ~70 kDa and a weaker band signal with higher MW 
(~200 kDa) from the triple-transfected COS-1 cells. The 70 kDa band has a strong correlation 
with the sialylated MFE23-Ig5-FN1, while the ~200 kDa band could be considered to be the 
polysialylated MFE23-Ig5-FN1 fusion protein, due to the immuno-detection specificity of the 
FN1 domain. However, no bands were obtained in CHO cells upon anti-FN1 immunoblotting. 
No bands were seen with all untransfected cells by both immunoblots as expected. 
 
Additional immunoblotting against protein-tags (His6 or c-Myc) genetically fused with the 
MFE23-Ig5-FN1 protein were also processed, and either the same results as anti-FN1 
immunoblotting were obtained (results not shown). 
 
 
4.3.2.2 Cells without MFE23-Ig5-FN1 Fusion Protein Expression 
The immunoblot results from the transient co- or triple-transfections of the two PolySTs and 
MFE23-Ig5-FN1 plasmid DNAs into several different cell types indicated the existence of 
polysialic acid in the cell culture which suggested the correct polysialylation process with the 
additional incorporation of PolyST genes compared to previous findings in Chapter 3. 
However, this does not conclusively prove that the MFE23-Ig5-FN1 fusion protein was 
produced and recognized as the protein substrate for polysialylation under the catalysis of the 
PolySTs. In the case of triple-transfection of 3T3, HeLa, and CHO cells, polysialylation was 
detected despite any expression of the MFE23 fusion protein. Even in the more promising 
cases of the NB2a MFE23-Ig5-FN1 stable cell and COS-1 cells which showed positive anti-
FN1 detection from the collected cell culture, no strong immunoblotting results correlated 
with the smear found in the corresponding anti-PSA immuno-detections. Further proof was 
needed to determine that the MFE23-Ig5-FN1 fusion protein was undergoing specific 
polysialylation. One experiment to test the protein substrate specificity of the two PolySTs 
was to examine the cell secretions after PolyST transfection into cells not expressing NCAM 
or the Ig5-FN1 domains (responsible for polysialylation). According to the findings above, 
COS-1 cells, having the most potential to study the potencies of PolySTs in MFE23-Ig5-FN1 
fusion protein polysialylation, were chosen for the PolyST alone transfection tests.  
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As shown in Figure 4.6, the result interestingly suggests that the PolyST-catalysed 
polysialylation was not NCAM Ig5-FN1 domain exclusive, as the culture medium from COS-
1 cells doubly or individually transfected with PST and STX plasmid DNAs showed strongly 
positive anti-PSA immuno-detection, which also showed as a smear with almost identical 
MW ranging (~100 to more than 250 kDa) as the MFE23-Ig5-FN1 incorporated 
polysialylation immuno-detection (Figure 4.4). 
 
 
  
 
Figure 4.6. Anti-PSA immunoblots of transient transfections of polysialyltranferases to COS-1 cells. 
Culturing medium collected from co-transfection of both PST and STX, and individual transfections of PST and 
STX to COS-1 cells are detected after separation through SDS-PAGE (8% acrylamide). Wild-type (WT) 
untransfected COS-1 cell culturing medium and HEMB were used as negative and positive control respectively. 
 
 
One possible explanation for the smears in Figure 4.6 is that it is caused by the PolySTs 
themselves (by cell lysis or alternative splicing), as both PST and STX have the capacity to 
autopolysialylate (Close and Colley 1998). However, both anti-FN1 and anti-V5 showed no 
detection from the same COS-1 samples (results not shown), suggesting the polysialylation 
seen in Figure 4.4 was very likely to take place through neither NCAM polysialylatable 
domains nor autopolysialylating PolySTs. In addition, individual catalytic activity of both 
PST and STX was also demonstrated after individual transfections.  
 
 
4.3.2.3 Immunoprecipitation (IP) of Culturing Medium from PolyST Transfectants 
Immunoprecipitating the MFE23-Ig5-FN1 fusion protein through the genetically fused 
protein-tags was a direct and feasible way to investigate the production level of the fusion 
protein after transient triple-transfections of various cell lines, and to check the glycosylation 
pattern in the presence of the PolySTs. TALON
TM
 anti-His6 cobalt resin was used for 
precipitating MFE23-Ig5-FN1 fusion protein from the cell culture medium after mammalian 
Anti-PSA 
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cell transient transfections, which was consequently analysed by SDS-PAGE and Western 
blottings (Figure 4.7).  
 
As shown in Figure 4.3(a), immunodetections of triply transfected COS-1 cell culture 
mediated by three different antibodies were inconclusive. Both anti-His6 and anti-Myc 
antibodies did not detect any bands before the His6-tag specific IP, and the IP flow-through, 
which also reflects similar findings by anti-FN1 antibody (see in Figure 4.4), while the ¼ of  
IP concentrated His6-tag containing protein was detected by the two antibodies with major 
bands slightly below 70 kDa and weak signals visualized from high MW range (> 130 kDa)  
 
 
 
 
 
 
 
 
Figure 4.7. Immunoblots of TALONTM anti-His6 cobalt resin immunoprecipitated culturing medium 
collected after different transient transfections. (a) The cell medium (12ml) from triple-transfected COS-1 
cells was immunoprecipitated and specifically detected by anti-His6, anti-Myc and anti-PSA antibodies. (b) Anti-
PSA immunoblotting for immunoprecipitated cell culture medium from COS-1 cells transfected with PST and 
STX jointly or individually. Wide type COS-1 cell culture medium and HEMB were used as negative and 
positive control respectively. For all IP samples, only one quarter of each immunoprecipitated samples were 
loaded onto the SDS-PAGE.  
(a) COS-1 cell with triple-transfections of PST, STX and MFE23-Ig5-FN1 cDNAs 
(b) COS-1 cell transfected with PST and/or STX cDNAs 
 PST and STX PST STX No transfection 
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by anti-Myc detection. However, the other immunoblot using anti-PSA antibody illustrated 
positive polysialylation detection of all three samples with MW ranging approximately 
between 100 to > 250 kDa, indicating not only the protein pulled down by IP was 
polysialylated, but also other substances in the cell supernatant. On the other hand, 
immunoprecipitated samples from COS-1 cells transfected with the PolySTs (Figure 4.7b) 
were specifically detected by anti-PSA antibody before IP (same results as Figure 4.6), but no 
detection by the antibody to the His6-tag specifically immunoprecipitated culturing media, 
despite the joint transfection of the two PolySTs or the individual incorporations.   
 
Immunoprecipitation of MFE23-Ig5-FN1 from NB2a PolyST Cells 
The His6-tag specific IP was also carried out on the NB2a MFE23-Ig5-FN1 cells transiently 
co-transfected with the two PolySTs or transfected individually. Results illustrated in Figure 
4.8 strongly support MFE23-Ig5-FN1 fusion protein polysialylation. Sample pulled down by 
His6-tag specific IP indicated several features that are uniquely and genetically possessed by 
the MFE23-Ig5-FN1 fusion protein. Such features including protein-tags (His6- and Myc-tags) 
and domains (FN1) which were specifically detected by the corresponding antibodies 
producing similar smear-like immunoblotting results ranging approximately from 70 to 250 
kDa. The anti-PSA antibody detection also intensively depicted a smear but ranging from ~ 
100 to 250 kDa. The shortened smear range of anti-PSA immuno-detection indicated that 
protein detected between 70 to 100 kDa by othe ther three antibodies was the MFE23-Ig5-
FN1 fusion protein, but not the polysialylated format. Potential protein degradations was also 
suggested by two bands with smaller MWs (~60 and 50 kDa respectively) from the  
 
 
Figure 4.8. Immunoblots of immunoprecipitated culturing media from NB2a MFE23-Ig5-FN1 cell line 
transiently co-transfected with PST and STX. Four antibodies, including anti-His6, anti-Myc, anti-FN1, and 
anti-PSA antibodies were used to identify the corresponding properties of samples after running through 7.5% 
SDS-PAGE. Lane 1: PolyST co-transfected before IP (35µl loaded); Lane 2: IP flow-through (35µl loaded); 
Lane 3: immunoprecipitated samples (1/4 of total IP). 
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immunoblots, which were also found in previously purified sialylated MFE23-Ig5-FN1 fusion 
protein (Chapter 3). A weak single band (~ 70 kDa) was found in the pre-IP lane from both 
protein-tag and domain specific immunoblots, while no bands were detected by these 
antibodies from the IP flow-through samples. However, smear-like detection was 
demonstrated in both pre-IP and IP flow-through samples from the anti-PSA blot, and both 
smears showed a similar high MW, but less intensively visualized than the 
immunoprecipitated sample. 
 
Additional IP experiments were also carried out with NB2a MFE23-Ig5-FN1 and original un-
modified NB2a culture medium with or without single PolyST transfections (Figure 4.9). 
Further confirmation of MFE23-Ig5-FN1 fusion protein polysialylation is shown in Figure 4.9, 
as all PolyST (single or co-transfected) samples of NB2a MFE23-Ig5-FN1 cells confirmed 
similar findings to those illustrated in Figure 4.8. Other than the ~70 kDa sialylated MFE23-
Ig5-FN1 protein band and its degraded smaller MW bands, no smear (100 – 250 kDa) 
detection was detected with either anti-Myc or anti-FN1 antibodies to the non-PolyST  
 
 
 
 
 
 
 
 
 
 
NB2a MFE23-Ig5-
FN1 
Original NB2a NB2a MFE23-Ig5-
FN1 
NB2a MFE23-Ig5-
FN1 
Original NB2a 
Original NB2a 
Figure 4.9. Immunoblots of immunoprecipitated 
culturing medium from NB2a MFE23-Ig5-FN1 
and original NB2a cells with/without PolyST 
transfections. Anti-Myc, anti-FN1 and anti-PSA 
antibodies were used for specific Western blots. 
One quarter of the total IP samples were 
investigated. Samples from left to right for each cell 
line were non-PolyST transfected (lane 1), PST 
transfected (lane 2), STX transfected (lane 3) and 
PST + STX co-transfected (lane 4) from NB2a 
MFE23-Ig5-FN1 cells and original NB2a cells. 
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transfected MFE23-Ig5-FN1 expressing cells, which also had no anti-PSA detection. None of 
the immunoblots revealed any bands with the original un-modified NB2a cells, even with 
additional PolyST incorporations. 
 
Immunoprecipitation of Other MFE23 Fusion Proteins from NB2a PolyST Cells 
The capacity of PolyST to polysialylate other MFE23 fusion protein expressing NB2a cell 
lines was also tested by transiently transfecting PolyST DNAs into NB2a MFE23-FN1 and 
LS-MFE23 monoclonal cell lines selected previously (Chapter 3). In order to detect the 
glycosylation status of the MFE23-FN1 and MFE23 scFv proteins with the expression of 
PolyST intracellularly, the fusion proteins after transfections were specifically 
immunoprecipitated and characterized by Western blots (Figure 4.10). 
 
Produced from MFE23-FN1 and LS-MFE23 expressing NB2a cell lines, the cell culture 
samples under the co-expression of PolyST were concentrated by TALON
TM
 anti- His6 cobalt 
resin and demonstrated to have the same MW (~55 kDa for MFE23-FN1 and ~35 kDa for 
MFE23 scFv) by anti-Myc immunoblotting, as compared to the immunoprecipitated culture 
medium from two cell lines un-transfected with the PolyST (Figure 4.10). In addition, anti-
PSA antibodies did not detect any signal in the same samples used in Figure 4.10. 
 
 
 
Figure 4.10. Anti-Myc immunoblot of immunoprecipitated (His6-tag specific) culturing medium collected 
from NB2a MFE23-FN1 and LS-MFE23 cell lines with/without transient PolyST transfections. Single and 
co-transfections of PST and STX DNAs were introduced to the two cell lines. “-” denotes cells without 
transfection with the PolyST. Previously purified MFE23-FN1 (Chapter 3) was used as positive control (+) for 
anti-Myc antibody detection.  
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4.3.3 Stable Transfection of PolyST in NB2a MFE23-Ig5-FN1 Cell Line 
Following the protocols described in section 2.2.3.7, NB2a MFE23-Ig5-FN1 cells were stably 
co-transfected with PST and STX, and the polyclonal cell line was selected by the neomycin 
resistance gene co-encoded within the PolyST cDNAs. This polyclonal cell line was then used 
to largely express recombinantly polysialylated MFE23-Ig5-FN1 fusion protein on a large 
scale and the protein was subsequently purified for further functional and structural 
investigations. 
 
Based on the information obtained from the immunoprecipitation experiments (Figure 4.8 and 
4.9), the MFE23-Ig5-FN1 fusion protein was specifically purified by the His6-tag binding 
TALON
TM
 resins. As shown in Figure 4.11, immunoblots of the IMAC eluate using anti-FN1, 
anti-Myc and anti-PSA antibodies confirmed the presence of the fusion protein as well as the 
associated polysialylation, which were in correspondence with previous results with 
transiently transfected cells (Figure 4.8 and 4.9). Thorough washing steps using 1xTBS were  
 
 
 
 
Figure 4.11. IMAC purification of MFE23-Ig5-FN1 fusion protein from NB2a MFE23-Ig5-FN1/PolyST 
polyclonal cell expression. TALON
TM
 (anti-His6) cobalt metal affinity resin was used in the purification. 
Coomassie protein staining, and three different immunoblottings were applied to identify the IMAC purified 
protein. Number denotations: 1. column flow-through; 2. first 1xTBS wash of the resin in purification; 3. second 
wash of the resin; 4. purification eluate. 
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applied in the IMAC until no protein remained in the eluate as measured by Coomassie blue 
staining. Fusion protein specific characteristics were weakly shown in anti-FN1 and anti-Myc 
immunoblotting (bands ~70 kDa) from the sample flow-through, which were used to repeat 
the IMAC purifications for more efficient fusion protein collection. These results demonstrate 
that the selected polyclonal cell line is capable of producing polysialylated MFE23-Ig5-FN1 
stably. 
 
4.3.4 Ion Exchange Purification of Recombinantly Polysialylated Proteins  
4.3.4.1 Manual Optimization Tests 
As already suggested from the IP results (Figure 4.8 and 4.9) and the IMAC purification 
(Figure 4.11), proteins eluted from the TALON
TM
 cobalt resin were a mixture of differentially 
glycosylated MFE23-Ig5-FN1 fusion proteins, and even the polysialylated forms showed a 
range of DP. In order to further separate the polysialylated fusion proteins from the non-
polysialylated isoforms, and to refine the despersion of the polysialylated protein, anion 
exchange chromatography was used for further purification based on the negative charge of 
the sialic acid residues within the fusion protein‟s carbohydrate composition. AcroSepTM 
Chromatography Column (1ml bed volume) with the strong anion exchanger Q Ceramic 
HyperD
®
 F was selected for this purification purpose. As described in section 2.2.4.4, the 
anion exchanger resin was firstly activated and equilibrated with the anion exchange running 
buffer, and manually tested prior to utilisation with automatic chromatography systems. 
Protein collected from the IMAC purification was dialysed into the anion exchange running 
buffer before being manually injected into the column at a flow rate of 1ml/min. After 
washing the column with 10ml running buffer, protein elution was optimised using 5 different 
NaCl concentrations (50mM, 100mM, 200mM, 400mM, and 1M), which were injected (10ml 
each) from low to high salt concentration. Eluates were collected every 1ml. 
 
In order to determine the elution conditions required to separate fusion protein with different 
polysialylation levels, five NaCl concentrations were investigated for anion exchange protein 
elution. As shown in Figure 4.12(a), the anti-Myc antibody was used to identify all 
glycosylation types of MFE23-Ig5-FN1 fusion protein produced by PolyST stably transfected 
fusion protein expressing NB2a polyclonal cells. Initially, 50mM NaCl buffer was unable to 
elute any negatively charged proteins from the anion exchange column. The fusion protein 
was eluted with the second NaCl concentration, as all 10 fractions eluted by 100mM NaCl 
buffer were levelled up and strongly revealed a band at approximately 70 kDa in anti-Myc 
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immunoblots. However, the anti-PSA antibody did not detected a band in the 100mM NaCl 
elutes (results not shown). The polysialylated fusion proteins began to be eluted with the 
200mM NaCl buffer, as short smears (around 70 to 100 kDa) were predominately detected by 
anti-Myc antibody from the first five 200mM NaCl elution fractions, and corresponding anti-
PSA detection of these fractions also showed positive signals, which were weakly indicated  
and restricted to bands with MW around 90 or 100 kDa, rather than smears (Figure 4.12b). 
Fusion proteins with higher polysialylation levels were found to be eluted at 400mM NaCl 
 
 
 
 
 
 
 
Figure 4.12. Immunoblots of manually eluted MFE23-Ig5-FN1 fusion protein from anion exchange 
column. Both anti-Myc and anti-PSA antibodies were utilized for specific immunoblots. All five different 
concentrations of NaCl buffers were tested for eluted fusion proteins, and every 1ml fraction of each elution 
buffer was collected and applied to the Western blots. From left to right, the sample sequence of each set of 
NaCl concentration followed the elution order, from fraction 1 to 10. Samples (40μl each) were loaded into SDS-
PAGE (10% acrylamide) initially. 
(a) Anti-Myc 
(b) Anti-PSA 
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concentrations, as both anti-Myc and anti-PSA immuno-detected smears were revealed up to 
250 kDa. The final 1M NaCl elution did not have any fusion protein immuno-detection at all 
(results not shown).Immunoblots also revealed that smears detected by the anti-Myc antibody 
in 200mM and 400mM elution fractions began from ~70 kDa which did not match the MW 
ranges of the forms detected with anti-PSA antibodies (starting from ~ 90 kDa or higher MW). 
 
4.3.4.2 Programmed Anion Exchange 
The anion exchange column was connected to a BIO-RAD BioLogic DuoFlow system which 
was subsequently used to achieve an automated ion exchange purification protocol for 
polysialylated fusion protein. With the understanding gained from the manual optimisation 
tests of the anion exchange column, different purification programmes were designed, and 
analysed to establish an ideal automatic purification protocol for separating proteins with 
different polysialylation level. 
 
Elution under Increasing NaCl Concentration Gradient   
Fusion protein elution from the anion exchange column was closely correlated to the NaCl 
concentration. In order to further investigate this correlation, a steadily increasing NaCl 
concentration gradient was programmed with 10mM increase per 1ml eluation beffer with the 
concentration ranging from 0 to 1M.  
 
The chromatography profile is showed in Figure 4.13(a) with the elution gradient initiated at 
fraction number 50. An elution peak was clearly seen in the chromatogram encompassing 
fractions 61 to 80, which corresponded to NaCl concentrations of 100 - 300mM. The peak of 
the elution was found at fraction 63 or 64 eluted by 130mM NaCl buffer. Immunoblotting 
analysis of these fractions was performed with anti-Myc antibody (shown in Figure 4.13b) to 
detect, and anti-PSA was utilised to identify the polysialylated fusion proteins. The anti-Myc 
immunoblotting suggested that all investigated fractions shared very similar detection as a 
protein smear with MW between approximately 70 to 250 kDa was detected in all fraction 
samples. This implied that different fusion protein glyco-forms were not distinctly separated 
by the gradually-increasing NaCl concentration. Degraded fusion protein fragments with 
Myc-tag were also found at lower MWs. Anti-PSA immmuno-detection showed a weakly 
polysialylated protein smear from fraction 61 to 70, and much stronger smear signals from 
fraction 71 to 80. Despite the intensity of the anti-PSA immunoblotting, polysialylated protein 
smears implied a trend that started with a wider MW range (~ 90 to 250 kDa) from fraction 62, 
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leading to nearly no detection (fraction 69), which then gradually widened out again and 
finally returned to the MW range covering between 90 to 250 kDa at fraction 79 and 80 (with 
probably more eluates up to fraction 90).  
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Automatic anion exchange purification with a steadily increasing NaCl concentration 
gradient. (a) Chromatography profile of protein purification process. UV absorbance at 280nm was used for 
monitoring the protein elution, alongside NaCl concentration gradient curve; (b) Western blotting analysis of 
peak fractions. Both anti-Myc and anti-PSA antibodies were used for specific protein and carbohydrate 
characteristic detections. Peak fractions from eluate 61 to 80 were analysed, and 40μl of each sample was 
applied on SDS-PAGE (8% acrylamide) directly after the ion exchange purification.  
 
(a) 
Anti-Myc 
Anti-PSA 
(b) 
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Step-wise NaCl Elution 
Based on the unsuccessful separation scheme under the gradually increasing NaCl 
concentration, step-wise NaCl concentrations were then applied automatically according to 
the same protocol used in the manual anion exchange purification with approximately four 
times more materials injected through the column. Five stepped phases (10ml/phase) were 
tested, including elution buffers with NaCl concentrations of 50mM, 100mM, 200mM, 
400mM, and 1M. Peaks of protein eluates under each NaCl concentrations were clearly 
demonstrated by the chromatogram shown in Figure 4.14. 
 
 
 
Figure 4.14. Chromatography of automatic anion exchange purification with different five phases of NaCl 
concentration for protein elution. Plots of protein absorbance at UV wavelength 280nm and 214nm Quad-Tec 
laser, alongside NaCl concentration changes respectively against eluate fraction number were depicted with 
different colours. 
 
 
After sample injections into the purification system, the elution procedure commenced from 
fraction 60 with the 50mM NaCl phase, although no absorbance peak was detected with this 
concentration. Subsequently, the remaining four NaCl concentrations were applied, and 
absorbance peaks were detected with each concentration. Generally, the higher the eluting salt 
concentration, the higher peak absorbance values were obtained. Although the 214nm 
wavelength Quad-tec detector depicted more sensitive signal than the UV for absorbance 
detections, the same chromatographic trend was shown. Moreover, the 400mM NaCl elution 
had a sharper peak with its maximum at fraction 92, while the other two peaks seen in 
100mM and 200mM elutions were relatively broader. In order to characterize the purification 
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product, eluates from each NaCl concentration were separated by SDS-PAGE and analysed 
by anti-Myc and anti-PSA immunoblots (Figure 4.15). 
 
 
 
 
 
 
 
Figure 4.15. Immunoblotting of peak fractions eluted from each NaCl concentration phase. Both anti-His6 
and anti-PSA antibodies were used and 40μl of each sample was applied on SDS-PAGE (8% acrylamide) 
directly after the ion exchange purification. 
 
 
The two Western blots shown in Figure 4.15 indicate some similarities to the manual anion 
exchange purification also using the same five NaCl concentrations for elution purpose 
(Figure 4.12). For fusion protein detection, anti-Myc antibody outlined three different smear 
ranges of protein eluted by 100mM, 200mM and 400mM salt concentrations, which all began 
at a MW of ~70 kDa. The peak fractions of 1M NaCl elutions were also detected by anti-Myc 
Anti-Myc 
Anti-PSA 
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antibodies but only found at high MW ranges. Anti-PSA immunoblotting showed no 
detection of all fractions collected by 100mM salt elution, and limited smear range (~90 to 
110 kDa) for 200mM NaCl eluates. Most of the fractions from 400mM and 1M NaCl elutions 
were intensively detected by anti-PSA antibody, which predominantly covered a MW range 
between 90 to 250 kDa, although the very last two fractions of the 400mM NaCl elution and 
very beginning two 1M NaCl eluates did not contain a robust anti-PSA signal. More precisely, 
the 1M NaCl fractions seemed to have anti-PSA detection with a larger MW range, however 
most of these fractions were not correspondingly detected by the anti-Myc antibodies. No 
bands were revealed with the 50mM NaCl elutions by either immunoblots. 
 
Optimized Automatic Anion Exchange Purification Programme 
With all the findings from the data above, an optimized anion exchange purification of the 
polysialylated fusion protein was programmed for the automatic system. In general, the 
phase-wise elution scheme with step-wise increase in NaCl concentrations was modified with 
prolonged additional inter-phase washing steps. 
 
Compared to the chromatogram shown in Figure 4.14, the final optimized protocol for the 
anion exchange purification employed two additional washing steps with 100mM and 200mM 
NaCl elution buffers after the adjacent sample elution phases, which were indicated in the 
absorbance chromatography in Figure 4.16(a). Moreover, the 400mM NaCl elution phase was 
substituted by the highest salt molarity (1M) to directly remove all highly negatively charged 
molecules. For each 100mM, 200mM and 1M NaCl elution phase, extra 10ml collections 
were  made, and the washing steps in between were added with the intention of removing 
weakly negatively charged molecules from the highly polysialylated fusion protein. 
 
Maximal fractions of each chromatographic peak under 100mM, 200mM and 1M NaCl 
eluting concentrations were taken for anti-Myc and anti-PSA immunoblotting analysis. 
Results are shown in Figure 4.16(b), which particularly shows the smears detected by anti-
Myc antibody were not initiated from ~70 kDa for all eluates anymore (outlined by a red 
dotted line), leaving only the 100mM NaCl eluates (fraction 63 & 64) with a strong anti-Myc 
detection around 70 kDa, whereas the 200mM NaCl peak eluates revealed bands between a 
MW of ~80 to 110 kDa, and the 1M NaCl peak fractions showed smears started around 100 
kDa and migrated even further towards the higher MW. The anti-PSA blot showed roughly 
the same results as the anti-Myc detection with much stronger sensitivities, while no bands 
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were detected with the 100mM NaCl eluates. Overall, the optimized anion exchange 
purification method successfully separated the polydispersively polysialylated MFE23-Ig5-
FN1 fusion proteins into three major isoforms which were eluted under 100mM, 200mM and 
1M NaCl buffers (Figure 4.16a), and based on the indications from Figure 4.16(b), they were 
identified as sialylated, weakly polysialylated and highly polysialylated glycol-forms of the 
fusion protein. 
 
 
 
 
 
 
 
Figure 4.16. Optimized automatic anion exchange purification process for separating different glyco-
forms of polysialylated MFE23-Ig5-FN1 fusion protein. (a) Chromatography. Two additional washing steps 
were applied by using 100mM and 200mM NaCl buffers (200ml and 300ml respectively) after the corresponding 
elution phases. (b) Immunoblotting of peak fractions from 100mM, 200mM and 1M NaCl buffer elutions. Both 
anti-Myc and anti-PSA antibodies were used for immuno-detections. The red dotted line outlines the MW at 70 
kDa cross both blots. 
 
 
 
Washing with 
300ml of 200mM 
NaCl elution buffer 
Washing with 
200ml of 100mM 
NaCl elution buffer 
(a) 
Anti-Myc Anti-PSA 
Fraction     63      64       92      93     120    121   122  63     64      92      93     120     121    122 
(b) 
- 194 - 
4.3.5 Glycosidase Treatment of Anion Exchange Purified Fusion Protein 
Further confirmation of carbohydrate compositions from each MFE23-Ig5-FN1 fusion 
isoform were carried out by specific glycosidase treatments and protein band-shift observation. 
As mentioned in Chapter 3, treatments by glycosidases including Endo- and Exo-
Neuraminidases and PNGase F were investigated followed by other specific analysis. 
 
As shown in Figure 4.17, three glyco-forms of MFE23-Ig5-FN1 were clearly displayed by  
 
 
 
 
 
 
Figure 4.17. Glycosidase treatment of MFE23-Ig5-FN1 fusion protein after anion exchange purification. 
Three glyco-forms (sialylated, weakly, and highly polysialylated) of the fusion protein were treated by specific 
glycosidases including Endo-N, Exo-N, and PNGase F. The results were revealed by Coomassie staining, and 
immunoblots mediated by anti-FN1 and anti-PSA antibodies. S, W and H are abbreviations of sialylated, weakly 
and highly polysialylated MFE23-Ig5-FN1 fusion proteins. Samples were separated by SDS-PAGE (7% 
acrylamide)  
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Coomassie staining with the majority of sialylated isoform at a MW of 70 kDa, weakly 
polysialylated isoform at ~80 to 110 kDa, and highly polysialylated isoform at approximately 
110 to 200 kDa. Similar results were also obtained with the anti-FN1 immunoblot. As 
indicated by previous glycosidase treatment (section 3.3.6), no significant protein band-shift 
was observed with the sialylated fusion protein after the glycosidase treatments. For the two 
polysialylated fusions some degree of band-shifts towards the lower MW was detected after 
Endo-N, and combinational Endo-N plus Exo-N treatment in Coomassie stained gels, which 
were more clearly revealed by the anti-FN1 antibody detection. The most detectable band-
shift of the two polysialylated isoforms was the Endo-N plus PNGase F treatment that 
sequentially removes PSA and N-glycans from the fusion protein and approximate 40 and 160 
kDa band-shifts respectively could be estimated for the weakly and highly polysialylated 
fusion isoforms.  
 
More importantly, the total N-glycan (PSA inclusive) removed fusion isoforms aligned at the 
same MW of ~65 kDa. The anti-PSA immunoblot depicted the expected results with no PSA 
detection from sialylated and Endo-N treated polysialylated isoforms. The weakly 
polysialylated MFE23-Ig5-FN1 was detected with confined MW, while the highly 
polysialylated form showed a wider MW range covering between 100 to 250 kDa. 
 
 
4.3.6 Initial PSA Speculation by Mass Spectrometry  
With the confirmation of polysialylation and successful separation of MFE23-Ig5-FN1 from 
the non-polysialylated glyco-forms, we were now in a position to carry out mass spectrometry 
analysis (Biopolymer Mass Spectrometry Group, Imperial College London) to understand the 
fusion protein carbohydrate composition and polysialylation profile. The highly polysialylated 
MFE23-Ig5-FN1 fusion protein samples were used for the MALDI-MS analysis according to 
the procedure outlined in Scheme I below, and the corresponding methodological preparations 
are described in section 2.2.6.  
 
Based on the understanding of NCAM polysialylation (section 1.4.2), and the previous MS 
investigation of the sialylated fusion protein, the initial attempt to analyse the polysialylation 
profile from the MFE23-Ig5-FN1 fusion protein was processed by PNGase F removal of the 
entire N-glycans from the trypsin digested fusion protein glycopeptides (Scheme I-a). 
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Indicated by the previous experiments (Powell and Harvey 1996), standard permethylation 
using ICH3 in DMSO (section 2.2.6.7) was carried out to block the carboxyl groups in order  
 
 
 
 
Scheme I. Preparation procedures for MALDI-MS and MS/MS analysis of NB2a cell highly polysialylated 
MFE23-Ig5-FN1 fusion protein. Three MALDI-MS preparation routes were experimented, which are indicated 
as (a), (b) and (c). C18SP: Sep-pak
®
 C18 cartridge, a procedure separating oligosaccharides with 
peptides/glycopeptides. ICH3: methyl iodide, which blocks the carboxyl groups in the oligosaccharides by 
methyl esterifying reaction, allowing sialic acid stabilization for MALDI-MS analysis. 
 
 
to get stabilized volatile sialic acid derivatives from the N-linked polysaccharides. However, 
this method failed to initiate either positive or negative ion MALDI-MS, suggesting the 
traditional permethylation method was not able to stabilize the highly negatively charged PSA, 
which led to the potential spectral signal split due to the formation of both positive and, to a 
greater extent, negative ions (Powell and Harvey 1996). Subsequently, the polysialylated N-
glycan was hydrolysed with Endo-N, and the mixture of oligosialic acid fragments and N-
glycan core compositions were permethylated for MALDI-MS analysis (Figure 4.18). 
 
Analysis by MALDI TOF-MS revealed the general carbohydrate composition of the 
polysialylated MFE23-Ig5-FN1 fusion protein which is illustrated in Figure 4.18. As 
indicated in Scheme I-a, the Endo-N hydrolysis of the N-terminal PSA from the PNGase F 
cleaved N-glycans enabled the permethylation process to create volatile derivatives in both 
oligosialic acid and N-glycan cores. Signals of short oligosialic acid fragments were more 
sensitively demonstrated than the relatively longer oligosialic acid fragment, and signals for 
 (a) 
(b) 
 (c) 
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fragments containing more than 12 NANA residues were considered as insignificant. Both 
complex and oligomannosidic N-glycan core structures were deduced from the MALDI-MS 
analysis with potential polysialylation along one antenna on their N-termini. Di-, tri- and 
tetra-sialylated glyco-structures also possibly occurred based on the peaks from this MALDI-
MS spectrum with potentially multiple sialic acid elongations of each antenna. 
 
 
 
Figure 4.18. MALDI (reflectron positive) MS analysis of Endo-N hydrolysed N-glycan from highly 
polysialylated MFE23-Ig5-FN1 fusion protein. Peaks on the spectrum were predominately produced by 
[M+Na]
+
 species. Based on the biosynthesis of mammalian glycosylation, possible oligosaccharide structures 
were indicated according to the mass to charge ratio (m/z). Information of each monosaccharide (symbol 
denotation, structure, permethylated monoisotopic mass) was provided in Appendix 11. 
 
 
In an alternative process, the polysialylated fusion protein glycopeptide was repeatedly treated 
with Endo-N initially for complete PSA hydrolysis and removal, and subsequently samples of 
both the PSA portion (Scheme I-b) and the de-polysialylated N-glycan portion (Scheme I-c) 
were prepared for MALDI-MS analysis under the standard permethylation process.  
 
As shown in Figure 4.19, several fragmented sialic acid oligosaccharides containing different 
NANA residues aligned on the MALDI-MS spectra resulted from the PSA portion after 
Endo-N hydrolysis of the polysialylated glycopeptide from MFE23-Ig5-FN1 fusion protein. 
Shorter sialic acid fragments (≤7 NANA residues) possibly existed compared to the sialic acid 
oligosaccharides produced by the regular Endo-N treatment found in Figure 4.18. In Figure 
4.19(b), further MALDI-MS/MS analysis by re-ionization of the longest fragment (2597.2 Da) 
causing cleavages of glycosidic linkages confirmed that Neu5Ac was the only sugar 
component within this oligosaccharide fragment with unique α2-8 ketosidic linkage to each 
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other. This was based on the average mass of permethylated Neu5Ac molecule, which has 
five –OH groups methylated when the monosaccharide is involved in the chain structure, 
while the monosaccharide at one end of the oligosaccharide fragment can be additionally 
methylated with one extra –OH group and one oxygen molecule can be contained or not 
depending on the breakage of the α2-8 ketosidic linkage (showed in Figure 4.19b). As shown 
in Appendix 11, the MW of permethylated Neu5Ac is 361 Da. For one single ionized Neu5Ac 
molecule in the MALDI TOF-MS analyses, one dominant isoform contains an extra 
methylated –OH group, one oxygen element and was produced as [M+Na]+ species, which 
gives an overall MW of 415 Da (detected as 416.3 Da in Figure 4.19b). The other single 
Neu5Ac isoform released by MALDI-MS/MS without the oxygen molecule from the α2-8 
 
 
 
 
 
 
Figure 4.19. MALDI (reflectron positive) MS analysis of Endo-N digested PSA removed from highly 
polysialylated MFE23-Ig5-FN1 fusion protein. (a) MS spectrum of the Endo-N hydrolysed oligosialic acid 
fragments. (b) Oligosaccharide with MW of 2597.2 Da was further ionized and analysed by MALDI- MS/MS. 
Oligosialic acid fragment structures were speculated based on the peaks produced by [M+ Na]
+
 species. Two 
isotypes of each fragments were detected, which were differentiated by one oxygen element content due to the 
breakage of α2-8 ketosidic linkage of Neu5Ac schematically illustrated in the inset diagram. 
(a) 
(b) 
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ketosidic link breakage did not show a significant signal, however other fragmented sialic 
acid oligosaccharides appeared as two isoforms with the difference of one oxygen element 
content. 
 
The de-polysialylated N-glycan properties of the fusion protein was analysed simultaneously 
by MALDI-MS, and all possible N-glycan core structures are presented based on the m/z 
signals (Figure 4.20 and 4.21). Further analysis of the N-glycan structures of the 
polysialylated MFE23-Ig5-FN1 fusion protein after complete removal of the PSA content 
(Figure 4.20 and 4.21) also revealed the same core structure compositions that was found in 
Figure 4.18. Potential cleavages were observed to occur at each glycosidic linkage of the N-
glycan alongside its MALDI-MS spectrum, and additional non-primate mammalian 
glycosylation featuring the glycosidic linkage, Gal(α1-3)Gal was also determined according 
to the spectral signals.  
 
 
 
Figure 4.20. MALDI (reflectron positive) MS analysis of de-polysialylated N-glycan cores of the highly 
polysialylated MFE23-Ig5-FN1 fusion protein. Peaks on the spectrum were predominately produced by 
[M+Na]
+
 species. “C” indicates contaminating polymer signals and the red arrow points out the xenogenic 
galactose(α1,3)galactose or Gal(α1-3)Gal disaccharide expressed in one of the fusion protein N-glycan variations. 
Information of each monosaccharide (symbol denotation, structure, permethylated monoisotopic mass) was 
provided in Appendix 11. 
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In order to determine whether polysialic acid was elongated as a mono-antennary structure of 
the N-glycan from the fusion protein, one oligosialylated N-glycan indicated in Figure 4.21(c), 
containing three NANA residues, was re-ionized and analysed by MALDI-MS/MS for further 
dissection of this molecule (Figure 4.22).  
 
 
 
 
 
 
 
Figure 4.21. Enlarged MALDI-MS spectra analysis of de-polysialylated N-glycan cores of the highly 
polysialylated MFE23-Ig5-FN1 fusion protein. Spectra mass ranges from (a) 1499 to 2500 m/z, (b) 2500 to 
3500 m/z, and (c) 3500-5000 m/z were interpreted respectively. Oligoman standards for oligomannose structure 
with two GlcNAc residues and up to 6 Mannose residues. Red arrows point out the xenogenic Gal(α1-3)Gal 
disaccharide expressing in the fusion protein N-glycan structures. “MS-MS” highlighted N-glycan structure was 
re-ionized for MALDI-MS/MS analysis consequently. Information of each monosaccharide (symbol denotation, 
structure, permethylated monoisotopic mass) was provided in Appendix 11. 
(a) 
(b) 
(c) 
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Figure 4.22. MALDI-MS spectrum of an oligosialylated N-glycan from polysialylated MFE23-Ig5-FN1 
fusion protein. Fragment ions are indicated by the arrows. Information of each monosaccharide (symbol 
denotation, structure, permethylated monoisotopic mass) was provided in Appendix 11. 
 
 
As indicated in Figure 4.22, the fragmentation of the selected oligosialylated N-glycan 
demonstrated that the three Neu5Ac monosaccharide were continuously linked to each other 
on the N-terminal of the N-glycan core, which suggested polysialylation of the fusion protein 
was highly likely to occur as a single antennary structure.  
 
 
4.3.7 Antigen Binding Affinity Determination of the Fusion Proteins 
Recombinant polysialylated of MFE23 scFv fusion protein was successfully achieved after 
introducing PolySTs to the NB2a MFE23-Ig5-FN1 stable cell line, but the retention of antigen 
binding affinity from the glycosylated isoforms of the scFv fusion protein required study. This 
information is very important before investigating whether there is any pharmacokinetic 
improvement, as reduction of target binding affinity is considered to be the most common 
drawback of polymer or any conjugation to proteins. ELISA was initially carried out to 
identify the KD values of the fusion proteins comparing to the original MFE23 scFv. As 
described in previous chapters, the recombinant protein N-A1 containing the binding 
sequences of MFE23 scFv, was used to serve as the antigen. Fusion proteins including LS-
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MFE23, MFE23-FN1, and the three glyco-forms of MFE23-Ig5-FN1 were prepared for the 
ELISA experiment (Figure 4.23).  
 
 
 
Figure 4.23. ELISA analysis of antigen binding affinity of all MFE23 fusion proteins produced by NB2a 
PST cells. In triplicate, a serially diluted protein concentrations (from 0.5nM to 1μM) was prepared for each 
fusion protein including bacteria made MFE23 scFv, and NB2a cell expressed MFE23 scFv (LS-MFE23), 
MFE23-FN1, and three types of glycosylated MFE23-Ig5-FN1 isoforms (depicted in different colours). The 
ELISA was mediated by Myc-tag specific antibodies. N-A1 antigen-binding was confirmed for the 
polysialylated MFE23-Ig5-FN1, and the KD values of each type of fusion protein were also indicated ± standard 
errors. 
 
 
Determined by the ELISA analysis mediated by anti-Myc antibody (Figure 4.23), all 
transfected NB2a cell expressed fusion proteins and MFE23-Ig5-FN1 glyco-forms shared 
very similar KD values of approximately 7nM, similar to that obtained with bacterially 
expressed MFE23 scFv. The MFE23-FN1 fusion protein showed a slight decrease in N-A1 
binding affinity with the KD increased to 10.32nM. However, the polysialylated MFE23-Ig5-
FN1 isoforms showed excellent antigen binding affinities which were similar to the KD of the 
scFv alone.  
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4.4 Discussion 
 
As clearly shown by the experimental results described in Chapter 3, the NB2a neuroblastoma 
cells used in this investigation were not able to polysialylate the MFE23-Ig5-FN1 fusion 
protein. Additionally negative results were obtained from NB2a endogenous PSA and NCAM 
immuno-detections further confirming the existing NB2a cells used for fusion protein 
transfection were different to NB2a cells previously reported where the expression of PSA-
NCAM was obtained (Gallagher et al. 2000; Poongodi et al. 2002; Beecken et al. 2005), and 
they no longer contained the machinery to achieve NCAM polysialylation.  
 
From the studies described in Chapter 3, the MFE23-Ig5-FN1 fusion protein expressed by 
NB2a cells was found to be N-glycosylated with terminal sialic acid residues by mass 
spectrometry analysis, and the essential polysialylation disaccharide epitope - Neu5Acα(2-
6)Gal and Neu5Acα(2-3)Gal were also indicated by the corresponding lectin-detections 
suggesting sialic acid has been successfully biosynthesized and sialyltransferases catalysing 
Neu5Acα(2-6)Gal and Neu5Acα(2-3)Gal disaccharides existed within the cell. Therefore, 
according to the polysialic acid biosynthesis pathway (Figure 1.17), the only missing factors 
were postulated to be the PST and STX polysialyltransferases. Kindly provided by Prof. 
Karen Colley, both Golgi resident PST and STX cDNAs were subsequently introduced into 
the NB2a MFE23-Ig5-FN1 stably transfected cell. In order to monitor the performance of 
transfected PolySTs, transient co-transfections of the fusion protein and PolyST cDNAs were 
also carried out in a few endogenous NCAM- and PolyST-free cell lines including 3T3, HeLa, 
COS-1 and CHO cells, which successfully produced PSA confirming previous studies (Close 
and Colley 1998; Kudo et al. 1998; Close et al. 2000; Franceschini et al. 2001; Mahal et al. 
2001; Close et al. 2003). As illustrated by Figure 4.3 and 4.5, culture media from all 
transfected cells showed strong positive immuno-detection by anti-PSA antibodies. This 
result encouragingly suggested successful polysialylation after the cells incorporated the 
PolyST cDNAs. However, apart from the NB2a MFE23-Ig5-FN1 transfectants that stably 
expressing the fusion protein, other cell lines co-transfected with the fusion cDNA did not 
show noticeable MFE23-Ig5-FN1 fusion expression according to the FN1 domain specific 
immunoblotting (Figure 4.3, 4.4 and 4.5). More interestingly, culture medium from COS-1 
cell transfected with the PolyST cDNA alone also demonstrated polysialylation as evidenced 
by anti-PSA immunoblotting (Figure 4.5). Further negative results from anti-FN1 and anti-V5 
immunoblots on the same sample failed to reveal endogenous NCAM or the soluble form of 
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autopolysialylated PolySTs. According to this experimental outcome, it was speculated that 
unexpected polysialylation was likely to have occurred on unidentified cellular secretions, 
whilst the soluble format of autopolysialylated PolySTs missing the V5-tags could be another 
possible explanation. 
 
With the contamination of the unidentified polysialylated protein from the culture media of 
PolyST transfectants, the specific MFE23-Ig5-FN1 fusion protein polysialylation induced by 
PolySTs was consequently determined by His6-tag specific immunoprecipitation. As 
recombinantly engineered to contain a His6-tag, the MFE23-Ig5-FN1 fusion protein was 
pooled and isolated from the rest of the culture medium by this method. The following 
immunoblot detection for the immunprecipitated samples (Figure 4.8 and 4.9) specifically 
determined that MFE23-Ig5-FN1 fusion protein was polysialylated and was distinguished 
from the unexpected polysialylation contaminants. The credibility of this conclusion was 
proved by COS-1 and the original NB2a cells transfected by PolyST alone after their culture 
media was processed through the same His6-tag specific IP and immunoblotting. As expected, 
none of these IP samples showed any positive results (Figure 4.7b and 4.9). Further more, 
immunoprecipitation from PolyST and MFE23-Ig5-FN1 co-transfected COS-1 cells also 
indicated fusion protein specific polysialylation (Figure 4.7a). 
 
Further data on the PolyST transient transfections of different cell lines (under the same cell 
culturing and transfection protocol and conditions) implied different polysialylation 
capabilities based on the variations of the PSA specific immuno-detections from 5 different 
types of cells investigated in Figure 4.3 and 4.5. It is already known that the two 
polysialyltransferases displaying different catalytic efficiencies under different circumstances 
(section 1.4.4), but this study also suggested that polysialylation was a cell type specific 
glycosylation feature too. 
 
Both polysialylation negative fusion proteins, MFE23-FN1 and LS-MFE23 were also co-
expressed with PolySTs, and as expected, neither polysialylation nor MW increase were seen 
with direct Western blot analysis (Figure 4.10). All the demonstrable results confirmed the 
successful polysialylation of MFE23-Ig5-FN1 fusion protein achieved by the PolyST catalysis, 
and consequently both PST and STX cDNAs were stably co-transfected into the previously 
selected NB2a MFE23-Ig5-FN1 expressing monoclonal cell line, followed by polyclonal 
neomycin selection. This cell line was then considered to be the first mammalian host capable 
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of systematic polysialylation of MFE23-Ig5-FN1 fusion protein, and the system stability, 
fusion protein production, purification and characterizations were subsequently analyzed. 
 
His6-tag specific IMAC purification shares the same principle as the IP, and results presented 
in Figure 4.11 suggested the polysialylated fusion protein was isolated from the culture 
medium and concentrated. However, a mixture of polysialylated and non-polysialylated 
(mostly sialylated with MW ~70 kDa) was also indicated by Figure 4.11. The polysialylated 
material illustrated by anti-PSA immunoblotting only covered the MW range ~100 kDa to 
250 kDa, while the protein domain specific immunoblots (anti-FN1 and anti-Myc) suggested 
a wider MW range (~65 kDa to 250 kDa) which contained the non-polysialylated fusion 
protein isoforms as well. Furthermore, the MW range demonstrated by the anti-PSA 
immunoblotting implied a polydispersive degree of polysialylation of the fusion protein, 
which was similarly suggested by previously reported NCAM polysialylation studies (Troy 
1995; Rutishauser 1998; Georgopoulou and Breen 1999). In order to separate the 
polysialylated fusion protein from its non-polysialylated isoforms, anion exchange 
purification was utilized as described in previous studies (Angata et al. 1998; Jain et al. 2003). 
This system is based on sialic acid being a negatively charged molecule (Figure 1.16). 
However, it is very important to purify the fusion protein by IMAC first, as contaminating 
polysialylated substances were also detected in the cell culture (discussed above). Several 
optimisations based on the ion exchange elution profile were examined through 
chromatography and Western blot analysis (Figure 4.12 to 4.16). Initial manual ion exchange 
using five NaCl concentration (50, 100, 200, 400, and 1000mM) increments illustrated a 
rudimentary profile capable of separating different glyco-forms of the MFE23-Ig5-FN1 fusion 
protein. As shown in Figure 4.12, eluates with the 100mM NaCl buffer only demonstrated a 
single band around 70 kDa by anti-Myc Western blot, but no bands when subjected to anti-
PSA immunoblotting. However protein eluted by 400mM NaCl buffer showed a smear signal 
covering the correct MW ranges in response to both anti-Myc and anti-PSA immunoblots. 
Western blot analysis of the eluates collected according to the automatic anion exchange 
chromatogram (Figure 4.14 and 4.15) showed similar results to that observed from the manual 
purification. In addition, polysialylated fusion proteins eluted by 1M NaCl buffer after 10ml 
400mM NaCl elution were showed by the automatic anion exchange chromatography as 
three-times more purification material was loaded than the manual purification, of which 
revealed that all fusion proteins were eluted by 400mM NaCl buffer. Experimental attempts to 
elute the anion exchanged MFE23-Ig5-FN1 fusion proteins under a gradually increased NaCl 
- 206 - 
concentration gradient failed to separate the polysialylated and non-polysialylated fusion 
proteins (Figure 4.13), which was predominately contaminated by the sialylated isoform and 
degraded fragments (≤70 kDa) indicated by anti-Myc Western blot. However, as also seen in 
Figure 4.13, fractions from 70 (correlates to 200mM) onwards showed an expected elution 
profile according to the anti-PSA immuno-detections, indicating a gradual polysialylation 
degree increase alongside the NaCl concentration gradient.  
 
Taking these findings together, an optimized anion exchange purification programme was 
obtained (Table 2.9) and its elution profile is reported in Figure 4.16. Three NaCl 
concentrations (100mM, 200mM and 1M) was used for eluting the MFE23-Ig5-FN1 fusion 
proteins within three MW categories (~70 kDa, 70-110 kDa, and 100-250 kDa) based on the 
anti-Myc Western blot. Two separate and prolonged washing steps with 100mM and 200mM 
NaCl buffer were added in order to remove the corresponding fusion protein glyco-forms 
which contaminated the following purification processes (Figure 4.16). By doing this, the 
non-polysialylated fusion protein was efficiently eliminated from the polysialylated 
population. Eluates were subjected to two UV detections, 214nm and 280nm wavelengths. As 
reported previously, sialic acid had a strong absorption at UV-215nm (Spyridaki and Siskos 
1999). Due to different levels of sialic acid present on the sialylated or polysialylated fusion 
proteins, more sensitive detections were made by UV-214nm than UV-280nm, which detects 
the aromatic amino acids and protein absorptions.  
 
Specific glycosidase treatment and band shift experiments (Figure 4.17) indirectly illustrated 
α2-8 linked PSA and other glycosidic linkages within MFE23-Ig5-FN1 fusion protein 
carbohydrate compositions. Efficient oligosaccharide/glycan release by the glycosidases was 
ascertained before, mass spectrometry as one of the most accurate and sensitive methods to 
analyse the glyco-composition of glycoprotein/peptide was consequently utilized for further 
investigation of the polysialylated fusion protein. Following the three investigatory routes 
shown in Scheme I, the released sugar samples were methylated to volatile derivatives prior to 
application on the MALDI TOF-MS instrument. Based on the glyco-biosynthesis of 
mammalian glycoprotein, glycan and oligosaccharide structures were analysed according to 
the m/z peaks from MS or MS/MS spectra (Figure 4.18 to 4.22). The overall MS information 
suggested the polysialylated fusion protein was a complex and/or oligomannosidic N-glycan 
core structure, and the α2-8 linked Neu5Ac existed in an oligo-chain structure (limited by the 
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detection power), which could possibly be elongated as a mono-antenna on the N-terminal of 
the N-glycan.  
 
On the other hand, due to the highly negative charge of PSA, the polymer was very labile and 
resistant to becoming volatile after the standard permethylation process. Endo-N hydrolysis 
fragmented the polymer into oligomers with different NANA residues, which were 
successfully methylated and ionized for MS investigation. Unfortunately, these hydrolysed 
PSA polymer fragments were not usable to determine the entire degree of polymerization and 
to structurally understand the polydispersive profile of the PSA obtained from the MFE23-
Ig5-FN1 fusion proteins. In addition, non-primate mammalian glycoprotein specific 
glycosidic linkage, Gal(α1-3)Gal was also detected by MALDI-MS as expected. After fusion 
protein polysialylation on introduction of the PolySTs to the mouse NB2a MFE23-Ig5-FN1 
expressing monoclonal cell line, the next phase of establishing a polysialylation system in a 
human cell line was consequently required. Similar sialylated N-glycan structure detections 
by MALDI TOF-MS were also reported previously in adult rat brain tissue suggesting mono-, 
di- and trisialylated components, together with components substituted with four (or more) 
Neu5Ac residues (Zamze et al. 1998). Other important glycosidic linkages including 
NeuAc(α2-3 or -6)Gal and Gal(α1-3)Gal were also indicated from their studies (Zamze et al. 
1998).  
 
Furthermore, in vitro antigen binding affinity was determined especially for the polysialylated 
MFE23-Ig5-FN1 fusion proteins. As shown in Figure 4.23, no antigen binding hindrance was 
found with the polysialylated fusion protein comparing to the MFE23 scFv, and the KD values 
were consistently retained with all MFE23 fusion proteins.  
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Recombinantly Polysialylated MFE23 scFv 
Fusion Protein from HEK-293 Cells 
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5.1 Introduction  
 
 
Generation of polysialylated MFE23-Ig5-FN1 fusion protein was successfully achieved after 
transfection of PST and STX cDNAs into the mouse NB2a fusion protein-expressing 
monoclonal cell line (Chapter 4). Having the optimized purification procedures, the only issue 
arising from the fusion protein produced from the mouse cell line was the expression of 
xenogenic glycosidic linkage, Gal(α1-3)Gal within the fusion protein glyco-composition. As a 
product of the enzyme α1,3galactosyltransferase (αGalT), galactose-α1,3galactose-β1,4N-
acetylglucosamine-R (αGal) epitopes are synthesised in all mammals except Old World 
primates (Galili et al. 1988). During the course of evolution, αGalT has been mutationally 
inactivated from Old World primates, and the α-gal epitope is therefore absent in humans but 
largely expressed on glycolipids and glycoproteins in non-primate mammals, prosimians and 
New World monkeys (Galili et al. 1988; Galili 2005). More significantly, natural anti-Gal 
antibody is abundantly present in all humans. As a result, transplantation of tissue xenografts 
from animals to humans is rejected by the natural anti-Gal anti-sera binding to the α-gal 
epitopes, and injection of substances exposing the α-gal epitopes can cause serious 
immunogenic problems to humans (Galili 2005). This fact raised the seriousness and 
requirement for producing the fusion proteins without the α-gal epitopes. The human 
embryonic kidney (HEK)-293 cell line has been widely used by the biotechnology industry to 
produce therapeutic proteins (Thomas and Smart 2005; Pham et al. 2006; Backliwal et al. 
2008). I was therefore considered an appropriate human cell host for the systematic 
expression of polysialylated fusion proteins without the biosynthesis of the xenogenic α-gal 
epitopes within the protein carbohydrate composition.  
 
Successful polysialylation from the mouse NB2a cell line confirmed the importance of active 
PolySTs for elongating α2-8 linked Neu5Ac from N-glycosylated proteins within mammalian 
cells. In order to establish a proper polysialylation system, human cell lines (or cells which do 
not produce α-gal epitopes) stably expressing active intracellular PolyST are therefore needed 
to be used as a “universal cell host” for producing recombinantly polysialylated proteins with 
available polysialylatable domain structures.  
 
For analyzing oligo or polysialic acids, methods include nuclear magnetic resonance (NMR) 
(Michon et al. 1987), high-performance capillary electrophoresis (Cheng et al. 1998), thin-
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layer and high performance anion-exchange chromatography (HPAEC) combined with mild 
acid hydrolysis (Kitazume et al. 1992; Zhang and Lee 1999), high performance liquid 
chromatography (HPLC) combined with fluorometic detection (FD) (Sato et al. 1999; 
Galuska et al. 2006), fluorometric C7/C9 analysis (Sato et al. 1998), and Western blotting 
using specific antibodies/lectins combined with different glycosidase treatment (Sato 2004). 
However, limitations and inaccuracies are associated with these detections. Methylation 
modified sialic acid derivatives were analysed through mass spectrometry (Finne et al. 1977), 
however, understanding the integrity and degree of polymerization of the PSA molecule was 
problematic. Such limitation with analysis was also observed from the MALDI TOF-MS 
results described in Chapter 4 for the polysialylated MFE23-Ig5-FN1 fusion protein. As a 
very rapid, and probably one of the most sensitive structural analysis approaches, MALDI 
TOF-MS was continuously used for characterizing oligo- and polysialic acids. In addition, 
recent research demonstrated unambiguous identification of polysialylation based on the exact 
mass determinations after direct lactonization on the MALDI target (Galuska et al. 2007). 
According to the research, lactonized oligo/polysialic acid also provided specific information 
including the type of sialic acid, potential side-group substitutes, and the number of NANA 
residues in the polymeric chain through MALDI TOF-MS analysis (Galuska et al. 2007). 
 
The concept of oligo/polysialic acid lactonization was suggested many years ago, firstly 
highlighted by the existence of lactones in oligo/polysialic acid (McGuire and Binkley 1964). 
Reported by different investigators, natural sialic acid lactones were found on glycolipids 
extracted from cell lines and brain specimens (Gross et al. 1980; Riboni et al. 1986; 
Kawashima et al. 1994; Kielczynski et al. 1994). These studies suggested that the lactone 
derivation significantly preserves labile and reducible Neu5Ac in an alkaline condition, in 
order to ensure the recognition and signalling through the sialic acid presented on the 
glycolipids. However, occurrences of sialic acid lactonization are still poorly understood 
whether acid-catalysed through chemical reactions or actively controlled by specific enzymes. 
In terms of chemical reactions, previous laboratory examinations of α2,8- and α2,9-linked 
oligo/poly-Neu5Acs under acidic conditions detected rapid formation of lactonized polymer 
derivatives. This modification was then suspected to have physicochemical and biological 
alterations to the properties of sialic acid polymers, such as charge density and conformation 
(Lifely et al. 1981; Lifely et al. 1984). Mild and slow lactonization of PSA was also induced 
simply by dialysing the polymer dissolved in a sodium salt solution against water (Zhang and 
Lee 1999). Loss of negative charge for PSA after lactonization was determined by several 
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experiments. Insufficient de-lactonization of oligo- and polysialic acid mixture severely 
limited their separation by capillary electrophoresis and anion exchange column (Cheng et al. 
1998; Zhang and Lee 1999).  
 
As shown in Figure 5.1, two adjacent α2,8-linked Neu5Ac residues within PSA chain can be 
lactonized. The COOH-group of one Neu5Ac residue esterifies the OH-group linked to the C9 
and forms a 6-membered lactone ring. The same ring structure was also observed by NMR 
between naturally occurring α2,8-linked sialic acid residues in GD3 and GD1b ganglioside 
lactones (Ando et al. 1989; Acquotti et al. 1991).  
 
 
 
Figure 5.1. Acid-catalysed α2,8 linked PSA lactonization.  Lactone rings are marked by asterisks. Carbon 
atoms are numbered in the reducing end monosaccharide. Figure is take from (Galuska et al. 2007). 
 
 
This acid-catalysed lactonization method (chemically removing the negative charge from PSA) 
was firstly described by Zhang et al. (protocol mentioned in section 2.2.6.6), and then 
expanded to MALDI TOF-MS for studying PSA polymerization (Zhang and Lee 1999; 
Galuska et al. 2007). As mentioned above, apart from the precise MALDI MS results Galuska 
et al. obtained from their studies on PSA, the successful MS investigations and DP indications 
on highly polysialylated colominic acid and PSA bound to NCAM after lactonization 
treatment suggested a promising way for understanding of the scFv-Ig5-FN1 fusion protein 
polysialylation (Galuska et al. 2007).  
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5.2 Aims and Objectives 
 
In order to eliminate the α-gal xenogenic glycosidic linkage featured by mammalian protein 
glycosylation, the human HEK-293 cell line was positioned to replace the mouse cell line to 
produce MFE23-Ig5-FN1 fusion protein with human-type glycosylation. A polysialylating 
HEK-293 cell host was planned to be engineered with stable expression of PolyST that could 
actively polysialylate any suitable protein format (i.e. scFv-Ig5-FN1) in the future. As already 
proved to be polysialylated in Chapter 4, MFE23-Ig5-FN1 fusion protein was then scheduled 
for HEK-293 cell host transfection and monoclonal selection for best fusion protein 
expression and polysialylation levels. Following the successfully optimized purification 
process, this part of the study focused on more detailed glyco-structure investigation on PSA 
by MALDI-MS by using the lactonization preparation method, and exploring the 
polysialylated fusion protein antigen binding profiles by several sensitive measurement 
methods and instruments. 
 
The objectives are: 
■ Stable transfection and polyclonal selection of human cell line, HEK-293 for PolySTs 
expression.  
■ Transfection of MFE23-Ig5-FN1 and other MFE23-bond fusion protein cDNAs to the 
HEK-293 PolyST cells and selection of individual monoclonal cell lines with best protein 
expression and polysialylation level. 
■ Generation and purification of recombinantly polysialylated MFE23-Ig5-FN1 fusion protein. 
■ Determination of degree of polymerization of lactonized PSA from the polysialylated 
MFE23 fusion proteins by Mass Spectrometry. 
■ In vitro antigen binding affinity investigation of polysialylated MFE23 fusion proteins and 
other recombinant MFE23 proteins – ELISA and BIAcoreTM. 
■ In vitro live cell binding studies of polysialylated MFE23 fusion proteins and other 
recombinant MFE23 proteins – FACS and confocal microscopy.  
■ Molecular size property studies of the polysialylated MFE23 fusion proteins and other 
recombinant MFE23 proteins – Size exclusion chromatography. 
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5.3 Results 
 
5.3.1 Polyclonal Selection of HEK-293 Cells Transfected with PolyST DNA 
The human cell line, HEK-293, was used to substitute the NB2a (mammalian cell) protein 
production system, in order to avoid the expression of xenogenic oligosaccharide such as 
Gal(α1-3)Gal sugar linkage in the carbohydrate composition of the glycosylated fusion 
proteins. With the intention of creating an in situ recombinant protein polysialylation system 
from a human cell line, HEK-293 cells were stably transfected with the PolyST plasmid DNA, 
and the polyclonal PolyST transfected HEK-293 cell lines were collected under the neomycin 
antibiotic selection. 
 
In order to confirm the endogenous expression of PST and STX after stable transfections, 
FACS analysis was used to investigate the polyclonally selected cell lines (section 2.2.5.9). 
As shown in Figure 5.2(a), the PolyST encoded V5 protein-tag was specifically targeted. The 
peak-shifts were clearly noticed from both HEK-293 PST and STX transfectants by 
comparing the ones without the involvement of anti-V5 antibody and the untransfected HEK-
293 cells. The corresponding values of average fluorescent intensity of each tested samples 
were statistically analysed, and the two PolyST transfectants had approximately a threefold 
increase of the mean fluorescent intensity compared to the non-transfected HEK-293 cells.  
 
As mentioned in Chapter 1, autopolysialylation was found in both PST and STX (Close and 
Colley 1998), and as is also suggested in Chapter 4, the active enzymes were potent enough to 
polysialylate other endogenous proteins. Therefore, positive polysialylating enzymatic 
activities of the two PolyST transfectants were confirmed specifically by anti-PSA antibody 
detections. The FACS results showed in Figure 5.2(b) clearly indicated a peak-shift of PST 
transfected HEK-293 cells with or without the mediation of anti-PSA antibody, while only a 
slight shift was observed from the STX transfectants. A doubled geometric mean fluorescence 
value (GMean) mediated by anti-PSA antibody was indicated for the PST transfectants in 
comparison with the wild type HEK-293, whereas the STX transfectants had almost the same 
value as the untransfected.   
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The lysed cell samples from original HEK-293 and the two PolyST transfected cells were also 
immunoblotted with an anti-PSA antibody (Figure 5.2c). Smears ranging from ~120 to 250 
kDa showed strongly from the PST transfectant lysate, whilst only a weak signal was 
obtained from the lysate of STX transfected HEK-293 cells covering the similar MW range. 
No anti-V5 immunoblotting results were found for all lysates. 
 
UT HEK-293 
2.56 
2.63 
4.98 
 
HEK-293 + PST 
3.55 
3.30 
13.36 
 
HEK-293 + STX 
3.12 
3.63 
12.63 
 
2.34 
2.11 
 
UT HEK-293 
2.19 
2.98 
 
HEK-293 + STX HEK-293 + PST 
2.56 
4.53 
 
  (b) 
Anti-V5 
Anti-PSA 
(a) 
(c) 
Figure 5.2. Confirmations of PolyST expression by FACS and 
immunoblotting. (a) V5-tag specific FACS analysis; (b) PSA specific 
FACS analysis; (c) Anti-PSA immunoblotting of cell lysate. 
Approximately 4 x10
6
 cells were lysed and ¼ of the total lysate of 
each sample was analysed. Untransfected (UT), alongside PST and 
STX individually transfected HEK-293 cells were analysed in all 
three experiments. FACS samples are denoted by different colours, 
and the GMean values of each sample are also indicated. 
 
     : Cells with FITC secondary antibody only;  
     : Cells with primary anti-V5 and FITC secondary antibodies; 
     : Cells with FITC isotype control antibody. 
 
      : Cells with FITC secondary antibody only;             : Cells with primary anti-PSA and FITC secondary antibodies 
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5.3.2 Monoclonal Selection of MFE23 Fusion Protein Expressing HEK293 
PolyST Cell Lines 
The creation of sustainable human cell lines with expression of active polysialyltransferase 
provided the cellular mechanism for engineered protein recombinant polysialylation under a 
human glycosylation pattern. With the successful polysialylation of MFE23-Ig5-FN1 fusion 
protein produced by the mammalian NB2a PolyST cells, the polysialylatable fusion construct 
was stably transfected into the polyclonal HEK-293 PST or STX cells under zeocin antibiotic 
selection pressure, and monoclonal cell lines performing the best fusion protein expression as 
well as the polysialylation level was selected by an ELISA-derived selection method (section 
2.2.3.7 and 2.2.4.1). 
 
Two separate bar-charts shown in Figure 5.3 demonstrate the monoclonal selection status of 
polysialylated MFE23-Ig5-FN1 expressing cell lines from both HEK-293 PST and STX cells. 
Generally speaking, the majority of monoclonal cell lines picked from HEK-293 PST 
MFE23-Ig5-FN1 transfectants expressed polysialylated fusion protein in their culturing 
medium, whilst the STX MFE23-Ig5-FN1 monoclonal cells only showed an equally good 
fusion protein production yield, but none of them was found to express the polysialylated 
version of MFE23-Ig5-FN1 (almost the same level as the un-transfected cells). The idea of the 
monoclonal selection was to find a cell line that had a high fusion protein expression levels 
and high polysialylation efficiency of the fusion proteins. Clone 2D2 from HEK-293 PST 
MFE23-Ig5-FN1 transfectants indicated the best anti-PSA ELISA result among all isolated 
monoclonal cell lines, and also had a relatively good fusion protein yield implied by the anti-
Myc ELISA result. Clone HEK-293 PST 2D2 was chosen as the optimal cell line for 
expressing polysialylated MFE23-Ig5-FN1 fusion proteins with human glycosylation features. 
Other monoclonal cell lines including HEK-293 PST 1D1, 2A1, 2A5, 2B1, 2B3, 2C4, and 
2C6, alongside the HEK-293 STX MFE23-Ig5-FN1 polyclonal cell line were selectively 
retained as well. 
 
In addition, MFE23-FN1 plasmid DNA was also transfected into the HEK-293 PST cells (as 
it appeared to be more effective for MFE23-Ig5-FN1 protein polysialylation) as a negative 
polysialylation control, and the polyclonal cell line was selectively collected for MFE23-FN1 
protein expression, in order to avoid unnecessary xenogenic glycosylation.  
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Figure 5.3. Monoclonal selection of MFE23-Ig5-FN1 transfected HEK-293 PolyST cell line. Culturing 
medium samples of each MFE23-Ig5-FN1 transfected HEK-293 PST or STX monoclonal cell line were 
immuno-detected by anti-Myc and anti-PSA antibodies respectively, and correspondingly, their consequent 
ELISA results were analysed for determining fusion protein yield and polysialylation status. “+” denotes 10μg 
purified highly polysialylated MFE23-Ig5-FN1 proteins made by NB2a cells; “-” indicates cell culture medium 
from HEK-293 PolyST polyclonal cells without fusion protein transfection. Clone 2D2 is indicated with red 
arrow. 
 
 
 
5.3.3 Expression and Purification of MFE23 Fusion Proteins from HEK-293 
PST Cells 
Standard serum-free medium culturing and purification procedures (TALON
TM
 cobalt anti-
His6 IMAC and ion exchange purifications) described for the NB2a cell expression system in 
Monoclonal selection of HEK-293 PST MFE23-Ig5-FN1 cell line 
Monoclonal selection of HEK-293 STX MFE23-Ig5-FN1 cell line 
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Chapter 4 were accordingly applied to the selected HEK-293 PST MFE23 fusion protein 
transfectants. Subjected to the polysialylated MFE23-Ig5-FN1 purification, the automatic 
anion-exchange chromatography optimized in section 4.3.4.2 with additional washing steps 
successfully separated the HEK-293 cell line-expressed polysialylated fusion protein into 
sialylated, weakly polysialylated and highly polysialylated isoforms. Results from Coomassie 
staining, various immunoblottings and glycosidase treatments indicated the same findings that 
illustrated previously by the NB2a cell products (Figure 4.16 and 4.17 in Chapter 4).  
 
In addition, confirmation of the abolishment of Gal(α1-3)Gal disaccharide glyco-composition 
from HEK-293 expressed MFE23 fusion protein was determined by immunoblotting using an 
antibody that recognises the Gal(α1-3)Gal linkage (Figure 5.4).  
 
 
Figure 5.4. Anti-Gal(α1-3)Gal disaccharide immunoblotting for MFE23 fusion proteins produced from 
both NB2a and HEK-293 cell expression systems. Sia, Weak, and High indicate three different glycosylation 
isoforms of polysialylated MFE23-Ig5-FN1 fusion protein. Bovine and human transferrins were used to show 
positive and negative signals from Gal(α1-3)Gal glycosidic linkage. Arrows indicate detected disaccharide 
containing protein bands. 
 
 
Illustrated by the sugar linkage specific immunoblotting in Figure 5.4, xenogenic Gal(α1-
3)Gal disaccharide was weakly displayed according to protein MWs by murine NB2a cell-
expressed sia- or polysialylated MFE23-Ig5-FN1 fusion proteins. However, the NB2a-made 
MFE23-FN1 and LS-MFE23 fusion proteins did not show any signals from Gal(α1-3)Gal 
disaccharide specific immuno-detection. All human HEK-293 cell-produced MFE23 fusion 
proteins showed the expected negative results, indicating the abolishment of the mammalian 
cell specific glycosylation feature. Transferrins from both bovine and human origins depicted 
positive and negative outcomes from the sugar linkage specific antibody. 
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5.3.4 MALDI TOF-MS for Polysialylation Speculation  
 
5.3.4.1 Colominic Acid (DP≥100) 
Different concentrations of commercially purified colominic acid were initially analysed as 
controls for exploring MALDI TOF-MS detected PSA profiles. As suggested by Galuska et 
al., on-target lactonized colominic acid was combined with ATT matrix and detected in the 
negative-ion mode MALDI TOF-MS (protocol described in section 2.2.6.8) for satisfactory 
signal-to-noise ratios and better resolution signals particularly when high mass range (i.e. 
m/z > 10,000) involved in the MS detection (Galuska et al. 2007). Because of the PSA 
lactonization, no additional permethylation process was required for masking the negative 
charge from sialic acid, leading to each Neu5Ac residue appearing on their monoisotopic 
mass, 291 Da (Appendix 11). However, the formation of the lactone ring removed one OH-
group and H molecule from each sialic acid residue. Therefore, receiving the addition of a 
proton from ionization, the MW of lactonized α2,8-linked Neu5Ac monomer should be 274 
Da. The exact mass determination of each peak signal is indicated in Figure 5.5 and 5.6, 
implying different multiplications of lactonized Neu5Ac MW. 
 
Also showed in Figure 5.5, an average 274 Da difference of two adjacent peak values was 
clearly stated indicating the homogenous constitution of the polymer by α2,8-linked Neu5Ac 
monomers. The maximally detectable colominic acid chain length was found to be more than 
100 NANA residues (Figure 5.5a inset) when a relatively large sample amount (6.25μg) was 
MALDI-MS analysed by negative linear mode. Improving peak resolution for more accurate 
identification of molecule masses was achieved by setting the MALDI TOF-MS instrument 
into a negative reflection mode (Figure 5.5b). Although sharper peak signals were observed, 
the detectable mass range was reduced compared to the linear mode. 
 
Furthermore, the increased peak resolution enabled the observation of satellite peaks differing 
by mass increment of 18 Da, of which was caused by a water molecule under the detection 
condition. Showed in Figure 5.6, the sensitivity (i.e. peak signal-to-noise ratios) and 
detectable mass range was considerably reduced when analysing a much smaller amounts of 
colominic acid (3ng). However, peak signals were still clearly revealed from the MS spectra 
with unambiguous MW information identifying unique α2,8-linked Neu5Ac polymerization 
as well as the determination of the chain length. The detected mass range indicated up to 
approximately 70 residues maximum from the sialic acid polymer by linear negative  
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Figure 5.5. Analysis of colominic acid (6.25μg) by MALDI TOF-MS.  Colominic acid was lactonized on-
target and analysed in:  (a) negative-ion linear mode with enlarged spectrum inset of mass range m/z 25573-
34477; (b) negative-ion reflectron mode with enlarged spectrum (mass range m/z 3707-5744) inset of DP14-20 
species and their satellite peaks caused by additional water molecule detected under the condition used for 
analysis. Average masses [M – H]- and corresponding DP values are given for selected signals. 
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Figure 5.6. Analysis of colominic acid (3ng) by MALDI TOF-MS.  Colominic acid was lactonized on-target 
and analysed in:  (a) negative-ion linear mode with enlarged spectrum inset of mass range m/z 14442-23432; (b) 
negative-ion reflectron. Average masses [M – H]- and corresponding DP values are given for selected signals. 
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mode (Figure 5.6a inset), while the reflection mode could only detect m/z signals showing DP 
of 30 NANA residues in the polymer (Figure 5.6b).   
 
 
5.3.4.2 Polysialylated MFE23-Ig5-FN1 Fusion Protein 
Successfully indicated by colominic acid MALDI TOF-MS studies, polysialic acid species 
and the degree of polymerization were clearly determined. Lacking this type of information 
from polysialylated MFE23-Ig5-FN1 fusion protein analysed in previous MS studies 
described in Chapter 4, glyco-structural studies of the polysialylated fusion protein newly 
expressed from the human monoclonal cell line were consequently performed by the mass 
spectrometry analysis. Outlined in Scheme II below, three investigatory pathways were 
explored. 
 
 
 
Scheme II. Preparation procedures for MALDI-MS and MS/MS analysis of HEK-293 cell made 
polysialylated MFE23-Ig5-FN1 fusion protein with additional lactonization treatment.  Three analytical MS 
preparations were made for (a) PSA, (b) N-glycan core and (c) O-glycosylation detections. Glycosidases and 
chemical β-elimination for sugar residue removal were marked in blue within the preparation process.  O-
phosphoric acid was used for PSA lactonization on target-plate. 
 
 
Based on the o-phosphoric acid catalysed lactonization method  (section 2.2.6.6) initially used 
by Galuska et al (Galuska et al. 2007), this lactonization treatment was also performed on the 
sialic acid derivatives of all three MFE23-Ig5-FN1 fusion protein glyco-forms (sialylated, 
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weakly and highly polysialylated isoforms) and analysed by MALDI TOF-MS (preparation 
outlined in Scheme II-a). High signal intensities from PSA NANA residues were 
subsequently detected.  
 
Without any further pre-treatment, direct MALDI TOF-MS analysis of lactonized MFE23-
Ig5-FN1 fusion proteins revealed PSA chains with up to ~40 α2,8-linked Neu5Ac residues 
from the linear negative-ion mode and halved residue numbers detected from the reflectron 
mode (Figure 5.7). On the other hand, higher resolution of peak signals was received from the 
reflectron mode with more exact mass determination (Figure 5.7b). An additional water 
molecule co-ionized with the PSA fragment was also revealed by the reflectron mode (Figure 
5.7b inset). Furthermore, according to the masses suggested by each MS peak signal, PSA 
chain structures were the only species detected on the MALDI TOF-MS spectra, which 
facilitated the determination of the polysialylation degree occurring on the fusion protein. 
However, the homogenous PSA chain signals also suggested a release of lactonized PSA from 
the glycopeptide which did not hamper the MS measurement. This release of lactonized PSA 
from glycopeptide also occurred in the polysialylated NCAM analysed by MALDI TOF-MS, 
and the reason of this occurrence is still under investigation (Galuska et al. 2007).   
 
Weakly polysialylated and sialylated MFE23-Ig5-FN1 fusion proteins (100μg of each) were 
also treated for lactonization preparation, followed by direct detection by MALDI TOF-MS. 
Unlike the highly polysialylated glycol-form, weaker signal resolution and sensitivity were 
produced. Shown in Figure 5.8(a), available signals suggested approximately ≤15 NANA 
residues of the weakly polysialylated fusion protein after lactonization. Although DPs 
extended to 20 and 28 were speculated according to the masses indicated by the spectral 
signals, these mass values were ambiguous and not accurate enough to confidently declare 
them as sialic acid repeats. Only one strong MS spectral signal of lactonized sialylated fusion 
protein suggested possible oligosialic acid structure (DP = 4), while other detectable signals 
seen from the spectrum did not represent any clear and decisive masses for Neu5Ac chain 
structure (Figure 5.8b).  
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Figure 5.7. Analysis of polysialylated N-glycan from highly polysialylated MFE23-Ig5-FN1 fusion protein 
(100μg) by MALDI TOF-MS.  Polysialylated N-glycan was lactonized on-target and analysed in:  (a) negative-
ion linear mode with enlarged spectrum inset showing mass range m/z 5933-14443; (b) negative-ion reflectron 
mode with enlarged spectrum (mass range m/z 2624-4204) inset of DP10-15 species and their satellite peaks 
caused by additional water molecule detected under the condition used for analysis. Average masses [M – H]- 
and corresponding DP values are given for selected signals. 
(a) 
(b) 
- 224 - 
 
999.0 2804.2 4603.4 6402.6 8201.8 10001.0
Mass (m/z)
0
50
100
%
 I
n
te
n
s
it
y
1419.2
2783.7
4151.7
5586.7
7779.8
DP 10
DP 5
DP 15
~DP 20
~DP 28
 
 
1005.0 2804.2 4603.4 6402.6 8201.8 10001.0
Mass (m/z)
50
100
%
 I
n
te
n
s
it
y
1110.7
DP 4
0
 
 
 
Figure 5.8. Analysis of N-glycans of other MFE23-Ig5-FN1 fusion protein glyco-forms by negative-ion 
linear mode MALDI TOF-MS.  N-glycans from (a) weakly polysialylated fusion protein (100μg) and (b) 
sialylated fusion protein (100μg) were lactonized on-target. Average masses [M – H]- and corresponding DP 
values are given for selected signals. “?” marks indicate unconfidently speculated DP values due to the 
ambiguous mass correspondences.    
 
 
 (b) 
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Another investigation was focused on the N-glycan core structures of MFE23-Ig5-FN1 fusion 
protein (Scheme II-b). All three glyco-forms of the fusion protein were Endo-N treated for 
PSA removal followed by N-glycan isolation by PNGase F treatment. The permethylation 
process was carried out prior to sending the samples to the MALDI TOF-MS instrument. As 
expected, with the same fusion protein backbone, all three fusion glyco-forms share the same 
N-glycan core carbohydrate profile that is illustrated in Figure 5.9. 
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Figure 5.9. Analysis of N-glycan core structures of MFE23-Ig5-FN1 fusion proteins by positive-ion 
reflectron mode MALDI TOF-MS.  Biosynthetically logical glycan structures were speculated according to the 
average mass [M – Na]+. Information of each monosaccharide (symbol denotation, structure, Permethylated 
monoisotopic mass) was provided in Appendix 11. 
 
 
In comparison with the N-glycan core structures detected from mouse NB2a cell expressed 
polysialylated MFE23-Ig5-FN1 fusion protein (Figure 4.18), both complex and 
oligomannosidic core N-glycan constitutions were also detected from the HEK-293 made 
fusion proteins with di-, tri- and tetra antennary structures involved, alongside bisecting N-
acetylglucosamine which was occasionally detected. Moreover, fucoses were typically found 
within the human cell made fusion protein N-glycan cores, which were not indicated from the 
MS spectrum of the fusion protein with the mouse glycosylation format.  
 
Additionally, the O-glycosylation profile of the fusion protein was also measured by mass 
spectrometry. Introduced in Scheme II-c, O-glycans from all three fusion glyco-forms (100μg 
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each) were removed by reductive elimination (or β-elimination) process (standard protocol 
described in section 2.2.6.4), followed by permethylation treatment. According to the m/z 
signals received from MALDI TOF-MS spectra (positive reflectron), no clear O-glycosidic 
linkage/structure as well as polysialylation could be postulated (results showed in Appendix 
14). 
 
 
5.3.5 In vitro Antigen Binding Affinity Investigation 
It is very important to understand the effect of polysialylation and recombinant protein 
domain fusion to the MFE23 scFv in terms of the antibody-antigen binding affinity. The 
exploration of the binding affinities of the fusion protein antigen target was achieved by two 
important in vitro antigen binding methods, of which were ELISA and BIAcore
TM
. In both 
cases, N-A1, the recombinant protein representing CEA binding-site to the MFE23 antibody 
was used as the antigen target. 
 
5.3.4.1 ELISA 
In order to compare the KD data received from NB2a cell expressed MFE23 fusion proteins 
(section 4.3.6), the same ELISA protocol was employed to identify the antigen targeting 
profiles of the HEK-293 cell made fusion proteins.  
 
Confirmed from the previous study (Figure 4.18), the NB2a cell expressed LS-MFE23 scFv 
molecule had an excellent N-A1 antigen binding affinity, and the scFv was used as a positive 
control to identify the in vitro antigen targeting motifs of other MFE23 fusion proteins 
produced by HEK-293 PST cells. Almost the same results of all MFE23 fusion constructs 
were shown in Figure 5.10 by comparing with the ELISA data from the NB2a products 
showed in Figure 4.23. Most N-A1 binding molecules tested here depicted their KD values 
between 4-6nM, including the positive control, whilst the MFE23-FN1 and sialylated 
MFE23-Ig5-FN1 fusion protein showed approximately tripled and doubled KD values in this 
binding test. 
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Figure 5.10. ELISA analysis for determining antigen binding affinities of all MFE23 fusion proteins 
produced by HEK-293 cells.  A serially diluted protein concentrations (from 0.5nM to 1μM) was prepared in 
triplicate for each fusion protein including NB2a cell expressed MFE23 scFv (LS-MFE23), HEK-293 PST cells 
produced MFE23-FN1 and three types of glycosylated MFE23-Ig5-FN1 isoforms (depicted in different colours). 
The ELISA was mediated by Myc-tag specific antibodies and the KD values (± standard errors) of each type of 
fusion protein were also signified. 
 
 
5.3.4.2 BIAcore
TM
 Affinity Kinetics Studies  
Behind the complex physical principles of surface plasmon resonance (SPR), BIAcore, the 
SPR-based biosensor system, has been recognised as one of the most widely used 
technologies by far for obtaining accurate quantitative data particularly in the investigations 
of molecular bindings and interactions. Particularly, BIAcore offers advantages such as 
sensitive analysis of weak molecular interactions, and specific on-rate and off-rate 
measurements under the real-time binding models. Subjected to the kinetic studies of the 
MFE23 scFv, and its different fusion and polysialylation formats, the BIAcore 3000 
instrument was used and the corresponding operation/analysis protocols have been described 
in section 2.2.5.8.  
 
Again, the recombinant N-A1 proteins were immobilized on the BIAcore chip to offer antigen 
binding. Previous BIAcore experiments using E.Coli expressed MFE23 scFv against the 
recombinant N-A1 antigen showed the KD of 5.33nM (Sainz-Pastor et al. 2006), and their 
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suggested protocol was followed in part. However, other than coupling the N-A1 antigen to a 
BIAcore
®
 CM5 sensor chip via amine coupling, the antigen proteins were initially 
biotinylated and consequently immobilized to a BIAcore
®
 SA sensor chip which was pre-
coated with streptavidin. Both 5:1 and 20:1 biotinylated N-A1 antigens were prepared (section 
2.2.5.6) to improve antigen immobilization on the SA sensor chip. Standard ELISA assays 
were carried out using LS-MFE23 scFv against the two differently biotinylated N-A1 antigens. 
Affinity constants were preserved from both ELISA tests (results not shown). Both 
biotinylated N-A1 showed good antigen immobilizations to the SA sensor chip with relatively 
low response unit signals (700-900 RU) reached. It is expected to have low enough antigens 
immobilized on the BIAcore chip surface in order to minimize the kinetic artifacts such as 
rate-limited mass transport (effecting on-rate measurement) and re-binding (effecting off-rate 
measurement). In order to minimize structural changes of the antigen, the 5:1 biotinylated N-
A1 was used in all BIAcore experiments. 
 
The results of BIAcore kinetics experiments with LS-MFE23 scFv, MFE23-FN1 and three 
different MFE23-Ig5-FN1 glyco-forms were shown in Figure 5.11. Exactly the same 
experimental process (i.e. association/dissociation period and regeneration condition) and 
evaluation method were carried out on all five MFE23 fusion samples (method described in 
section 2.2.5.8). Twenty cycles of each fusion protein BIAcore experiment covered sample 
concentrations from 0.4nM to 185nM. In terms of the data evaluation, the 7 highest 
concentrations (from 2.89nM to 185nM) of each fusion protein were used to fit best to the 1:1 
langmuir binding model, which evaluated the KD values and other kinetics parameters 
including kon, koff and their standard errors listed in Table 5.1. The Chi
2
 values were also 
indicated after the fitting of each fusion proteins BIAcore data, suggesting the closeness and 
statistical significance of each fit.  
 
Showed in Figure 5.11, well fitting models were evaluated and plotted as overlays of kinetic 
bindin of each sample concentration. Statistically approved in Table 5.1, the Chi
2
 values of 
each fusion protein were all less than 5% of their corresponding Rmax values indicating the 
adequacy the corresponding fitting models. In terms of the real-time kinetic binding, almost 
the same kon and koff values, consequently the KD values were obtained from the LS-MFE23 
scFv and MFE23-FN1 fusion protein. Much slower on-rates (~20-fold less than the scFv kon) 
were found for the two polysialylated fusion glyco-forms, however their off-rates were kept 
consistent, and approximately an 8-fold increase of the KD value of weakly polysialylated 
MFE23-Ig5-FN1 fusion protein, and a 10-fold increase to the highly polysialylated were 
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observed. The standard errors of both kon and koff values were at least 10-fold less than the 
corresponding kinetic parameters suggesting the reliability of the real-time binding kinetics.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. Kinetics of binding analysis of MFE23 recombinant fusion proteins.  Dilution series ranging 
from 0.4nM to 185nM were prepared respectively for fusion proteins including LS-MFE23 scFv, MFE23-FN1, 
sialylated MFE23-Ig5-FN1, weakly and highly polysialylated MFE23-Ig5-FN1, and their kinetic binding to N-
A1 recombinant antigen peptide were measured by SPR using BIAcore 3000 instrument. Each concentration was 
tested in duplicate. Due to low binding signals at the low concentrations, only traces for the highest seven 
concentrations (2.89nM to 185nM) are shown. The best fit (Langmuir 1:1 binding) lines (black) were also 
indicated as overlays of each corresponding kinetic bindings. Injection start (I-start) and stop (I-stop) are 
indicated, alongside association (2 minutes) and dissociation (only less than 4 minutes out of total 10 minutes 
were showed) phases marked in grey. 
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The KD increases found in the polysialylated MFE23-Ig5-FN1 fusion proteins were not 
suggested by the ELISA results (Figure 5.10). As mentioned previously, the N-A1 antigen 
peptides were biotinylated for coating on the BIAcore sensor chip, which has a 
carboxymethylated dextran matrix for pre-immobilizing with streptavidins, and a highly 
negative surface on the SA sensor chip due to the free carboxyl group in the dextran matrix 
(http://www.biacore.com/lifesciences). In this case the negative charges from the PSA were 
speculated as the reason that hindrance of the on-rate of the antibody-antigen binding occured, 
and the electronic repulsion generated opposite force against the affinity orientation. In order 
to support this idea, a de-polysialylated MFE23-Ig5-FN1 fusion proteins kinetic analysis 
(Figure 5.12) was processed consequently by the same BIAcore method (section 2.2.5.8) after 
treating the polysialylated fusion proteins with Endo-N for PSA removal (section 2.2.5.4).  
 
 
 
 
 
Figure 5.12. Kinetics of binding analysis of de-polysialylated MFE23-Ig5-FN1 fusion protein.  A dilution 
series of the fusion protein was prepared ranging from 0.4nM to 185nMand kinetic binding to N-A1 recombinant 
antigen peptide was measured by SPR using BIAcore 3000 instrument. Each concentration was tested in 
duplicate. Due to low binding signals at the low concentrations, only traces for the highest seven concentrations 
(2.89nM to 185nM) are shown. The best fit (Langmuir 1:1 binding) lines (black) were also indicated as overlays 
of each corresponding kinetic bindings. Injection start (I-start) and stop (I-stop) are indicated, alongside 
association (2 minutes) and dissociation (only less than 4 minutes out of total 10 minutes were showed) phases 
marked in grey. 
 
 
With all the kinetic parameters and adequate statistic values summarized in Table 5.1, the 
kinetic binding and corresponding fitting model of the de-polysialylated MFE23-Ig5-FN1 
fusion protein (Figure 5.12) indicated a restored on-rate, and consequently a decreased KD 
value, which was only ~2.5-fold higher than the scFv KD.  
 2.89nM 
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Table 5.1. Summary of SPR BIAcore kinetics analysis.  The kinetic and statistical values were generated 
according to the best fit models showed in Figure 5.11 and 5.12.  
 
Fusion proteins 
kon                
(M
-1
s
-1
) 
SE*- kon   
(M
-1
s
-1
) 
koff          
(s
-1
) 
SE*- koff   
(s
-1
) 
KD          
(M) 
Chi
2
 
LS-MFE23 6.28x10
4
 2.24x10
3
 9.23x10
-4
 2.27x10
-5
 1.48x10
-8
 1.87 
MFE23-FN1 8.78x10
4
 1.69x10
3
 7.59x10
-4
 1.43x10
-5
 8.64x10
-9
 1.13 
Sia MFE23-Ig5-FN1 5.36x10
3
 0.212 5.40x10
-5
 7.04 x10
-6
 1.01x10
-8
 1.7 
Weak PolySia          
MFE23-Ig5-FN1 
2.33x10
3
 85 2.88x10
-4
 1.05x10
-5
 1.24x10
-7
 1 
High PolySia           
MFE23-Ig5-FN1 
3.90x10
3
 386 5.51x10
-4
 8.92x10
-6
 1.41x10
-7
 0.286 
De-PolySIa             
MFE23-Ig5-FN1 
9.19x10
4
 3.75x10
3
 3.44x10
-3
 4.75x10
-5
 3.74x10
-8
 8.13 
 
*: Standard error (SE) – For excellent statistical reliability, SE values are needed to be at least 10-fold less than 
the corresponding parameter; 
Chi
2
: A score of less than 10% of the corresponding Rmax value is needed to determine the model used for fitting 
adequately describes the data. 
 
 
5.3.6 In vitro Live Cell Binding Studies 
The effect of recombinant polysialylation of antibody targeting on antigens expressed on live 
cells under culturing conditions was consequently investigated. The findings from the live cell 
models would give more appropriate answers of how suitable polysialylation could be in 
terms of serving as a drug delivery system for antibody fragments. For this part of the 
investigation, FACS and confocal microscopy were employed to understand the targeting 
profiles under different live cell conditions. 
 
5.3.6.1 FACS for Cell Surface Antigen Binding Detection 
Two colonic cancer cell lines, LS174T and LoVo, were cultured to supply CEA antigen 
expression, while KB, the epidermal carcinoma cell line was used for negative antigen 
expression control. Following the protocol described in section 2.2.5.9, all MFE23 containing 
fusion proteins were analysed by FACS for comparing their binding profiles and efficiencies 
to the live cell surface expressed CEA antigen. 
 
The CEA antigens expressed on the surface of colonic cancer cells, LS174T and LoVo, were 
specifically targeted by MFE23 containing recombinant fusion proteins, and this live cell 
CEA-MFE23 binding detected by FACS was bridged up by the antibodies recognising the 
characteristics brought by the fusion protein. Shown in Figure 5.13(a), anti-Myc antibody 
directed FACS indicated all MFE23 containing fusion proteins recognised the antigen 
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Figure 5.13. In vitro live cell binding investigation by FACS. 
Antibodies specifically recognising Myc-tag (a), and PSA (b) 
were used, and all mammalian expressed MFE23 fusion 
proteins (0.2μg/μl each) were analysed in replicate upon 
LS174T, LoVo, and KB cells. Protein constructs were 
differentiated by colours (denotations on the left) with the 
average GMean values indicated respectively. 
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expressing cells by comparing with the cells absent of the mammalian cell made MFE23 
proteins. Generally, according to the associated GMean values from cells bound with the 
MFE23 protein, the LS-MFE23 scFv and MFE23-FN1 constructs depicted better binding 
efficiencies than the three glycosylated MFE23-Ig5-FN1 isoforms. However, in the case of 
anti-PSA directed FACS analysis, only the highly polysialylated MFE23-Ig5-FN1 showed a 
significant shift, where approximately a 12-fold increase in average fluorescent value was 
evaluated by comparing to the other constructs which had almost the same fluorescent 
intensity as the non-MFE23 protein incubated colonic cancer cells (Figure 5.13b). CEA-
negative KB cells were prepared and analysed the same way as the other two cell lines, and 
no live cell binding evidence could be detected.  
 
 
5.3.6.2 Confocal Microscopy for Cell Surface Antigen Binding Detection 
In addition to FACS live-cell binding analysis, more in-depth detection was carried out by 
using confocal laser scanning microscopy (CLSM) (section 2.2.5.10), which allowed focused 
observation of antigen-binding profiles by all MFE23 fusion proteins on live cells with high-
resolution optical images, and topologically investigation of the binding from multiple depths 
of a cell. Again, LS174T cells were used as the CEA expressing cell line, and KB cells were 
prepared as the CEA-negative cell line. Antibodies recognising different features of 
recombinant MFE23 fusion proteins were exploited for antigen-binding development. 
 
Fluorescent CLSM images mediated by Myc-tag specific identifications shown in Figure 5.14, 
5.15 and 5.16(a), directly illustrated the mammalian cell produced MFE23 scFv and fusion 
proteins had generally equivalent CEA antigen binding ability under live cell binding 
conditions. Images received from different post-binding conditions including temperature 
(4ºC and 37ºC) and incubation time (10 minutes and 2 hours) showed the same results 
revealed in the figures above according to each corresponding fusion protein construct (results 
not shown). The in-depth z-stack images of individual cell models demonstrated an identical 
surface antigen binding profile to all MFE23 involving recombinant proteins, especially the 
highly polysialylated MFE23-Ig5-FN1 fusion protein. This proved to have a live cell antigen-
binding profile as the non-glycosylated MFE23 scFv as well, and the overall antibody-antigen 
binding only happened around the cell surface with hardly any internalization interpretations 
indicated by images of planes at various depths. Phase-contrast CLSM images outlining the 
cell shapes further identified the cell surface binding observation after 
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Figure 5.14. Binding of cell surface CEA antigen expressed on LS174T cells by LS-MFE23 scFv and 
MFE23-FN1 fusion proteins.  Fluorescein (Alexa Fluor
®
 488) associated anti-Myc specific detection (I) and 
phase-contrast (II), alongside their merged CLSM images (III) are shown. Images of planes at various depths 
(from bottom to top with 1µm depth interval between each plane) within individual cell samples are illustrated. 
The middle plane images of cell clusters are displayed for the overall CEA binding profiles of both recombinant 
MFE23 proteins. 
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Figure 5.15. Binding of cell surface CEA antigen expressed on LS174T cells by sialylated and weakly 
polysialylated MFE23-Ig5-FN1 fusion proteins.  Fluorescein (Alexa Fluor
®
 488) associated anti-Myc specific 
detection (I) and phase-contrast (II), alongside their merged CLSM images (III) are shown. Images of planes at 
various depths (from bottom to top with 1µm depth interval between each plane) within individual cell samples 
are illustrated. The middle plane images of cell clusters are displayed for the overall CEA binding profiles of 
both MFE23 fusion proteins. 
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Figure 5.16. Binding of cell surface CEA antigen expressed on LS174T cells by highly polysialylated 
MFE23-Ig5-FN1 fusion protein.  Alexa Fluor
®
 488 associated anti-Myc (a) and Alexa Fluor
®
 594 associated 
anti-PSA (b) specific CLSM images (I) are shown alongside their corresponding phase-contrast (II) and 
fluorescent merged images (III). Images of planes at various depths (from bottom to top with 1µm depth interval 
between each plane) within individual cell samples are illustrated. The middle plane images of cell clusters are 
displayed to depict the overall CEA binding profile. 
 
 
overlapping with the fluorescent images. The fluorescent imaging signals mediated by the 
anti-PSA antibody (Figure 5.16b) were only discovered from the highly polysialylated 
MFE23-Ig5-FN1 protein as expected, which also depicted the cell surface targeting 
orientation of the fusion protein. Negative control experiments using KB cell line repeated the 
CLSM preparation protocols using all MFE23 recombinant protein and the positive control 
IgG under the same post-binding incubation conditions. No positive fluorescent signal was 
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revealed under the same CLSM detection settings (described in section 2.2.5.10) (Figure 5.17). 
Positive control experiments using a commercial bivalent IgG antibody against the CEA 
antigen expressed on the LS174T cells also revealed live cell binding (Figure 5.17), 
suggesting the MFE23 motif containing fusion proteins followed the same antigen targeting 
principle.  
 
 
   
 
 
       
      
    
 
    
 
Figure 5.17. CLSM control experiments.  (a) Negative control experiment using KB cells were carried out by 
all MFE23 fusion proteins with the same fluorescent negative results. (b) Binding of cell surface CEA antigen 
expressed on LS174T cells by a commercial bivalent anti-CEA IgG antibody.  Alexa Fluor
®
 488 conjugated anti-
Fc specific CLSM images (I) and phase-contrast (II), alongside their merged CLSM images (III) are shown. 
Images of planes at various depths (from bottom to top with 1µm depth interval between each plane) within 
individual cell samples are illustrated. The middle plane images of cell clusters are displayed to depict the 
overall CEA binding profile. CLSM setting of fluorescent detector-gain reduced 200 degrees comparing to 
recombinant MFE23 proteins. 
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5.3.7 Gel Filtration and Size Exclusion Chromatography 
SEC is a widely used technique for the purification and analysis of synthetic and biological 
polymers. The gel filtration column (HiLoad
TM
 Superdex 200 prep grade) was used to 
compare and define the hydrodynamic radius of each protein construct under aqueous 
environment. Based on the concept of SEC, the larger the size of the water-soluble molecule 
the faster it is filtrated through the column, while a longer time and higher running buffer 
volume will be spent by smaller size molecules trapped in the column gel pores. To identify 
the size improvement after differential sia- and polysialylation post-translational 
modifications, the fusion protein samples were separately injected into the gel filtration 
column (protocol described in section 2.2.5.11). Samples were compared to standard MW 
marker molecules (Table 2.10) for plotting the standard size exclusion curve, of which was 
important to calculate the sample proteins‟ apparent molecular size and hydrodynamic radius 
increment. 
 
Showed in Figure 5.18(a), the gel filtration column was calibrated by the four MW markers 
indicating standard analytical SEC profile. The peak fraction of dextran polymer (2000 kDa) 
defined the void point (52ml fraction) suggesting the largest molecule that the column can 
analytically separate. Under the same physiological buffer conditions, the SEC profiles of all 
MFE23 fusion proteins and glyco-forms are illustrated in Figure 5.18(b). Following the MW 
difference of each fusion protein, fusion proteins containing higher MW were eluted quicker 
than the lower MW ones. Having the same amino acid backbone, the highly polysialylated 
MFE23-Ig5-FN1 fusion protein was eluted more rapidly than the other two glyco-forms, 
which showed its peak fraction just within the maximum column capacity (void point). This 
finding may suggest that under physiological buffer conditions, the increase of sialic acid 
chain length (causing small MW increment) amplified the hydrodynamic volume possession 
of the fusion protein and eventually increased its apparent molecular size. Secondary peaks 
(peak-2s in Figure 5.18b) of each fusion protein and glyco-form were also found from the 
SEC, which were eluted earlier than the predominant peaks (Peak-1s in Figure 5.18b). On the 
other hand, highly polysialylated MFE23-Ig5-FN1 fusion protein showed an opposite eluting 
profile with a major peak (~55ml fraction) appearing more rapidly than a minor eluting drag 
(covering approximately from 60 – 70ml fractions). In addition, protein collected from the 
peak fractions indicated in the SEC (Figure 5.18b) were revealed by SDS-PAGE, and 
specifically identified by various immunoblottings (Figure 5.19). 
 
- 240 - 
 
 
 
 
 
Figure 5.18. Analytical SEC on HiLoadTM Superdex 200 prep grade gel filtration column under 
physiological buffer condition. Size exclusion chromatograms of (a) Standard MW markers and (b) MFE23 
motif containing recombinant proteins were plotted according to the normalized absorbance data (recorded at 
laser wavelength 214nm) against running buffer consumptions for protein elution. Predominantly, two elution 
peaks were found for each MFE23 construct, and were labelled by 1 (higher peak) and 2 (lower peak) with 
corresponding colour indications of the protein samples. Void limit of SEC were signified in both plots based on 
the peak elate value of dextran polymer (2000 kDa). PBS (pH7.4) was used as the running buffer for the SEC 
analysis. 
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Figure 5.19. Western blotting and Coomassie staining analysis of the SEC peak fractions eluted from each 
MFE23 fusion protein or glyco-form. Both anti-Myc and anti-PSA antibodies were used respectively for 
fusion protein and PSA detections. The SEC peak numbers are indicated in correspondence to the labelling 
showed in Figure 5.18(b). Reducing SDS-PAGE was used for separating the proteins and four times more 
sample materials were loaded for Coomassie staining in comparison with the immunoblottings.  
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Dimerization of most of the fusion proteins was speculated to cause the appearances of the 
secondary peaks that eluted more quickly, while the minor SEC elution fractions found in the 
highly polysialylated fusion protein were thought to be caused by the polydispersive PSA 
chain lengths associated with the fusion protein. Based on the SEC, protein fractions were 
collected and concentrated before loading into the reducing SDS-PAGE. Western blot and 
Coomassie staining analysis were followed to identify the protein content. Shown in Figure 
5.19, almost identical results were found for both SEC peaks of each fusion protein, 
particularly demonstrated by anti-Myc immunoblotting and protein staining. The anti-PSA 
antibodies only picked up weakly and highly polysialylated MFE23-Ig5-FN1 fusion protein 
as expected and the smear indicating polysialylation of peak-1 fraction from highly 
polysialylated fusion protein reached higher MW level than its peak-2 elution fraction. In 
addition, weak anti-Myc antibody detections were shown for the LS-MFE23 scFv and 
MFE23-FN1 fusion protein suggesting potential hydrolysis to these proteins without the 
“watery shield” masking established by the additional glycosylation components.  
 
To further analyse the SEC results, the standard elution curve (Figure 5.20) was plotted based 
on the MWs of the four standard markers against their peak elution volumes showed in Figure 
5.18(a). According to the standard curve equation, the apparent MWs (or MWapps) of each 
MFE23 recombinant protein formats were determined in correspondence with their higher 
peaks showed in Figure 5.18(b), as well as the lower peaks apparent MW correspondences. 
Presented in Table 5.2, the apparent MW of the MFE23 scFv indicated by SEC peak 1 was 
almost the same as its calculated MW, while the other fusion proteins‟ apparent MWs 
determined by their SEC peak 1 were much higher than their calculated MWs. Particularly, 
the hydrodynamic volume recruited by the highly polysialylated MFE23-Ig5-FN1 fusion 
protein was worth a protein of 746 kDa alone, however, its calculated MW was only 54 kDa 
despite additional MW from glycan cores and polysialylation (70 kDa maximally). SEC peak 
2 found as an earlier eluate of all protein formats apart from the highly polysialylated MFE23-
Ig5-FN1, determined approximately doubled or tripled apparent MWs of the recombinant 
proteins than the SEC peak 1 indications, while the highly polysialylated MFE23-Ig5-FN1‟s 
second peak showed an reduced apparent MW. Overall, based on the SEC measurement the 
highly polysialylated MFE23-Ig5-FN1 fusion protein demonstrated approximately a 25-fold 
increase of the apparent MW than the MFE23 scFv, and a 6-fold increase over the sialylated 
MFE23-Ig5-FN1. Comparing with the calculated MWs, the apparent MWs determined by 
reducing SDS-PAGE (Table 5.2), on the other hand, suggested relatively consistent LS-
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MFE23 scFv and MFE23-FN1 fusion protein MWs, whilst the three MFE23-Ig5-FN1 glyco-
forms showed increased MWs but not in proportion with their glyco-possession increments.  
 
 
Figure 5.20. SEC standard curve on HiLoadTM Superdex 200 prep grade gel filtration column. The 
standard curve was plotted according to the MW logarithm values of standard markers: (a). Beta-amylase (200 
kDa); (b). BSA (66 kDa); (c). Carbonic anhydrase (29 kDa), against their peak elution volumes. Aligned on the 
standard curve, the apparent MW logarithm values of each MFE23 recombinant fusion protein were calculated 
according to the standard curve equation from their maximum (peak 1) elution volumes. 
 
 
 
 Calculated 
Monomer MW  
(kDa) 
Apparent MW (kDa) 
Peak 2 
Peak 1 SDS-PAGE 
SEC 
Peak 1 Peak 2 
LS-MFE23 29.251 28 29.272 64.011 2.187 
MFE23-FN1 43.706 50 86.827 172.473 1.986 
Sialylated 
MFE23-Ig5-FN1 
53.615 + 0.291n 
~75 119.430 288.026 2.412 
Weakly PolySia 
MFE23-Ig5-FN1 
~75 - 100 150.290 337.418 2.245 
Highly PolySia 
MFE23-Ig5-FN1 
~ 100 - 250 745.641 253.034 0.339 
 
Table 5.2. The SDS-PAGE and SEC measured MWs against the calculated MWs of all MFE23 
recombinant fusion formats.  The table contains the statistical conversion of SEC information display in Figure 
5.18(b) and Figure 5.20, including the two protein chromatogram peaks of each MFE23 fusion protein species 
indicated in Figure 5.18(b), and the direct MW readings from the Coomassie staining showed in Figure 5.19. The 
calculated MWs of each protein were displayed previously in Chapter 3, Table 3. Additional MW that MFE23-
Ig5-FN1 fusion protein gained from different degree (n ≤20 in average) of polysialylation (291 Da per Neu5Ac 
residue) was also indicated. 
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5.4 Discussion 
 
Following on from the success of recombinantly polysialylating MFE23-Ig5-FN1 fusion 
protein in the mouse NB2a cell line (described in Chapter 4), this chapter develops the 
technology via a human cell line. The proof-of-concept investigation in the mouse cell line 
distinctively proved the indispensable involvement of PolyST for PSA elongation along the 
minimal polysialylatable NCAM structure. However, the production of rodent specialized 
Gal(1,3)Gal disaccharide linkage associated in the fusion protein glyco-composition made it 
xenogenic to humans. Consequently, the human cell host (HEK-293 cell line) was transfected 
for the production of recombinantly polysialylated fusion protein. 
 
Prior to switching the fusion protein expression cell host from a mouse to a human cell line, a 
universal biological polysialylation system was established initially through selection of 
HEK-293 cells stably expressing polysialyltransferases - PST or STX. The same transfection 
and selection procedures were performed for both of the PolyST cDNAs on the HEK-293 
cells, and the polyclonal cell lines of both transfectants were collected. The polysialylation 
enzymatic activities of the two polyclonal cell lines were preliminarily determined from the 
autopolysialylation exhibited by the two PolySTs, which was reported previously (Close and 
Colley 1998; Close et al. 2000). From the experimental results, the HEK-293 PST 
transfectants appeared to have a better PolyST endogenous expression level (indicated by 
anti-V5 FACS, Figure 5.2b) and autopolysialylation activity (indicated by anti-PSA Western 
blot and FACS, Figure 5.2a & c).  
 
Rather than selecting a monoclonal cell line with optimal PolyST performance, only a broad 
polyclonal selection was made to generate HEK-293 PST or STX expressing cell lines. This 
was because a secondary monoclonal selection was consequently performed for picking the 
cells with comparatively the best MFE23-Ig5-FN1 fusion protein expression and 
polysialylation levels. An ELISA selection platform was established for this monoclonal 
selection with double parameters after transfection of MFE23-Ig5-FN1 fusion cDNA to the 
HEK-293 PST or STX polyclonal cells. Shown in Figure 5.3, culture media from each of the 
selected monoclonal cell lines were immuno-screened by anti-Myc (for protein expression 
level) and anti-PSA (polysialylation level) antibodies respectively. Monoclonal cell line 2D2 
was eventually selected for producing the polysialylated MFE23-Ig5-FN1 fusion protein with 
a better expression yield and consistency. In addition, poor polysialylation levels were 
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detected from all monoclones selected from STX transfectants (Figure 5.3), which conflicted 
with the positive STX polysialylation activity indicated from the results shown in Figure 5.2. 
It was speculated that the polyclonal HEK-293 STX cell population might contain a number 
of cells that were unable to polysialylate but survived during antibiotic selection alongside 
active STX expressing HEK-293 transfectants. Through a number of cell sub-culturing steps, 
the population of unpolysialylating cells might have overwhelmed the total cell population of 
HEK-293 STX cells, which led to a very low polysialylation level from the MFE23-Ig5-FN1 
fusion construct transfected STX cells. Re-selection of HEK-293 STX cells with stable and 
active STX expression might be required for further study of STX induced polysialylation as 
well as the dual expression of PST and STX to the polysialylatable scFv-Ig5-FN1 fusion 
proteins.  
 
The generation and purification of the polysialylated fusion protein from the selected 
monoclonal cell line 2D2 were followed using the procedures optimized in Chapter 4. 
Consistent purification steps (His6 specific IMAC followed by anion exchange 
chromatography) separated the polysialylated MFE23-Ig5-FN1 fusion protein into sialylated, 
weakly and highly polysialylated glyco-forms again under 100mM, 200mM and 1M NaCl 
eluting conditions. Confirmed by anti-Myc, FN1 and PSA immunoblottings and different 
glycosidase treatment (same results were showed in Figure 4.16 and 4.17 from Chapter 4), the 
glyco-complexity of the fusion protein was analysed by mass spectrometry again. As 
previously encountered, the highly negatively charged PSA chain associated with the fusion 
protein N-glycans was too labile to be measured by MALDI TOF-MS. In order to mask the 
negative charge from the sialic acid carboxyl group, the fusion protein was treated with o-
phosphoric acid, which induced lactonization between the two adjacent Neu5Ac residues 
within the PSA chain. Several different acids and matrix substances for lactonization were 
examined in previous studies, and the current method using o-phosphoric acid and ATT 
(section 2.2.6.8) was suggested to offer the best mass spectra quality (Galuska et al. 2007). 
 
MALDI TOF-MS Analysis 
Purified colominic acid (commercially available) was initially on-target lactonized and 
measured by MALDI TOF-MS. In correspondence to the MALDI TOF-MS results initially 
showed by Galuska, et al (Galuska et al. 2007), sialic acid residues of colominic acid were 
measured with high resolution signal and accurate mass (Figure 5.5 and 5.6). The sensitivity 
of the MS signals was strongly increased when more material was used for the analysis. 
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Signals indicating DP more than 100 NANA residues were able to be detected with 
reasonably high mass accuracy when 6.25μg of colominic acid was measured under the linear 
mode of MALDI TOF-MS (Figure 5.5a), while the reduced amount (3ng) only supported a 
detection range up to approximately 70 NANA residues under the same MS settings (Figure 
5.6a). In comparison with the linear mode for MALDI TOF-MS detection, previously 
described in Figure 4.1, reflectron mode was added to reflect ions, which focuses detection of 
each m/z molecule with same mass but different kinetic energies at the detector. By doing this, 
greatly enhanced mass resolution is achieved compared to the linear mode spectrum with 
consequent increased mass accuracy and reduced noise signals. Particularly shown in Figure 
5.5(b), more sharp and distinguishable mass signals were illustrated in the MS spectrum in 
comparison with the linear mode (Figure 5.5a), and the zoom-in analytical windows clearly 
identified differently ionized small molecules. Shown in the inset of Figure 5.5(b), an H2O 
molecule often associated with the sialic acid fragment was co-ionized and detected with 
exactly 18 Da difference to the singly ionized sialic acid fragment. Signals indicating two or 
more co-ionized water molecules were also clearly detected in the zoom-in analytical 
windows (m/z values not pointed out in Figure 5.5b inset). This detailed information cannot 
be distinguished from the linear mode MALDI TOF-MS detection, and only average mass 
information can be offered from the ion peaks. In addition, shown in Figure 5.6, the detection 
sensitivity, mass resolution and range were greatly reduced when considerably less (3ng) 
sample amount was used for the MS analysis, whilst the reflectron mode remained as 
producing better mass resolution and mass indications than the linear mode, and also 
efficiently demonstrated an average of mass increment (273 Da) reflecting a Neu5Ac (291 
Da).  
 
Polydispersive chain lengths of the commercial colominic acid were also suggested by the 
MS data (Figure 5.5 and 5.6). As suggested by both of the linear and reflectron modes of 
MALDI TOF-MS analysis, different DPs of sialic acid chains were detected. Implied by the 
spectral intensities of both linear and reflectron modes (Figure 5.5), normal distributions of 
colominic acid species were shown based on the amount of each colominic acid species 
(varied by sialic acid chain length). Apparently, species with DP 10 to 25 sialic acid residues 
existed as the majority population in the commercial colominic acid sample, and the amount 
was gradually reduced when the DP increased. The maximal detectable DP reached more than 
100 sialic acid residues when 6.25μg colominic acid was analysed through a linear mode 
MALDI TOF-MS (Figure 5.5a). Linear mode offers a relatively mild condition to measure 
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ionized molecules flying from one side to the other within the MALDI instrument, which 
considerably preserves the integrity of the PSA chain structure. However, despite the 
enhanced detection resolution, sialylated glycans have been reported with substantial loss of 
sialic acid when their spectra were recorded with reflectron-TOF instrument (Papac et al. 
1996; Harvey et al. 2000; Mechref and Novotny 2002). This evidence explained the reduction 
of PSA DP detections on the reflectron mode MALDI MS spectrum (Figure 5.5b), as the loss 
of sialic acid residues or physical breakage of the lactonized PSA chains could easily occur in 
the reflectron mode, resulting differentially fragmented PSA chain structures being measured 
by the MS detector.  
 
Other factors, including acid hydrolysis of PSA during mild acid treatment for lactonization, 
and incompletely lactonized PSA species could also affect the sensitivity, mass accuracy and 
reduce the DP detections for the polysialylated glycans, even under the linear mode. MALDI 
TOF-MS studies on lactonized colominic acid in low temperatures (below 10ºC temperature 
for reducing PSA hydrolysis) (Galuska et al. 2007), or through linear positive ion mode 
analysis (Hsu et al. 2007) suggested similar findings shown in Figure 5.5 and 5.6. To 
conclude, unambiguous identification of PSA species from the polydispersive colominic acid 
sample was determined alongside the polymer chain lengths. Maximum DP value (~100 
NANA residues) was determined by the linear negative ion mode MALDI TOF-MS under the 
average mass indications. The sensitive reflectron mode MALDI TOF-MS analysis confirmed 
the poly-Neu5Ac structure indicated by the linear mode through the exact mass 
determinations. In general, the dispersion of the PSA species was determined with majority 
populations having DP between 5 to 25 NANA residues. 
 
Successful reproduction of colominic acid MALDI TOF-MS analysis confirmed the 
capability of the lactonization method for analysing the PSA composition associated with the 
fusion protein. Previous studies suggested that the maximally detectable PSA chain length 
depends strongly on the amount of material used (Galuska et al. 2007). MS spectra 
comparison between 6.25μg and 30ng colominic acid (Figure 5.5 and 5.6) also supported this 
suggestion, as a much more sensitive and milder detection range was obtained from the 
abundant polysaccharide sample. Also documented in previous studies, purified PSA-NCAM 
(500ng) from postnatal mouse brain was directly on-target lactonized and analysed by 
MALDI TOF-MS with up to ~40 sialic acid residues contained in the associated PSA chains 
(Galuska et al. 2007). The same group also recorded ~55 NANA residues from the same PSA-
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NCAM with roughly 100-fold of the sample amount by HPLC/FD detection (Galuska et al. 
2006). Therefore, in order to minimise the material amount attributed analysis discrepancy, 
100μg of MFE23-Ig5-FN1 fusion protein was used for on-target lactonization treatment prior 
to MALDI TOF-MS measurement. With the colominic acid detections, sensitive and 
unambiguous MS spectra were demonstrated by both linear and reflectron modes for the PSA 
chains associated with the fusion protein (Figure 5.7). Increased mass resolution with accurate 
m/z signal details was again revealed by the reflectron mode (Figure 5.7b inset). Indicated by 
the average mass signals, maximally ~40 sialic acid residues were revealed by the linear mode 
MALDI TOF-MS for the highly polysialylated MFE23-Ig5-FN1 fusion glyco-form (Figure 
5.7a), while the reflectron mode interpreted reduced maximal DP detections (~20 sialic acid 
residues) again due to the instrumental interruptions (Figure 5.7b). These data also showed  
that the highly polysialylated MFE23-fusion protein had a comparable DP and dispersion 
profile with the MOLDI TOF-MS detected the PSA-NCAM extracted from mouse brain 
(Galuska et al. 2007). 
 
Based on the MS detection intensities, the polydispersive profile of highly polysialylated 
MFE23-Ig5-FN1 fusion protein showed most of the fusion proteins had PSA DP between 5 to 
20 NANA residues (Figure 5.7a). In order to avoid the physical breakage conceived by the 
reflectron mode MALDI TOF-MS measurement, only the linear mode detection was used for 
analysing the oligosialic acid chain lengths from the weakly polysialylated and sialylated 
fusion protein glyco-forms. Due to the limited mass accuracy, approximately less than 15 
NANA residues could be detected maximally in the weakly polysialylated glycans (Figure 
5.8a), and their PSA polydispersity was much reduced with most of the chain lengths 
containing around 5 sialic acid residues. The spectrum of sialylated fusion protein confidently 
revealed mass signal for four Neu5Ac chains (Figure 5.8b), while other mass signals were not 
able to be interpreted for sialic acid chain structures. Furthermore, the MS data also supported 
the SDS-PAGE data (Figure 4.16 and 4.17) that was used to define the three fusion glyco-
form with different polysialylation levels. 
 
As an experimental phenomenon, the direct release of the on-target lactonized poly-/oligo-
sialic acid chains from the fusion protein glyco-peptide was encountered during MALDI 
TOF-MS analysis. The question remained unresolved as to whether this release was caused by 
acidic lactonization treatment or partially cleaved by the MALDI instrumental process, 
however, the same PSA release was also reported when analysing lactonized PSA-NCAM by 
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MALDI TOF-MS (Galuska et al. 2007; Hsu et al. 2007). Therefore, the same preparation used 
in Chapter 4 was performed again for understanding the N-glycan core structures from the 
human cell line made fusion proteins. Spectra shown in Figure 5.9 clearly indicated all 
available N-glycan core structures present from the fusion protein, which were similarly found 
from the mouse NB2a cell made fusion protein (Chapter 4, Figure 4.20 and 4.21). In contrast, 
human glycosylation features were expressed from the fusion proteins produced by HEK-293 
cells with no Gal(α1-3)Gal glycosidic linkage detected but additional fucose linkage to the 
first N-acetylglucosamine was detected in most N-glycan core structures.  
 
A specific mutation of the NCAM FN1 domain has been engineered in previous studies, 
which claimed additional polysialylation based on the O-glycans from the FN1 mutate 
(Mendiratta et al. 2006). In order to understand the polysialylation profile of the MFE23-Ig5-
FN1 fusion protein, additional MS experiments were carried out for determining the 
polysialylated O-glycans from the fusion protein. Chemical O-glycan release and 
lactonization steps were processed prior to the reflectron mode MALDI TOF-MS analysis. 
Spectral results showed in Appendix 14 suggested no mass signals indicating NANA repeats 
from the O-glycans of all three fusion protein glyco-forms. 
 
In vitro Antigen Binding Experiment 
The antigen binding properties of all MFE23 fusion protein were detected by: (a) Kinetic 
affinity constant determination using N-A1 as antigen target, and (b) live-cell binding tests on 
CEA antigen expressing cells.  
 
Two major sets of experiment - ELISA and BIAcore
TM
 were used for determine the kinetic 
constants of each MFE23 fusion protein. According to the ELISA results (Figure 5.10), the 
KD values (~3nM) were consistent for all MFE23 fusion proteins and remained unchanged by 
comparing with mouse NB2a made MFE23 fusion proteins (Chapter 4, Figure 4.23). The 
surface plasmon resonance based BIAcore
TM 
system was used to measure the real-time kinetic 
binding profiles of the MFE23 fusion proteins with separate analysis of association (kon) and 
dissociation (koff) rates, which consequently determined the affinity constant (KD) under the 
equation: KD = koff / kon. In comparison with the ELISA determinates, the BIAcore kinetic 
binding models (1:1 langmuir binding) shown in Figure 5.11 suggested slightly higher KD 
values of MFE23 scFv and MFE23-FN1 (~3-5-fold of the ELISA KD), which were more close 
to the MFE23 scFv KD value (~6nM) determined by BIAcore against N-A1 (Sainz-Pastor et al. 
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2006). Moreover, a course of 20 cycles were experimented for each fusion protein sample on 
the same N-A1 immobilized BIAcore
®
 sensor chip. Although the 10mM HCl regeneration 
buffer efficiently cleared the sensor chip for the next cycle sample-run after each dissociation 
phase, a slight drifting baseline perhaps due to the unnecessary bindings to the antigen chip 
could be observed, which led to an artificially increased off-rate, and increased KD value as a 
consequence. Treatments such as subtracting the sample-run with an immediate blank buffer-
run during the evaluation analysis (“double-reference” treatment) was used to reduce the 
drifting baseline effect on the kinetic parameters. Strict BIAcore instrument maintenance and 
cleaning procedures were also carried out to avoid additional contaminations. Furthermore, 
during data evaluation, 1:1 langmuir binding with drifting baseline option was also used, 
however the conducted the fitting models were inadequate as the resulted Chi
2
 values were 
higher than 10% of the Rmax value. 
 
In contrast to the ELISA findings which indicated consistent KD values of all MFE23 fusion 
proteins (Figure 5.10), the BIAcore system presented slower on-rates and eventually higher 
KD values of the polysialylated MFE23-Ig5-FN1 fusion proteins. The high negative charge on 
the BIAcore
®
 sensor chip surface (due to the free carboxyl groups within its 
carboxymethylated dextran matrix) was speculated to cause the hindrance to the association 
of the polysialylated MFE23 fusion proteins which also possess negatively charged PSA. As 
illustrated in Figure 5.21A, the electric repulsion between the two negative charge clusters – 
PSA associated with the MFE23 fusion protein and the SA sensor chip surface, could cause 
the slowing down of the interaction rate between MFE23 and N-A1. The off-rates listed in 
Table 5.1 of all MFE23 fusion proteins behaved consistently comparing to each other, which 
suggested the alterations of affinity constant were focused on the association phases, and 
additional potential reasons are hypothesized in Figure 5.21 to explain the decrease in 
apparent on-rates of the polysialylated fusion proteins.  
 
The potential on-rate reducing factors such as Figure 5.21B, C and D were also suggested by 
the binding kinetics of PEGylated proteins (Kubetzko et al. 2005). The BIAcore kinetic 
analysis of site-specific PEGylated (20 PEG residues) scFv fragment indicated  ~6-fold 
slower on-rate in comparison with the scFv alone (Kubetzko et al. 2005). In our case, the 
highly polysialylated MFE23-Ig5-FN1 had ~16-fold reduced on-rate compared to the MFE23 
scFv alone. This was potentially due to the addition of extra PSA chains recombinantly  
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Figure 5.21. Potential reasons for the decrease in the apparent on-rates of the polysialylated scFv-fusion 
proteins from SPR based BIAcore system. In principle, there are several factors that could reduce the on-rates 
of polysialylated scFv fusion proteins. A. the presence of electric repulsion force (F) that generated by the 
negatively charged PSA possessions of the polysialylated scFv fusion proteins and the BIAcore sensor chip 
surface. This electric repulsion force could also happen between the adjacent polysialylated fusion proteins 
affecting the kinetic binding rates and the antigen sites (1+ n) occupied on the chip surface. B. The PSA chains if 
there were long enough could intramolecularly block the binding region temporarily with rate constants (k1 and 
k-1) for switching polymer conformation between binding-block and binding-unblock status.  C. Translocational 
(kt) and rotational (kr) diffusion limitations would slow the molecule association rate, especially after 
polysialylation, which potentially increases the apparent molecular size and slightly slows down the kt and kr 
rates in real-time binding. D. Polysialylated fusion protein in antigen bound state could temporarily mask other 
antigen sites (n) through its PSA tails, which may intermolecularly hinder the antigen binding of other scFv 
fusion proteins to these sites. Figure was modified from (Kubetzko et al. 2005). 
C. Slower translational or rotational diffusion D. Intermolecular blocking 
A. Electric repulsion B. Intramolecular blocking 
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conjugated to the fusion protein with electric repulsions mentioned above and illustrated in 
Figure 5.21A. The off-rate is concentration independent, and not affected by the factors 
shown in Figure 5.21 during BIAcore analysis. Referring to the BIAcore kinetic results shown 
in Table 5.1, decreased kon values were found from the scFv-Ig5-FN1 fusion proteins, but 
their koff values were kept relatively consistent in comparison with the MFE23 scFv. Shown in 
Figure 5.12, further BIAcore studies where PSA was removed from the fusion protein using 
Endo-N treatment restored the antibody-antigen binding on-rate and the KD value by 
comparing with the scFv kinetic results (Table 5.1), which further confirmed the effect of the 
polymeric glycosylation on reducing the scFv-fusion protein binding on-rates. In order to 
determine the PSA negative charge effect to the antibody-antigen binding kinetic parameters, 
a low or non-charged BIAcore sensor chip with alternative antigen immobilization method 
should be tested. Overall, with the kinetic binding results so far, the on- and off-rates and KD 
values of all MFE23-fusion proteins were significantly evaluated and less than 10-fold 
affinity reduction was determined to the highly polysialylated MFE23-Ig5-FN1 fusion protein. 
Although the highly negatively charged BIAcore sensor chip may exaggerate the electric 
repulsion hindering the association of the polysialylated scFv-fusion proteins, this gives us an 
insight into the biophysical affects of the charged PSA and highlights the need to carry out 
physiological binding studies on live cells. 
 
The understanding of the MFE23-fusion proteins antigen-binding profiles under live cell 
conditions weas determined by FACS and CLSM mediated by specific detecting antibodies. 
Based on the nature of CEA, a cell-surface expressing antigen, colonic cancer cell lines, such 
as LS174T and LoVo cells were used to express native CEA antigen, which can be targeted 
by the MFE23 fusion proteins. Shown in Figure 5.13(a), the anti-Myc mediated FACS 
detections indicated live cell antigen targeting by all MFE23 fusion proteins at the same 
saturating concentration (0.2μg/μl or ~3mM). However, slightly reduced curve shifts from the 
un-targeted cell population, which were also indicated by the mean fluorescent intensity 
values of the three N-glycosylated MFE23-Ig5-FN1 fusion isoforms might suggest some 
degree of inefficiency of antigen targeting to live cells. The potential reasons for decreased 
binding efficiencies can also be explained by Figure 5.21, which cause the polysialylated 
fusions slower on-rates in the BIAcore system. In Figure 5.13(b), only the anti-PSA antibody 
mediated FACS revealed significant positive shift from the highly polysialylated fusion as 
expected. However, rather than a distinguishable narrow cell population, the targeted cell 
populations detected by anti-PSA antibody were very broad. This could possibly be caused by 
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the polydispersity of the PSA chain lengths, which may alter the targeting ratio between the 
anti-PSA antibody and the PSA chains; and conformational variations and water molecule 
masking of the PSA chains in physiological buffer conditions, which may make the secondary 
antibody binding more difficult.  
 
The anti-Myc antibody mediated fluorescent confocal microscopic images showed the same 
cell surface antigen binding profile for all MFE23 fusion proteins (Figure 5.14-5.16a), 
suggesting the polysialylated fusion proteins have comparable antigen localization capacity to 
the scFv. Particularly revealed by the z-stack images, after different post-targeting incubation 
periods (10 minutes and 2 hours) and temperatures conditions (4ºC and 37ºC), similar binding 
and cell surface localization profiles were demonstrated by all MFE23 fusion proteins. 
Potentially having the same issues seen in the FACS experiment, the anti-PSA mediated 
fluorescent CLSM images appeared to be weakly detected, but indicated typical CEA cell 
surface binding throughout the entire cell z-stack imaging by the polysialylated MFE23-Ig5-
FN1 fusion proteins (Figure 5.16b). 
 
Molecular Size 
The concept of using water-attracting polymers to increase the apparent size has already been 
introduced with PEGylated proteins (Figure 1.13). Using PSA, an organic polysaccharide, 
polysialylation followed this concept and successfully proved a prolonged blood circulation 
period and improved pharmacokinetics through chemical conjugations to various proteins 
(section 1.3.1.3). As an alternative polysialylation approach, the apparent molecular size of 
recombinantly polysialylated MFE23-Ig5-FN1 fusion protein was studied by running it 
through a size exclusion column under physiological (1xPBS, pH 7.4) buffer conditions. 
 
Calibrated by MW markers (Figure 5.18a), the size differences of different MFE23-fusion 
proteins and glyco-forms were clearly demonstrated from the SEC (Figure 5.18b). Only 
differing in PSA chain length, the three MFE23-Ig5-FN1 glyco-forms showed significantly 
distinctive elution profiles, and supported the theory of the highly polysialylated glyco-form 
drawing the largest hydrodynamic volume, followed by the weakly polysialylated and lastly 
the sialylated MFE23-Ig5-FN1 fusion protein. Rather than one predominate elution peak from 
the SEC shown in Figure 5.18(b), a secondary elution peak (labelled as 2) suggesting a larger 
molecular size was found for all MFE23 fusion proteins except the highly polysialylated 
MFE23-Ig5-FN1 glyco-form. Under physiological buffer conditions, these secondary peaks 
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were speculated as being dimers (or multimers) of each MFE23 fusion protein species, which 
were presumably caused by the cross-linking between two MFE23 scFvs, as the MFE23 scFv 
has been reported previously to form homogenous dimers (Verhaar et al. 1996; Boehm et al. 
2000; Lee et al. 2002; Constantinou et al. 2009). This hypothesis was further developed by 
running all the peak fractions through reducing SDS-PAGE, which resolves the dimers into 
monomers. Shown in Figure 5.19, anti-Myc and anti-PSA immunoblots and Coomassie 
protein staining revealed identical results between the two peak eluates collected according to 
the SEC shown in Figure 5.18(b), which confirmed that peak 2 (earlier SEC elution peak) was 
a homogenous multimer formation of the MFE23 moiety. Compared to the other fusion 
species, the highly polysialylated fusion protein, however, showed a different gel filtration 
profile with a wider eluting volume range (Figure 5.18b) indicating the polydispersive 
distribution of its apparent size caused by the differential PSA chain lengths associated. The 
SEC peaks suggested that most of the highly polysialylated fusion proteins drew the largest 
apparent size (peak 1 red), while the rest showed gradually smaller sizes until the smallest 
indicated as the peak 2 (red). The anti-PSA immunoblot (Figure 5.19) also demonstrated that 
higher MW was reached by the peak 1 eluate than the peak 2 eluate of the highly 
polysialylated fusion protein. Worth noticing was that the smallest apparent size lay out by 
the highly polysialylated fusion protein was still found to be larger in size than the monomeric 
weakly polysialylated fusion glyco-form (peak 1 pink, Figure 5.18b), which additionally 
confirmed efficient anion exchange separation of the polysialylated fusion protein glycol-
species from the previous purification stages. 
 
Another way to interpret the SEC measurement is to convert the proteins elution peaks 
corresponding in size to apparent molecular masses. Based on the standard conversion curve 
(y = -0.0343x + 4.7245, where y = logMWapp and x = elution volume) plotted by the SEC 
standard MW markers (Figure 5.20), the average MW of a molecule could be calculated 
corresponding to its SEC elution volume (within the analytical gel filtration column 
measuring limit). Listed in Table 5.2, the SEC apparent MW conversions of each MFE23 
fusion proteins were calculated according to their elution profiles and shown in Figure 5.18(b). 
Apart from the highly polysialylated fusion protein, the MWapps of other proteins‟ minor 
peaks (peak 2) showed their ratios to the corresponding peak 1 indicated MWapps resulted in 
approximately a doubled multiple, which again suggests the possible dimerization formation 
of these fusion proteins. Based on the average MWapps of each monomeric fusion protein, the 
corresponding molecular sizes of each molecule can be directly compared following the 
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mathematical equation: V = m/ρ, where V is the volume (or molecular size), m is the mass (or 
MWapp), and ρ is the average density. Assuming the molecules being compared were all 
proteins as material, so they have the same average density, and their size comparison will be 
equally the comparison between their MWapps. In order to compare the hydrodynamic radius, 
a sphere shape assumption for each protein molecule under physiological buffer conditions 
was made, so that the hydrodynamic radius (r) of each sphere can be calculated based on the 
formula:  
 
Therefore, the comparison of the hydrodynamic radius of the fusion protein (rf) against the 
hydrodynamic radius of LS-MFE23 scFv (Ø) can be calculated as: 
 
where mf  stands for the MWapp of the MFE23 fusion proteins, and mØ stands for MWapp of the 
LS-MFE23 scFv. 
 
With the MWapp values availably presented in Table 5.2, the hydrodynamic radii of each 
fusion protein can then be interpreted as ratios of the hydrodynamic radius of LS-MFE23 
scFv (Ø), and the great circles implying each fusion protein spherical size are therefore shown 
in Figure 5.22(a) below. 
 
Based on the prediction (Figure 5.22a), the maximal 2.94-fold hydrodynamic radius 
improvement was made by the polysialylated MFE23-Ig5-FN1 fusion protein in comparison 
with the MFE23 scFv. Although the apparent shapes of each fusion protein might not appear 
to be a complete sphere, the analytical postulations shown in Figure 5.M illustrate the average 
proportional comparisons against the scFv molecules in terms of the apparent size differences 
under physiological aqueous conditions. Schematically explained in Figure 5.22(b), the 
effectiveness of molecular size enhancements after recombinant polysialylation of the MFE23 
fusion proteins induced by the increased hydrodynamic volume from the water attracting PSA 
molecules has been clearly demonstrated by the SEC experiments. Based on these results, 
size-related improvement of antibody fragment pharmacokinetics including blood circulation 
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longevity and kidney elimination rate after intravenous injection (i.v.) were expected from the 
consequent in vivo studies. 
 
 
 
 
Figure 5.22. Postulated schematic illustrations of MFE23 fusion protein apparent hydrodynamic radii. 
Molecules were postulated as sphere shape in aqueous condition. (a) Hydrodynamic radii indicated in great 
circles of each protein spheres. MFE23-FN1 (blue), sialylated (green), weakly polysialylated (pink) and highly 
polysialylated (red) MFE23-Ig5-FN1 fusion protein hydrodynamic radii were calculated and indicated as 
multiplications of MFE23 scFv (black) hydrodynamic radius (Ø). Due to the polydispersive degree of 
polysialylation, the dotted and solid red circles outlined the apparent size range the highly polysialylated 
MFE23-Ig5-FN1 induced. (b) Schematic comparison of apparent size differences in proportion to the 
hydrodynamic radius increments. Hydrodynamic volumes are interpreted by light blue circles masking the 
embedded proteins. 
 
 
 
 
 
 
 
 
(a) 
(b) 
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6.1 Introduction  
 
A series of SEC experiments described in Chapter 5 suggested an incremental relationship 
between polysialylation and hydrodynamic radius. Caused by the hydrophilicity and water 
attraction of the associated PSA molecules, different hydrodynamic volume sizes were also 
suggested by SEC based on variations from the PSA chain length (sialylated, weakly and 
highly polysialylated scFv-fusion proteins). After estimating the increase of the 
hydrodynamic radii of the polysialylated scFv-fusion proteins in comparison with the scFv, 
further understanding of how size affects the renal ultrafiltration, and protein blood clearance 
in live animal models was the next logical step.  
 
As already mentioned in section 1.2.2.3, renal ultrafiltration is one of the main routes that 
small molecules, such as scFvs, is eliminated from the blood circulation (within hours after iv 
injection) (Tang et al. 2004; Mahmood and Green 2005). In the kidneys, glomerular 
permeabiliy is selectively restricted by a double barrier constituting a basement membrane 
that primarily functions as a coarse filter, and an epithelial slit diaphragm that operates at a 
more distal site in the capillary wall as a fine screen (Deen et al. 1979; Caliceti and Veronese 
2003). Despite other factors that kidneys utilize for permeaselectivity, such as charge and 
glycosylation, the glomerular capillary wall can simply be considered as a porous filter 
capable of size-selective discriminations. Having a MW cut-off of about 70 kDa for 
eliminating native globular proteins from kidney, which is close to the MW of serum albumin, 
macromolecules possessing effective sizes larger than the size of a 70 kDa protein or albumin, 
will avoid the ultrafiltration and return into the bloodstream (Deen et al. 1979; Rabkin and 
Dahl 1993).  
 
Although renal clearance of macromolecules usually refers to their MW, it does not 
accurately define the effective size of macromolecules. Due to the compact and globular 
structure of proteins, the blood half-life of a protein, with its coiled and extended 
conformation, can be the same as a hydrophilic polymer wth a much lower MW. For example, 
cytochrome c (13 kDa) displays the same hydrodynamic radius (2nm) as a 5 kDa PEG, and 
shares the same blood half-life of 18minutes (Nakaoka et al. 1997; Sherman et al. 1997). 
Hydrophilic polymers, such as PEG and PSA have been effectively used to increase the 
antibody fragment hydrodynamic volume with minimum MW increase, and with improved 
phamarcokinetics, have eventually prolonged protein blood circulation time (Caliceti and 
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Veronese 2003; Constantinou et al. 2009). Other than knowing the MW cut-off for kidney 
elimination, previous studies also reported that the pore size of the glomerular basement 
membrane is in the range of 3-5 nm (Nakaoka et al. 1997), which more precisely defines the 
minimum hydrodynamic radius for macromolecules to avoid being sieved-off by the 
glomerular filtration. Furthermore, Yamaoka et al. studied the effect of MW on the time 
course of PEG elimination from blood. They concluded that PEGs smaller than 8 kDa cleared 
very quickly without any restriction via kidney ultrafiltration, whereas the elimination of 
PEGs in the range of 8-30 kDa was controlled by the apparent size difference. Lastly for PEG 
MW over 30 kDa, the blood clearance was slowed down and no significant difference could 
be observed (Yamaoka et al. 1994; Yamaoka et al. 1995). Nakaoka et al. consequently 
revealed that the 30 kDa PEG has a hydrodynamic diameter of about 8nm which indirectly 
outlines a size cut-off for kidney elimination as compared to its pore size (Nakaoka et al. 
1997).   
 
 
 
6.2 Aims and Objectives 
 
In order to investigate on the in vivo blood clearance effect by the recombinantly 
polysialylated scFv-fusion protein, the laboratory-bred BALB/c mouse, the most widely used 
inbred strains used in animal experimentations was used for intravenous injections of radio-
labelled protein samples through the tail vein. Blood samples at different post-injection time 
points were collected for analysing the clearance rates as well as tissue distribution studies. 
 
The objectives are: 
■ Determining the blood clearance rates of LS-MFE23 scFv, sialylated and highly 
polysialylated MFE23-Ig5-FN1 fusion proteins by measuring the radioactivity from of the 
collected mouse blood samples at different time points after intravenous injections. 
■ Biodistribution analysis of the scFv and scFv-fusion proteins at 6 hours and 24 hours after 
in vivo intravenous injections, including the average radioactivity measurement of major 
tissues and the radioactivity ratio against the blood content for non-specific binding 
investigations. 
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6.3 Results 
 
6.3.1 In vivo Blood Clearance Studies 
In order to ascertain the effect of the recombinant MFE23 fusion protein and its polysialylated 
isoform on scFv blood clearance, laboratory-bred normal female BALB/c mice were injected 
with 300μl (~10μg) 125I-labelled LS-MFE23 scFv, sialylated MFE23-Ig5-FN1 and highly 
polysialylated MFE23-Ig5-FN1 fusion proteins respectively (section 2.2.7.1) intravenously 
into the tail veins (section 2.2.7.2). Collected according to different post-injection time points 
(0.5, 1, 2, 4, 6, 24 hours) by microhematocrit capillary tubes (section 2.2.7.3), blood sample 
radio-activity was measured by a gamma counter and analysed after correction for the same 
weight of blood (Figure 6.1). 
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Figure 6.1. Blood clearance of different MFE23 fusion proteins.  I
125
 -labelled LS-MFE23 scFv, sialylated 
and highly polysialylated MFE23-Ig5-FN1 fusion protein samples in vivo blood clearance rates were measured. 
Substrates were injected i.v (20μg/mouse) and blood samples were taken over the subsequent 24 hours. The 
dotted line (grey) separates the redistribution phase α and elimination phase β of the fusion protein blood 
clearance curves.  In particular, the radioactively labelled highly polysialylated MFE23-Ig5-FN1 fusion protein 
(2) was compared with the over-oxidized highly polysialylated MFE23-Ig5-FN1 (1) for the clearance study. 
 
 
Comparing blood clearance curves between the three MFE23 recombinant fusions (Figure 
6.1), the polysialylated MFE23-Ig5-FN1 fusion protein clearly showed the slowest blood 
Redistribution phase α 
Elimination phase β 
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clearance profile and prolonged residence time within the body circulation. The sialylated 
fusion protein showed a comparatively steeper slope of the β phase to the polysialylated, 
suggesting quicker blood clearance rate, however it is clearly found to be much slower than 
the scFv within the course of 24 hours. A much slower redistributional α phase was also 
found for the highly polysialylated fusion protein than the sialylated and scFv. In addition, the 
protocol used for over-oxidizing the fusion proteins through radio-iodination by mixing with 
activated iodide in the Pierce® Pre-Coated Iodination Tubes (section 2.2.7.1) could 
potentially change the physiochemical property of PSA, hence its water-attracting capacity. 
This is because the iodination tubes are coated with the iodination reagent (1,3,4,6-
tetrachloro-3α, 6α-diphenylglycouril; formerly called “IODO-GEN” Iodination Reagent), 
which is an effective oxidizer (Saha et al. 1989; Bailey 1996). As shown in Figure 6.1, a 
much less significant blood clearance effect was found for the highly polysialylated MFE23-
Ig5-FN1 that was over-oxidized in comparison with its more gentle labelled form. Based on 
Figure 6.1, more precise statistical analysis of the fusion protein blood clearance profiles are 
listed in Table 6.1. 
 
Fusion 
proteins 
t1/2α (hr) t1/2β (hr) 
Increase 
of t1/2β 
(fold) 
AUC 
(% hour/gram) 
Incresae 
of AUC 
(fold) 
MFE23 scFv 0.301 ± 0.188 2.658 ± 0.438 1.0 19.791 1.0 
Sialylated 
MFE23-Ig5-FN1 
0.353 ± 0.067 4.784 ± 1.100 1.8 37.856 1.9 
Highly PolySia 
MFE23-Ig5-FN1 
1.474 ± 2.320 39.383 ± 7.265 14.8 519.140 26.2 
Highly PolySia 
MFE23-Ig5-FN1  
(over-oxidized) 
0.441 ± 0.124  8.004 ± 2.189 3.0 54.501 2.8 
 
Table 6.1. Summary of Pharmacokinetic Parameters. Based on the blood clearance profiles shown in Figure 
6.1, the blood clearance profile was fitted to a biexponential decay model and t1/2α and t1/2β were determined. 
The bioavailability or blood exposure was determined by calculating the area under the blood clearance curve 
(AUC). 
 
 
As listed in Table 6.1, short half lives of the α phase (t1/2α) were displayed by both MFE23 
scFv (~18 minutes) and the sialylated MFE23-Ig5-FN1 fusion protein (~21 minutes) before 
venturing off into different tissues. Considerably improved, the highly polysialylated MFE23 
fusion protein showed a much reduced clearance rate with longer t1/2α (~5-fold comparing 
with the scFv). In terms of blood circulation time, the highly polysialylated fusion protein 
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demonstrated a significantly increased half life of the elimination phase (t1/2β), which was 
found to be ~15-fold higher than the scFv that only appeared to be maintained in the body 
around 2 and half hours. The sialylated fusion protein also showed moderately improved 
blood circulation time, but only ~1.8-fold enhancement was measured in comparison with the 
scFv. Also shown in Table 6.1, the AUCs indicating the bioavailablity of the three MFE23 
recombinant fusions were analysed according to the blood clearance profile shown in Figure 
6.1. The AUC value of the highly polysialylated fusion protein was approximately 26-fold of 
that of the scFv and 14-fold of the sialylated fusion. This suggests that a high proportion of  
polysialylated fusion species were kept in the body without being eliminated within 24 hours 
due to the slowest blood clearance rate of the out of the three recombinant fusions. Already 
illustrated from Figure 6.1, the over-oxidized PolySia MFE23-Ig5-FN1 appeared to 
ineffective compared to the fusion protein under the normal radio-labelling process, and it had 
almost the same t1/2α as the sialylated MFE23 fusion protein. An inefficient blood circulation 
time was also found as only 3-fold increase of t1/2β and 2.8-fold improvement of AUC were 
demonstrated by the over-iodinated PolySia MFE23-Ig5-FN1 compared to the scFv.  
 
 
6.3.2 In vivo Biodistribution Analysis 
In order to investigate the tissue distribution of the three MFE23 recombinant fusions after 
sample injection, mice culled at 6 hours and 24 hours were dissected, and the radioactivity of 
six different tissues including spleen, kidney, liver, heart, lung, and gastrointestines alongside 
blood collections were measured. The results (outlined in Table 6.2) are presented as the 
percentage of the radioactivity out of the injected dose (ID) against the weight (gram) of the 
measured tissue and compared in Figure 6.2.     
 
Compared in Figure 6.2, the blood contents of the three MFE23 recombinant fusions follow 
the clearance profile shown in Figure 6.1, as more polysialylated fusions were kept in the 
circulation than the sialylated that was left more than the scFv at both 6 hours and 24 hours 
post-injection time points. Clear contrasts are demonstrated for each protein blood level 
between 6 hours and 24 hours, and more than 92% scFv was eliminated during the two time 
points, while ~84% and 82% reductions were found for the sialylated and polysialylated 
fusion proteins (Table 6.2) 
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Table 6.2. Biodistribution of MFE23 scFv, sialylated and over-oxidized highly polysialylated MFE23-Ig5-
FN1 fusion proteins in mice at 6 and 24 hour post-injection time points. Normal BALB/c mice were culled at 
6 and 24 hour time point after i.v. The average radioactivities of each tissue were measured, and the results were 
displayed as mean values ± standard deviations (SD) of four mice. 
 
 
Time 
(hr) 
% Injection dose/gram of tissue 
Blood Spleen kidney Liver Heart Lung GI 
MFE23 
scFv 
6 1.04 ±0.57 0.89 ±0.47 3.07 ±1.45 0.79 ±0.75 0.61 ±0.37 2.60 ±2.27 0.90 ±0.44 
24 0.08 ±0.01 0.14 ±0.03 0.84 ±0.13 0.16 ±0.06 0.05 ±0.01 0.31 ±0.09 0.03 ±0.01 
Sia 
MFE23-
Ig5-FN1 
6 1.65 ±0.40 0.67 ±0.15 1.87 ±0.77 0.83 ±0.24 0.68 ±0.18 1.49 ±0.50 0.57 ±0.25 
24 0.27 ±0.06 0.12 ±0.05 0.78 ±0.39 0.13 ±0.08 0.12 ±0.05 0.32 ±0.16 0.07 ±0.03 
PolySia 
MFE23-
Ig5-FN1 
(over-
oxidized) 
6 2.83 ±0.71 1.39 ±0.49 3.54 ±2.62 1.20 ±0.90 0.95 ±0.06 1.60 ±0.32 1.46 ±0.87 
24 0.51 ±0.18 0.47 ±0.26 2.55 ±0.61 0.53 ±0.33 0.15 ±0.05 0.35 ±0.06 0.08 ±0.04 
 
 
 
 
Figure 6.2. Biodistribution analysis of MFE23 scFv, sialylated and over-oxidized highly polysialylated 
MFE23-Ig5-FN1 fusion proteins. This bar-chart directly interprets the data listed in Table 6.3.  
 
 
The biodistribution data shown in Table 6.2 can also be evaluated as the tissue to blood ratios. 
Based on the values shown in Table 6.3, if the ratio found is less than one, it means that a 
higher protein sample level remains in the blood than the specific tissue. Alternatively, if ratio 
is more than 1, an accumulation of the protein content in specific tissues can be explained, or 
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the blood clearance rate is faster than the protein transporting rate from tissues back to the 
circulation system. Displayed graphically in Figure 6.3, despite the kidney, in other tissues 
both sialylated and polysialylated fusion proteins showed tissue/blood ratios of less than one 
at both 6 hours and 24 hours after injection, suggesting a higher blood content due to the 
reduced clearance rate. The scFv showed spleen, liver and lung to blood ratios more than 1 
particularly at the 24 hours time point, indicating a rapid blood elimination rate. For the 
kidney, all three recombinant fusion proteins showed kidney/blood ratios more than 1 at 24 
hours. As the site where small molecules are being filtered out from the body, accumulations 
of the protein samples were indicated, especially the scFv which showed closely to a value of 
10 for this ratio, while the polysialylated fusion protein only had a ratio value of 5, suggesting 
a prolonged period of the sample circulating in the blood. In addition, free iodines degraded 
from the conjugated protein are quickly eliminated from the circulation, leading to a relatively 
high radioactivity measurement in the kidney at early time points. 
 
Overall, all these data suggested that the MFE23 fusion proteins did not produce non-specific 
tissue bindings. However, the biodistribution study for the polysialylated MFE23-Ig5-FN1 
fusion protein after normal radio-labelling is still needed in order to understand the non-
specific tissue binding profile of biosynthesized PSA, as the polysialylated MFE23 fusion 
proteins used in the biodistribution were over-oxidized during iodination. 
 
Table 6.3. Mouse tissue/blood ratios of MFE23 scFv, sialylated and highly polysialylated MFE23-Ig5-FN1 
fusion proteins at 6 and 24 hour post-injection time points. Results were displayed as mean values ± standard 
deviation (SD) of four mice. 
 
 
Time 
(hr) 
Tissue to blood ratio 
Spleen kidney Liver Heart Lung GI 
MFE23 scFv 
6 0.86 ±0.45 2.95 ±1.39 0.76 ±0.72 0.58 ±0.36 2.50 ±2.19 0.87 ±0.43 
24 1.75 ±0.33 9.97 ±1.58 1.94 ±0.70 0.61 ±0.16 3.69 ±1.04 0.35 ±0.05 
Sia 
MFE23-Ig5-FN1 
6 0.41 ±0.09 1.14 ±0.47 0.51 ±0.14 0.41 ±0.11 0.91 ±0.30 0.35 ±0.15 
24 0.45 ±0.20 2.83 ±1.44 0.46 ±0.31 0.45 ±0.17 1.17 ±0.57 0.24 ±0.10 
PolySia  
MFE23-Ig5-FN1 
(over-oxidized) 
6 0.49 ±0.17 1.25 ±0.92 0.42 ±0.31 0.34 ±0.02 0.55 ±0.11 0.52 ±0.31 
24 0.92 ±0.51 5.01 ±1.20 1.05 ±0.64 0.30 ±0.10 0.68 ±0.13 0.16 ±0.07 
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Figure 6.3. Mouse tissue/blood ratios of MFE23 scFv, sialylated and highly polysialylated MFE23-Ig5-FN1 
fusion proteins at 6 and 24 hour post-injection time points.  This bar-chart directly interprets the data listed in 
Table 6.3. A red dashed line outlines the tissue/blood ratio equals to 1. 
 
 
 
 
 
6.4 Discussion 
 
Based on the hydrodynamic volume analysis using size exclusion chromatography (described 
in section 5.3.7), protein samples (LS-MFE23 scFv, sialylated MFE23-Ig5-FN1 and highly 
polysialylated MFE23-Ig5-FN1 fusion proteins) with in vitro apparent size discriminations 
were radio-labelled and intravenously injected into healthy laboratory-bred BALB/c mice for 
blood clearance and in vivo biodistribution studies.  
 
Due to the size-selective function of animal kidney, rapid circulation elimination was found 
by the scFv molecule (eliminated within 1 day), which was also reported by previous 
investigations (Verhaar et al. 1995; Adams et al. 1998). As expected, having increased 
hydrodynamic volumes, the sialylated and polysialylated scFv-fusion protein indicated 
significantly delayed blood clearance rates, where the latter was found to be more slowly 
eliminated (t1/2β) with longer bioavailablity (AUC) within the mouse body (Figure 6.1 and 
Table 6.1). Mentioned in the introduction of this chapter, it is very important to understand 
1 
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the actual size outlines of the MFE23 fusion proteins in comparison with the size cut-off for 
kidney elimination and how this correlated to the protein pharmacokinetic behaviours 
obtained from the in vivo studies. Previous study showed that human serum albumin (HSA) 
had only a minor difference between apparent MW from SEC and its calculated MW (66 kDa) 
(Stork et al. 2008). With the knowledge of the hydrodynamic radius of HSA (3.5nm) (Stork et 
al. 2007), the hydrodynamic radius of LS-MFE23 scFv (Ø) can be estimated following the 
equation introduced in the discussion section of Chapter 5: 
 
where the rf and mf values are the hydrodynamic radius and SEC apparent MW of HSA, and 
the MWapp of LS-MFE23 scFv (mØ) is obtained from Table 5.2. 
 
Consequently, following the statistical comparison showed in Figure 5.22(a), the 
hydrodynamic radius can be calculated as ~4.3nm for the sialylated MFE23-Ig5-FN1 fusion 
protein, and within the range of ~5.4 – 7.8nm for the highly polysialylated fusion. Clearly, 
both fusion glyco-forms exceeded the glomerular membrane pore size, whereas the 
polysialylated fusion also greatly surpassed the size cut-off limit (radius: ~4nm) for kidney 
elimination. These findings correlate to the results from in vivo PK studies listed in Table 6.1, 
and explained the increases in t1/2α and overall AUC from the scFv to the polysialylated 
fusion protein. 
 
Although studies on PEGs possessing hydrodynamic volumes exceeded the size cut-off for 
kidney elimination, they did not show a significant blood clearance difference between each 
other (Yamaoka et al. 1994; Yamaoka et al. 1995). Hydrolysis of biodegradable material (i.e. 
PSA) and the protein itself will lead to a gradual size reduction process until it becomes 
smaller than the size cut-off limit and is eliminated more rapidly through glomerular filtration. 
Therefore, for protein-polymer conjugates having an apparent size more than the kidney 
elimination cut-off, in general the longer of the associated polymer, the slower the blood 
elimination rate (t1/2β) will become, alongside longer circulation exposure time. Also 
supported by PEGylated proteins (Knauf et al. 1988; Caliceti and Veronese 2003), and 
chemically polysialylated antibody fragments (Constantinou et al. 2008; Constantinou et al. 
2009), proteins conjugated with higher MW of hydrophilic polymers resulted in significantly 
increased apparent sizes and prolonged residence in the blood. These polymers used for 
chemical conjugation were composed in linear forms, and their MW increases directly 
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correlated with the prolongations of polymeric chain length or DP. The in vivo experiments 
(Figure 6.1) using two fusion proteins with different degree of polymerization (DP) 
consequently indicated the importance of the polymer chain length in delaying the protein 
blood clearance rates. The DPs of sialylated and highly polysialylated MFE23-Ig5-FN1 fusion 
proteins were determined by MALDI TOF-MS previously, where average of approximately 4 
and 20 sialic acid repeats were detected respectively (Figure 5.7 and 5.8). Therefore, 
statistically the highly polysialylated fusion protein had DP ~5-fold of the sialylated fusion 
protein, which led to its in vitro hydrodynamic radius ~3.8-fold of the MFE23 scFv (Figure 
5.22) and ~26-fold of the scFv‟s blood AUC. In comparison, the chemically conjugated 
MFE23 scFv with single 11 kDa (DP~37 NANA residues) has been previously reported to 
increase the blood AUC to ~10-fold of the scFv, as well as ~1.7-fold and 3.6-fold increase of  
in vivo t1/2α and t1/2β respectively (Constantinou et al. 2009). It is then noticeable that the 
highly polysialylated MFE23 fusion protein gains additional Ig5 and FN1 NCAM-domains 
and one extra N-glycosylated PSA chain, leading to potentially a larger hydrodynamic volume 
and better AUC than the site-specific chemical-polysialylated MFE23 scFv. 
 
Additionally, the negative charge masking from the PSA can also alter protein ultrafiltration 
through the kidney. Based on the structure of glomerular basement membrane, expression of 
very proximal sialoprotein-rich elements in the membrane epithelium and lamina rara interna 
predominately retard the filtration process of the circulating polyanions, whereas the more 
distal elements found in the lamina rara externa of the glomerular basement membrane retard 
the clearance of cationic macromolecules (Deen et al. 1979; Rabkin and Dahl 1993). 
Moreover, additional studies suggested that the anionic macromolecules appeared to be 
cleared by renal ultrafiltration more slowly than neural or positive ones (Takakura et al. 1990). 
Therefore, the negative property of the associated sialic acid can be more beneficial for 
prolonging protein stability in the bloodstream, and enhancing this negative charge possession 
(i.e. increased PSA DP) can be another potential factor to slow down the protein blood 
clearance rate. Other factors, such as polymer flexibility, conformation, and deformability, 
alongside the hydrolysis rate of polysialylated fusion protein, could also affect the protein 
kidney elimination profiles (Caliceti and Veronese 2003; Olafsen et al. 2004). 
 
The biodistribution studies of the three MFE23 recombinant fusions showed rather similar 
results, suggesting the recombinant fusion of the polysialylated NCAM domains to the 
MFE23 scFv did not effect the antibody fragment localization within animal body tissues 
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after injection. Especially suggested by Figure 6.3, the kidney/blood ratios of the 
polysialylated fusion protein were found to be lower than the scFv, indirectly indicating a 
slower clearance rate, as less polysialylated fusion content was found trapped in the kidney 
during the clearance process comparing too the scFv. In order to investigate the in vivo 
antigen targeting profile of the fusion proteins, further biodistribution studies can be made on 
mice bearing CEA expressing tumours. Properties including high tumour specific localization, 
prolonged tumour retention time and good tumour/blood ratio of the polysialylated MFE23-
Ig5-FN1 fusion protein are expected in comparison with the MFE23 scFv.   
 
The over-oxidization of the PSA from fusion proteins could possibly occur when radio-
labelling the fusion protein with excessive iodination reagent (“IODO-GEN”), which is an 
effective oxidizer. This modification has been showed to reduce the PSA capacity for 
increasing the hydrodynamic radius (Figure 6.1 and Table 6.1). Shown in Figure 5.1, 
lactonized PSA as one major product can be easily formed from acid-catalysed oxidation 
process (Zhang and Lee 1999), and the hydrophilicity of lactonized PSA has not been 
reported so far. Although the normal iodination process avoided direct contact of the 
polysialylated fusion protein with the iodination tube (section 2.2.7.1), a lower degree of PSA 
oxidation can still occur during the radioactive iodine labelling process, which can affect the 
PK modulation performance from the polysialylated species. For improvements, alternative 
radio-labelling methods that avoid any potential physiochemical changes to the PSA and 
protein should be considered. In addition, it will be important to investigate the non-specific 
binding profile of the biosynthesized PSA from the polysialylated fusion protein, as only the 
potentially over-oxidized PSA fusion forms were used in the biodistribution studies.   
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CHAPTER 7 
 
Generation of Recombinantly Polysialylated 
C6.5 scFv Fusion Protein  
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7.1 Introduction  
 
Based on the successful development (in vitro and in vivo) of recombinant polysialylation 
using the MFE23-Ig5-FN1 fusion protein, another scFv model was consequently tried to 
further exemplify the concept of recombinant polysialylation through fusion with specific 
NCAM domains, and verify the adaptability of the recombinant polysialylation technology for 
different scFv models.  
 
As determined from previous studies on chemically polysialylated MFE23 scFv 
(Constantinou 2005; Constantinou et al. 2009), as well as the recombinantly polysialylated 
MFE23-Ig5-FN1 fusion proteins (previous chapters), the antigen interaction between the 
polysialylated MFE23 scFv (or fusion) and the CEA were retained compared to the scFv 
alone. With a relatively good understanding of surface antigen binding by the polysialylated 
scFv, unanswered question was whether the association of the polyanionic PSA interrupts the 
process of internalization. In addition, studies on the surface charge of mammalian cells 
showed the negative charge of the inner leaflet of the plasma membrane, to be predominantly 
made up of two low-negatively charge of the high lipid content monovalent phospholipids, 
phosphatidylserine (PS) and phosphatidylinositol (PI) (McLaughlin and Murray 2005; Yeung 
and Grinstein 2007; Yeung et al. 2008; Goldenberg and Steinberg 2010). Differing to other 
bio-polymers, PSA possesses a highly negative charge which increases with the PSA DP. A 
potential electric repulsion between the cell membrane, particularly the inner-leaflet and the 
polysialylated scFv would be generated especially during transmembrane processes after scFv 
binding to internalizing cell receptors. 
 
As an important oncogene product and therapeutic target particularly overexpressed in breast 
and prostate cancer, HER2 represents a type of cell surface tumour antigen that undergoes 
dimerization and internalization. Background on the HER2 antigen, especially in malignant 
conditions has been described previously in section 1.1.4.1 (trastuzumab) and its signal 
transduction was also showed in Figure 1.4. Based on the induction of HER2 internalization, 
C6.5 scFv was chosen as another antibody fragment model to be genetically engineered for 
recombinant polysialylation. Overcoming the limitations of whole IgG molecules (section 
1.2.1), the human scFv molecule, C6.5 was selected by phage display of antibody gene 
repertoires, and has a high affinity (KD of 16nM) for the human c-erbB2, the extracellular 
domain of HER2 antigen, and a KD of 20nM to the HER2 expressing cell line – SKOV3 
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(human ovarian cancer cell) (Schier et al. 1995). Like trastuzumab, C6.5 scFv or its diabody 
format were used in previous studies for monitoring HER2 internalization process under live 
cell conditions (Nielsen and Marks 2000; Adams et al. 2004; Robinson et al. 2005; Robinson 
et al. 2008).  
 
 
 
7.2 Aims and Objectives 
The aim for this chapter was to genetically create another recombinant polysialylated scFv-
Ig5-FN1 fusion protein, in order to expand the concept of antibody fragment polysialylation 
through a recombinant fusion approach. C6.5 scFv was chosen as the model scFv based on its 
transmembrane activity after HER2 ligand binding. Following the already established 
recombinant polysialylation protocols and materials (i.e. HEK-293 PolyST cell host), C6.5 
recombinant fusion proteins could be produced. In additionto characterisation of the fusion 
protein, HER2-polysialylated C6.5 fusion protein internalization was also investigated. 
 
The objectives are: 
■ Genetically clone C6.5 scFv cDNA into polysialylatable mammalian expression vector, 
alongside with other fusion motifs, and generate C6.5-Ig5-FN1, C6.5-FN1, and LS-C6.5 
fusion construct cDNAs. 
■ Transfection C6.5-Ig5-FN1 and other C6.5 fusion protein cDNAs to the HEK-293 PolyST 
cells and selection of individual monoclonal cell lines with good protein expression and 
polysialylation level. 
■ Generation, purification and characterization of recombinantly polysialylated C6.5-Ig5-FN1 
fusion protein, alongside other C6.5 fusion proteins. 
■ In vitro antigen binding affinity investigation of polysialylated C6.5 fusion proteins and 
other recombinant C6.5 proteins. 
■ In vitro live cell binding studies of polysialylated C6.5 fusion proteins and other 
recombinant C6.5 proteins. 
■ Preliminary in vitro investigations on C6.5 bound HER2 internalizations under different 
live cell incubation conditions 
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7.3 Results 
 
7.3.1 Cloning of Recombinantly Polysialylatable C6.5 Fusion Protein 
The construction of recombinantly polysialylatable C6.5 fusion protein cDNA was based on 
the successful genetic construction of MFE23 fusion proteins. Figure 7.1 illustrates the 
principle of genetically making recombinant fusion antibodies for polysialylation.  
 
 
Figure 7.1. Schematic genetic cloning process for C6.5-Ig5-FN1 and C6.5-FN1 constructions in 
mammalian expression vector pcDNA4a.  The general recombinant polysialylation scheme is simultaneously 
illustrated as the scFv portion can be potentially available for any scFv candidates or substituted by other protein 
constructs that require polysialylation. Important restriction sites are indicated, alongside different protein 
domain information. LS: NCAM expression leader sequence. Figure modified from (Constantinou 2005). 
 
 
Previously generated by Dr Constantinou (Constantinou 2005), the intermediate constructs 
maintained in the mammalian expression vector pcDNA4a contained essential NCAM 
domain genes, and served as starting clones for incorporating the recombinantly 
Hind III Hind III 
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polysialylatable fusion constructs. Illustrated in Figure 7.1, double digestion of the 
intermediate constructs with PciI and NotI restriction endonucleases was shown to create 
ligation sites for incorporating other sub-genes. Digested PciI and NcoI restriction sites can 
re-ligate to each other, however both restriction sites are lost after such ligation. The cloning 
scheme was firstly introduced to incorporate recombinantly polysialylatable MFE23 fusion 
proteins (Constantinou 2005), and was used here for generating the C6.5 scFv fusion 
constructs as the first succession of the MFE23 scFv fusions. 
 
C6.5 scFv Gene Extraction  
The C6.5 scFv gene was originally maintained in the bacterial expression vector pUC119 
vector. Through PCR (protocols described in section 2.2.2.4), C6.5 scFv gene was isolated 
with additions of NcoI and NotI restriction sites on the N- and C-terminals respectively 
introduced by specifically designed primers (Chapter 2, Table 2.2). Temperature gradient 
PCR was performed for ensuring a successful reaction, and determining the optimal annealing 
condition. Shown in Figure 7.2, bands ~760bp appeared in lanes 1 to 12 indicated right base-
pair size of C6.5 scFv sequence, and according to the band intensity, annealing temperatures 
around 56 ± 4ºC outlined the optimal conditions applied to this PCR.  
 
 
 
Figure 7.2. C6.5 gene extractions from bacterial expression vector. Temperature gradient PCR was used for 
determining the coordinative annealing temperatures of the specially designed C6.5 NcoI (forward) and C6.5 
NotI (backward) primers. The annealing temperature gradient applied covered from 40ºC (lane 1) to 60.02ºC 
(lane 12) with 1.82ºC increment between each lane. Samples without DNA template were also prepared for PCR 
according to each temperature gradient, and their product were pooled together and revealed in the negative 
control (-) lane. Previous DNA template with corresponding primers determined to have successful PCR under 
annealing temperature at 60ºC was provided as  positive control (+). Samples were loaded into 1% agarose gel, 
and Hyperladder I was used as base-pair marker. 
 
 
Selection of C6.5 scFv Recombinant Fusion Constructs 
Following the process outlined in Figure 7.1, the C6.5 scFv gene and intermediate constructs 
were ligated, and transformed into chemically competent E. Coli strain XL-1 Blue. Under 
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ampicillin antibiotic selection, fusion vector incorporated in bacteria formed colonies on the 
2TY agar plates. As shown in Figure 7.3, colony PCR (cPCR) was then applied for selecting 
positive bacteria colonies correctly transformed with ligated DNA. The same primers were 
used as the ones in the C6.5 extraction PCR, and the cPCR was run under optimal annealing 
temperature at 56ºC.  
 
 
 
Figure 7.3. Colony PCR for selecting positive bacterial colonies correctly transformed with ligated C6.5-
Ig5-FN1 or C6.5-FN1 DNAs. Each lane represents a candidate bacterial colony. Red arrows indicate colonies 
selected for DNA preparation and sequencing. PCR products were loaded into 1% agarose gel, and Hyperladder 
I was used as base-pair marker. 
 
 
The ~760bp C6.5 scFv gene fragment from the plasmid DNAs were generated from the 
bacterial colonies correctly transformed with fully ligated C6.5 fusion DNAs after cPCR 
(Figure 7.3). The chosen colonies were then used for DNA preparation and analysed by DNA 
sequencing for final verification. 
 
Construction of LS-C6.5 scFv in pcDNA4a Vector 
Based on the successful incorporations of C6.5-Ig5-FN1 and C6.5-FN1 fusion constructs in 
mammalian expression pcDNA4a vector, the LS-C6.5 recombinant construct was 
consequently generated. Illustrated in Figure 7.4(a), the LS-C6.5 sequence was double 
digested and fused into the mammalian expression vector pcDNA4c. The selection of 
bacterial colonies transformed with LS-C6.5 sequence was processed by cPCR under the 
same conditions as C6.5-Ig5-FN1 and C6.5-FN1 cPCRs. As indicated in Figure 7.4(b), 
colonies presenting C6.5 fragement in the cPCR product were used for DNA preparation and 
sequence for further verification. 
 
800  
600 
 bp bp 
                   
   800  
   600 
- 275 - 
       
 
Figure 7.4. (a) Schematic genetic cloning process for LS-C6.5 construction in mammalian expression 
vector pcDNA4c. Important restriction sites are indicated, alongside different protein domain information. (b) 
Colony PCR for selecting positive bacterial colonies correctly transformed with ligated LS-C6.5 DNA in 
pcDNA4c vector. Red arrows indicate colonies selected for DNA preparation and sequencing. PCR products 
were loaded into 1% agarose gel, and Hyperladder I was used as base-pair marker. 
 
 
Finally, all three C6.5 recombinant fusion DNA constructs were correctly cloned. As shown 
in Figure 7.1 and 7.4(a), double digestions by HindIII and XhoI release the fusion inserts LS-
C6.5 (861bp), LS-C6.5-FN1 (1272bp), LS-C6.5-Ig5-FN1 (1535bp) from the corresponding 
DNA constructs (calculated base-pair number in brackets). Shown in Figure 7.5 are the 
correctly sized products of the restriction digestion for each C6.5 construct. 
 
 
 
Figure 7.5. HindIII and XhoI double digestion of LS-C6.5, C6.5-FN1 and C6.5-Ig5-FN1 fusion constructs.  
All three samples were loaded into 1% agarose gel, alongside Hyperladder I as the base-pair marker.  
(a) (b) 
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7.3.2 Monoclonal Selection of C6.5 Fusion Protein Expressing Cell Lines  
Based on the successful monoclonal selection of MFE23 fusion transfectants from HEK-293 
PST cells (section 5.3.2), all three recombinant C6.5 fusion clones were transfected into HEK-
293 PST polyclonal cells, followed by zeocin antibiotic treatment. As shown in Figure 7.6 
and 7.7, selection of the ideal monoclonal cell lines of each fusion construct was achieved by 
dot-blot and ELISA method using collected cell-cultured medium as described previously 
(section 2.2.4.1). 
 
 
 
Figure 7.6. Anti-Myc antibody detected dot-blot for LS-C6.5 and C6.5-FN1 monoclonal selections. HEK-
293 PST cells were used in transfections. Only the monoclones (indicated with clone labels) showed positive 
signals by anti-His6 antibody detection were displayed, and the best protein expression clones were outlined by 
red squares. 
 
 
The Myc protein-tag specific dot-blot results (Figure 7.6), directly illustrate the monoclonal 
cell lines to exhibit the best fusion protein expression level for both LS-C6.5 and C6.5-FN1 
HEK-293 PST transfectants. Clone 2-4A5 and 2-3B1 were selected for stable expression of 
LS-C6.5 and C6.5-FN1 fusion proteins respectively. 
 
As described in section 5.3.2, the dual-characteristics of polysialylation and protein 
expression were required for selection of the scFv-Ig5-FN1 fusion protein from the PolyST 
expressing mammalian cell host. In the case of selecting the best monoclonal cell line 
expressing polysialylated C6.5-Ig5-FN1 fusion protein, the ELISA method was used, with 
hErbB2/Fc fusion protein coated as antigen trapping the C6.5-Ig5-FN1 fusion protein. Anti-
PSA specific detection illustrated 10 out in total 40 collected monoclonal cell lines to exhibit 
high-levels of PSA, among which the clone numbered 4 showed the highest anti-PSA ELISA 
absorbance (Figure 7.7a). Protein expression yield was also detected by Myc protein-tag 
specific dot blotting (Figure 7.7b). In particular, the anti-PSA ELISA selected 10 clones, 
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clone 4 also demonstrated a relatively good fusion protein secretion level when compared to 
the others. Clone 8, 9 and 10 showed exceptional PSA expression results in Figure 7.7(a). 
C6.5-Ig5-FN1 HEK-293 PST clone 4 was chosen for consistent expression of polysialylated 
C6.5 fusion protein. 
 
 
 
 
 
 
 
 
 
Figure 7.7. Monoclonal selection of polysialylated C6.5-Ig5-FN1 fusion protein expressing HEK-293 PST 
transfectants.  (a) Anti-PSA specific ELISA monoclonal selection method for polysialylation screen of all 40 
collected monoclonal cell lines after C6.5-Ig5-FN1 transfection. (b) Anti-Myc dot-blotting for screening the best 
10 monoclonal clone samples selected from (a). For positive control (+), previously purified highly 
polysialylated MFE23-Ig5-FN1 (5μg) was used in both selection method (pink bar), and untransfected HEK-293 
PST culturing mediam (green bar) was applied as the negative control (-). Culture media from LS-C6.5 (purple 
bar) and C6.5-FN1 (black bar) polyclonal cell lines were tested in the anti-PSA ELISA. Clone 4 was labelled in 
red. 
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7.3.3 Purification and Characterization of C6.5 Fusion Proteins 
Both TALON
TM
 IMAC and optimized anion exchange purification methods previously 
described for MFE23 fusion protein investigations (section 4.3.3 and 4.3.4) were routinely 
used for purifying the polysialylated C6.5-Ig5-FN1 and other C6.5 fusion proteins. The 
purified proteins are showed in Figure 7.8 and 7.9 below. 
 
 
 
 
 
 
                    
 
Figure 7.8. Purified C6.5 recombinant fusion proteins.  (a) TALON
TM IMAC purified LS-C6.5 scFv and 
C6.5-FN1 fusion protein. Coomassie staining and anti-Myc Western blot were used for identifying the two 
proteins. Ion-exchange purified C6.5-Ig5-FN1 fusion protein isoforms were revealed by coomassie staining (b) 
and anti-PSA immunoblot (c). Sialylated (1), weakly polysialylated (2) and highly polysialylated (3) C6.5-Ig5-
FN1glyco-forms were analysed. Endo-N treated highly polysialylated fusion glyco-form (3‟) was also used in 
anti-PSA immunoblot.  
 
 
As Shown in Figure 7.8(a), both LS-C6.5 and C6.5-FN1 fusion proteins were correctly 
generated and purified with corresponding MW from SDS-PAGE alongside recombinant 
protein-tag immunodetections. The two-step purification for separating the glycosylated C6.5-
Ig5-FN1 fusion protein showed expected results after the first His6-tag specific IMAC 
purification (results not shown), of which were similar to the findings of IMAC purified 
MFE23-Ig5-FN1 glyco-proteins as shown in Figure 4.11 previously. The following anion 
Coomassie staining Anti-Myc 
LS-C6.5 LS-C6.5 C6.5-FN1 C6.5-FN1 
(a) 
(b) (c) 
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exchange of the fusion protein produced the similar chromatographic image of the MFE23-
Ig5-FN1 fusion protein (Figure 4.16a) and the DP defined C6.5-Ig5-FN1 fusion glyco-forms 
are shown in Figure 7.8(b), where the three fusion glyco-forms were separated with expected 
MW range. In comparison to the MFE23-Ig5-FN1 fusion proteins, C6.5 fusion proteins 
appeared to be easily degraded, as very weak anti-protein tag immunodetection signals were 
found (results not shown). A proteolysed fragment (~26 kDa) was also revealed from the 
fusion glyco-forms protein staining gel (Figure 7.8b). Without strong indications from the 
protein-tag immunodetections, the fusion protein content was defined by the anti-FN1 
Western blot shown in Figure 7.9 below. 
 
Anti-PSA immunoblot (Figure 7.8c) only revealed polysialylation signals from the highly 
polysialylated glyco-form (or 1M NaCl elution). No PSA detection was found from the 
weakly polysialylated glyco-form, suggesting the 200mM NaCl eluted C6.5-Ig5-FN1 fusion 
protein potentially composed higher DP than the sialylated isoform but not enough to be 
recognised by the anti-PSA antibodies. Endo-N treated highly polysialylated fusion isoform 
clearly removed the PSA immunodetection (Figure 7.8c), indirectly confirming the succession 
of recombinantly polysialylating C6.5 fusion protein. Additional glycosidase treatments are 
illustrated in Figure 7.9. 
 
 
Figure 7.9. Glycosidase treatments of polysialylated C6.5-Ig5-FN1.  Three glycosylated fusion isoforms – 
sialylated, weakly polysialylated, and highly polysialylated C6.5-Ig5-FN1 were treated by glycosidases 
including Endo-N, Exo-N, and PNGase F, and consequently separated by SDS-PAGE and revealed by anti-FN1 
Western blots. 
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Similar to the glycosidases treated MFE23-Ig5-FN1 fusion glyco-forms (Figure 4.17), 
different degrees of band-shift are also revealed by each C6.5-Ig5-FN1 fusion glyco-form in 
correspondence to each glycosidase specification (Figure 7.9), and an approximate 65 kDa 
band was produced for each C6.5 fusion glyco-form after total N-glycan removal by PNGase 
F. In addition, the anti-FN1 immunodetections of the three glyco-form before any glycosidase 
treatment showed no signal below ~70 kDa for the highly polysialylated C6.5 fusion 
suggesting an expected anion exchange separation of the glycosylated C6.5-Ig5-FN1.  
 
 
7.3.4 Antigen Binding Affinity Determination of the C6.5 Fusion Proteins 
The in vitro antigen binding profile of all C6.5 fusion proteins was determined by ELISA, and 
the human ErbB2/Fc fusion protein containing the extracellular domain of HER2 antigen was 
used to as antigen target. Following the ELISA protocol described in section 2.2.5.7, the EC50 
or dissociation constants (KD) of each C6.5 fusion protein were determined (Figure 7.10). 
 
 
Figure 7.10. ELISA analysis for determing antigen binding affinities of all C6.5 fusion proteins. A serially 
diluted protein concentrations (from 0.1nM to 1μM) was prepared in triplicate for each fusion protein (depicted 
in different colours), including LS-C6.5 scFv, C6.5-FN1, and the three glyco-forms of C6.5-Ig5-FN1 fusion 
proteins. The ELISA was mediated by Myc-tag specific antibodies and the KD values (± standard errors) of each 
type of fusion protein were also signified. 
 
 
Figure 7.10 shows the KD values analysed by anti-Myc antibody mediated ELISA to be 
comparable for antigen binding capacities of all C6.5 fusion proteins. Although the 
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polysialylated C6.5-Ig5-FN1 fusion proteins displayed ~2-fold KD of the C6.5 scFv, the 
antigen binding affinity was retained again after the recombinant fusion and polysialylation 
modification of the scFv. Moreover, as suggested from the previous section (protein staining 
and immunodetections), the fusion protein glyco-forms were found to be easily degraded 
leading to protein-tag missing. This could also lead to an apparent increase in the KD values of 
the recombinant C6.5-Ig5-FN1 fusion proteins. 
 
 
7.3.5 Antigen Binding Profile under Live Cell Conditions  
In contrast to the recombinant MFE23 fusion proteins, which targets the CEA receptor 
expressed on the cell surface, the recombinant C6.5 fusion proteins interacts with the HER2 
receptor, which dimerizes and internalizes. Conditions such as post-targeting incubation 
temperature and time were analysed during immuno-mediated FACS and CLSM analysis. 
 
7.3.5.1 Detection of Antigen Expressing Live Cell Binding by FACS 
After the KD determination by ELISA, SKOV-3, the HER2-expressing human ovarian cancer 
cell line was used for investigating live cell binding of the C6.5 recombinant fusion proteins 
using FACS analysis. In order to avoid protein-tag degradation problems, shown in Figure 
7.11(a) anti-FN1 antibody mediated FACS was used, and C6.5-FN1 was considered as the 
positive control in comparison with the three C6.5-Ig5-FN1 fusion glyco-forms. Anti-PSA 
specific FACS detection was also carried out and demonstrated in Figure 7.11(b). The FACS 
analysis was only used for investigating the HER2 binding at the cell surface level, in order to 
prevent HER2 internalization, all incubation procedures were taken at 4ºC (section 2.2.5.9). 
 
Clearly shown in Figure 7.11, positive antigen binding was revealed by anti-FN1 antibody 
detected FACS for all three C6.5-Ig5-FN1 fusion glyco-forms after incubating with HER2 
expressing SKOV-3 cells. In comparison with the non-glycosylated C6.5-FN1, the antigen 
targeting capacities of all three fusion glyco-forms under live cell condition remained 
consistent, particularly indicated by the geometric mean fluorescence values (GMean) from 
each sample detection. The anti-PSA mediated FACS results were also demonstrated in 
Figure 7.11 for the three C6.5 fusion glyco-forms, from which only the highly polysialylated 
C6.5-Ig5-FN1 fusion species was found to show a significantly positive curve shift. The PSA 
structure of the C6.5 fusion protein remained intact during targeting of the cell surface 
expressed HER2. The same sample preparations were also carried out on the HER2 negative 
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KB cell line, and as expected, no positive curve shift was detected by either antibody directed 
FACS (Figure 7.11).  
 
 
                     
 
 
 
 
 
 
 
7.3.5.2 CLSM for Cell Surface Antigen Internalization Detection 
To investigate internalization between HER2 and the C6.5 scFv as well as C6.5 fusion 
proteins, live cell (SKBR-3) binding steps took place initially at 4ºC for an hour, and confocal 
microscopy was used to capture the localization as well as potential cell uptake of HER2 
bound C6.5 fusion proteins under different in vitro post-targeting incubation temperatures 
(described in section 2.2.5.10). In particular, the localization status of HER2 bound 
recombinantly polysialylated C6.5-Ig5-FN1 fusion proteins was studied, in order to 
understand the effect of negatively charged PSA on protein complex internalization. 
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Figure 7.11. C6.5 fusion protein in vitro live cell binding 
investigation by FACS. Antibodies specifically recognising 
NCAM FN1 domain and PSA were used for detecting the three 
C6.5-Ig5-FN1 isoforms (0.2μg/μl of each) live cell binding 
profile. Interactions with HER2 expressing SKOV-3 and negative 
control KB cell lines were analysed in replicate and the average 
GMean values of each FACS detection are indicated alongside.  
Colour denotations are provided on the left. 
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Figure 7.12. CLSM showing LS-C6.5 scFv and HER2 cell surface binding and internalization. After 1 hour 
antigen binding incubation at 4ºC, CLSM images were taken under two post-targeting incubation conditions: (a) 
4ºC for 5mins and (b) 37ºC for 1.5 hours. Anti-Myc mediated fluorescein staining (I) and phase-contrast (III), 
alongside their merged CLSM images (II) are shown. Z-stack images of a representative cell were taken from a 
serial of plane levels (1µm depth interval from bottom to top of the cell), and the z-stack middle plane images 
suggesting overall cell population fluorescent-staining profile were taken randomly within corresponding 
specimen areas.  
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Figure 7.13. CLSM showing C6.5-FN1 fusion protein and HER2 cell surface binding and internalization. 
After 1 hour antigen binding incubation at 4ºC, CLSM images were taken under two post-targeting incubation 
conditions: (a) 4ºC for 5mins and (b) 37ºC for 1.5 hours. Anti-FN1 mediated fluorescein staining (I), phase-
contrast (III) and their merged CLSM images (II) are shown. Z-stack images of a representative cell were taken 
from a serial of plane levels (1µm depth interval from bottom to top of the cell), and the z-stack middle plane 
images suggesting overall cell population fluorescent-staining profile were taken randomly within corresponding 
specimen areas. 
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Figure 7.14. CLSM showing interactions between C6.5-Ig5-FN1 fusion glyco-forms and HER2 expressed 
by SKBR-3 cells. (a) With 5mins post-targeting incubation at 4ºC. (b) Targeting status of sialylated or weakly 
polysialylated glyco-forms with 1.5 hours post-targeting incubation at 37ºC. (c) Targeting status of highly 
polysialylated C6.5-Ig5-FN1 fusion protein with 1.5 hours post-targeting incubation at 37ºC. Representative 
single cell confocal z-stack images were showed including anti-FN1 mediated fluorescein staining (I), phase-
contrast (III) and their merged CLSM images (II) are shown. Z-stack images were taken with a serial of plane 
levels (1µm depth interval from bottom to top of the cell). 
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Figure 7.15. CLSM showing human anti-HER2 IgG and HER2 cell surface binding and internalization. 
After 1 hour antigen binding incubation at 4ºC, CLSM images were taken under two post-targeting incubation 
conditions: (a) 4ºC for 5mins and (b) 37ºC for 1.5 hours. Anti-human Fc domain mediated fluorescein staining (I) 
and phase-contrast (III), alongside their merged CLSM images (II) are shown. Z-stack images of a representative 
cell were taken from a serial of plane levels (1µm depth interval from bottom to top of the cell), and the z-stack 
middle plane images suggesting overall cell population fluorescent-staining profile were taken randomly within 
corresponding specimen areas.  
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As shown in Figure 7.12 and 7.13, both C6.5 scFv and C6.5-FN1 fusion proteins bound to the 
SKBR-3 cell surface at 4°C, and internalized at 37°C after 1.5 hours post-targeting incubation. 
Same surface binding and more complete internalization profiles were demonstrated by the 
positive control anti-HER2 IgG (Figure 7.15) with the same post-targeting incubation 
conditions, of which outlines the standard HER2 activity from live cells. In terms of the C6.5-
Ig5-FN1 fusion isoforms, the sialylated and weakly polysialylated showed comparable 
localization profiles as the C6.5 scFv and C6.5-FN1 fusion proteins (Figure 7.14a&b), which 
clearly indicated the differences between cell surface binding and internalization under 
corresponding preparation conditions. On contrast, the confocal images of the highly 
polysialylated C6.5-Ig5-FN1 fusion glyco-form showed minor difference between the 4°C 
and 1.5-hour 37°C post-targeting incubations (Figure 7.14a&c). However, a few fluorescent 
signals can be detected from the 37°C incubated cells, suggesting heterogeneous cellular 
activity of HER2 bound to the highly polysialylated C6.5-Ig5-FN1 fusion protein, which 
potentially due to the inconsistent chain length of the associated PSA. In addition, standard 
cell surface targeting profiles were detected by all C6.5 fusion protein as well as the anti-
HER2 IgG at 4°C for 1.5 hours and 37°C for 5 minutes post-targeting incubations (results not 
shown). 
 
 
 
7.4 Discussion 
 
The investigation in this chapter expanded the application of recombinant polysialylation to 
another antibody fragment, C6.5 scFv. In comparison with the initial scFv example (MFE23 
scFv), C6.5 scFv targets HER2 antigen expressed on the cell surface, and followed by 
dimerization and internalization (Adams et al. 2000; Nielsen and Marks 2000; Robinson et al. 
2005; Robinson et al. 2008). With a high affinity binding C6.5 scFv and HER2, effects of the 
highly negatively charged polysialic acid associated with the C6.5-Ig5-FN1 fusion protein 
during HER2 internalization process was preliminarily investigated. Furthermore, charged 
molecule cannot freely pass across the lipid bi-layer and very negatively charged species 
could leave a weaker association with lipid membrane, therefore additional information could 
be provided from the study of recombinantly polysialylated C6.5 fusion protein.  
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As demonstrated in section 7.3.1, the recombinantly polysialylatable C6.5-Ig5-FN1 fusion 
construct as well as the control constructs, including LS-C6.5 scFv and C6.5-FN1 were 
constructed using the intermediate Ig5-FN1 and FN1 pcDNA4 vectors provided previously 
(Constantinou 2005). After DNA sequencing verifications, vectors containing fusion 
constructs were respectively transfected to the HEK-293 PST cell line (Chapter 5), and three 
monoclones were stably selected for LS-C6.5, C6.5-FN1 and C6.5-Ig5-FN1 expressions. The 
standard cell culture, expression, and purification procedures that utilized and verified for the 
MFE23 system (Chapter 4) were applied for the C6.5 system. In terms of the C6.5-Ig5-FN1 
fusion protein, three glyco-forms (sialylated, weakly and highly polysialylated) were 
produced and similarly detected by SDS-PAGE and Western blots (Figure 7.8) in comparison 
with the MFE23-Ig5-FN1 fusion glyco-forms (Chapter 4). The polysialylation was also 
confirmed by Endo-N, Exo-N and PNGase F involved glycosidase treatments (Figure 7.9), 
and similar results were outlined by the MFE23-Ig5-FN1 fusion isoforms. In vitro antigen 
binding affinity test using ELISA determined comparable KD values of all recombinant 
proteins, whereas a small KD increase was found from the highly polysialylated C6.5-Ig5-FN1 
fusion protein indicating ~2-fold higher than the LS-C6.5 scFv and ~3.5-fold higher than the 
originally determined C6.5 scFv KD value (16nM) (Schier et al. 1995). Consequently, live-cell 
binding tests using FACS further demonstrated the cell surface expressed HER2 targeting 
capacity of the recombinantly polysialylated C6.5-fusion protein. Having the FACS 
preparations at 4°C (avoiding HER2 internalization), slight reductions in terms of curve shifts 
and GMean values were showed by the three C6.5-Ig5-FN1 glyco-forms comparing with the 
C6.5-FN1 fusion protein through anti-FN1 antibody mediated detection, and only the highly 
polysialylated C6.5-fusion protein suggested considerable curve shift from anti-PSA antibody 
mediated FACS (Figure 7.11). Prepared with a saturating concentration (0.2μg/μl or ~3mM) 
for the FACS analysis, factors that deduced for MFE23 fusion proteins FACS analysis 
including PSA antigen masking and negative charge repulsion (Figure 5.21), as well as 
potential protein degaradation issues could possibly affect the targeting efficiencies of the 
glycosylated C6.5 under live cell conditions. Further study of live cell binding affinities (KD) 
can be determined with a serial dilution of concentrations of each C6.5 fusion protein by 
FACS verified GMean values, and KDs can be thus measured.  
 
CLSM was consequently performed for understanding the potential effect from PSA on 
HER2 internalization. As expected, standard cell surface localization was demonstrated by all 
C6.5 fusion proteins when incubated at 4°C, which slows down all receptor-mediated 
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endocytosis activity. Under normal culturing condition (37°C), HER2 internalization was 
revealed by most of the C6.5 fusion proteins after 1.5 hours post-targeting incubation time. 
However, the highly polysialylated C6.5-Ig5-FN1 fusion protein only showed a very low 
level of internalization, suggesting the inhibition of HER2 internalization potentially induced 
by the long PSA chain associated with the C6.5-Ig5-FN1 fusion protein. Compared with the 
sialylated and weakly polysialylated fusion glyco-forms, the highly polysialylated isoform 
possesses longer PSA chain leading to much larger hydrodynamic volume and higher 
negative charge of the fusion protein. The hydrodynamic radii of the polysialylated C6.5 
fusion proteins were expected to be similar as the MFE23 fusion proteins. According to Table 
5.2, the highly polysialylated MFE23-Ig5-FN1 fusion protein had a SEC determined apparent 
MW much bigger than the IgG molecule. It was not sure whether the excessive size increment 
restricts the internalization process of the HER2-fusion protein complex, as large protein 
molecule such as IgM has been found to be internalized (Della Torre et al. 1987; Chao et al. 
1997). However, the increased negative charge from the highly polysialyalted C6.5 fusion 
protein could potentially enhance negative charge repulsion between the fusion protein and 
the cell membrane which counteract the internalizing process (Figure 7.16a).  
 
 
Figure 7.16. Possible PSA involved mechanisms that inhibit HER2 mediated highly polysialylated C6.5-
Ig5-FN1 internalization. (a) Negative charge repulsion (F); (b) HER receptor dimerization interference. 
 
 
HER2 internalization is initiated by HER receptor dimerization (Maier et al. 1991; Gilboa et 
al. 1995; Spector and Blackwell 2009). In addition to the PSA associated negative repulsion, 
another possible internalization inhibition mechanism was explained in Figure 7.16(b). The 
close contact of highly polysialylated C6.5 fusion protein and HER2 after their high affinity 
interaction could potentially extend the long PSA chain to interfere the dimerization process 
(a) 
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Extracellular 
Intracellular 
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of HER2 and other HER family receptors, which consequently hamper the receptor mediated 
internalization. Unaffected internalization outlined by the sialylated and weakly polysialylated 
C6.5-Ig5-FN1 glyco-forms further suggests an impact of PSA elongation to the HER2 
internalization process. In addition, due to the dispersive hydrodynamic radius (2.05<Ø<2.94) 
predicted by SEC for the highly polysialylated MFE23-Ig5-FN1 fusion protein (Figure 5.22), 
individuals having shorter PSA chain lengths in the highly polysialylated category could 
potentially internalize as a low internalization level was spotted to the highly polysialylated 
C6.5-Ig5-FN1 fusion protein. Further CLSM studies as well as other analysis (i.e. FACS) 
should be carried out in order to prove the polysialylation affect on HER2 internalization. 
Presumably, a certain polysialylation level might also need to be decided for understanding 
the HER2-C6.5 fusion protein complex internalization  
 
In addition, other studies undertaken in the investigation of polysialylated recombinant MFE23 
– for example, measurement of antigen binding kinetics by BIAcore, MALDI-TF MS 
determination of the DP of PSA, measurement of hydrodynamic volume and in vivo 
pharmacokinetics – need to be applied to the polysialylated recombinant C6.5 fusion protein to 
develop a more detailed understanding of this molecule. Moreover, the effect of polysialylation 
on C6.5 activated HER2 internalization needs to be further studied in order to understand the 
applicability of the recombinant polysialylation in such circumstances. Internalization induced 
endocytosis can significantly accelerate the antibody fragment lost from the blood circulation, 
and should be considered during future in vivo PK study.  
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CHAPTER 8 
 
General Discussion and Conclusions 
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Modern bioscience exploitation of the specificity and affinity of antibody targeting has been 
greatly advanced by various biotechnological developments. Described as a “magic bullet”, 
antibody drugs target specific disease areas significantly reduce the side-effect received from 
traditional radio- and chemo-therapies, particularly seen in cancer treatment. As shown in 
Table 1.1, at least 36 monoclonal antibody related products have already been approved and 
launched into the market worldwide with significant medical/therapeutic effects and 
commercial successes. Humanisation of recombinantly engineered antibodies enabled the 
development of antibodies into a more “human friendly” system, leading the new generation 
antibody products with much less side-effect problems seen from the pioneering murine-
originated antibodies (Holliger and Hudson 2005; Wu and Senter 2005; Reichert 2008).  
 
Also shown in Table 1.1, most available therapeutic antibodies are provided as an IgG format, 
which initiats the immunological function by recruiting the effectors cells (via the antibody 
Fc-domain) to take on the targeted cells. However, a few limitations of using full-length IgGs, 
including tissue cross-reactivity, poor tissue penetration, slow extravasation and capillary 
diffusion and heterogenous biodistribution significantly reduce the antibody therapeutic 
efficacy of a number of diseases, and therefore restrict their clinical applications (i.e. 
diagnostic imaging). Antibody directed therapies, using antibodies to deliver powerful 
therapeutic agents including drugs, toxins, radionuclides; or fusing antibodies with effective 
proteins (outlined in Figure 1.5), have also shown promised potencies in therapies, such as 
cancer and arthritis treatment (Wu and Senter 2005; Schrama et al. 2006). IgG antibody has a 
large molecular weight, exhibits slow blood clearance, and inappropriate Fc-domain cross-
reactivity with Fc receptors (FcγR and FcRn), which often results in high exposure to normal 
tissues thus leading to high risk of cytotoxic effects inflicted on normal cells. 
 
Antibody fragments (Fab2, Fab and scFv) with reduced sizes in comparison with their parent 
immunoglobulins have been designed and produced to overcome the problems seen with the 
intact MAbs. Exceptionally amenable to various molecular library selection methods (e.g. 
phage-display), high affinity antibody fragments can be readily selected and produced in 
large-scale with high yields, economically. With the antigen targeting moiety, a number of 
antibody fragment multimers (e.g. diabodies, triabodies, and bis-scFv) and fusion variants 
have been developed to provide additional valency, specificity, function and stability for 
therapeutic efficacy improvements. Most importantly, the smaller size of the antibody 
fragment allows rapid tissue penetration, enhanced vascular extravasation and more uniform 
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biodistribution outcomes, which enables fast and specific delivery of powerful therapeutic 
agents to the disease areas and greatly lowers the unnecessary hazard to the healthy cells 
(Holliger and Hudson 2005; Jain et al. 2007; Weisser and Hall 2009). With a number of 
antibody fragments approved for medical diagnosis and imaging applications, at least 5 
fragmented antibodies have been launched for direct disease treatment, and numerous pipeline 
products are under different development levels (Nelson and Reichert 2009). 
 
Although there are significant advantages to the reduced molecular size of antibody fragments 
in comparison with intact antibodies in therapeutic applications, these fragments have been 
found to have very short circulation times in vivo, predominantly caused by rapid elimination 
through the kidneys. To overcome this drawback, various technologies (described in section 
1.3) were developed principally following two PK modulation concept: (i) increasing 
hydrodynamic volume of antibody fragment via coupling with hydrophilic molecules (i.e. 
PEG and PSA); (ii) association with long-lived plasma proteins (i.e. albumin). Demonstrated 
by a number of commercially available drugs and protein products conjugated with 
polyethylene glycol (PEG) or PEG derivatives, and numerous PEGylated pipeline products 
during clinical and animal tests (introduced in section 1.3.1.2), hydrophilic polymer-linked 
PK modulation method has been effective for improving protein bioactivity after intravenous 
injection. Successfully introduced with antibody fragments, PEGylation showed significant 
improvement in blood circulation duration (Chapman 2002). Specific tumour localization and 
retention was also observed, of which was enhanced by the enhanced permeability and 
retention (EPR) effect associated with water soluble polymers (Maeda et al. 2000; Chapman 
2002).  
 
As a non-biodegradable material, repeated treatment with PEGylated therapeutics can lead to 
the accumulation of PEGs in the body (i.e. liver) with toxic effect to patients, and the long 
term clinical effect are not known. Immuno-response can also be generated over prolonged 
exposure of PEG (Gregoriadis et al. 2005; Jevsevar et al. 2010). Over the risk of using non-
biodegradatable synthetic polymers in vivo, an alternative natural polymer, polysialic acid 
(PSA) was consequently proposed by Gregoriadis et al. under the PK modulation principle 
that PEGylation indicates (Gregoriadis et al. 1993). The biodegradable PSA is hoped to 
extend the therapeutics half-life with minimized immunogenic and toxic side-effects that 
associated with PEG. A number of protein candidates were chemically polysialylated and 
showed in vitro and in vivo with increased solubility and stability, reduced immunogenicity, 
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preserved function, and improved pharmacokinetics (Gregoriadis et al. 2005). Focused on 
antibody fragments, both Fab and scFv were chemically polysialylated recently (Constantinou 
et al. 2008; Constantinou et al. 2009). Although random amine coupling detrimentally 
hampered antigen targeting of scFv, conjugating PSA via a C-terminal site-specific method 
thus avoiding interference with the antibody binding site further confirmed the polysialylation 
as a capable application for increasing the longevity of circulating antibody fragments and 
improve their in vivo PK. The latter work also opened up ideas for recombinant site-specific 
polysialylation. 
 
It is well known that chemically conjugating polymers to drugs and proteins has been 
provided with decades of research experience and industrialized production scale. However, 
due to the process, major concerns including protein inactivation, downstream processing, 
high cost (production costs of both bio-therapeutics and polymers), and conjugation yield 
have been noticed from the development of PEGylation and chemical polysialylation 
(Constantinou et al. 2010). To overcome these problems, and setting up an alternative 
polysialylation approach, this thesis focuses on the establishment of a chemistry-free 
polysialylation method. As an extreme glycosylation feature, biosynthesized PSA on the 
NCAM protein with a significant level was found during mammalian early brain development. 
In order to preserve the advantages antibody fragment gained from size reduction, the 
polysialylation approach described in this thesis genetically fuses the minimal human NCAM 
polysialylatable domains (Ig5-FN1 domain, ~20 kDa) to the C-terminal of model scFvs, in 
order to produce recombinantly polysialylated scFv-Ig5-FN1 fusion proteins with enhanced 
PK properties.  
 
 
 
8.1 Succession in Recombinantly Polysialylating scFv-Ig5-FN1 
Fusion Protein  
 
The recombinant polysialylation of scFv-Ig5-FN1 fusion protein investigated in this PhD 
project is principally following the process of intracellular PSA biosynthesis (Figure 1.17) 
and NCAM polysialylation pathways (section 1.4.2). Described in Chapter 3, the initial 
attempt of recombinant polysialylation by transfecting the MFE23-Ig5-FN1 fusion cDNA into 
- 295 - 
murine NB2a cells, a line that previously reported with PSA-NCAM expression (Hildebrandt 
et al. 1998; Gallagher et al. 2000; Poongodi et al. 2002; Beecken et al. 2005) produced the 
expected fusion protein composition. However, at best, two sialic acid monomers were found 
in this N-glycosylated fusion protein. Additional glycosidic linkage detection assays (using 
specific lectins) further indicated the presence of essential polysialylation epitopes - 
NeuNAcα(2-3/6)Gal, alongside the potential subterminal Galβ1-4GlcNAc linkage, suggesting 
potential polysialyltransferase deficiencies from the initially used NB2a cell line. 
 
In order to accomplish the mammalian PSA biosynthesis alongside the polysialylation 
epitopes on the scFv-Ig5-FN1 fusion protein, the essential PolyST cDNAs were introduced to 
the fusion protein expressing NB2a cells (Chapter 4). This revolutionary modification for the 
first time enabled positive detection of PSA specifically associated with the scFv-Ig5-FN1 
fusion protein. In correspondence with the previous NCAM and NCAM fragment 
polysialylation immunoblot results (Close et al. 2003; Mendiratta et al. 2005; Colley 2008), 
the polysialylated MFE23-Ig5-FN1 showed a polydispersive apparent MW covering from ~70 
up to potentially over 250 kDa, whilst the previous sialylated version only had a defined MW 
about 70 kDa. Stable polyclonal selections of polysialylated MFE23-Ig5-FN1 NB2a cell line 
was consequently selected to provide with consistent fusion protein expression.  
 
Alongside positive polysialylation detection from other PolyST transfected cell lines 
including COS-1, CHO, 3T3, HeLa cells (Chapter 4), a universal human recombinant protein 
expression cell line (HEK-293) that was capable of stably polysialylating scFv-Ig5-FN1 
fusions was created for producing polysialylated fusion proteins with human glycosylation 
features (elimination of xenogenic antigens, such as Galα1-3Gal detected from murine NB2a 
expressed fusion proteins). Using the HEK-293 PolyST cell line, two polysialylated scFv-
fusion proteins, MFE23-Ig5-FN1 (Chapter 5) and C6.5-Ig5-FN1 (Chapter 6) were produced 
respectively after transfecting their cDNAs to the cell host, and monoclonally selected, the 
polysialylated fusion proteins were stably expressed with a relatively good yield (~1mg/L). 
The success of producing more than one specificity of polysialylated scFv-Ig5-FN1 fusion 
proteins further suggested the systematical usability of the concept of recombinant 
polysialylation technology.  
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8.2 Polydispersity and the Degree of Polymerization of the 
Recombinantly Polysialylated scFv-Ig5-FN1 Fusion Proteins 
 
One major concern of using polymer to modulate protein PK is the polydispersity of most 
water soluble polymers particularly natural ones. As a quality problem, protein conjugated 
with polydispersive polymer species can make proteins behave heterogeneously and 
potentially variable PK modulation efficacy as well as uncontrolled therapeutic effects. Either 
produced synthetically (i.e. PEG) or by living organisms (i.e. colominic acid), polymers are 
normally found as heterogeneous species, particularly differentiated in residual numbers of 
each individual. A high cost is normally associated with purifying or classifying polymer 
species with a relatively unified and low polydispersity before conjugating to the proteins 
(Gregoriadis et al. 2000; Veronese and Pasut 2005; Veronese and Mero 2008). In terms of 
natural polysialylation, both endogenous and recombinant PSA-NCAM has been reported 
with a broad MW range on SDS-PAGE due to the polydispersive PSA expression (Troy 1995; 
Fujimoto et al. 2001; Close et al. 2003; Colley 2008), of which was also confirmed by several 
structural studies such as using mass spectrometry (Galuska et al. 2007). 
 
Following the NCAM polysialylation intracellular process, the polysialylated scFv-Ig5-FN1 
also showed a polydispersive profile initially from the SDS-PAGE and Western blot covering 
a broad MW range. In order to narrow down the polydispersity of the scFv-fusion protein and 
the characterization of the glyco-species, an anion exchange purification protocol (Chapter 4) 
was used based on the negative charge composition of each sialic acid. Following the negative 
charge increase alongside the polysialylation DP, the anion exchange protocol was optimized 
to produce three glyco-forms of scFv-Ig5-FN1 fusion protein eluted by characterized NaCl 
concentrations. In turn, they were named as sialylated (eluted by 100mM NaCl), weakly 
polysialylated (eluted by 200mM NaCl) and highly polysialylated (eluted by 1M NaCl), and 
more restricted PAGE profiles were revealed showing the sialylated as one single band (~70 
kDa), weakly polysialylated covering from ~70 kDa to 100 kDa, while the highly 
polysialylated occupying the rest above 100 kDa. 
 
Delicate structural studies using mass spectrometry further investigated DP of PSA and the 
polydispersive distribution of each MFE23-fusion protein glyco-forms (section 5.3.4). 
Following the MOLDI TOF-MS protocol utilized for analyzing colominic acid and 
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polysialylated NCAM (Galuska et al. 2007), Based on the experimental results, both 
sialylated and weakly polysialylated MFE23-Ig5-FN1 fusion proteins showed much defined 
DP (4 and ~10 NANA residues respectively), as well as the highly polysialylated (~25 NANA 
residues on average), which appeared to be more dispersive than the former two. In 
comparison with the MOLDI TOF-MS analyzed PSA-NCAM, a rather similar mass spectrum 
profiles was received by the highly polysialylated MFE23-Ig5-FN1 fusion protein, and 
approximately 40 NANA residues were maximally indicated by both mass spectra (Galuska et 
al. 2007), suggesting a normal and natural recombinant polysialylation process was carried 
out on the highly polysialylated fusion species. 
 
 
 
8.3 Recombinant Polysialylation Retains the Antigen Binding 
Affinity of Antibody Fragment 
 
Reduction in antigen binding affinity was considered as one of the most severe drawbacks of 
many PK modulation approaches, including PEGylation and chemical polysialylation to 
small-size antibody fragment (Chapman 2002; Constantinou et al. 2009). Introduced 
previously in the PEGylation (section 1.3.1.2), chemically-modified active groups from 
hydrophilic polymers enable coupling reaction with the formation of carbamate, amine, amide 
and thioether bonds between protein and polymers. These chemical conjugations can be 
randomly mixed, leading to a high risk of coupled polymers at or near the antibody binding 
site and severely compromising antigen binding affinity (Pedley et al. 1994; Francis et al. 
1998; Chapman et al. 1999; Constantinou et al. 2009). One way to effectively reduce this risk 
is to engineer specific binding sites from the antibody fragment, which avoid the unnecessary 
polymer intervention at the antigen binding site. However, other factors that may induce 
variations in targeting kinetics due to polymer involved conjugation methods (for example 
polymer masking of the binding domains from either antibody or antigen) were discussed in 
Chapter 5. Particularly relevant to PSA, the possession of a highly negative charge should 
also be considered during antigen binding and other bioactivities (Figure 5.21).  
 
The recombinantly polysialylated scFv-Ig5-FN1 theoretically introduced an alternative site-
specific approach for adding PSA to the antibody fragment, which ideally reduces the risk of 
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polymer interference at the antigen targeting site. In order to understand the actual antigen 
binding profile for the recombinantly modified fusion protein, both ELISA and BIAcore 
studies were carried out. Considerably, KD values received from the ELISA suggested that the 
polysialylated scFv-Ig5-FN1 fusion proteins (for both MFE23 and C6.5) had almost no effect 
to in vitro antigen binding in comparison with their corresponding scFvs. However, the 
kinetic binding studies using SPR (BIAcore) for the MFE23 fusion proteins revealed 
approximately 10-fold increase of overall KD to both weakly and highly polysialylated fusion 
formats, of which both of them was predominately caused by the decreased kon values (~20-
fold decrease) (Table 5.1). This experimental phenomenon was speculated to be induced by 
the negatively charged surface (free –COOH group) of BIAcore® SA sensor chip used for 
immobilizing the antigen proteins. Receiving the polyanionic possessions from the associated 
PSA molecules, an electrical repulsion force can be generated against the interaction between 
the polysialylated MFE23-fusion proteins to their antigens coated on the negatively charged 
BIAcore chip surface, resulting decreased on-rates (Figure 5.21a). This hypothesis was 
approved by further BIAcore experiment using PSA removed (hydrolysed by Endo-N) 
MFE23-Ig5-FN1 fusion protein, which kinetically retrieved the fusion protein on-rate and 
overall KD back to the scFv level.  
 
Generally speaking, the recombinant polysialylation approach genetically arranged the N-
glycosylation sites on Ig5 domain for site-specific polysialylation of the scFv-Ig5-FN1 fusion 
protein, avoiding the polysialylation directly taking place on the scFv and interrupting the 
antigen binding site. The antigen binding affinity was retained comparing with the 
corresponding scFv under physiological buffer condition, but can be potentially reduced when 
targeting antigens located on a negatively charged surface. The cell plasma membrane is 
acknowledged as a weakly negative-charged surface with sialylated membrane protein 
covering from the outside, and low-negatively charged monovalent phospholipids on the inner 
leaflet (McLaughlin and Murray 2005; Yeung and Grinstein 2007; Yeung et al. 2008; 
Goldenberg and Steinberg 2010), leaving potential binding hindrance to cell membrane 
antigens by the polysialylated antibody fragments. Live cell binding experiments using CEA 
expressing cell lines suggested comparable results between MFE23 scFv and polysialylated 
MFE23-Ig5-FN1 fusion protein by both FACS and confocal laser scanning microscopy 
(CLSM). Surface staining of the cell membrane located CEA was also equally demonstrated 
by all MFE23 fusion proteins using CLSM. Furthermore, previous studies on chemically 
polysialylated insulin showed comparable insulin-receptor binding on the cell surface 
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additionally suggesting the negatively charged PSA does not prevent the conjugated 
interaction with corresponding ligand expressed on the cell surface (Jain et al. 2003). Standard 
in vivo tumour uptake of chemically polysialylated Fab and scFv respectively targeting cell 
surface expressed placental alkaline phosphatase (PLAP) and CEA antigens also supporting 
the applicability of polysialylation (Constantinou et al. 2008; Constantinou et al. 2009). 
Standard HER2 receptor cell surface staining was also demonstrated by the recombinantly 
polysialylated C6.5-Ig5-FN1 fusion protein. However, the interference of HER2 
internalization was initially found by the CLSM studies through interaction with the highly 
polysialylation C6.5 fusion species (Chapter 7). The highly negative-charge of PSA was 
speculated to generate an electric repulsion force against the cell membrane and hinder the 
HER2 internalization. Moreover, other possible reasons such as PSA interrupted HER2 
dimerization were speculation (Figure 7.16). 
 
 
 
8.4 Recombinant Polysialylation Increases the Molecule 
Hydrodynamic Volume and Prolongs the in vivo Bioactivity 
 
This PK modulation can be classed as a method using hydrophilic polymer to increase 
molecule apparent size under physiological aqueous conditions. Experimentally the 
recombinantly polysialylation approach successfully proved this effect. Using size exclusion 
chromatography (SEC) with physiological buffers, significant size increase was measured 
from the polysialylated MFE23-Ig5-FN1 fusion protein in comparison with the scFv molecule, 
and the hydrodynamic volume increased proportionally along with the degree of 
polysialylation (Figure 5.18). Discussed previously in Chapter 5 according to the SEC results, 
the three fusion glyco-forms were found to have excessive apparent MW than the calculated 
MW based on the MFE23-Ig5-FN1 amino acid sequence (Table 5.2). The increments of 
apparent MW were directly reflected by the hydrodynamic size improvements from each 
fusion molecule. The same concepts were also suggested by PEGylated proteins (Chapman 
2002; Veronese and Harris 2002; Veronese and Mero 2008) and other hydrophilic polymers 
modified antibody fragments, such as dextran (Mikolajczyk et al. 1996) and homo-amino-acid 
polymer (Schlapschy et al. 2007).  
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A relationship between the protein‟s hydrodynamic radius and its SEC-measured MW were 
postulated assuming the soluble fusion proteins displayed a globular shape within the aqueous 
condition (Figure 5.22). Furthermore, knowing that the human serum albumin (HSA) with the 
hydrodynamic radius of 3.5nm displays almost the same MW determined by SEC 
measurement comparing to its amino acid MW (Muller et al. 2007), the hydrodynamic radii 
of the MFE23-fusion proteins were estimated based on the equation indicating the ratio 
between hydrodynamic radius and SEC apparent MW (discussed in Chapter 6). 
Approximately, the hydrodynamic radius of the sialylated MFE23-Ig5-FN1 was ~4.3nm, and 
~5.4-7.8nm for the highly polysialylated fusion protein according to the SEC data, whereas 
the radius of scFv only appeared to be less than 2.7nm. Knowing the MW cut-off of kidney 
elimination is around 70 kDa, which can be more precisely interpreted as the pore size of 
glomerular basement membrane (3-5nm) (Nakaoka et al. 1997), the in vivo pharmacokinetic 
data (Chapter 6) outlined differential blood clearance profiles between MFE23 scFv, the 
sialylated and highly polysialylated MFE23-Ig5-FN1 fusion proteins regarding to their 
apparent size differences.  
 
The results from in vivo PK studies on mice practically demonstrated the concept of the 
recombinant polysialylation to improve antibody fragment blood circulation longevity. 
Already mentioned from Chapter 6, longer distributional phase (t1/2α) and elimination phase 
(t1/2β) alongside increased overall AUC were monitored by the MFE23-Ig5-FN1 fusion 
proteins in comparison with the MFE23 scFv, and the highly polysialylated glyco-form 
appeared to be significantly effective. Previously, approximate 10-fold blood AUC increase 
was achieved by the chemical-conjugated MFE23 scFv to the engineered cysteine site with 
one 11 kDa (DP~37) PSA chain (Constantinou et al. 2009). Gaining both PSA chains (with 
average DP of 20) from the two N-glycosylation sites on the Ig5 domain (Colley 2008), a 
much promised PK-improvement was observed from the highly polysialylated MFE23-Ig5-
FN1 fusion glyco-form with ~26-fold increase of blood AUC than the scFv. Typically, IgG 
molecules have an average circulation time between 24-72 hours in mice, and 324 (% h/g) 
blood AUC was also reported previously (Constantinou et al. 2008). Found with similar 
circulation half-life, the highly polysialylated MFE23 fusion protein showed a blood AUC 
(514 % h/g), of which was ~1.6-fold of the IgG (Table 6.1), suggesting the significant 
capacity of the recombinantly polysialylated proteins with reduced blood clearance profile. 
Oxidation of PSA during protein sample radio-labelling was considered to reduce PSA 
hydrophilicity. The animal PK studies are needed to be repeated with more careful protein 
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sample preparation, alternative radio-labelling methods, and accurate time interval control as 
well as the blood sample measurement.  
 
Results from the biodistribution study suggested minimal variations between the scFv and the 
polysialylated fusion protein. Other than kidney, most organs showed accumulation ratios of 
less than one suggesting a desired non-specificity of the fusion proteins. In terms of kidney 
accumulation for small size proteins due to its size-selective nature (Verhaar et al. 1995; 
Verhaar et al. 1996), progressively, deceased kidney/blood ratio was observed from the 
glycosylated scFv-Ig5-FN1 fusion proteins than the scFv alone, which indirectly indicated the 
improvement of prolonged circulation period for the polysialylated scFv-fusion protein, and 
this fact can also be beneficial in terms of reducing the non-specific kidney toxicity induced 
by the antibody fragment accumulation. 
 
 
 
8.5 Future Studies, Refinements and Improvements 
 
8.5.1 Future Studies 
For establishing and developing the recombinant polysialylation technology, based on the 
research achievement so far, there are still many more investigatory aspects need to be 
determined, including (1) in vivo antigen localization and tissue penetration/uptake (e.g. for 
tumour treatment); (2) PSA immunogenicity; (3) polydispersity of polysialylated fusion 
protein. (4) New targets which could be benefit. 
 
In vivo Antigen Localization and Tissue Penetration/Uptake 
Previously, the site-specifically chemical-polysialylated MFE23 scFv demonstrated a high 
level of in vivo tumour uptake (tumour/blood ratio) and tumour retention (30-fold more than 
the scFv at 48 hours) (Constantinou et al. 2009). Based on these features, the recombinantly 
polysialylated MFE23-Ig5-FN1 is expected to show similar rational of results from CEA-
tumour bearing mouse models, and the percentage of CEA-expressing tumour uptake, 
tissue/blood ratio as well as further investigations such as tumour penetration using 
immunohistochemistry on tumour sections.  
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Immunogenicity 
In terms of PSA immunogenicity, indeed, as a naturally occurring polymer, PSA has been in 
involved in a number of infectious microbial including the serogroup B capsular 
polysaccharide from Neisseria meningitidis B and Escherichia coli Kl, the serogroup C 
capsular polysaccharide C from N. meningitidis C, and the polysaccharide K92 from E. coli 
K92, as well as their shorter chain derivatives (Troy 1992; Troy 1995; Janas and Janas 2004). 
However, under the masking of bacteria capsular PSA, (also known as colominic acid with 
DP up to 200 NANA residues), these neuro-invasive bacteria can escape from immune 
surveillance to achieve virulence (Troy 1992; Troy 1995). Moreover, it is also found as a 
glycosylation feature for a number of mammalian proteins (e.g. polysialylated NCAM) and 
tumour cells, the naturally biosynthesized α2,8-linked polysialic acid (without a known 
receptor in human body) has important role in brain development and tumour progression 
(mentioned in section 1.4.2). Without provoking the immune response, the fact that PSA has 
been popularly used by bacteria or malignant cancer cells also suggests that PSA can be 
applied to masking the immunogenic determinant from therapeutic proteins that often raised 
with non-self properties eliciting anti-sera antibody productions. Furthermore, PSA masking 
may sterically hinder the approach of pre-formed antibodies and proteases to their 
corresponding sites on the therapeutic proteins (Gregoriadis et al. 1993). In terms of PSA 
conjugated proteins, the potential of enhancing immunogenicity from a PSA covalently 
coupled carrier protein has been previously suggested by converting them to thymus-
dependent antigens (Devi et al. 1991). PSA was also reported as poor immunogen after 
conjugation with proteins, and expected potential alterations of the net surface charge as well 
as the three-dimensional structure of the conjugates with possibly enhanced immunogenicity 
(Jennings and Lugowski 1981; Jennings et al. 1986). An evaluation study was carried out in 
order determine the immunological properties of chemically polysialylated proteins using 
asparaginase as an example. To that end, they conjugated 10 kDa PSA chains to asparaginase 
via random amine-coupling, and found that without provoking additional immune response, 
polysialylation reduced the antigenicity of asparaginase and as a result prolonged its 
circulation in the blood even in the presence of anti-asparaginase antibodies (Fernandes and 
Gregoriadis 2001). Based on these findings, theoretically the recombinant polysialylation 
approach produces PSA via a human glycoprotein biosynthesis pathway is expected to have 
much less immunogenicity issues but equivalent antigenic/proteomic site masking purposes as 
the chemical-polysialylation. In terms of the immunogenicity of the entire fusion protein, in 
vivo experiments using immunized animal with MFE23-Ig5-FN1 (with or without 
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polysialylation) can be done to detect the generation of anti-fusion protein IgGs. In addition, 
although PSA is a biodegradable material, its toxicity at a high dose should also be studies as 
well as related side effects. 
 
Polydispersity 
Polydispersity can be considered as an inevitable feature of synthetic polymers. A measure of 
the distribution of molecular mass in a given polymer sample (also know as the polydispersity 
index or PDI) is normally used to define the polydispersity of the polymer. The PDI is 
calculated as a ratio between the weight average molecular weight (Mw) and the number 
average molecular weight (Mn), and gives indications to the distribution of individual MW in 
a batch of polymers. The value of PDI can be equal to or more than 1, although the closer to 
the value of 1, the uniform chain length the polymer batch displays (Rudin 1999). As a 
negative property, the polymer polydispersity is reflected in polydispersity of the conjugates, 
and significantly restricts the application of polymer derived PK modulation approaches to 
small protein therapeutics. Compare with other polymers, PEG has a relatively narrow 
polydispersity with PDI equals to 1.01 for PEGs less than 5 kDa, and 1.1 for the ones above 
50 kDa (Roberts et al. 2002). However, it was still suggested that PEG-conjugate is composed 
of molecules with different number of PEG monomers, yielding a Gaussian distribution of 
MWs. Therefore, conjugating with a certain MW PEG in fact produces a diverse conjugate 
population, which might induce different functional impact, including blood circulation time 
and immunogenicity (Veronese and Pasut 2005; Veronese and Mero 2008). Based on the 
development of polymer synthesis and purification procedures, much less polydispersive 
PEGylated products have been introduced; however the polydispersity problem still needs to 
be considered for the low MW therapeutics, such as antibody fragments, as they can be more 
effective in relation to their molecular size changes (Veronese and Pasut 2005). In addition, 
high cost in producing more uniform chain length polymers for conjugation should also be 
considered. Consequently, the same polydispersity limitation also comes to the fore for the 
polysialylation technologies, and concerns of PSA polydispersive have been suggested by 
almost all the chemically polysialylated protein studies (Gregoriadis et al. 2005). Reported 
that natural bacterial colominic acid (DP~200) has a PDI value (<1.1) similar to high MW 
PEG (Troy 1992; Troy 1995), it is equally important to control the polydispersity of 
polysialylated antibody fragment. In terms of the recombinantly polysialylation, lower PDI 
could be found due to shorter PSA chain length. However, from the MOLDI TOF-MS and 
SEC results for the polysialylated MFE23-Ig5-FN1 fusion protein, a polydispersive profile 
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can be already detected even after ion-exchange purification (Chapter 5). Better purification 
methods, such as more specific ion exchange or SEC purifications should be involved in the 
future studies for further reducing the polydispersity of the polysialylated fusion protein 
species, and in terms of quality control, monitoring the PDI of recombinantly polysialylated 
product should be strictly considered.  
 
In addition, questions on potential structure conformational change of scFv-Ig5-FN1 fusion 
proteins after recombinant polysialylation, as well as serum/in vivo degradation profile of 
recombinantly polysialylated antibody fragment may also need to be studied.  
 
New Targets 
New antibody fragment models (e.g. neutralizing antibody) as well as protein/peptide (i.e. 
TNF, VEGF, and toxins) examples should also be tested for recombinant polysialylation with 
pharmacokinetic investigations for understanding the universality of the modification 
approach. These proteins/peptides require prolonged circulation half-life for therapeutic 
purposes, making them perfect pipeline candidate to apply recombinant polysialylation as an 
alternative technology for PK enhancement. 
 
 
8.5.2 Improvements for Current Recombinant Polysialylation Approach 
As a novel PK modulation approach, the recombinant polysialylation technology described in 
this thesis requires a number of refinements, in order to keep the technology developing in a 
right direction with better application value. Based on the experimental data described from 
each result chapter, the predominant inefficiencies emerged from the control and the degree of 
polymerization, which again can easily lead to polydispersity involved quality problems. 
 
Different from the chemical-conjugation method, recombinant polysialylation is an 
intracellular protein glycosylation process that involves the biosynthesis of polysialic acid 
from the specific polysialylation epitopes on specific protein substrate. A cascade of 
enzymatic reactions is involved in this process (Figure 1.17), and these enzyme activities are 
highly correlated to the culturing cell conditions. A strictly good and uniform cell culturing 
technique with a standard cell passage number control needs to be performed routinely for 
maintaining the enzyme activities with minimized polysialylation level changes.  
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From anion exchange purification results (Chapter 4 and Chapter 7), three different scFv-Ig5-
FN1 fusion glyco-forms with increasing polysialylation levels were detected, and the 
sialylated glyco-form took a significant proportion of the total fusion protein production, 
which therefore reduced the yield of polysialylated fusions. Based on the same amino acid 
backbone, this phenomenon might suggest an inefficient polysialylation to the sialylated and 
weakly polysialylated fusion glyco-form, and potentially they can be pushed toward the 
highly polysialylated level. With correct polysialylation improvement strategies, it is 
achievable to produce more homogenous fusion proteins with probably a higher DP level. 
 
Technically, more selective monoclonal selection methods (e.g. FACS) can be improved for 
identifying mammalian cell monoclones with higher polysialylation and fusion protein 
production levels. Cell culture conditions, including incubation time, temperature, culture 
medium pH, and other cell metabolic product levels). More optimized purification protocols 
are also needed to purify and define the polysialylated species with more distinctive DP. A 
DP controllable polysialylation process will be beneficial for modifying protein with adequate 
half-lives to their corresponding applications, where a too long plasma circulation might not 
be an advantage to certain applications (e.g. radioisotope conjugate). 
 
Moreover, several methods for increasing sialylation of recombinant glycoproteins have been 
introduced previously (Bork et al. 2009), and some of these methods are also very prospective 
for improving the recombinant polysialylation, such as (1) application of N-
acetylmannosamine (Man-NAc) - the specific precursor for increasing intracellular sialic acid 
pool (Pels Rijcken et al. 1995), hence CMP-Neu5Ac level for polysialylation, (2) 
overexpression of enzymes involved in the biosynthesis of glycans (i.e. α2,3/2,6 and 2,8-
sialyltransferases) (Jenkins et al. 1996), (3) over-expression of GNE (the rate-limiting step in 
the biosynthesis of sialic acid) (Bork et al. 2009) (see Figure 1.17), and (4) inhibition of 
sialidase (Munzert et al. 1996). In addition, a number of synthetic N-acyl-modified D-
mannosamines have also been introduced as sialic acid precursors for sialic acid biosynthesis 
(Keppler et al. 1999), however, the ability of these unnatural sialic acid to form into PSA 
chain structure, and the consequent immunogenicity hazard have to be noticed. Combind with 
optimized purification process, the success of these cell or metabolite engineering methods 
can additionally increase the yield and decrease the PDI of polysialylated species.  
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Other than producing the recombinantly polysialylated from inside of the cell, it might be also 
possible to elongate the glycosylated scFv-Ig5-FN1 fusion protein in test tubes. Previously, 
Cho et al. successfully polysialylated several exogenous sialyl accepting glycosphingolipids 
(GSLs) with E. coil K1 polyST. They also reported that a structural feature common to the 
preferred sialyl accepors was the disialylglycotope, Siaα2,8Sia, α2,3-linked to galactose (Cho 
and Troy 1994). Sharing the similar structural of the sialylated scFv-fusion protein, this “in 
test tube” method might be able to re-polysialylate the sialylated glyco-species using PST or 
STX, and also monitor the upper limit of recombinant polysialylation DP with sufficient 
CMP-Neu5Ac substrate. 
 
Factors responsible for the yield of recombinantly polysialylated scFv-Ig5-FN1 from the 
mammalian cell expression system should also be improved for better application of the 
technology. Further more, based on the existing approaches and the development to the 
production of homogeneous human glycoproteins with human-type glycans from other 
biological expression systems, such as bacteria or yeast (Rich and Withers 2009), alternative 
ways for producing recombinantly polysialylated proteins could possibly be considered with 
increased production yield.  
 
 
8.5.3 Future Development Concepts 
Based on the successful application from recombinantly polysialylated scFv-Ig5-FN1 fusion 
protein, a number of pipeline fusion concepts (listed in Figure 8.1) can then be processed in 
order to further verify and accomplish the development of antibody fragment recombinant 
polysialylation technology and facilitate antibody fragments to apply their advantageous 
features after getting smaller. 
 
As mentioned in section 1.4.4, the natural NCAM FN1 domain was suggested as a docking 
site for PolyST contacting with NCAM and consequently starting elongating the N-glycans on 
adjacent the Ig5 domain (Figure 1.18). In the case for scFv-Ig5-FN1 fusion protein, once the 
polysialylation completes, the FN1 domain becomes more redundant to the fusion protein. 
Minimizing the fusion protein moiety by the removal of FN1 domain post-polysialylation can 
be beneficial for antigen localization and tissue penetration. To achieve this, a recombinant 
protease-recognizing linker between Ig5 and FN1 domain can be introduced, and the specific 
enzymatic hydrolysis treatment to the collected fusion protein with new linker can specifically 
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detach the FN1 domain from the polysialylated scFv-Ig5 fusion moiety (Figure 8.1a, b, c). 
Based on the polysialylation evidence from an engineered O-glycosylation site of the 
recombinantly modified NCAM FN1 domain (also referred as Δhelix TT) (Mendiratta et al. 
2006), linking the scFv moiety with this polysialylatable FN1 domain can lead to another 
fusion option (Figure 8.1d). Ultimately, the CDR grafts that responsible for the antigen 
binding specificity of an antibody can be genetically extracted and recombinantly fused with  
 
 
 
         
 
Figure 8.1. Schematic of future recombinantly polysialylatable scFv-fusion constructs. Based on the 
construct of scFv-Ig5-FN1 fusion protein (a), FN1 domain, the PolyST docking site can be removed by 
introducing a specific protease recognizing linker (pink) between Ig5 and FN1 domains (b), which leads to a 
polysialylated scFv-Ig5 fusion protein (c) that is smaller than the original. An engineered FN1 domain alone with 
additional O-glycosylation site was suggested to be polysialylated (Mendiratta et al. 2006). Fusing this 
polysialylatable FN1 domain with scFv (d) can be considered as another alternative construct. CDR grafts can be 
extracted from the scFv and fused with the original polysialylatable Ig5-FN1 domains (e), as well as the Ig5 and 
FN1 connected by the hydrolysable linker (f). Eventually the polysialylated CDR-Ig5 fusion construct can be 
produced with probably the smallest protein content. The amino acid MWs of each fusion construct are also 
indicated accordingly.   
~53 kDa ~45 kDa 
~43 kDa ~53 kDa 
~22 kDa ~22 kDa ~10 kDa 
a. 
b. c. 
d. 
e. f. g. 
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the immunoglublin-like Ig5 domain (Figure 8.1e). Such species with non-antibody format but 
effective antigen-binding affinity are also known as affibodies, and have been successfully 
produced through different protein manipulation studies (Nord et al. 1997; Gunneriusson et al. 
1999). The first NCAM Ig-like domain has also been investigated for fusing with antibody 
CDR graft (Casey 2009).Consequently, by removing the redundant FN1 domain after 
polysialylation, the smallest polysialylated antigen binding motif (~10 kDa) among all 
polysialylatable fusion constructs can be produced (Figure 8.1f, g). 
 
In addition to PK modulation, PSA has already been used as degradable scaffold material for 
making hydrogels for drug release (Haile et al. 2008). The recombinant polysialylation 
method also offers an alternative platform of using PSA as a potential scaffold for 
nanotechnology or drug conjugations. Based on the DP of PSA, a fine balance of the amount 
between short, medium and long PSA chains associated with the polysialylated therapeutic 
product can lead to a differential clearance portfolio, which serves in a sense of drug release 
concept with a continuous drug supply based on the circulation half-life.  
 
 
 
8.6 Benefits of Recombinant Polysialylation 
Overall, the recombinant polysialylation technique described in this thesis establishes a 
promising and alternative platform for modulating the pharmacokinetics of bio-therapeutics. 
Using antibody fragment (i.e. scFv) as example, small proteins which can lose their 
therapeutic potency significantly by rapid blood clearance through kidney filtration have been 
shown to re-gain in vivo circulation longevity after recombinant polysialylation modification. 
Fundamentally, this new technology follows the PK modulation principle demonstrated by 
PEGylation, chemical-polysialylation and other hydrophilic polymer involved hydrodynamic 
volume improving approaches. Suggested previously in the thesis (section 1.5.1), water-
attracting polysialic acid was biosynthesized and specifically manipulated to increase the 
hydrodynamic size of the associated scFv molecule, and preventing fast kidney clearance as 
seen with scFv.  
 
On contrast to all other polymer involved approaches using chemical-conjugation, the 
recombinant polysialylation offers a chemistry-free method that reduces the potential 
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immunogenic hazard induced from chemical engineered proteins and polymers, and 
particularly to antibody fragment, it retains the integrity of the antigen-binding moiety of the 
scFv without being chemically modified. The genetically arranged site-specific 
polysialylation also avoids the interruption of the antigen-binding site from polymer 
conjugation. Moreover, the polysialylated scFv through the recombinant approach requires 
only one production line, while the chemical-conjugation needs the production of scFv and 
the hydrophilic polymers as well as additional conjugation process of the two and the 
downstream purification of the conjugate. Significant material wasting from various 
purification processes greatly increases the production cost of the chemical-conjugation 
approaches. With further optimization, the recombinant polysialylation promises to offer an 
easy and cheaper platform technology to reduce the rapid kidney elimination of small bio-
therapeutics. Furthermore, already introduced by chemical-polysialylation (section 1.3.1.3), 
PSA is a polysaccharide, organically biodegradable, FDA approved polymer material, and has 
already been used as protein conjugate in clinical trial stages. PSA is expected to reduce the 
risk of accumulation within the body that leads to consequent toxicity and immune response 
stimulating by many synthetic polymers. 
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Appendix 1: 
 
Vector Map for pcDNA4TM/TO/myc-His Vectors 
 
 
 
 
The pcDNA4TM system was used for the construction of scFv MFE-23 and C6.5 alongside 
their fusion constructs. Transformed E.coli XL-1 blue cells were selected by ampicillin 
resistance conferred by this vector. Stable mammalian cell lines of NB2a and HEK-293 cells 
were maintained by selection against zeocin resistance conferred by the vector. All constructs 
were tagged by c-terminal Myc and His6. The tetracycline controlled operator (TO) normally 
used for expression of potentially toxic proteins was not exploited in this study. 
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Appendix 2: 
 
Vector Map for pIg Vector 
 
 
 
The pIg vector system shown above originally contained a chimeric NCAM-140 fusion 
construct (incorporated via the Hind III/Bam HI sites of the multicloning region) with a C-
terminal Fc tail (provided by Dr. Jane Saffell, Imperial College London). The NCAM 
domains including Ig5-FN1 and FN1 alone were extracted from the NCAM-140 sequence 
within this vector and fused with MFE23 scFv sequence consequently (Constantinou 2005). 
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Appendix 3: 
 
Vector Map for pcDNA 3.1/V5-His Vectors 
 
 
 
 
Both PST and STX sequences were provided as insertions in pcDNA3.1/V5-His B vector 
between EcoRV and XbaI restriction sites (from Professor Karen Colley, University of Illinois, 
USA). Transformed E.coli XL-1 blue cells were selected by ampicillin resistance conferred 
by this vector. Stable HEK-293 cells were maintained by selection against neomycin 
resistance conferred by the vector. Both the inserted PolyST constructs were tagged by c-
terminal V5 and His6. 
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Appendix 4: 
 
pUC119 DNA Vector 
 
 
 
 
 
 
 
pUC119 vector was originally used for containing C6.5 scFv in its multi-cloning site. E.coli 
XL-1 blue cells were transformed with this vector and selected by ampicillin for DNA 
amplification.  
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Appendix 5: 
 
pEGFP-C1 Vector  
 
 
 
 
 
pEGFP-C1 encodes a red-shifted variant of wild-type GFP which has been optimized for 
brighter fluorescence and higher expression in mammalian cells. A bacterial promoter 
upstream of this cassette expresses kanamycin resistance in E. coli. For the research purpose 
of this project, pEGFP-C1 vector was used as positive control in transfection optimization 
experiments. 
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Appendix 6 
 
Sequence of MFE23 scFv 
Sequence Range: 1 to 732 
 
10        20        30        40        50        60 
CAGGTGAAACTGCAGCAGTCTGGGGCAGAACTTGTGAGGTCAGGGACCTCAGTCAAGTTG 
GTCCACTTTGACGTCGTCAGACCCCGTCTTGAACACTCCAGTCCCTGGAGTCAGTTCAAC 
Q  V  K  L  Q  Q  S  G  A  E  L  V  R  S  G  T  S  V  K  L 
 
        70        80        90       100       110       120 
TCCTGCACAGCTTCTGGCTTCAACATTAAAGACTCCTATATGCACTGGTTGAGGCAGGGG 
AGGACGTGTCGAAGACCGAAGTTGTAATTTCTGAGGATATACGTGACCAACTCCGTCCCC 
S  C  T  A  S  G  F  N  I  K  D  S  Y  M  H  W  L  R  Q  G 
 
       130       140       150       160       170       180 
CCTGAACAGGGCCTGGAGTGGATTGGATGGATTGATCCTGAGAATGGTGATACTGAATAT 
GGACTTGTCCCGGACCTCACCTAACCTACCTAACTAGGACTCTTACCACTATGACTTATA 
P  E  Q  G  L  E  W  I  G  W  I  D  P  E  N  G  D  T  E  Y 
 
       190       200       210       220       230       240 
GCCCCGAAGTTCCAGGGCAAGGCCACTTTTACTACAGACACATCCTCCAACACAGCCTAC 
CGGGGCTTCAAGGTCCCGTTCCGGTGAAAATGATGTCTGTGTAGGAGGTTGTGTCGGATG 
A  P  K  F  Q  G  K  A  T  F  T  T  D  T  S  S  N  T  A  Y 
 
       250       260       270       280       290       300 
CTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTATTATTGTAATGAGGGGACT 
GACGTCGAGTCGTCGGACTGTAGACTCCTGTGACGGCAGATAATAACATTACTCCCCTGA 
L  Q  L  S  S  L  T  S  E  D  T  A  V  Y  Y  C  N  E  G  T 
 
       310       320       330       340       350       360 
CCGACTGGGCCGTACTACTTTGACTACTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA 
GGCTGACCCGGCATGATGAAACTGATGACCCCGGTTCCCTGGTGCCAGTGGCAGAGGAGT 
P  T  G  P  Y  Y  F  D  Y  W  G  Q  G  T  T  V  T  V  S  S 
 
       370       380       390       400       410       420 
GGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCAGAAAATGTGCTCACC 
CCACCTCCGCCAAGTCCGCCTCCACCGAGACCGCCACCGCCTAGTCTTTTACACGAGTGG 
G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  E  N  V  L  T 
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       430       440       450       460       470       480 
CAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATAACCTGCAGTGCC 
GTCAGAGGTCGTTAGTACAGACGTAGAGGTCCCCTCTTCCAGTGGTATTGGACGTCACGG 
Q  S  P  A  I  M  S  A  S  P  G  E  K  V  T  I  T  C  S  A 
 
       490       500       510       520       530       540 
AGCTCAAGTGTAAGTTACATGCACTGGTTCCAGCAGAAGCCAGGCACTTCTCCCAAACTC 
TCGAGTTCACATTCAATGTACGTGACCAAGGTCGTCTTCGGTCCGTGAAGAGGGTTTGAG 
S  S  S  V  S  Y  M  H  W  F  Q  Q  K  P  G  T  S  P  K  L 
 
       550       560       570       580       590       600 
TGGATTTATAGCACATCCAACCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGA 
ACCTAAATATCGTGTAGGTTGGACCGAAGACCTCAGGGACGAGCGAAGTCACCGTCACCT 
W  I  Y  S  T  S  N  L  A  S  G  V  P  A  R  F  S  G  S  G 
 
       610       620       630       640       650       660 
TCTGGGACCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTAT 
AGACCCTGGAGAATGAGAGAGTGTTAGTCGGCTTACCTCCGACTTCTACGACGGTGAATA 
S  G  T  S  Y  S  L  T  I  S  R  M  E  A  E  D  A  A  T  Y 
 
       670       680       690       700       710       720 
TACTGCCAGCAAAGGAGTAGTTACCCACTCACGTTCGGTGCTGGCACCAAGCTGGAGCTG 
ATGACGGTCGTTTCCTCATCAATGGGTGAGTGCAAGCCACGACCGTGGTTCGACCTCGAC 
Y  C  Q  Q  R  S  S  Y  P  L  T  F  G  A  G  T  K  L  E  L 
 
730 
AAACGGGCGGCC 
TTTGCCCGCCGG 
K  R  A  A 
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Appendix 7 
 
Sequence of C6.5 scFv 
Sequence Range: 1 to 768 
 
10        20        30        40        50        60 
CAGGTGCAGCTGTTGCAGTCTGGGGCAGAGTTGAAAAAACCCGGGGAGTCTCTGAAGATC 
Q  V  Q  L  L  Q  S  G  A  E  L  K  K  P  G  E  S  L  K  I 
 
        70        80        90       100       110       120 
TCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGCCTGGGTGCGCCAGATG 
S  C  K  G  S  G  Y  S  F  T  S  Y  W  I  A  W  V  R  Q  M 
 
       130       140       150       160       170       180 
CCCGGGAAAGGCCTGGAGTACATGGGGCTCATCTATCCTGGTGACTCTGACACCAAATAC 
P  G  K  G  L  E  Y  M  G  L  I  Y  P  G  D  S  D  T  K  Y 
 
       190       200       210       220       230       240 
AGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGTCGACAAGTCCGTCAGCACTGCCTAC 
S  P  S  F  Q  G  Q  V  T  I  S  V  D  K  S  V  S  T  A  Y 
 
       250       260       270       280       290       300 
TTGCAATGGAGCAGTCTGAAGCCCTCGGACAGCGCCGTGTATTTTTGTGCGAGACATGAC 
L  Q  W  S  S  L  K  P  S  D  S  A  V  Y  F  C  A  R  H  D 
 
       310       320       330       340       350       360 
GTGGGATATTGCAGTAGTTCCAACTGCGCAAAGTGGCCTGAATACTTCCAGCATTGGGGC 
V  G  Y  C  S  S  S  N  C  A  K  W  P  E  Y  F  Q  H  W  G 
 
       370       380       390       400       410       420 
CAGGGCACCCTGGTCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGC 
Q  G  T  L  V  T  V  S  S  G  G  G  G  S  G  G  G  G  S  G 
 
       430       440       450       460       470       480 
GGTGGCGGATCACAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAG 
G  G  G  S  Q  S  V  L  T  Q  P  P  S  V  S  A  A  P  G  Q 
 
       490       500       510       520       530       540 
AAGGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGGAATAATTATGTATCCTGG 
K  V  T  I  S  C  S  G  S  S  S  N  I  G  N  N  Y  V  S  W 
- 319 - 
 
       550       560       570       580       590       600 
TACCAGCAGCTCCCAGGAACAGCCCCCAAACTCCTCATCTATGGTCACACCAATCGGCCC 
Y  Q  Q  L  P  G  T  A  P  K  L  L  I  Y  G  H  T  N  R  P 
 
       610       620       630       640       650       660 
GCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATC 
A  G  V  P  D  R  F  S  G  S  K  S  G  T  S  A  S  L  A  I 
 
       670       680       690       700       710       720 
AGTGGGTTCCGGTCCGAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTG 
S  G  F  R  S  E  D  E  A  D  Y  Y  C  A  A  W  D  D  S  L 
 
730       740       750       760 
AGTGGTTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTTAG 
S  G  W  V  F  G  G  G  T  K  L  T  V  L  G   
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Appendix 8 
 
Sequences of Recombinantly Polysialylatable Fusion Components 
 
NCAM mammalian expression leader sequence: 
 
ATGCTGCAAACTAAGGATCTCATCTGGACTTTGTTTTTCCTGGGGACTGCAGTTTCTCTG 
CAGGTGGACATGG 
 
 
 
NCAM Ig5 domain (264bp): 
 
TATGCCCCAAAGCTACAGGGCCCTGTGGCTGTGTACACTTGGGAGGGGAACCAGGTGAAC 
ATCACCTGCGAGGTATTTGCCTATCCCAGTGCCACGATCTCATGGTTTCGGGATGGCCAG 
CTGCTGCCAAGCTCCAATTACAGCAATATCAAGATCTACAACACCCCCTCTGCCAGCTAT 
CTGGAGGTGACCCCAGACTCTGAGAATGATTTTGGGAACTACAACTGTACTGCAGTGAAC 
CGCATTGGGCAGGAGTCCTTGGAA 
 
 
 
NCAM FN1 domain (300bp): 
 
TTCATCCTTGTTCAAGCAGACACCCCCTCTTCACCATCCATCGACCAGGTGGAGCCATAC 
TCCAGCACAGCCCAGGTGCAGTTTGATGAACCAGAGGCCACAGGTGGGGTGCCCATCCTC 
AAATACAAAGCTGAGTGGAGAGCAGTTGGTGAAGAAGTATGGCATTCCAAGTGGTATGAT 
GCCAAGGAAGCCAGCATGGAGGGCATCGTCACCATCGTGGGCCTGAAGCCCGAAACAACG 
TACGCCGTAAGGCTGGCGGCGCTCAATGGCAAAGGGCTGGGTGAGATCAGCGCGGCCTCC 
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Appendix 9 
 
ST8Sia IV (PST) DNA Sequence 
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 [ Homo sapiens ]  
(http://www.ncbi.nlm.nih.gov/protein/NP_005659.1) 
 
 
Sequence (1077bq): 
ATGCGCTCCA TTAGGAAGAG GTGGACGATC TGCACAATAA GTCTGCTCCT 
GATCTTTTAT AAGACAAAAG AAATAGCAAG AACTGAGGAG CACCAGGAGA 
CGCAACTCAT CGGAGATGGT GAATTGTCTT TGAGTCGGTC ACTTGTCAAT 
AGCTCTGATA AAATCATTCG AAAGGCTGGC TCTTCAATCT TCCAGCACAA 
TGTAGAAGGT TGGAAAATCA ATTCCTCTTT GGTCCTAGAG ATAAGGAAGA 
ACATACTTCG TTTCTTAGAT GCAGAACGAG ATGTGTCAGT GGTCAAGAGC 
AGTTTTAAGC CTGGTGATGT CATACACTAT GTGCTTGACA GGCGCCGGAC 
ACTAAACATT TCTCATGATC TACATAGCCT CCTACCTGAA GTTTCACCAA 
TGAAGAATCG CAGGTTTAAG ACCTGTGCAG TTGTTGGAAA TTCTGGCATT 
CTGTTAGACA GTGAATGTGG AAAGGAGATT GACAGTCACA ATTTTGTAAT 
AAGGTGTAAT CTAGCTCCTG TGGTGGAGTT TGCTGCAGAT GTGGGAACTA 
AATCAGATTT TATTACCATG AATCCATCAG TTGTACAAAG AGCATTTGGA 
GGCTTTCGAA ATGAGAGTGA CAGAGAAAAA TTTGTGCATA GACTTTCCAT 
GCTGAATGAC AGTGTCCTTT GGATTCCTGC TTTCATGGTC AAAGGAGGAG 
AGAAGCACGT GGAGTGGGTT AATGCATTAA TCCTTAAGAA TAAACTGAAA 
GTGCGAACTG CCTATCCGTC ATTGAGACTT ATTCATGCTG TCAGAGGTTA 
CTGGCTGACC AACAAAGTTC CTATCAAAAG ACCCAGCACA GGTCTTCTCA 
TGTATACACT TGCCACAAGA TTCTGTGATG AAATTCACCT GTATGGATTC 
TGGCCCTTCC CTAAGGATTT AAATGGAAAA GCGGTCAAAT ATCATTATTA 
TGATGACTTA AAATATAGGT ACTTTTCCAA TGCAAGCCCT CACAGAATGC 
CATTAGAATT CAAAACATTA AATGTGCTAC ATAATAGAGG AGCTCTAAAA 
CTGACAACAG GAAAGTGTGT AAAGCAA 
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Appendix 10 
 
ST8Sia II (STX) DNA Sequence 
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 
(http://www.ncbi.nlm.nih.gov/protein/AAH69584.1) 
 
 
Sequence (1128bq): 
ATGCAGCTGC AGTTCCGGAG CTGGATGCTG GCCGCGCTCA CGCTGCTCGT 
GGTCTTCCTC ATCTTCGCAG ACATCTCAGA GATCGAAGAA GAAATCGGGA 
ATTCGGGAGG CAGAGGTACA ATCAGATCAG CTGTGAACAG CTTACATAGC 
AAATCTAATA GAGCTGAAGT TGTAATAAAC GGCTCCTCAT CACCAGCTGT 
TGTTGACAGA AGTAATGAAA GCATCAAGCA CAACATCCAG CCAGCCTCGT 
CCAAATGGAG ACATAACCAG ACGCTCTCTC TGAGGATCAG GAAGCAGATT 
TTAAAGTTCT TGGATGCTGA AAAGGACATT TCTGTCCTAA AGGGAACCCT 
GAAGCCTGGA GATATTATTC ATTACATCTT CGATCGAGAC AGCACCATGA 
ATGTGTCCCA GAACCTCTAC GAGCTCCTCC CCAGGACTTC GCCACTGAAG 
AATAAGCACT TTGGGACTTG TGCCATCGTG GGCAACTCGG GGGTCTTGCT 
GAACAGCGGC TGTGGGCAGG AGATTGACGC CCACAGCTTC GTCATCAGGT 
GCAACCTGGC CCCAGTACAG GAGTATGCCC GGGATGTGGG GCTCAAGACA 
GACCTGGTAA CCATGAACCC CTCGGTCATC CAGCGGGCCT TTGAGGACTT 
GGTCAATGCC ACGTGGCGGG AGAAGCTGCT GCAACGGCTG CACAGCCTCA 
ATGGCAGCAT CCTGTGGATC CCTGCCTTCA TGGCCCGGGG CGGCAAGGAG 
CGTGTTGAGT GGGTCAACGA GCTTATCCTG AAGCACCACG TCAACGTGCG 
CACTGCATAC CCCTCGCTGC GCCTGCTGCA CGCCGTTCGC GGATACTGGC 
TGACCAACAA AGTCCACATC AAAAGACCCA CCACCGGCCT CTTGATGTAT 
ACCCTGGCCA CACGTTTCTG CAAACAAATC TACCTCTACG GCTTCTGGCC 
CTTTCCGCTG GATCAGAACC AGAACCCAGT CAAGTACCAC TATTATGACA 
GCCTCAAGTA TGGCTACACC TCCCAGGCCA GCCCGCATAC CATGCCCTTG 
GAGTTTAAGG CCCTCAAGAG CCTACATGAG CAGGGGGCTT TGAAACTGAC 
TGTCGGCCAG TGCGATGGGG CCACGTAG 
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Appendix 11: 
 
The principle monosaccharides found in mammalian glycoproteins 
Information of symbols, structures, underivatised and permethylation derivatised 
monoisotopic mass (m/z) of each monosaccharides were listed and specifically applied for the 
mass spectrometry analysis in this project. 
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Appendix 12: 
 
The raw data obtained from MALDI-MS analysis of the permethylated N-
glycans released from MFE-Ig5-FN1 using PNGaseF.  
 
Signals consistent with some under and/or over methylation were observed, which was most 
noticeably in high mass complex structure 
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Appendix 13: 
 
The raw data obtained from ES-MS analysis of the permethylated N-
glycans released from MFE-Ig5-FN1 using PNGase F. 
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Appendix 14 
Analysis of O-glycan structures of MFE23-Ig5-FN1 fusion proteins by negative-ion 
reflectron mode MALDI-TOF MS. No typical O-glycosylation was indicated by the signals 
detected from the three glyco-forms, known as (a) highly polysialylated, (b) weakly 
polysialylated, and (c) sialylated MFE23-Ig5-FN1 fusion proteins. 
 
         
 
         
 
         
(a) 
(b) 
(c) 
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